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ABSTRACT
cDNAs coding for the E l structural protein of the Thomas strain of RV have 
been cloned and sequenced. Comparisons between the predicted amino acid 
sequences of the E l structural protein of other strains reveals only one 
unique change in the Thomas sequence at position El^^g. 
cDNA coding for the complete E l protein and subfragments of E l have been 
expressed as glutathione-S-transferase fusion proteins in E.coli. The two 
smallest soluble fusion proteins from pUS1503 and pUS1509 which contain 
only previously identified epitopes, were used as antigens in an ELISA assay 
for rubella antibody screening. From the analysis of 42 human sera, the 
protein from pUS1503 showed a sensitivity of 53% and a specificity of 80% 
whereas protein from pUS1509 gives a sensitivity of 81% and specificity of 
80%.
The E l and E2 proteins have been expressed in eukaryotic systems both in 
vitro and in vivo. In vitro expression confirmed that a bovine IgG signal 
peptide could substitute for the putative rubella E l signal peptide and allow 
processing by microsomal membranes. Expression of an E l  variant lacking 
the trans-membrane anchor failed to produce detectable levels of a secreted 
protein in COS-1 cells even when intracellular protein was produced.
To provide new data on the location of rubella E l epitopes and to investigate 
the human antibody response to rubella, overlapping synthetic octameric 
peptides covering the E l sequence were used in binding studies with rubella 
positive and negative sera. Each human sera analysed displayed a unique 
profile of antibody binding to specific peptides. Pooled data identified groups 
of peptides which consistently bound antibodies from rubella positive sera. 
The majority of antibody binding sites were outside the previously defined 
region containing four epitopes (epsl-4). The majority of sera showed no 
binding to eps2 and eps3.
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Chapter 1 
INTRODUCTION
INTRODUCTION
1.1 PROPERTIES OF THE VIRUS
1.1.1 Classification
Rubella is classified as a non-arthropod-borne togavirus and belongs to the 
genus Ruhivirus. The family Togaviridae, "toga" meaning mantle or cloak, 
are enveloped viruses (Fenner, 1976). The Togaviridae genome consists of a 
single strand of RNA of positive polarity that is encapsidated by a single 
species of protein, the capsid protein, arranged in an icosohedral 
configuration. The nucleocapsid is enveloped by a lipid bilayer derived from 
the host cell and from which project the viral glycoproteins.
The Togaviridae comprises three genera based on serology (Shope, 1985; 
Westaway, 1985), n?imé[y Alphavirus, Rubivirus and Pestivirus. Members of 
the Alphavirus are arthropod-borne viruses (arboviruses), whereas the other 
two genera are non-arthropod-borne viruses.
The Alphavirus is the largest genus and consists of more than two dozen 
distinct arthropod-transmitted viruses that cause diseases in humans ranging 
from fever, rash and arthritis to rapidly fatal encephalitis. The arboviruses
Cybo**
characteristically cause a rapidly^lytic infection in mammals with a less 
persistent infection in the invertebrate host. Ross River virus, Semliki Forest 
virus (SFV), and Venezuelan equine virus produce demyelinating disease in 
laboratory models (Chew-Lim et al., 1978; DalCanto and Rabinowitz, 1981; 
Seay and Wolinsky, 1983). The structure and replication of SFV and Sindbis 
(SIN) have been studied in great detail (Strauss and Strauss, 1986).
The Pestivirus genus includes three viruses, border disease virus of sheep, 
bovine viral diarrhoea virus, and hog cholera virus. All three viruses can be 
transmitted to the foetus and cause congenital malformations (Brinton,
1980). Rubella virus (RV) is the only member of the genus Ruhivirus with 
no known invertebrate host, and man is the only known natural reservoir for 
the virus.
1.1.2 Structure
RV is a small pleomorphic particle 60-70nm in diameter (Bardeletti et ah, 
1975; Payment et al., 1975), with a 30nm electron dense core surrounded by 
a lipid envelope (Murphy et al., 1968), (fig 1.1, 1.2). Between the core and 
the envelope is an electron-lucent zone, this distinguishes rubella from the 
other togaviruses (Murphy, 1980). The virion contains one molecule of 
positive polarity RNA with a molecular weight of 3.8kDa enclosed in the 
nucleocapsid. The nucleocapsid has icosqhedral symmetry and is made up 
from single species of protein. RV contains three structural proteins, two 
envelope glycoproteins, E l  and E2, and the capsid protein. The 
glycoproteins form regular spaced projections, 5-8nm in length, (Bardeletti et 
al., 1975), on the viral envelope.
1.1.3 Physical and chemical properties
Like other enveloped viruses eg Herpes, Influenza, rubella is inactivated by 
ether, chloroform and detergents due to the lipids in the envelope (Parkman 
et al., 1964). RV is inactivated at pH 3 (Chagnon and Laflamme, 1964), with 
exposure of the virus to pH 5 causing irreversible conformational changes in 
the envelope glycoproteins effecting the susceptibility to trypsin (Katow and 
Suguira, 1988), E l becomes more resistant and E 2  more sensitive, as seen 
with SFV and SIN (Edwards et ah, 1983; Kielian and Helenius, 1985). The 
exposure to the low pH induces fusion of rubella infected cells and with it the 
acquisition of liposome binding activity (Katow and Suguira, 1988), 
suggesting that rubella virions fuse with host cell membranes in an acidic
ss +RNA
Fig 1.1 Schematic figure of a rubella virus showing the single stranded 
RNA genome encapsidated in the nucleocapsid. The E l and E2 
glycoproteins are embedded in the lipid bilayer envelope 
(Mauracher a/., 1991).
Fig 1.2 Negat ively  stained p repara t ion  o f  rubella  virus.  Inse r t  is an 
enlarged part icle showing the spikes o f  the virus (Wil son  et a l ,  
1984).
environment in the same way as alphaviruses do.
The virus can be stored for several days at 4°C and is stable at -70°C but it is 
heat labile with a slow decrease in infectivity at 37°C with rapid inactivation 
at 56°C.
Haemagglutination by RV (Stewart et al., 1967) has been shown to be 
associated with the E l  glycoprotein (Waxham andWolinsky, 1983; Ho-Terry 
and Cohen, 1985), as has the haemagglutinin of SIN (Chanas et al., 1982). 
RV induced haemolysis, which involves virus adsorption to the cells followed 
by cell lysis (Kobayashi, 1978) is also associated with the E l  glycoprotein. 
The degree of haemolysis depends on the cell type with chicken red blood 
cells being the most sensitive of those tested (Kobayashi and Suzuki, 1982).
1.1.4 Growth in cell culture
RV can be grown in a range of primary and continuous cell lines (Herrmann, 
1979). RK-13 (rabbit kidney) cells are often used for primary isolation
because they show a visible cytopathic effect (CPE) on viral infection (Nawa, 
1979). Primary African green monkey kidney (AGMK) cells are also used for 
virus isolation because the infected cells can be used in an interference assay 
with echovirus 1 1  within several days of the rubella isolation attempt 
(Parkman et al., 1965). Two other cell lines, one a continuous cell line 
derived from AGMK cells (Vero), (Liebhaber et al., 1967), and the other 
from baby hamster kidney (BHK-21) cells are frequently used for virus 
cultivation. Some sublines of Vero cells do not produce a CPE (Best and 
Banatvala, 1990). RV titre yields tend to be low, however, increased titre 
yields of cell free virus have been achieved by cultivation in Vero cells 
attached to glass beads in a propagator (Thomson et al., 1989).
RV can be induced to form plaques in RK-13 cells (Fogel and Plotkin, 1969), 
in SIRC (rabbit cornea) cells, BHK-21 cells and Vero cells (Liebhaber et al., 
1967). Plaque formation is influenced by such conditions as pH, presence of 
agar inhibitors and the condition, subline and source of the cells employed 
(Banatvala and Best, 1984). A plaque assay utilising haemadsorption of 
pigeon red blood cells (Schmidt et al., 1969) and haemadsorption 
negative-plaques resulting from interference with the growth of 
paramyxovirus (Toms and Mostratos., 1973) have been described.
1.1.5 Infection in experimental animals
There are no reliable animal models for the study of clinically acquired 
rubella. However, a variety of laboratory animals can be infected with RV. 
Rhesus and African green monkeys develop viremia, shed virus in respiratory 
secretions, and develop humoral immune responses similar to man (Parkman 
et al., 1965). Baboons and chimpanzees show similar response to 
experimental infection (Horstmann, 1969). Marmosets are susceptible to 
infection, but they do not show any clinical disease or teratogenesis 
(Patterson et ah, 1973). Congenital infection has been reported in rats 
(Avila et al., 1972), rabbit (Kono et al., 1969), and ferrets (Rorke and Spiro, 
1967), but the results appear inconsistent and lacked adequate controls (Best 
and Banatvala, 1990).
1.2 MOLECULAR BIOLOGY OF THE RUBELLA VIRUS
1.2.1 The genome
The genome of the RV is a 40S single molecule of single stranded RNA 
(Hovi and Vaheri, 1970 ; Robinson and Merigon, 1969; Sedwick and Sokol, 
1970) with positive polarity. RV genomic 40S RNA has a structure typical 
of eukaryotic mRNA with a capped 5' terminus and a poly(A) tail 
(Oker-Blom et al., 1984). The length of the RV genomic RNA is 9757 
nucleotides, excluding the poly(A) tail (Dominguez et al., 1990)(Appendix 
1). In addition to the structural protein open reading frame (ORF), of 3189 
nucleotides, at the 3' end of the genomic RNA there is a second long ORF 
which codes for the non-structural proteins. This ORF begins at nucleotide 
41 and terminates at nucleotide 6656 with an opal stop codon (TGA) which is 
followed 1 2  nucleotides downstream by a second in-frame opal stop codon. 
This non-structural ORF is 6615 nucleotides in length and encodes a 2205 
amino acid polypeptide. The structural ORF which covers nucleotides 
6507-9696 codes for the structural proteins and overlaps the non-structural 
ORF by 149 nucleotides (Dominguez et al., 1990).
At nucleotide 3 of the 5' terminus of the non-structural ORF there is an AT G 
initiation codon. Translation initiated at this AT G would terminate at a TAG 
codon beginning at nucleotide 54, resulting in a 16 amino acid product 
(Dominguez et ah, 1990). In eukaryotic mRNAs, most ATGs at which 
translation is initiated are 20-100 nucleotides from the 5' end of the mRNA 
(Kozak, 1987). Initiation of translation at ATGs less than 15 nucleotides 
from the 5' end of eukaryotic mRNAs is less efficient than at ATGs greater 
than 15 nucleotides from the 5' end (Sedman et al., 1990), therefore, it is not 
uncommon to find mRNAs which contain ATGs close to the 5' end also 
contain downstream ATGs at which translation is also initiated (Kozak, 
1987), as is found with RV RNA.
A region of 57 nucleotides exists between the termination of the 
non-structural ORF and the poly(A) tail (Frey et al., 1986). This 
nontranslated sequence is shorter than that in the alphaviruses, SFV has 264 
residues (Garoff et al., 1980), SIN has 318 residues (Rice and Struass, 1981) 
and Ross River virus has 524 residues (Dalgarno et al., 1983). A region of 
20 nucleotides located in the nontranslated region adjacent to the poly(A) tail 
has been found to be highly conserved in the alphaviruses (Ou et ah, 1981), 
but no homology between the alphaviruses and RV was found. This sequence 
could be the replicase recognition site (Ou et al., 1981). At the 3' end of the 
RV genome there is a palindromic sequence that can form a stable hairpin 
structure (Fig 1.6a)(Nakhasi et al., 1990) with a DeltaG of -29.6 kcal/mol at 
25°C (Frey et ah, 1986).
Base composition
The base composition of the RV genomic RNA is 14.9% A, 15.4% U, 30.8% 
G and 38.7% C, therefore it has the highest G/C content (69.5%) of any RNA 
virus sequenced (Dominguez et al., 1990). The high G/C content is evenly 
maintained throughout the genome except for the first 65 nucleotides of the 
genome, which has a G/C content of 49%, and 78 nucleotides around the 
subgenomic RNA start site, which has a G/C content of 47%. The lower G/C 
content in these regions would result in corresponding regions of the double 
stranded replicative form having a lower T^, possibly facilitating recognition 
and local dénaturation by factors involved in initiation and synthesis of the 
genomic and subgenomic RNA (Dominguez et al., 1990).
Comparison to alphaviruses
The alphavirus genome has a single ORF of approximately 7.4kb and spans 
the 5' two-thirds of the genomic RNA. The polyprotein is translationally 
processed into four non-structural proteins, nsPl, nsP2, nsP3, and nsP4 
(Strauss and Strauss, 1986). In SIN there is an in-frame opal termination
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codon between the non-structural proteins nsP3 and nsP4 which is 
occasionally read through (Strauss et al., 1983). SFV lack this opal codon 
(Strauss et al., 1988). Studies of mutants indicate that nsP4 is the RNA 
polymerase, nsPl functions in the minus- polarity RNA synthesis as well as 
the methyltransferase and guanylytransferase activities required for the 
capping of the viral plus strand RNA (Mi et al., 1989). nsP2 functions in 
subgenomic RNA synthesis (Hahn et al., 1989) and contains the autoprotease 
required for post-translational processing of the non-structural polyprotein 
(Ding and Schlesinger, 1989).
Four regions in the genomic RNAs of alphaviruses have been found to be 
highly conserved and are thought to be regulatory signals for viral replication 
(Strauss and Strauss, 1986). Sequences homologous to three of these 
regions have been found in RV (Dominguez et al., 1990). The first is a stem 
loop structure at the 5' end of the genome. The complementary minus-strand 
equivalent of this structure is hypothesised to be recognised by the replicase 
as a binding site for initiation of transcription of the plus-strand genomic 
RNA. The second conserved region in the alphavirus is a stretch of 51 
nucleotides located 156 nucleotides from the 5' end. A stretch of 46 
nucleotides located 224 nucleotides from the 5' end of the RV genome has a 
50% homology with this region. The third stretch of nucleotides is at the 
start of subgenomic RNA synthesis (Frey et al., 1989). There is no 
homologous sequence in the RV genome corresponding to the fourth 
conserved region at the 3' terminus (Vidgren et al., 1987). There is a short 
region of 122 amino acids showing significant homology between RV and 
alphavirus non-structural ORF (fig 1.3). This region of homology is located 
at the NH 2  terminus of nsP3 in the alphavirus genome. The limited degree of 
homology between RV and the alphaviruses indicates that these viruses are 
only distantly related (Domingeuz et al., 1990)
The RV non-structural ORF contains two global amino acid motifs conserved 
in a large number of positive-polarity RNA viruses, a motif indicative of 
helicase activity and a motive indicative of replicase activity (figl.3). The 
order of the helicase motif and the nsP3 homology region in the RV genome 
is reversed with respect to the alphavirus genome indicating that a genetic 
rearrangement has occurred during the evolution of these viruses (Domingeuz 
et al., 1990). In addition, other putative domains have been assigned to RV, 
namely a putative methyltransferase domain, a Y domain (200 amino acids 
downstream of the methyltransferase domain), a putative papain-like protease 
domain and an X domain (a conserved domain of unknown function) linked to 
the papain-like protease (Koonin et ah, 1992). The alphaviruses also have the 
X domain, and the helicase and protease domains are fused in the nsP2 
protein. Koonin et al., (1992) have also identified these putative domains, by 
computer assisted alignment, in hepatitis E virus (HEV). Phylogenetic 
analysis of the polymerase, helicase and the presence of the Y domain has 
suggested evolution from a common ancestor virus for RV, HEV and beet 
necrotic yellow vein virus (a plant furovirus).
1.2.2 The subgenome
In addition to the 40S genomic RNA there is a 24S RNA species that is 
derived from the 3' end of the 40S RNA, which encodes a llOkDa 
polypeptide and represents the precursor to the structural proteins 
(Oker-Blom et al., 1984a), fig 1.4. The RV subgenomic 24S RNA is capped 
at the 5' end and polyadenylated at the 3' end of the sequence. The length of 
this RNA is 3327 nucleotides, excluding the poly(A) tail. The first 
translation initiation codon encountered on the subgenomic RNA is the initial 
AUG of the structural protein ORF. This AUG begins at the 78th nucleotide 
of the subgenomic RNA, excluding the capped guanine (m^G), therefore there 
is a 5' nontranslated sequence of 77 nucleotides (Frey a/., 1989). The
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nucleotide is a G which agrees with the consensus of a purine as 
the nucleotide found in most eukaryotic mRNAs (Kozak, 1983).
The internally initiated subgenomic RNAs of positive polarity RNA viruses 
also have a purine as the penultimate nucleotide (Ou et al., 1982).
There is a short region of sequence homology between RV and the 
alphaviruses. A stretch of 28 nucleotides within the RV genome is located 
96 nucleotides upstream from the 5' end of the structural protein ORF. In 
the alphavirus this stretch of nucleotides is highly conserved and is 
immediately upstream of the initiation site of the subgenomic RNA (Ou et al., 
1982). Frey et a /.,(1989) have shown that initiation of RV subgenomic RNA 
occurs 20 nucleotides downstream from the analogous site of alphavirus 
subgenomic RNA synthesis within this conserved sequence. It is therefore 
possible that this conserved sequence is the recognition site for initiation of 
RV subgenomic RNA synthesis and that subgenomic RNA synthesis in these 
two genera differs in the spacing of initiation relative to this stretch of 
nucleotides (Frey et al., 1989). The RV sequence of these 20 nucleotides can 
form a secondary structure while the comparable alphavirus sequence cannot 
(Dominguez a/., 1990).
1.2.3 Structural proteins
The subgenomic RNA encodes for the precursor to the structural proteins, 
the capsid (C) protein and the envelope proteins E l,  E2a and E2b. The 
structural proteins are coded for by three genes, the E2a and E2b being 
coded for by the same gene (Kalkkinen et ah, 1984). The order of 
translation of the virion structural proteins is NH 2 -C-E 2 -EI-COOH 
(Oker-Blom et al., 1984b).
Early studies of the structural proteins had conflicting reports on the number
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and size of the RV proteins with the three major polypeptides being 
55-63kDa, 42-50kDa and 30-35kDa (Bardeletti et al., 1975; Ho-Terry and 
Cohen, 1980, 82; Payment et al., 1975; Vaheri and Hovi, 1972; Trudel et al.,
1982). Other polypeptides found were 44, 41, 24, 19kDa (Van Alstyne et 
al., 1981) and 63, 60, 32, 30kDa (Liebhaber and Gross, 1972).
Current studies show that the C protein has a molecular weight of 33kDa and 
is unglycosylated whereas E l (M  ^ of 58kDa) and E2 (M^ of 42-47kDa) are 
glycosylated (Oker-Blom et al., 1983). E2 migrates as two bands, E2a and 
E2b, on a polyacrylamide gel, due to differential glycosylation (Kalkkinen et 
al., 1984).
Details of the nucleotide and predictive amino acid sequence of the structural 
proteins of RV are discussed in chapter 3.
1.2.4 Replication of RV
Adsorption of viruses to the cell surface is the first step leading to infection. 
This process is mediated through the recognition of specific receptors on the 
plasma membrane by defined sequences of proteins on the virus surface. The 
specific receptors for RV have been identified as membrane phospholipids 
and glycolipids (Mastromarino et al., 1989, 1990), this is also the case with 
rhabdoviruses.
In the alphaviruses the receptors have been shown to be proteinaceous 
(Schlesinger and Schlesinger, 1990) and once bound to a susceptible 
host-cell surface the virus gains entry to the cytoplasm via the endocytic 
pathway. In this process the virus accumulates in coated pits which are 
endocytosed to form coated vesicles. These vesicles are subsequently 
uncoated to form acidified endosomes, providing conditions that trigger
14
fusion of the virus membrane with the vesicle membrane (Schlesinger and 
Schlesinger, 1990).
Low pH has been shown to cause irreversible conformational change of the 
RV envelope glycoproteins, E l  and E2, with a marked reduction in both 
infectivity and haemagglutinating activity of the virus. Low pH also results 
in an increased resistance of E l and decreased resistance of E2 polypeptides 
to proteolytic digestion with trypsin (Katow and Suguira, 1988). These 
changes may mimic the events occurring in the acidic environment within 
endosomes following endocytosis. Resistance of glycoproteins to digestion 
by trypsin in acid conditions has also been shown for SFV (Kielian and 
Helenius, 1984). As a result of the fusion reaction between the viral 
membrane and the endosomal membrane, the nucleocapsid is released into the 
cytoplasm. With SFV the glycoprotein spikes that are integrated into the 
endosome membrane during fusion, and any unfused virus particles, are 
subsequently transported to the lysosomes and degraded (Helenius et al., 
1980). It has been suggested that the low pH induces a solubility shift in the 
RV capsid, from being hydrophilic to hydrophobic, allowing it to associate 
with the endosome membrane, causing intra-endosomal uncoating. Upon 
fusion the RV RNA is released into the cytoplasm (Fig 1.5) (Mauracher et 
al., 1991).
RV 40S genomic RNA is of positive polarity and can therefore function as a 
normal cellular mRNA. After release from the nucleocapsid translation is 
initiated at the AT G at nucleotide 41 (Dominguez et al., 1990). The 
non-structural proteins produced include the molecules necessary for virus 
replication, transcription and protease activity (Wolinsky, 1990). Translation 
of the non-structural region gives rise to the RNA polymerases required for 
the synthesis of the negative-strand templates. The negative strand acts as a 
template for the synthesis of more positive strands. Genomic and
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subgenomic RNAs are synthesised from a genomic length negative polarity 
template with the subgenomic RNA synthesised in a greater molar quantity 
than the genomic RNA (Hemphill et ah, 1988).
Flow of events during the replication of togaviruses (Roizman, 1990)
(+) strand parental 
RNA
I
(-) strand parental 
RNA
(+) strand progeny 
RNA
progeny virus
Non-structural proteins 
-► encoded in the 5'end of 
genomic RNA
( + )mRNA— ►proteins encoded 
in the 3'end of 
genomic RNA
In the alphaviruses there is a conserved region of 19 nucleotides at the 3' 
terminus which serves as a binding site for the initiation complexes (Ou et 
al., 1982). This region is not found in RV but another region has been 
attributed the same function. An inverted repeat sequence of 12 nucleotides, 
capable of forming a stem-loop structure, (fig 1.6a), is located at the 3' end 
of the RNA, 59 nucleotides upstream from the poly(A) tail. Three cytosolic 
proteins show specific high affinity binding to the stem-loop structure 
(Nakhasi et al., 1990). The binding of the host proteins is greatly increased 
after infection and coincides with the appearance of the negative strand RNA. 
The three proteins with of 61, 63,and 68kDa, form a complex which 
assembles on the stem-loop, the main protein responsible for the complex 
being the 61kDa protein.
At the 5' end of the RV genomic RNA, there are sequences that can form a 
potentially stable stem-loop structure. The complementary negative strand
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Fig 1.6a Nucleotide sequence of the RV 3' positive strand RNA 
stem-loop structure (Nakhasi et al., 1990).
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Fig 1.6b Nucleotide sequence of the RV 3' negative strand RNA 
stem-loop structure (Nakhasi et al., 1991).
equivalent of the 5' stem-loop structure of the positive strand RV RNA is 
thought to serve as a promoter for the initiation of positive strand synthesis 
(Nakhasi et al., 1991) (fig 1.6b). The 64 nucleotide long potential stem-loop 
structure has the ability to bind three cytosolic host proteins (M^ of 56, 79 
and 97kDa). The 56kDa protein was found to recognise similar structures to 
the 61kDa protein with the conclusion that the two proteins may be the same, 
therefore the 56kDa appeared to be involved with the initiation of positive 
strand synthesis and negative strand synthesis (Nakhasi et al., 1991). 
Binding interactions with the same proteins have been shown for SIN which 
has similar stable RNA secondary structures (Nakhasi et al., 1991).
The alphaviruses have a 20 nucleotide conserved sequence at the junction of 
the genomic and subgenomic RNA, which is involved in subgenomic RNA 
synthesis (Grakoui et al., 1989). The homologous sequence in the RV 
genome is 20 nucleotides upstream from the subgenomic RNA start site (Frey 
et al., 1989). This RV sequence can form a stem-loop while the comparable 
sequence in the alphavirus can not (Dominguez et al., 1990). The 24S 
positive strands are able to function as mRNA for the synthesis of structural 
proteins.
A schematic diagram representing RV replication with the interactions 
between viral and cellular proteins is shown in fig 1.7.
Macromolecular synthesis
Time course studies of virus specific macromolecular synthesis during RV 
infection of Vero cells showed that there is a longer latent period with RV 
than with the alphaviruses (Hemphill et al., 1988). The alphaviruses have a 
latent period of 2-3 hours with the maximal rate of virus production at 
4-8hours. Maximal synthesis of viral macromolecules occurs 5-10 hours 
post-infection with complete shut-off of cell macromolecular synthesis. Cell
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REPUCATION REQUIRES CELL AND VIRAL PROTEINS
CELL PROTEINS BIND TO 3 ’ HAIRPIN:
VIRAL PROTEINS: REPUCASE C «9»-
HEUCASE
61
63
+  GENOME
Cap
REPUCATES ANTI-SENSE (-) STRAND
1  
J i
+  GENOME
- GENOME
L(a)^
CELL PROTEINS BIND TO 3 ' HAIRPIN OF ANTISENSE (-) GENOME:
l i a  f s e i  PLUS r ï ï v
r m .- GENOME
Fig 1.7 Schematic diagram of RV replication based on the findings of 
Nakhasi et al.^ 1990, 1991) (P.Sanders, PC).
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death occurs 12 to 24 hours post-infection (Kaarianen and Soderlund, 1978). 
Hemphill et ah, (1988) showed that the RV genomic and subgenomic RNA 
species were detectable 12 hours post-infection with the rate of synthesis 
peaking at 26 hours. The virus structural proteins were detectable 
intracellularly 16 hours post-infection. At this time the rate of synthesis was 
maximal and remained constant through 48 hours post-infection By 
immunofluorescence, cells expressing viral proteins were observed 12 hours 
post-infection. The rate of virus production was found to increase rapidly 
until 24 hours post-infection after which time the rate of virus production 
rose more slowly, reaching a peak level at 48 hours post-infection. This peak 
rate of virus production was maintained through 72 hours post-infection. 
Cell death occurred in 20-30% of the cells between 24-48 hours 
post-infection, with most cells surviving for 96 hours post-infection. RV had 
no effect on Vero cell RNA synthesis and only a modest inhibitory effect on 
cell protein synthesis. The effects on cellular synthesis contradicts the 
findings of others (Payment et al., 1975; Chantier and Tingle, 1980) but may 
reflect the different cell lines used.
Processing
Translation of the 24S mRNA results in the synthesis of a llOkDa 
polyprotein precursor for the structural proteins as discussed earlier. 
Processing of the structural proteins of RV through the endoplasmic 
reticulum (ER) and Golgi is discussed in detail in section 1.2.3, 4 and 5 in 
relation to each of the structural proteins.
Budding
Maturation of the RV occurs when the RNA containing nucleocapsid core 
buds from a virus modified cellular membrane, thus acquiring a viral envelope 
consisting of viral glycoproteins and host cell lipids. The budding process 
may occur from intracellular membranes eg the Golgi apparatus, or from the
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plasma membrane of the host cell (Bardeletti et al., 1979). The capacity of 
RV to mature within intracellular vacuoles and thus avoid detection by the 
host immune system may be important in establishing persistent infections in 
humans.
1.2.5 RV capsid protein
The RV capsid protein is 300 amino acids in length, unglycosylated with a 
of 33kDa (Oker-Blom et al., 1983). The nucleotide sequence of the C 
protein gene has a high G/C ratio of 73% (Takkinen et al., 1988). The C 
protein has a blocked amino-terminus (Kalkkinen et al., 1984) as does the C 
protein of SIN and SFV (Boege et al., 1980). When a blocked protein is 
formed by cleavage of a precursor, the blocked product is located at the 
amino-terminus of the precursor polypeptide. The amino acid composition 
analysis shows that the RV C protein is rich in proline and arginine 
(Kalkkinen et al., 1984), as is the C protein of SFV (Garoff et al., 1980), and 
SIN (Rice and Strauss, 1981), forming clusters of prolines and basic amino 
acids. It has been suggested that these clusters are involved in binding 
proteins to nucleic acids via salt bridges from the basic amino acid side 
chains to the phosphate group in nucleic acids (Garoff et al., 1980). The 
composition of the amino-terminus makes it hydrophilic in nature (Frey and 
Marr, 1988) and is putatively the region of the protein which interacts with 
the virion RNA. The proline rich hydrophilic domain of the alphavirus C 
protein has been shown to interact with the virion RNA (Dalgarno et al.,
1983). At the carboxy-terminus of the C protein is a stretch of 23 
hydrophobic amino acids which serves as the E2 signal peptide (Frey and 
Marr, 1988).
The C protein has two inframe AT G codons, seven codons apart. The first 
codon at nucleotide position 77, has the sequence CCCGAATGG and the
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second has the sequence TCACCATGG. the latter sequence is closer to the 
translation initiation consensus CCA/GCCATGG (Kozak, 1984). 
Mutagenesis has shown that both ATGs can function as start codons but the 
first AT G acts as the C protein translational start (Clarke et al., 1988; Frey 
et ah, 1989).
Processing of Capsid protein
Polyprotein processing differs to that in the alphaviruses. The alphavirus C 
protein autoproteolytically cleaves itself from the polyprotein and the signal 
sequence of the following membrane protein (p62) remains part of that 
protein (Melancon and Garoff, 1987). RV C protein retains a hydrophobic 
anchor and remains membrane associated due to the signal peptide of E2 
remaining at the carboxy-terminus of the C protein (Suomalainen et ah,
1990). The association of the RV C protein with membranes was shown to 
be less efficient than that of the RV E2 protein probably due to the structural 
differences between the E2 signal peptide and normal membrane anchors. 
Usually the anchor peptide consists of 20 or more uncharged, mostly 
hydrophobic amino acids, flanked on the cytoplasmic side by charged amino 
acids. The RV E2 signal sequence uncharged region is less hydrophobic than 
is normal for anchor sequences and includes a number of residues (three 
glycines, a proline, and a glutamine) normally excluded from trans-membrane 
domains (Suomalainen et al., 1990). A trans-membrane anchor traverses the 
membrane bilayer and divides the protein into lumenal and cytoplasmic 
domains, but the RV C protein has no lumenal domain, which could effect the 
association between protein and membrane. The membrane association of the 
C protein may provide the basis for a membrane associated assembly pathway 
for the nucleocapsid (Suomalainen et ah, 1990).
A mutation in the cleavage site between the C and E2 proteins results in a 
decrease in the efficiency of processing of the C/E2 precursor polyprotein
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and also prevents the transportation beyond the ER (McDonald et al., 1991). 
Baron et al., (1992) has shown that in COS cells expressing the C protein 
alone, the C protein was only found in association with the ER membrane. In 
cells expressing the entire structural polyprotein or a C/E2 construct, the C 
protein was found with E2 (and E l)  in the Golgi complex. When C and E2 
were co-expressed the C protein remained in the ER membrane, suggesting 
that the concentration of the C protein in the Golgi depends on the 
co-translational insertion of the carboxy-terminus into the membrane when it 
acts as a signal sequence for E2. A construct with the C protein devoid of 
the anchor peptide (C .J ,  when expressed gave dimers, possibly forming large 
aggregates (Baron et a l ,  1992).
Antigenicity of the capsid protein
The C protein is an internal protein not normally exposed to the immune 
system in its native form. Cytotoxic T-cell immunity may therefore be more 
important than humoral immunity (Chaye et al., 1992a; Ou et ah, 1992b). 
The majority of individuals exposed to RV have anti-C antibodies, with a 
relatively large proportion of individuals having proliferative responses (T- 
cell) to C (Chaye et al., 1992a). Anti-C antibodies may be found in the IgG, 
IgM, and IgA classes (Zhang et al., 1992). Detailed analysis of the immune 
response to different regions of the C protein has shown that 10% of the RV 
positive subjects recognised the region C^-C^p using recombinant proteins in a 
lymphocyte proliferation assay (Lovette et al., 1993). In addition, 
lymphoproliferation stimulated by overlapping peptides to this region 
suggested that 70% of the immune population may recognise this domain 
(Lovette et al., 1993). This region, which contains two T-cell motifs
(glycine or a charged amino acid residue in the first position, then two or 
three hydrophobic residues, and either a glycine, a polar, or a charged 
residue in the last position) (Rothbard et al., 1988), may actually contain two 
independent epitopes in C -^C^g and in C^ -^C^ p The epitope within C^ -^C^ p was
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considered to be an immunodominant T- proliferative epitope recognised by 
50% of the test population (McCarthy et al., 1993). However, it was 
observed that the variability in the fine specificity of T-proliferative epitopes 
in the amino-terminal sequence may require the screening of a larger 
population of immune donors to detect consistent peptide specific 
lymphoproliferative response. This could explain the different results by Ou 
et a/., (1992a), who failed to detect responses to this region in the six 
subjects tested. A linear B-cell epitope was mapped to Cj-Cg^ (Ou et ah, 
1992a).
Monoclonal antibodies to the capsid protein
Wolinsky et al., (1991) used a panel of RV monoclonal antibodies (Mab) to 
define binding domains within C. Six of the nine anti-C Mabs bind to 
epitopes that resist dénaturation ie linear determinants. Three of the Mabs 
appeared to have a similar target confined to the region Cg-C^g, with another 
Mab binding to the region Cg^ -Cg^ . The latter Mab has been shown to cross 
react with a 52kDa molecule of rat pancreatic islet tumor cells. This 
molecule also binds antibody from the sera of nonobese diabetic mice that 
have spontaneously developed anti-islet cell antibodies and to a proportion of 
human sera from patients with type 1 diabetes mellitus (Karounos and 
Thomas, 1990). By the age of 10, the likelihood of diabetes among children 
with congenital rubella syndrome (CRS) is four times greater than the general 
population (Cooper, 1975). A portion of patients with diabetes mellitus 
following congenital rubella have been shown to have autoantibodies reactive 
to islet-cell antigens (Schopfer et al., 1982). There may be some similarity in 
shape or amino acid sequence between the C epitope and a site on the 52kDa 
protein which might be important in understanding some of the late 
consequences of CRS through some form of molecular mimicry (Wolinsky et 
a l ,  1991).
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*at position Asn 353, Asn 371, Asn 410 and Asn 429,
3 6  ft.
1.2.6 RV E2 protein
The E2 protein is glycosylated and migrates as two species designated E2a 
(47kDa) and E2b (42kDa) (Oker-Blom el al., 1983). The two forms were 
found to have the same amino-terminal and carboxy-terminal sequences, 
indicating translation from one gene (Kalkkinen et al., 1984; Oker-Blom et 
al., 1984). The E2 protein is 282 amino acids in length (Frey and Marr,
1988) with a G/C ratio of 71.4% (Vidgren et al., 1987). At the 
carboxy-terminus of E2 there are three hydrophobic regions 20,18 and 19 
amino acids in length (Frey and Marr, 1988). The proximal carboxy-terminal 
sequence (20 amino acids) is the signal peptide of E l (Frey et ah, 1986). 
The middle 18 amino acid sequence is the most hydrophobic of the three and 
is followed by a heptapeptide, five of whose members are arginine. This 
sequence has the features of a membrane spanning domain with a hydrophilic 
sequence on the cytoplasmic side. The role of the distal 19 amino acid 
hydrophobic region is unclear. The signal sequence for E2 is located at the 
carboxy-terminus of the C protein and remains attached to the C protein after 
cleavage (Suomalainen et ah, 1990), (section 1.2.5).
Sequence data
Comparison of the E2 nucleotide sequence of the different strains of RV 
indicate more than 90% homology (Al-Mumin, 1991). The predicted amino 
acid sequence of the strains differs at amino acids 411-413 of the structural 
protein sequence (Dominguez et al., 1990)(Appendix 1) which results in the 
presence or absence of a glycosylation site thus altering the total number of 
potential sites for a particular RV strain. There are therefore four 
glycosylation sites in E2 of RV strain Thomas (Al-Mumin, 1991), Therien 
(Frey et al., 1988), RA27/3 (Nakhasi et al., 1989), M33 (Zheng et al., 1989), 
"^but only three glycosylation sites in E2 of RV strain M33 (Clarke et ah,
1987) and HPV77 (Zheng et al., 1989). There is a discrepancy in the 
published M33 sequence by Clarke et al., (1987) which has now been
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corrected (T.Frey, PC).
Glycosylation
An outline of the process of glycosylation is shown in fig 1.8. Glycosylation 
involves the transfer of an oligosaccharide, a total of 14 sugar residues 
composed of N-acetylglucosamine, mannose and glucose, en bloc to the side 
chain of an asparagine residue of the protein in the ER. This process begins 
on the cytoplasmic side of the ER and once the initial complex is assembled it 
is transported across the ER membrane and continues in the ER lumen. 
N-linked glycosylation occurs at the sequence Asn-X-Ser or Asn-X-Thr, 
where X is any amino acid except proline. While still in the ER, trimming or 
processing of the oligosaccharide occurs resulting in the loss of three glucose 
residues and one mannose residue. This processing continues in the Golgi 
apparatus leading to the formation of either complex oligosaccharides or high 
mannose oligosaccharides. The high mannose oligosaccharides have no new 
sugars added to them in the Golgi. After further trimming the complex 
oligosaccharides can gain more than the original two N-acetylglucosamines as 
well as a number of galactose and sialic acid residues. Each complex 
oligosaccharide consists of a core region plus a terminal region. All terminal 
sugars are added in the trans Golgi. During the latter stages of processing 
the bonds between the two N-acetylglucosamine residues in the core become 
resistant to attack by endoglycosidase (Endo H). The addition of the 
oligosaccharide to the polypeptide chain results in an increase in the 
molecular weight of the protein Alberts et al., 1989.
0-linked glycosylation involves the transfer of sugars, one monosaccharide at 
a time, usually N-acetylgalactosamine or galactose, to selected serine and 
threonine side chains on the lumen side of ER membranes or while on 
transport to the Golgi. Additional capping sugars, including the same 
spectrum used in N-linked glycosylation are added in the Golgi to complete
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In the Golgi stack, mannosidase I 
removes three more mannose residues 
and N-acetylglucosamine transferase 1 
adds a residue of GlcNAc, which 
enables mannosidase II to I'emove two 
additional mannose residues. This 
yields the final core of three mannose 
residues that is present in a "complex" 
type of oligosaccharide. At this stage the 
bond between the two GlcNAc residues 
in the core becomes resistant to attack 
by a highly specific endoglycosidase 
(Endo HI. Since all later stmctures in 
the pathway are also Endo H-resistant, 
treatment with this enzyme is widely 
used to distinguish complex from high- 
mannose oligosaccharides. Finally, 
additional GlcNAc, galactose, and sialic 
acid residues are added. The extent 
of processing depends on the protein 
and on the location of the asparagine 
residue within the protein to which 
the oligosaccharide is attached. Some 
oligosaccharides will escape processing 
in the Golgi apparatus, whereas others 
will follow the pathway shown to 
vaiying extents.
Fig  1.8 Chemical  p rocesses  involved  in g lycosy la t ion  (Alber ts  et al.,
1989).
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However, it has been shown that the presence of alpha 1,6-fucose can 
prevent digestion by endo H in insect cells (N.Jenkins, PC).
* However, it has been shown that the presence of alpha 1,6-fucose can 
prevent digestion by endo H in insect cells (N.Jenkins, PC).
the carbohydrate group.
Glycosylation of E2 proteins
The difference in the migration of E2a and E2b is thought to be due to 
differential glycosylation (Oker-Blom et al., 1983; Kalkkinen et al., 1984). 
Studies on the type of glycosylation in E2 has produced varying results due 
to the utilisation of different RV strains and expression systems. E2b 
appears to be glycosylated with Endo H sensitive high mannose 
oligosaccharides (Sanchez and Frey, 1991; Hobman et al., 1990; Bowden and 
Westaway, 1985)^ E2a appears to be glycosylated with Endo H resistant 
complex oligosaccharides and 0-linked glycans (Sanchez and Frey, 1991; 
Lundstrom et al., 1992).
Expression of M33 RV E2 glycosylation mutants in COS cells has given an 
insight into the function of the carbohydrates (Qui et al., 1992). All three 
potential glycosylation sites were N-linked and were processed in the Golgi 
gaining Endo H resistance. Inactivation of the glycosylation sites impaired 
the processing as well as the intracellular stability of the E2 proteins, the 
severity of the defect depending on the number and position of the
glycosylation site deleted. Deletion of one site considerably reduced the rate
of transport. The site proximal to the N-terminus (G l) seems to be less
important than the site proximal to the C-terminus (G3). G2 and G3 are
flanked by cysteine residues therefore it is possible that the oligosaccharides 
attached to the G2 and G3 sites are important in preventing improper 
intramolecular disulphide bond formation and protein misfolding, whereas 
glycosylation at the Gl site has less effect on proper folding and transport 
(Qui et al., 1992). In rhabdoviruses (eg vesicular stomatitis virus) 
glycosylation has been shown to influence the conformation of the protein by 
promoting correct disulphide bond formation (Grigera et al., 1991). The 
presence of 0-linked glycans on RV E2 may impart a conformation to this
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protein that is important for its incorporation into the virion in the 
maturation process (Sanchez and Frey, 1991). It is also possible that the 
glycoproteins of virions which have budded intracellularly are less processed 
than those that bud at the cytoplasmic membrane (Sanchez and Frey, 1991).
Processing of E2
The signal peptide preceding E2 mediates translocation in to the ER. The E2 
trans-membrane anchor locates the polypeptide in the ER membrane. 
Cleavage between the C protein and E2, and E l and E2 occurs in the ER by 
the action of a signal peptidase (Oker-Blom et al., 1990). The E2 signal 
peptide remains attached to the C protein (Suomalainen et al., 1990), with 
E2 retaining the E l signal peptide (Frey and Marr, 1988). E2 is transported 
to the Golgi as a heterodimer with E l (Baron and Forsell, 1991), as is p62 
and E l  of SFV. Transportation of E2 to the Golgi can occur without E l but 
the process is less efficient (Baron et al., 1992; Hobman et al., 1990) and 
less E2 is detected at the cell surface (Baron et ah, 1992; Hobman et ah, 
1993). A similar arrangement is found with other viruses, the interactions 
between the G1 and G2 proteins of Bunyaviruses, eg Uukuniemi and Punta 
Toro virus are necessary for G2 to be maintained in the Golgi (Hobman, 
1993). Analysis of the type and degree of glycosylation of E2 ie Endo H 
resistant and partially sialylated, indicates that E2 is predominately localised 
in the medialAm « 5  region of the Golgi in CHO cells (Hobman et al., 1993). 
The retention of E2 within the Golgi is thought to be due to a retention 
signal sequence located in the carboxy-terminal trans-membrane region 
(Hobman et al., submitted).
Antigenicity of E2 protein
Following RV infection antibodies to E2 are relatively more abundant in 
congenital rubella syndrome (CRS) than in other forms of RV infection 
(Katow and Suguira, 1985). In a lymphocyte proliferation experiment, the
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response to E2 was mainly observed for individuals with CRS. The E2 
response for the group of RV positive subjects with no rubella associated 
symptoms was weaker than the response to E l or C (Chaye et al., 1992a). 
The elevated level of anti-E2 IgG in CRS patients (Chaye et al., 1992a) may 
be a consequence of persistent RV infection (Katow and Suguira, 1985). 
Anti-E2 antibodies have been found in the IgG, IgM and IgA classes (Zhang 
et al., 1992). However, no IgA anti-E2 antibodies were detected in sera 
from men and the male sera also had significantly lower levels of IgG anti-E2 
antibodies (Mitchell et ah, 1992a), suggesting hormonal influences on the 
immune response to RV proteins.
A weak neutralising domain has been identified using a Mab specific for the 
E2 protein (Green and Dorset, 1986). In addition, Wolinsky et al., (1991) 
using a panel of six Mabs to E2 defined a B-cell antibody binding domain to 
the region E 2 j-E 2 „ 5 . More detailed analysis of this region using synthetic 
peptides and a lymphocyte proliferation assay located a T-cell binding domain 
to the region E2g -^E2^og (McCarthy et ah, 1993). It has been predicted that 
this region contains three T-cell motifs.
1.2.7 RV E l  protein
The E l glycoprotein is 481 amino acids in length (Frey et al., 1986), with a 
molecular weight of 58kDa (Oker-Blom et al., 1983) and a G/C ratio of 
66.4% (Vidgren et al., 1987). Preceding the E l sequence is a hydrophobic 
stretch of 20 amino acids which serves as the E l signal peptide for 
translocation into the ER (Frey et al., 1986). The E l signal peptide remains 
associated with E2 after cleavage by the signal peptidase (Frey and Marr,
1988). At the C-terminus of E l there is a stretch of 22 amino acids which 
serves as a trans-membrane anchor (Frey et al., 1986). Sequence analysis 
shows no homology between the RV E l and the alphaviruses (Dominguez et
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ah, 1990). However, there is over 95% homology in the E l  sequence 
between the different RV strains (Frey and Abernathy, 1993; Al-Mumin,
1991). Frey and Abernathy, (1993) have constructed a phylogenetic tree of 
the RV strains based on the E l sequence including data generated from this 
study on the Thomas strain (fig 1.9).
Glycosylation of E l
All the sequenced strains of RV E l have three N-linked glycosylation sites 
(section 1.2.4) at position Asn 77, Asn 177 and Asn 209 (Frey et ah, 1986; 
Clarke et ah, 1987; Vidgren et al., 1987; Nakhasi et al., 1989; Zheng et al.,
1989). The unglycosylated E l has a molecular weight of 53kDa (Oker-Blom 
et al., 1983). The glycans involved in E l glycosylation are the high mannose 
type and sensitive to Endo H digestion (Sanchez and Frey, 1991).
Glycosylation mutants of E l have been expressed in vaccinia (Qui et ah,
1992) and COS cells (Hobman et ah, 1991). The COS cell expression studies 
concluded that with mutants lacking any one glycosylation site there was no 
reduction in antibody binding with anti-RV human sera but double or triple 
mutants were not detected under non-reducing conditions. This was also the 
result with the three Mabs that they tested, concluding that aberrant folding 
of the mutant proteins masks the relevant epitopes. Glycosylation may be 
required for the folding of E l such that the haemagglutinating and 
neutralising epitopes are exposed (Hobman et al., 1992). Using vaccinia. Qui 
et ah, (1992) came to the same conclusions, as under reducing conditions all 
five glycosylation mutants reacted with the six Mabs tested, but under 
non-reducing conditions the double and triple mutants showed no reactivity. 
Reaction with the glycosylation mutants indicated that the Mabs reacted with 
carbohydrate independent epitopes. Removal of the carbohydrates after 
folding has less effect than blocking glycosylation during protein synthesis 
(Qui et al., 1992). Using the mutants as immunogens in mice indicated that
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the carbohydrates attached at the amino-terminal, G1 (glycosylation 1) site, 
are important in eliciting haemagglutination inhibition (HAI) antibody 
production. Viral neutralisation (VN) activity was observed in sera from 
mice immunised with the single site mutants but not in the double or triple 
mutants, further substantiating the important role of glycosylation on the 
correct folding of RV E l protein (Qui et al., 1992).
Processing of E l
The E l polypeptide is translocated into the ER via the signal peptide and 
secured in the membrane by the trans-membrane anchor. I f  the E l  protein is 
expressed alone, processing is arrested in a novel post-ER, pre-Golgi 
compartment (Hobman et ah, 1992; Baron et al., 1992) where the protein is 
unstable with a half-life of six hours (Hobman et al., 1992). Also, when 
expressed alone RV E l was not detected at the cell surface (Baron et ah,
1992). When E l and E2 are expressed together they form a heterodimer, this 
oligomerisation appears to be necessary to prevent later aggregation of E l 
and for efficient transport of E2 and E l from the ER to the Golgi (Baron and 
Forsell, 1991). E l was found to fold much slower than E2, suggesting that 
the delay in transport of the heterodimer to the Golgi may be due to the slow 
maturation of E l in the ER (Hobman et ah, 1993).
Antigenicity of the E l  protein
The E l  glycoprotein is the most antigenic of the three structural proteins in 
eliciting both cellular and humoral responses (Chaye et al., 1992a). In most 
sera, antibodies to E l were the predominant species following RV infections, 
the noticeable exception being in CRS sera in which the predominant 
antibody species was to E2 (Katow and Suguira, 1985). The higher levels of 
immune response to E l compared to E2 may be a result of antigenic 
competition between the glycoproteins of E l and E2 (Chaye et al., 1992a). 
In influenza virus infection this competition is affected by the relative
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amounts of competing immunogens resulting in an immune response that is 
predominantly directed against haemagglutinin (HA) (Johansson et ah, 1987). 
The higher levels of immune response to E l in RV infection may be due to 
accessibility of the protein to the hosts immune system. Anti-El antibodies 
may be found in the IgM, IgG and IgA classes at varying levels throughout 
the course of a RV infection (Zhang et al., 1992). Male sera showed an 
earlier onset of RV E l specific IgG and IgM antibodies than female sera 
(Mitchell et ah, 1992a). As with the differences in levels of anti-E2 
antibodies, this could be due to the influence of hormone levels.
Six spacially separate antibody binding sites were identified in the RV E l by 
the use of a panel of Mabs (Waxham and Wolinsky, 1985). Of the six Mabs, 
four inhibit haemagglutination (HAI), two cause viral neutralisation (VN), 
one has HAI and VN activity and one exhibits neither activity. Other 
workers have also identified HA and VN antigenic sites by analysis of Mabs 
directed to the E l glycoprotein (Green and Dorset, 1986; Ho-Terry and 
Cohen, 1985; Umino et ah, 1985). Three epitopes which react with HA and 
VN antibodies have been located between amino acids El^^^-El^gg (Terry et 
ah, 1988). In addition a HA epitope has been located at El^^^-El^^o and two 
VN epitopes at El^^^-El^gg and E I 2 1 9 -E I 2 3 3  (Chaye et ah, 1992b). Wolinsky et 
ah, (1991) also localised a VN epitope and a HA plus VN epitope to 
E l  2 0 2 -El 2 8 3 - These B-cell epitopes are discussed further in chapters three and 
seven . T-cell studies on the region E l 2 0 2 -El 2 5 3  (Wolinsky et ah, 1991) 
revealed that 15% of the RV immune subjects tested recognised a fusion 
protein containing this sequence and that 50% of the RV immune subjects 
recognised synthetic peptides representing this sequence (Lovett et ah,
1993). This sequence contains seven predicted T-cell motifs (Lovett et ah, 
1993; McCarthy et ah, 1993).
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1.3 THE DISEASE
Rubella was first described by two German physicians in the mid-eighteenth 
century and called "Rotheln". This was later changed to the more common 
name "German measles". For many years German measles was confused with 
measles and scarlet fever, each with a similar rash. The term "rubella" was 
first used in 1866 by an English physician. Dr Veale, when describing an 
outbreak of Rotheln in a boys' school in India. It was recognised as a 
distinct disease by the International Congress of Medicine in London in 1881. 
Because of the mild nature of the disease, rubella received little attention 
until it was associated with congenital defects in 1941 (Gregg, 1941). 
Gregg, an Australian ophthalmologist, observed that 78 babies with a similar 
type of congenital cataract, some with heart disease, were born after an 
extensive rubella epidemic in 1940. Later there were indications that rubella 
infections could result in miscarriages and stillbirths (Swan et al., 1948). 
Although predominantly a childhood disease it was the incidence of maternal 
rubella which provoked the most interest with many studies in the 1950's and 
early 60's due to the teratogenic effects of the virus (Banatvala and Best,
1984). RV was first isolated in 1962 by two groups (Parkman et al., 1962; 
Weller and Neva, 1962). Laboratory tests to detect antibodies to RV 
followed, with the introduction of an attenuated vaccine in the USA in 1969.
1.3.1 Postnatally acquired infection 
1.3.1.1Epidemiology
Rubella is endemic throughout the world, with outbreaks in the spring and 
summer in temperate climates. Infection is uncommon in pre-school children, 
with outbreaks tending to occur amongst school children and young 
institutionalised adults, eg colleges and the army. In the prevaccine era, 
epidemics of rubella occurred in the USA every 6-9 years (Herrmann, 1991), 
and in the UK every 3-5 years (Miller, 1991). In the UK extensive
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outbreaks of rubella occurred in 1978-79 and 1982-83, with 1800 cases 
reported in Manchester in 1978 and 1000 cases reported in Newcastle in 
1979 (Best et al., 1990), indicating localisation of the epidemic. The last 
major epidemic in the USA in 1964/65 resulted in 12,500,000 cases of rubella 
and 20,000 children with rubella associated birth defects (Cooper, 1975). 
Introduction of vaccines in the late 1960's reduced the incidence of rubella in 
these countries but not all countries have a vaccination programme, this is 
discussed further in section 1.5.
Surveillance of the incidence of rubella and CRS has improved over the years 
but in 1990 rubella was a notifiable disease in only 24 of 32 (75%) countries 
in the World Health Organisation European region, France and Germany are 
in the eight who do not report the disease. CRS is reported by only 13 
(41%) countries (Galazka, 1991). Due to the lack of data on the incidence of 
rubella and CRS some countries have not considered the disease to be a 
problem but sero-epidemiological studies reveal that many of these countries 
do have a high incidence of rubella eg China (Wannian, 1985), India 
(Bhaskaram et al., 1991) and Brazil (Schatzmayr, 1985). Studies of some 
tropical African countries eg Angola, Ghana, Nigeria, Ethiopia, Uganda, The 
Gambia, Upper Volta and Togo, indicate that rubella is widespread and 
endemic on the African continent (reviewed by Mingle, 1985). In The 
Gambia 93% of the female population have rubella antibodies but in most of 
the other countries studied 15-30% of women of child bearing age are 
sero-negative. Early studies indicated that island and migrant populations 
showed an increased risk of rubella in child bearing age groups, due to the 
lower sero-positivity resulting from less chance of exposure to rubella in 
childhood (Rawls et ah, 1967). Epidemics in Singapore in the 1970's were 
due to soldiers from overseas mixing with a susceptible population 
(Doraisingham et ah, 1981).
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Since the introduction of vaccines there has been a decline in the incidence of 
rubella in the UK and USA but the last few years has seen a resurgence of 
rubella. In 1988, in the USA, an all time low of 225 cases of rubella were 
reported, but 1,125 cases were recorded in 1990, 50% of which were in 
California (Lindegren et al., 1991), fig 1.10. Outbreaks were reported from 
ten prisons, four religious groups, four colleges and in workplace, community 
and recreational settings. For 30 states the race specific incidence was 
higher for Hispanics. In 1991 there were outbreaks amongst the Amish 
communities in six states (Center for disease control, 1992). In the UK the 
resurgence has been over the last year, with 2 0 1  laboratory confirmed cases 
for 1992 and 1547 for the first 49 weeks of 1993, with 9493 notifications 
(Communicable disease report, 31st December 1993).
1.3.1.2 Clinical features of primary rubella infection
Clinically apparent rubella is characterised by a combination of symptoms 
that include a maculopapular rash, lymphadenopathy, low grade fever, 
conjunctivitis, sore throat and arthralgia (Young and Ramsey, 1963). The 
rash appears first on the face and spreads rapidly to the trunk and then to the 
limbs (fig 1.11). RV can be isolated from the skin from areas with and 
without rash (Heggie, 1978). The rash clears after two to three days.
RV is spread principally by aerosolation with the mucosa of the upper 
respiratory tract and the nasopharyngeal lymphoid tissue being the sites of 
initial viral infection replication. The virus spreads via the lymphatic system 
and replication occurs in the suboccipital, postauricular and cervical lymph 
nodes, 5-10 days before the onset of the rash (Green et al., 1965). An 
incubation period of 7-9 days is followed by the appearance of rubella virus 
in serum and the onset of shedding of virus into the nasopharynx and stool 
(Heggie, 1969). Virus that is shed can spread to susceptible individuals in
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Fi g 1.10 Incidence of rubella, as reported to the National Notifiable 
Disease Surveillance System, and confirmed and compatible 
indigenous CRS cases, as reported by year of birth to the 
National CRS Registry, USA, 1966-1990. The vaccine was 
licensed in 1969 (Lindegren et al., 1991).
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Fig  l . I l Y oung  child with rubella type rash,  by permission  o f  D A L E  
NEVVCOMBE.
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aerosols. This viraemic phase results in prodromal symptoms of malaise. 
The rash appears 13-21 days after initial exposure.
A common complaint of rubella infection involves the joints. This condition 
may range in severity from a transient stiffness of the joints to an arthritis 
with pain, swelling and limitation of movement affecting the fingers, wrists, 
knees and ankles (Chantier et al., 1982). Symptoms usually begin within a 
week of the appearance of the rash and may persist upto a month, however, 
on rare occasions symptoms may recur over several years (Chantier et al., 
1981).
The most serious complication of natural rubella is postinfectious 
encephalopathy or encephalomyelitis which occurs in one of 6000 cases of 
natural rubella (Waxman and Wolinsky, 1984). Symptoms which include 
headache, vomiting, stiffneck, lethargy and generalised convulsions, appear 
1-6 days following the onset of the rash. RV appears to have the capacity to 
enter the central nervous system (CNS) and has been isolated from 
cerebrospinal fluid (CSF) (Squadrini et al., 1977). It is the ability of RV to 
enter the CNS which has prompted studies on the possibility that RV 
infections may act as a trigger for multiple sclerosis (MS). MS is a chronic 
demyelinating disease of the CNS and is immune mediated. It has been 
postulated that a virus may be involved in the aetiology of MS with the viral 
disease triggering MS years before any MS symptoms are seen (Waksman and 
Reingold, 1986). Candidate viruses have included Herpes simplex, 
parainfluenza virus I, corona virus, measles and Epstein-Barr virus, but 
epidemiological evidence points to a common childhood and/or upper 
respiratory virus as the agent (Waksman and Reingold, 1986). RV has been 
cultured in rat neural cell cultures (Atkins et al., 1991) and SFV has been 
shown to cause demyelination in a mouse model (Smyth et al., 1990). Atkins 
et al., (1991,) obtained evidence to suggest that RV could trigger
41
autoimmune demyelination by the generation of myelin debris, or by 
molecular mimicry as there is sequence similarity between the amino-terminal 
of myelin proteolipid protein and rubella E l protein (Atkins et al., 1990) .
GLLaCCAkCL Rubella E l glycoprotein
 ^ GLLECCARCLVGAPFA Myelin proteolipid protein
The appearance of the rubella rash coincides with the detection of 
rubella-specific antibodies suggesting that the rash may reflect an immune 
complex mediated phenomenon (Heggie et al., 1969). Rubella-specific serum 
IgG, IgM and IgA develop rapidly after the onset of the rash. 
Rubella-specific IgM usually appears within 4 days of the onset of the rash 
and persists for 6-12 weeks, in comparison rubella-specific IgG normally 
persists for life. Specific IgD and IgE responses develop rapidly after onset 
of infection and persist for 6  months (Salonen et al., 1985). Using IgG 
subclass-specific antibodies, the predominant subclass found was IgGl, and 
was detectable in all sera tested, IgG3 was detectable in 80% of sera from 
patients with acute and recent rubella (Enders et al., 1989). The IgG 
subclass-specific antibody avidity assay as well as the total IgG avidity assay 
can be used as an indication of reinfection (discussed in the section 1.3.1.3), 
(Enders et al., 1989; Thomas and Morgan-Capner, 1988).
1.3.1.3 Reinfection
Natural infection normally results in a very high order of protection from 
reinfection. Evidence of reinfection is usually obtained serologically by 
demonstrating a significant rise in the pre-existing IgG antibody titre. It may 
also be possible to distinguish reinfection from primary infection by 
examining the antigen-binding avidity of specific IgG. Antibody avidity 
increases with time due to the maturation of the immune response. This
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maturation is due to changes in the cell population producing the antibody. 
In the initial stages of an infection low avidity antibody-receptor B cells are 
likely to be stimulated, resulting in a specific antibody response with 
antibodies having a wide range of avidity. As time progresses the antigen 
level will fall and the remaining antigen will stimulate the high avidity, highly 
specific antibody receptor B-cell preferentially, leading to the production of 
more high avidity antibody-producing clones. This results in an increase in 
the number of high avidity specific antibodies over a period of time after the 
antigenic challenge. Hence, primary infection exhibits IgG antibodies of 
lower avidity than the IgG antibodies produced during reinfection (Rousseau 
and Hedeman, 1988; Thomas and Morgan-Capner, 1991; Enders et al.,
1989). Burgess (1992) found specific IgG3 present in all cases of primary 
infection but only in some cases of reinfection.
Reinfection is generally asymptomatic but may be accompanied by a rash, 
arthralgia and foetal infection. These events are rare and only a few cases of 
intrauterine infection have been reported (Morgan-Capner et ah, 1985; Best 
and O'Shea, 1989).
1.3.2 Congenitally acquired infection
1.3.2.1 Pathogenesis
Following maternal infection RV is able to cross the placenta and induce 
foetal damage. The virus enters the foetus via the chorion (Tondury and 
Smith, 1966), with necrotic changes to the epithelial cells as well as of the 
endothelial lining of the blood vessels, as early as the tenth day after the 
maternal rash. Damaged endothelial cells may then be desquamated into the 
lumen of the vessels and transported into the foetal circulation to infect the 
foetal organs. Viral replication causes damage to the foetal endothelial cells.
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In addition to virus induced tissue necrosis, RV induces a retardation in cell 
division, this being due to a rubella specific protein which reduces the rate of 
mitosis in infected cells. If  this occurs during the critical phase of 
organogenesis, the organ will contain fewer cells than those of uninfected 
infants and multiple developmental defects are likely to occur.
The degree of damage depends in which gestational period the infection was 
transmitted to the foetus, the earlier the infection the higher the chance of 
foetal damage (fig 1.12). Very early infection of the conceptus can result in 
resorption of the embryo. If  maternal rubella is acquired during the first 12 
weeks of pregnancy the risk of CRS is 80%, at 13-14 weeks 54% and at the 
end the second trimester, 25% (Miller et ah, 1982). Congenitally acquired 
rubella effects the major organs eg ears, eyes, heart, liver, brain, spleen, and 
also bones. If  maternal infection occurs after the first trimester deafness may 
be the only symptom and may be the commonest cause of congenital deafness 
in most developed countries (Best and Banatvala, 1990; Dereymaker et al., 
1991).
Most of the clinical manifestations of CRS are evident at birth, or shortly 
after, but some conditions are not apparent for many years. These delayed 
symptoms can involve endocrine organ dysfunction. Diabetis mellitus occurs 
in 2 0 % of young adults with CRS (Cooper, 1975). Another delayed 
condition is "progressive rubella panencephalitis", with symptoms of neural 
deterioration, which includes behavioural changes, intellectual decline, 
spasticity and seizures, and death often occurs within eight years (Wolinsky, 
1990).
The incidence of CRS has declined since the introduction of rubella vaccine 
but recent trends are indicating a resurgence of rubella infection and with it a 
resurgence of CRS. The 1990 figures for the USA showed an incidence rate
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Fig 1 . 1 2  Clinical manifestations of congenital rubella and time of
maternal infection, extrapolated from Cooper et al., 1969 (Best 
c/r//., 1990).
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of CRS of 0.3 per 1 0 0 , 0 0 0  live births (Center for disease control, 1991), fig. 
1.10, compared to <0.1 per 100,000 live births for 1989. In the UK there 
have been only 19 CRS infants born between 1990 and 1992 (Miller et ah, 
1993) but the increase in rubella cases for 1993 may give a higher figure for 
CRS cases in 1994. Of the 94 CRS infants born since 1987, 24% were born 
to Asian or Oriental women (Miller et ah, 1993).
1.3.2.2 Viral persistence in CRS subjects
Following intrauterine infection RV persists throughout gestation and can be 
isolated from most organs obtained at autopsy, or recovered from 
nasopharyngeal secretions, urine, stools, CSF and tears. RV has been 
recovered from a cataract of a three year old and the brain from a twelve year 
old (Best and Banatvala, 1990). The mechanism by which RV escapes 
immune elimination and establishes a persistent infection is unknown. Those 
with a persistent infection have impaired cell mediated immunity (CMI) 
(Buimovici-Klein et ah, 1979), but do produce detectable serum RV specific 
IgM, IgA and IgG. Laboratory studies have shown that RV persistence can 
be maintained in Vero cells for 45 weeks in the presence of anti-RV antibody 
of sufficient titre to completely neutralise the virus in culture fluid 
(Abernathy et ah, 1990).
1.3.2.3 Diagnosis of congenital rubella
The diagnosis of CRS may be made by the direct isolation of RV, detection 
of IgM in the cord blood or neonatal serum, or persistence of RV specific 
IgG in the infants serum beyond that expected from the passive transfer of 
maternal IgG. The serological profile of infants with congenitally acquired 
rubella is shown in fig 1.13 (Herrman, 1979).
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Fig 1.13 Immune responses of congenitally acquired rubella (Herrmann, 
1979).
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Conventional methods used to detect anti-RV antibodies (section 1.4) can 
give conflicting results when used for CRS patients. In the study by Hancock 
et ah, (1986), it was shown that sera from patients with CRS had elevated 
ELISA titres to whole RV antigens, compared to HAI titres. CRS patients 
have been shown to exhibit high levels of anti-E2 antibodies compared to 
anti-El antibodies (Katow and Suguira, 1985), ie high levels of non- 
haemagglutinating antibodies. This decreased ability of CRS patients to 
develop or sustain antibody responses to haemagglutinin may be due to 
intrauterine exposure to RV inducing a state of partial immunologic tolerance 
(Hancock et ah, 1986).
The foetus may not produce detectable levels of IgM until 22/23 weeks 
gestation. Early diagnosis of foetal infection may therefore be achieved by 
the detection of virus in chorionic villus biopsies and amniotic fluid using 
nucleic acid hybridisation to a rubella cDNA probe (Ho-Terry et al., 1988). 
Increased sensitivity has been achieved by amplification of virus RNA in the 
foetal tissue by using the polymerase chain reaction (PCR) (Ho-Terry et ah,
1990).
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1.4 LABORATORY DIAGNOSIS
1.4.1 Rubella virus isolation
In naturally acquired rubella, the virus can be isolated from swabs of the 
pharynx, or nasopharyngeal secretions, for six days before and after the 
appearance of the rash. In congenital rubella, virus can be isolated from 
nasopharyngeal secretions, stools and urine during the neonatal period. Later 
the throat and CSF become the best sources for virus isolation as the infant 
sheds less (Phillips et al., 1965). To detect RV susceptible cells (RK 13, 
Vero, SIRC) are inoculated with the specimen followed by culturing to detect 
the presence of a CPE, or more commonly used for immunofluorescence 
(Best and Banatvala, 1990). Figure 1.14 shows immunofluorescence of RV 
infected Vero cells with the characteristic cytoplasmic and perinuclear 
staining. Desquamated cells in throat swabs can be used for direct 
immunofluorescence for RV detection (Haire and Hadden, 1972).
1.4.2 Detection of viral antigens and nucleic acid
Virus isolation can take several weeks which is too long for diagnosis of 
congenital infection. RV antigens can be detected by flow cytometry which 
uses RV specific Mabs to detect viral antigens on the cell surface of 
leucocytes (O'Shea et al., 1988a). RV RNA and antigens in cultured cells 
can also be detected using in situ hybridisation and immunofluorescence 
(Filipenko et ah, 1988). Detection of RV RNA and antigens for the 
identification of foetal infection has been mentioned in section 1.3.2.3.
1.4.3 Serological techniques
Serology is used to determine the presence of both postnatally and 
congenitally acquired infection. Many of the standard serological tests are 
available as commercial kits or use commercial reagents. Differing amounts
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Fig 1.14 RV infected Vero cells detected by immunofluorescence using 
anti-rubella polyclonal sera and anti-human IgG FITC 
conjugate.
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of time are needed to set up the tests and each test has a different detection 
time and degree of sensitivity. Some tests are designed to detect IgG and 
others IgM. Routine serological tests used for the detection of rubella 
antibodies includes single radial haemolysis (SRH), haemagglutination 
inhibition (HAI), enzyme and radioimmune assay (EIA, RIA), latex 
agglutination (LA), immunofluorescence, neutralisation (not used for 
diagnostic purposes today). Rubella specific IgM can be detected by 
M-antibody capture RIA (MACRIA), and M-antibody capture EIA 
(MACEIA).
Most of the kit based assays mentioned above require the presence of RV 
antigen, which is normally rubella haemagglutinin prepared from BHK-21 
infected cells. The virus can be grown to a higher titre using roller bottles or 
suspension culture of BHK-21 cells. The haemagglutinin is extracted from 
the virus by treatment with ether and Tween 80 (Best et al., 1990). The main 
problems is the low yield of haemagglutinin and the batch variation in the 
haemagglutinin titre.
Due to the large number of samples that may be screened by the larger 
hospitals, commercial automated systems based on immunoassays are 
available for the detection of anti-rubella IgG and IgM. One such system 
uses RV bound to microparticles in an enzyme immunoassay (MEIA) (Abbot 
et ah, 1990).
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1.5 PREVENTION OF RUBELLA
1.5.1 Development of an attenuated vaccine
The first attenuated strain of RV was produced by passaging RV M3 3, 
isolated in 1961 from a US army recruit, 77 times in vervet monkey kidney 
cells to give the prototype vaccine HPV77 (Parkman et al., 1966). This 
attenuation has resulted in the loss of a putative glycosylation site in the E2 
structural protein (Zheng et ah, 1989). HPV77 also shows altered binding to 
cells with a delay in the synthesis of viral RNA and viral proteins (Nakhasi et 
al., 1989b), HPV77 was further attenuated by five passages in duck embryo 
fibroblasts (HPV77.DE5) (Hilleman et al., 1969). This strain was licensed in 
the USA and many European countries in 1969-1970. HPV77.DK12 (twelve 
passages in dog kidney) was licensed in 1969 but discontinued due to adverse 
reactions.
The Cendehill 51 strain was licensed in the USA in 1969 and in the UK in 
1970. This virus was isolated from a case of postnatally acquired rubella in 
1963 and passaged 51 times in primary rabbit kidney cells.
The most widely used vaccine today is the RA27/3 strain (rubella abortus, 
27th specimen, 3rd explant) isolated from a kidney of a rubella infected 
foetus and attenuated in WI-38 fibroblasts (Plotkin and Vaheri, 1965). 
RA27/3 was licensed in the UK in 1972, and is also a component of the 
measles, mumps and rubella (MMR) trivalent vaccine, licensed in the UK in 
1988.
The Japanese have five other licensed strains, Takahashi, Matsuura, Matsuba, 
TCRB19, with the most frequently used strain being To-336, which is used in 
the Japanese MMR vaccine.
52
1.5.2 Immune response following vaccination
An immune response is induced by rubella vaccines in 95% of susceptible 
vaccinees (Regamey et al., 1969), with antibodies developing against all 
three of the structural proteins (Cusi et al., 1989). The most persistent of 
these antibodies are to E l. HAI antibodies are usually 4-8 fold lower in titre 
in vaccinees than following natural infection (Best, 1991).
Specific IgG antibodies are detected 10-21 days after vaccination and reach 
maximum levels at about six months after vaccination. IgM can be detected 
in most vaccinees between three and eight weeks after immunisation with low 
levels of antibody persisting up to four years (Burke et al., 1985). 
Rubella-specific IgA can be detected in both sera and nasopharyngeal 
secretions. The level of IgA declines more rapidly than IgG, but has been 
detected twelve years post-vaccination (O'Shea et al., 1985).
The persistence of antibodies to rubella has been shown to last for 10-21 
years (O'Shea et al., 1988) in some individuals, but levels decline rapidly in 
others after only two years (Valensin et al., 1987). Antibody persistence 
depends on the strain of vaccine, with Cendehill and HPV77 giving lower 
antibody levels than RA27/3 (Best, 1991), and the sensitivity of the test 
employed.
In the UK it is current practise to vaccinate women with rubella antibodies 
levels of less than 15 iu/ml. Vaananen et al., (1986) have shown that 
antibody readings by SRH below this level can inhibit infection by the vaccine 
strain and therefore presumably the wild rubella virus.
1.5.3 Adverse reactions to the vaccine
Adverse reactions to the vaccine may occur but these are less severe than
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those observed after natural infection, and tend to be associated with adults 
rather than children. The symptoms include lymphadenopathy, fever, rash, 
arthralgia (painful joints) or arthritis (joint swelling) and may occur between 
ten days and four weeks post-vaccination. The frequency of joint symptoms 
depends on the vaccine strain with HPV77.DE5 and RA27/3 having a higher 
frequency than Cendehill and To-366 the lowest (Best et al., 1974; Polk et 
al., 1982). HPV77.DK12 vaccine was withdrawn because of the severe joint 
reactions, even in children.
The joint symptoms may be due to infection of the synovial cells, formation 
of immune complexes or to an autoimmune reaction. RV has been isolated 
from the peripheral blood lymphocytes of women with rubella associated 
arthritis (Chantier et al., 1982; Tingle et al., 1985), and from peripheral 
blood and synovial fluid of children with chronic arthritis (Chantier et al.,
1985). Wild type strains M33 and Therien have been shown to infect and 
persist in human foetal joint tissue (Miki and Chantier, 1992), although to a 
lesser degree this was also the case with the vaccine strain RA27/3. RA27/3 
therefore has the potential to elicit a chronic inflammatory reaction by 
providing a persistent foreign antigen stimulation of the immune system in 
the joint (Miki and Chantier, 1992).
1.5.4 Contraindications
Rubella vaccines are live vaccines and should not be given to patients who 
are immunosuppressed. The vaccine virus has been shown to cross the 
placenta and result in foetal infection and therefore should not be given 
during pregnancy. Studies have shown that there is no evidence of 
congenital malformations compatible with congenital rubella in the infants 
delivered to mothers vaccinated during pregnancy or within three months 
before conception (Best and Banatvala, 1990).
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1.5.5 Measles, mumps and rubella vaccine (MMR)
The trivalent MMR vaccine is composed of different viral strains depending 
on the country of origin. The rubella strain is the RA27/3 except in Japan 
which uses To-366. The MMR vaccine when introduced in the UK in 1988 
contained the Schwartz strain of measles and the Urabe Am 9 strain of 
mumps. Due to the increase in incidence of meningitis after MMR 
vaccination (Brown et al, 1991) the MMR vaccine containing the Urabe 
strain was withdrawn in the UK and Canada, the Jeryl-Lynn strain of mumps 
virus is now used instead.
The MMR vaccine is administered primarily before the second birthday, and 
is given to both sexes in order to try and eliminate all three virus diseases. 
The MMR vaccine is now the main format for rubella vaccination.
1.5.6 Vaccination policies
In 1984 the WHO set a target to eliminate congenital rubella from the 
European region by the year 2000. Recommendations included the use of a 
rubella vaccine in all European countries by 1990, with a 90% coverage of 
the target population by 1995.
Different countries have implemented differing immunisation programmes. In 
the USA rubella vaccine is recommended to all children and susceptible 
adults with both sexes vaccinated with the MMR vaccine at 15 months of age 
(Herrman, 1991). Evidence of vaccination is required prior to school entry. 
In the UK a selective vaccination programme was introduced in 1970 where 
girls between the age of 11-14 years were vaccinated. This is now only being 
used to augment the MMR vaccine which is given to both sexes at about 15 
months. In Sweden a two-dose schedule is used, with the MMR vaccine 
given to all children at 18 months and again at 12 years of age. A two-dose
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schedule is also used in Denmark, Finland, Norway and the Netherlands. 
Austria, Bulgaria, Italy and Poland only have selective vaccination of 10-16 
year old girls. The lack of both rubella and MMR vaccines either due to 
supply or costs means that in 1991 some countries had no vaccination 
programmes in operation eg Russia, Albania, Romania (Galazka, 1991).
Even though these vaccination programmes may have been implemented the 
level of coverage varies between countries eg in France it is 60% and in 
Ireland 68% (Bytchenko, 1990). In the UK in February 1991 the coverage 
for two year olds with MMR was 89% (Miller, 1991).
1.5.7 Vaccine storage
Rubella is a labile virus and is therefore inactivated by exposure to light and 
heat. Incorrect reconstitution and storage can cause inactivation of the virus 
resulting in vaccine failure. The vaccine should be stored at 2-8®C, and kept 
at this temperature after reconstitution and used within the hour. This is a 
serious problem in countries where clinics do not have facilities to keep the 
virus cold.
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1.6 AIMS OF THIS STUDY
In the UK 600,000 tests are performed every year to detect rubella 
antibodies. Primarily the tests are carried out during routine antenatal 
screening. Each test be it SRH, LA or ELISA incorporates viral antigens, the 
supply of which is effected by a low growth rate of the virus and batch to 
batch variations. There is potential for the viral antigens to be replaced by 
recombinant antigens. The aims of this study were:-
a) to clone and sequence the structural proteins of the Thomas strain of RV 
and utilise the cloned sequences in expression vectors to produce 
recombinant proteins.
b) to investigate the use of both prokaryotic and eukaryotic expression 
systems for the production of recombinant proteins.
c)to investigate the potential of these proteins as antigens in diagnostic 
assays to detect RV antibodies.
d) to identify new epitopes on the E l glycoprotein using overlapping 
synthetic octameric peptides which could be incorporated into recombinant 
proteins.
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Chapter 2 
MATERIALS AND METHODS
MATERIALS
2.1 Suppliers
Aldrich Chemical Co. Ltd., (Gillingham, Dorset)
Diisopropylethylamine, Ethanedithiol 
Amersham International pic., (Slough, Berks.)
cDNA synthesis kit; cDNA cloning kit; Packaging kit; ECL Western blotting
detection reagents; Hybond-N™ nylon membranes; Hybond-C™ super
nitrocellulose membrane; Multiprime labelling kit; Radiolabelled nucleotide 
([a-'"P]dCTP, [y-^'P]ATP], [a-^'S]dATP, L-['"S]methionine); RAV-2. 
Anderman and Co., Ltd., (East Moisey, Surrey)
NA 45 paper
Applied Biosystems , (Warrington,Lancs.)
Material for synthesis of oligonucleotides.
BDH Chemicals Ltd., (Eastleigh, Hampshire)
Ammonium persulphate; Boric acid; Bromophenol blue; Calcium chloride; 
Dichloromethane; D-Glucose; Formaldehyde; Glycine; Magnesium sulphate; 
Paraffin; Potassium dihydrogen orthophosphate; Propanol; Sodium acetate; 
Sodium chloride; Disodium orthophosphate; Sodium dihydrogen 
orthophosphate; Sucrose; Tri sodium citrate.
Biogenisis Ltd., (Bournmouth, Hants)
RNAzol™
Bio-Rad Laboratories Ltd., (Hemel Hepstead, Hertfordshire)
Silver stain kit; Silver stain protein markers; SDS-PAGE markers; 
Pre-stained protein markers;
Boehringer Mannheim UK Ltd., (Lewes East Sussex)
ATP; Caesium chloride; Calf intestinal phosphatase (CIP); IPTG; X-gal. 
Cambridge Bioscience 
Sequenase-2 kit.
Cambridge Research Biochemicals, (Northwich, Cheshire)
Epitope mapping kit; Monoclonal antibody.
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Dako Ltd., (High Wycomhe, Bucks.)
Secondary antibodies horseradish peroxidase conjugates,
Dupont (UK) Ltd., (Stevenage, Herts.)
En^hance^^; Enlightening^^
European marketing, (Ramsbottom, Lancs.)
Polaroid film
Fisons Scientific Equipment, (Loughborough, Leicestershire)
Acetone; Chloroform; Ethanol; Glacial acetic acid; Glycerol; Methanol.
Fluka Chemicals Ltd., (Gillingham, Dorset)
Anisole; Piperidine; Triethylamine;
Fuji Photo Film Co. Ltd., (London)
X-ray RX film.
Genetic Research Instruments, (Dunmow, Essex)
Saran-wrap™
Life Technologies, (Paisley, Scotland)
All molecular biology enzymes, unless otherwise stated; Agarose; DNA and 
RNA markers; DH5 competent cells; Formamide; Nunc plasticware; Phenol; 
Sealing tape; Tissue culture media.
National Diagnostics, (Hessle, Hull)
Acrylamide solution (protein gels)
New England Biolabs., (Bishop's Storford, Hants.)
M l3 reverse sequencing primer.
Northumbria Biologicals Ltd., (Cramlington, Northumberland)
Acrylamide solution (sequencing gels); Proteinase K; Restriction enzymes. 
Novabiochem (UK) Ltd., (Nottingham)
Dimethylformamide (DMF); Dichloromethane; Trifluoroacetic acid; Anisole; 
Acetic anhydride.
Oxoid Ltd., (Basingstoke, Hants.)
Agar No. 3; Bacto tryptone; Bacto Yeast extract; Nutrient broth; Phosphate 
buffered saline (PBS) tablets.
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Pharmacia Biosystems Ltd., (Milton Keynes)
DEAE-dextran; dNTP's; DNase; pGEX vectors; Polynucleotide kinase(PNK). 
Promega, (Southampton, Hants.)
TNT^^coupled reticulocyte system; Canine pancreatic microsomal 
membranes; pGEM™ vector; Magic™ miniprep columns; Magic™ maxiprep 
columns; Magic™ clean up columns; RNasin; Taq polymerase.
Sigma Chemical Co. Ltd., (Poole, Dorset)
All antibiotics; Azino-bis (3-ethylbenzthiazoline 6-sulphonic acid) 
diammonium (ABTS); Brij 58; Bovine serum albumin (BSA); Chloroquine 
diphosphate; Diethylpyrocarbonate; Ethidium bromide; FITC secondary 
antibody conjugates; Glutathione; Glutathione agarose; Herring testes DNA; 
Hydrogen peroxide; 1 -hydroxybenzotriazole (HOBt); 8-hydroxyquinoline; 
Lysozyme; 2-Mercaptoethanol; Nonidet-P 40 (N-P 40); Rabbit serum; 
Sodium dodecyl sulphate (SDS); TEMED; Thrombin; Trizma base; Urea; 
Stratech Scientific Ltd., (London)
Geneclean™ kit
Whatman Labsales Ltd., (Maidstone, Kent)
Whatman 3MM™ filter paper.
2.2 Bacterial Strains
Escherichia coli JM109: recKl, endKl, gyr96, thi, h sd K ll  (r^ '^m^ .^ ), supEAA, 
re lA l, X-, (/ac-proAB), [F', /raD36, /?roAB, /acUZAM15]
Purchased from Pharmacia Ltd.
Escherichia coli DH5a™ competent cells (maximum high efficiency)
F', (p80d/acZ A ml5, A(/acZYA-argF)U169, recKl, endKl, /?J6^17(ri.'m/), 
supEAA, X', thi-l, gyrA, relAl  
Purchased from Life Technologies.
Escherichia coli HB101F-, /z^<7S20(r'g,m'g), recA\3>, ara-14, p ro A l,  lacY l,  
galK l, rpsL2Q(svY) xyl-5, mtl-\, siipEAA, X- Obtained from CAMR.
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Escherichia coli NM514
Purchased from Amersham International (genotype not provided).
2.3 Plasmids
pUClS (Yanisch-Perron et al., \9%5)
pUC18 (Yanisch-Perron et ah, \9%5)
pGEM Purchased from Promega
pGEX Purchased from Pharmacia
pUSlOOO (Jackson et ah, 1992)
Plasmid pUSlOOO was derived from a vector ^EE6gpt., (Celltech Ltd). It 
contains an SV40 origin of replication with the SV40 early promoter region 
driving transcription of the xanthine-guanine phosphoribosyl transferase gene 
{gpt) from pSV2g/?^ (Whittle et ah, 1987). The plasmid contains a strong 
promoter/enhancer transcriptional control element from the human 
cytomegalovirus (HCMV) inserted into the unique Hindlll site upstream of 
the EcoRI site of ^EE6gpt. 
pUS1002 (Jackson et ah, 1992)
This plasmid was constructed by inserting the cDNA coding for the light 
chain of a bovine anti-testosterone IgGj monoclonal antibody into the EcoRl 
site of pUSlOOO. 
pUS1120 (Al-mumin, 1991)
This plasmid was constructed by inserting the cDNA coding for almost all of
the rubella E2 protein into pUSlOOO . The sequence was amplified by the 
polymerase chain reaction (PCR) from pE2T3 (this thesis) and modified to 
include an inframe 5' AT G start and 3' TAG stop codon prior to the E2 
trans-membrane sequence.
pUSlSOO- pUSlSlO (this thesis, Newcombe et ah, 1994)
Each plasmid contains a different rubella sequence of the E l coding region as 
a fusion with glutathione S-transferase in the pGEX vectors.
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pKTH345
A gift from R.Petterson (Karolinska institute,Sweden). The insert is a 
1.95kb cDNA from the Therien Rubella strain, cloned into the PstI site of 
pBR322. It covers the 3' end of the capsid gene, the whole of the E2 gene 
and part of the 5' end of the E l gene, (Vidgren et a l ,  1987). It was 
transformed into E.coli H B101, the hybrid plasmid confering ampicillin 
sensitivity and tetracycline resistance.
2.4 Bacteriophages
M 13m pl8 (Yanisch-Perron et ah, 1985)
M 13m pl9 (Yanisch-Perron et ah, 1985)
Lam bda -gtlO (Hyunh et ah, 1985)
2.5 M ammalian Cell Lines 
COS-1
African Green Monkey kidney CV-1 cells transformed with SV40 DNA 
containing a 6bp deletion in the origin of replication (ORI) which prevents 
replication of the viral DNA (Gluzman, 1981).
Obtained from Celltech Ltd.
Vero
African Green Monkey kidney cells susceptible to viruses.
Obtained from Dr. J.Best, St.Thomas' Hospital.
RK13
Rabbit kidney cells from a 5 week old rabbit, they are epithelial cells that are 
sensitive to rubella virus infection producing a cytopathic effect (CPE) 
which can be visualized as plaques on staining with methylene blue.
Obtained from Dr. J.Best, St.Thomas' Hospital.
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2.6 Viral Strains 
Rubella strain Thomas
Rubella virus isolated from a throat swab from a patient with Congenital 
Rubella Syndrome (CRS) in 1966, at St. Thomas' Hospital. The virus was 
passaged twice in RK13, once in Veros and twice in BHK cells prior to 
plaque purification and preparation of stocks in Vero cells (P.Sanders PC).
2.7 Rubella Positive and Negative Sera
Serum samples were provided by Dr. J. Smith, St Lukes Hospital, Guildford, 
Dr. J. Best, St. Thomas' Hospital and donations from V. Newcombe and W. 
McDougal.
2.8 Monoclonal Antibodies
Monoclonal antibodies to rubella E l glycoprotein were a gift from Dr. M. 
Revello ( Parvia, Italy),(Gerna et a l.,\9Z l).
2.9 Media
Cell culture media
All media components were purchased as sterile liquids and added 
asceptically to sterile MQ water.
DMEM
Dulbecco's modified Eagle's basal medium (DMEM) supplemented with 2mM 
glutamine, 0.15% sodium bicarbonate, 10% (v/v) heat inactivated foetal calf 
serum (PCS) and 0.005% gentamycin, adjusted to pH 7.0 
GMEM
Glasgow's modified Eagle's basal medium (GMEM) supplemented with 2mM 
glutamine, 0.15% sodium bicarbonate and 1 0 % (v/v) heat inactivated PCS, 
adjusted to pH 7.0. When this media was used for viral propagation the PCS 
was replaced with 0.2% BSA.
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met MEM
Modified essential medium (MEM) with Earle's salts, without methionine and 
without glutamine.
Microbial growth media
All media was sterilised by autoclaving at 121°C (ISp.s.i.) for 15 minutes or 
by filtration through a 0 .2 pm FlowPore filter. Unless stated otherwise all 
media were prepared in distilled water. Supplements to media, such as 
antibiotics, were added immediately prior to use.
Luria -Bertani (LB) broth Bacto tryptone 15g
Bacto yeast extract 5g
NaCl 5g
water to 1 0 0 0 ml, autoclaved
Luria- Bertani (LA) agar 
Minimal media (agar)
Minimal media (salts)
2xTY broth
2xTY agar 
H Top agar
L B containing 15 g/1 Bacto agar.
Bacto agar (double strength) 15g 
water to 500ml, autoclaved, double strength 
salts (500ml) are added after autoclaving 
along with 1 0 ml ( 1  mg/ml) vitamin Bj (filter 
sterilized) and 7ml (40%) glucose 
(autoclaved)
K,HPO, 14g
KH,PO, 6 g
Na^ 2 H 2 O 0.94g
MgSO, 7H,0 0.2g
(NH,),SO, 2 g
water to 1 0 0 0 ml, autoclaved
Bacto tryptone 16g
Bacto yeast extract lOg
NaCl 5g
water to 1 0 0 0  ml, autoclaved
2xTY broth containing 15 g/1 Bacto agar.
Bacto tryptone lOg
NaCl 8 g
Bacto agar 8 g
water to 1 0 0 0  ml, autoclaved
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H agar H top agar containing 15 g/1 Bacto agar.
soc Bacto tryptone
Bacto yeast extract
NaCl
KCl
MgCl^
MgSO,
Glucose
2 g 
0.5g 
lOmM 
2.5mM 
1ml (2M) 
1ml (2M) 
1ml (2M)
SOC was prepared in the absence of the 
magnesium salts and glucose with water to 
100ml pH 7.0. After autoclaving filter 
sterilised magnesium salts and glucose were 
added prior to use.
2.10 Antibiotics
Ampicillin stock solution (lOOmg/ml) was made in water, filter sterilised and 
added to LB or LA to a final concentration of lOOpg/ml.
Tetracycline stock solution (20mg/ml) was made in 50% ethanol and added to 
media to a final concentration of 50pg/ml.
2.11 General Buffers, Reagents and Solutions
These are listed in alphabetical order. Unless otherwise stated all solutions 
were made up in deionised water (MQ). Some specific buffers, reagents and 
solutions are included in the relevant method.
Alkaline lysis 
solution 1
Alkaline lysis 
solution 2
Alkaline lysis 
solution 3
Glucose
EDTA
Tris.HCl pH 8.0 
autoclaved
4mg/ml lysozyme prior to use
NaOH
SDS
50mM
lOmM
25mM
0.2M
1 .0 % (w/v)
Potassium acetate, 5M pH 4.8
Acetic acid
H^O
60ml 
11.5ml 
28.5ml
(the resulting solution is 3M potassium, 5M 
acetate) autoclaved
65
Brij/DOC Brij 58
Sodium deoxycholate 
TE (pH8.0) 
autoclaved
1%
0.4%
Caesium chloride/ 
isopropanol
Chloroform
Solid caesium chloride (high grade) saturated 
in isopropanol.
Prepared with isoamyl alcohol at 24:1 (v/v).
DE52-cellulose in LB DE52 cellulose lOOg
HCl 0.05M
NaOH 40%
Sodium azide 0.1%
LB
Several volumes of HCL were slowly stired into 
the DE52 until the pH was below 4.5. NaOH was added until the pH reached
7.5. The resin was washed several times in LB by sedimentation and
decanting the excess liquid. A final slurry was prepared in excess LB and
stored at 40C in the presence of sodium azide.
Denhardt’s solution 
lOOx
Ficoll (MW 400,000) 2%
Polyvinylpyrrolidone (MW40,00)2%
Bovine serum albumin 
filter sterilised
2%
DNA extraction buffer SDS
EDTA 
TE pH 8.0
0 . 1%
lOmM
DNA loading buffer, 6x Bromophenol blue
Glycerol
Tris acetate buffer
0.25%
30%
Ix
ECL
Stripping buffer
Tris HCl pH 6.7
2-Mercaptoethanol
SDS
62.5mM
lOOmM
2%
ELISA NaCl
Phosphate buffer (PBS) Na2HP0^.2H20 
xlO (O.IM) NaH2P0,2H20
water to 1000ml pH 7.2
85g 
1 0 .7g 
3.9g
ELISA
Pre-coat buffer
BSA
Tween 20 
Sodium azide 
PBS
2 % (w/v) 
0 . 1 % (v/v) 
0 . 1 % (w/v) 
xl
6 6
ELISA
Conjugate diluent
Rabbit serum 
Tween 20 
Sodium caseinate 
PBS
1 % (v/v) 
0 . 1 % (v/v) 
0 . 1 % (w/v) 
xl
ELISA
Substrate buffer
ELISA
Na^HPO, (IM)
Citric acid (IM) 
water
pH 4.0 with 0.8M citrate 
Substrate buffer
2 0 ml
16ml
1640ml
1 0 0 ml
ABTS substrate solution ABTS 50mg
Hydrogen peroxide (30% w/v) 0.01%
The hydrogen peroxide is added immediately prior 
to use.
ELISA
Disruption buffer
Ethidium bromide
Fixing solution 
(Sequencing)
Herring testis DNA
Hybridisation buffer 
DNA
Hybridisation buffer 
RNA (1)
Hybridisation buffer 
RNA (2)
Hybridisation 
Denaturing solution
Phosphate buffer O.IM
SDS 1% (w/v)
2-Mercaptoethanol 0.1% (v/v)
pH 7.2 before adding 2-mercaptoethanol
Ethidium bromide
Methanol 
Acetic acid
lOmg/ml
10%
10%
DNA lOmg/ml
boil for lOmin, 1ml aliquots at -20°C.
SSC
Denhardt's solution 
SDS
Herring testis DNA
SSPE
Denhardt's
SDS
Formamide 
Herring testis DNA
SSPE
Denhardt's
SDS
Herring testis DNA
NaOH
NaCl
autoclaved
6 x
5x
0.5%
2 0 pg/ml
5x
5x
0.5%
50%
2 0 pg/ml
5x
5x
0.5%
2 0 pg/ml
0.5M
1.5M
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Hybridisation 
Neutralising solution
NaCl
Tris HCl pH 7 
autoclaved
1.5M
l.OM
Lysis buffer Tris HCl pH 8.5
NaCl
MgCl,
Cycloheximide
N P-40
0.2M
0.14M
2mM
lOpg/ml
0.5%
Vanadyl ribonucleoside inhibitor 20mM 
The vanadyl was stored separately at -20°C, 
thawed on ice and added to the sterile buffer.
PEG/NaCl
Phenol
Phenol/chloroform
Quick buffer
RIPA buffer
RNA gel running 
buffer xlO
RNA gel buffer A
RNA loading dye
RNA loading buffer
Polyethylene glycol-6000 
NaCl
autoclaved
20%
2.5M
Equilibrated with IM Tris-HCl pH 8.0 (1:1) 
8 -Hydroxyquiniline to a final concentration of 
0 . 1%
Prepared as a 1:1 mixture (v/v) containing 
0 . 1 % 8 -hydroxyquinoline.
NaOH
SDS
EDTA
Bromophenol blue
NaCl
NP-40
DOC
SDS
Tris HCl pH 8.0
MOPS
EDTA
Gel running buffer
Buffer A 
Xylene cyanol 
Bromocreosol green 
Sucrose
Formamide 
RNA dye 
Formaldehyde
50mM
0.5%
5mM
0.05%
150mM
1%
0.5%
0 . 1%
50mM
0.5M
O.OIM
0.3x
0.3%
0.015%
0.015%
0 .8%
35%
50%
15%
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SDS-PAGE Methanol:Acetic acid:water 5:2:5
Coomassie Brilliant blue Coomassie blue 
stain
0 . 1 %
SDS-PAGE Methanol 30%
Fix / Destain Acetic acid 1 0 %
SDS-PAGE Stacking buffer x4 2.4ml
Loading dye x4 SDS (20%) 
Glycerol
Bromophenol blue 
2-Mercaptoethanol
4ml
4ml
0 .0 1 %
0.5ml
SDS-PAGE Tris-HCl pH 8 . 8 1.5M
Resolving buffer x4 SDS 0.4%
SDS-PAGE Tris-HCl pH 6 . 8 0.5M
Stacking buffer x4 SDS 0.4%
SDS-PAGE SDS 1 %
Tank buffer xlO Glycine
Tris
0.55M
0.5M
Sequencing gel plate 
non-stick coating
Dimethyl dichlorosilane C^ 7<^ ) 1 0 ml
Sequencing gel plate 
bonding solution
Ethanol (absolute)
Methacryloxypropyl-trimethoxy
silane
acetic acid, 1 0 %
1 0 ml
30pl
150pl
Sodium acetate Na acetate 
pH 5.2, autoclaved
3M
SM buffer NaCl
MgSO^.TH^O 
Tris HCl pH 7.5 (IM) 
Gelatin 2% (w/v) 
water to 1 0 0 0 ml
5.8ml
2 .0 ml
5ml
5ml
SSC, 20x NaCl
Sodium citrate 
pH 7.0, autoclaved
3M
0.3M
SSPE, 20x NaCl
NaH^PO,
EDTA
pH 7.6, autoclaved 
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3.6M
0.2M
0.02M
STET buffer
Sucrose
TAE buffer x l
TBE buffer x l
TBS
TBST
TE buffer x l  
Transfection cocktail 
Transfection media 
TSE
Western blot 
blocking solution
Tris HCl pH 8.0 
EDTA 
Sucrose 
Triton X 100
50mM
50mM
8%
5%
Sucrose 25%
in 50mM Tris HCl ph8.0, autoclaved
Tris acetate 40mM
EDTA 2mM
pH 8.0 with glacial acetic acid, autoclaved
Tris-borate 
Boric acid 
EDTA
pH 8.3, autoclaved
Tris
NaCl
pH 7.6, autoclaved
as TBS plus 0.1% Tween 20
Tris
EDTA
pH 8.0, autoclaved 
DNA
DEAE-dextran (lOmg/ml) 
PBS
90mM
90mM
2mM
20mM
137mM
lOmM
ImM
500ng
lOpl
190pl
(1) DMEM supplemented with DMSO (10% v/v)
(2) DMEM supplemented with chloroquine (80pM 
filter sterilised )
Tris HCl pH 8.5
EDTA
SDS
Dried low fat milk 
TBST
lOmM
5mM
0.5%
5%
Western blot 
transfer buffer
Tris 
Glycine 
Methanol 
water to 3L
25mM
190mM
600ml
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2.12 Enzyme Buffers
Most enzyme buffers were supplied with the respective enzyme by the 
manufacturer.
Restriction buffers lOx buffers supplied with enzymes.
Calf Intestinal Tris HCl pH 8.0
Phosphatase buffer, lOx MgCl^
ZnCl^
autoclaved
500mM
lOmM
ImM
Nick translation buffer Tris HCl pH 7.5
xlO MgCl,
DTT
0.5M
O.IM
ImM
Polynucleotide Kinase Tris HCl pH7.6
buffer, lOx MgCl,
Dithiothreitol 
Spermidine HCl 
EDTA
filter-sterilised
0.5M
O.IM
50mM
ImM
ImM
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METHODS
2.13 Animal Cell Culture
2.13.1 COS-1 cell culture
Reagents:
DMEM
PBS
Trypsin/EDTA
Procedure:
COS-1 cells were grown in DMEM at 37°C in air containing 5% COj, until 
the cells formed a confluent monolayer, where upon the cells were split 1 : 2  
or 1:3. The medium was aspirated off and the cells were washed in sterile 
PBS. Trypsin /EDTA was added and swirled to ensure all the surface was 
covered. The trypsin was decanted off leaving sufficient solution to wet the 
cells and incubated at 37°C until the cells had detached from the surface. 
The cells were resuspended in 10ml of fresh DMEM and added to new flasks 
containing an appropriate volume of fresh DMEM.
2.13.2Frozen cell stocks
Reagents:
DMEM plus 10% DMSO, 20% PCS 
PBS
Trypsin/EDTA
Procedure:
The cells were harvested and treated with trypsin as above, resuspended in 
10ml of medium and centrifuged at lOOg for 5min. The cells were then 
resuspended in sufficient medium to give a cell concentration of 5x10^ /ml 
and dispensed in 1ml aliquots. The cells were frozen slowly to -70® C 
overnight before storage in liquid nitrogen. To resuscitate cells a frozen 
aliquot was thawed in a 37®C waterbath and diluted very slowly with 1 0 ml of 
fresh medium. The cells were centrifuged (lOOg, 5 min), the pellet 
resuspended in 1 0 ml of fresh medium and transferred to a small tissue culture 
flask. The cells were incubated at 37®C in air containing 5% CO^ until 
confluent where upon transfer was made to a larger flask as detailed above.
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2.13.3 Cell counting
Cell counts were determined by diluting an aliquot of cells in trypan blue dye 
and counting using a Fuchs-Rosenthal Haemocytometer.
2.14 Viral Culture Techniques
2.14.1 Virus propagation
Rubella virus was propagated in Vero cells.
Reagents:
GMEM plus 0.2% BSA 
Procedure:
The Vero cells were infected at a m.o.i. of 0.5, allowing IxlO^cells/flask, 
just before confluence. The cells were left for Ihr to allow the rubella virus 
to adsorb to the cell surface before fresh medium was added, this was then 
incubated at 37®C in air containing 5% CO^. After 3 days incubation the 
medium was harvested at 24hr intervals over a 10 day period and frozen at 
-70®C, 1 ml was kept separate for determinations of virus titres.
2.14.2Rubella virus titration (plaque assay)
Titrations were made of the harvested medium as an indication of the virus 
concentration.
Reagents:
GMEM plus 2% FCS 
GMEM plus 10% FCS 
5% Agarose 
10% Formal saline 
methylene blue 
Procedure:
35mm wells were seeded with 1x10^ RK13 cells in 4ml of GMEM (10% FCS) 
and incubated until almost confluent, 37®C, 5% CO^ in air, for 2-3 days. The 
virus stock was diluted lO’^ lO'^ in GMEM (2% FCS). The medium was 
aspirated from each well of cells and replaced with 2 0 0 pl of virus dilution 
per well, medium only was used as a control. The virus was allowed to
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adsorb for 2-3hrs at 37°C after which time 4ml of GMEM (2% FCS) mixed 
with 1ml warmed agarose was added to each well. The agarose was allowed 
to set before being incubated for 7-10 days 37®C, 5% CO^ in air, in a 
polythene bag to prevent drying. The plates were then fixed for 15min with 
2ml 10% formal saline. The overlay was removed and the cells fixed as 
above before staining with methylene blue. The number of plaques were 
counted and the viral titre calculated.
2.14.3 Immunofluorescence
Reagents:
Trypsin/EDTA
PBS
DMEM (1% FCS)
Acetone (ice-cold)
Primary antibody
Secondary antibody (anti-species FITC conjugate)
Procedure:
Rubella infected Vero cells were grown as detailed in section 2.13.1, for 6  
days. The medium was poured off of the cell sheet and the cells washed with 
PBS and treated with trypsin (section 2.13.1). The trypsinized cells were 
resuspended in 10ml of media and centrifuged (lOOOg, 5min). The pellet was 
resuspended in the appropriate volume of medium (4ml for cells from a 25cm 
flask, 12ml for cells from a 75cm flask). 25pi of the cell suspension was 
placed into each well of a spot slide and incubated in a humidified chamber 
overnight (37®C, 5% CO^in air). This was repeated with uninfected cells with 
each spot slide holding one row of infected cells and one row of uninfected 
cells. The cells were then fixed by washing briefly in PBS, and in ice cold 
acetone, followed by 5-15min immersion in fresh ice cold acetone. The slides 
were then air dried. At this stage the slides can be processed or stored at 
-20®C. If  the slides were processed after freezing at -20®C they were first 
allowed to thaw and dry out. 25pi of diluted primary antibody was added to 
each spot, (PBS was used as the diluent and the negative control) and the
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slides were incubated in a humidified chamber (30min, 37°C). The slides 
were washed with PBS for 15min, with gentle agitation, followed by another 
15min in fresh PBS. The slides were air dried before the addition of 25pl of 
diluted anti -species FITC conjugated secondary antibody (1/80). Incubation 
and washing was carried out as detailed above with the addition of a final 
wash in water. Slide mountant and coverslips were applied to each slide 
before microscopic examination under UV light.
2.15 DNA Extractions
2.15.1Extraction and purification of plasmid DNA
(i) Rapid boiling method
This method allows for the rapid screening of bacterial transformants 
providing sufficient plasmid DNA for several restriction digests and is based
on the method of Holmes and Quigley (1981).
Reagents:
Isopropanol
LA (lOOpg/ml ampicillin)
LB (lOOpg/ml ampicillin)
Lysozyme (lOmg/ml)
STET buffer
Procedure:
One colony from a LA plate was picked off and grown overnight in 1.5ml LB 
with shaking at 37®C . The broth was centrifuged (14000g, 2min) and the 
pellet resuspended in 0.1ml STET buffer. lOpl freshly prepared lysozyme 
was added prior to heating in a boiling waterbath for 40sec. This was 
immediately centrifuged (14000g, lOmin) resulting in an insoluble pellet of 
genomic DNA and debris. The supernatant was removed and 0.1ml 
isopropanol added, this was mixed by vortexing before precipitation at -20®C 
for lOmin. The precipitate was collected by centrifugation (14000g, 5min), 
dried under vacuum and resuspended in 2 0 pl water.
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(ii) Alkaline lysis method
Small scale preparations of plasmid DNA based on the method of Birnboim
and Doly (1979).
Reagents:
Alkaline lysis solution I 
Alkaline lysis solution II 
Alkaline lysis solution III 
Ethanol absolute, 70%
LB (lOOpg/ml ampicillin)
Phenol/chloroform 
RNase (1 mg/ml)
Procedure:
1.5ml overnight cultures grown in LB were centrifuged (14000g, 2min) and 
the bacterial pellet resuspended in 150pl of ice-cold solution I and incubated 
for 5min at room temperature (RT). 300pl of solution II was added and the 
tube mixed by invertion before storing on ice for 5 min. 150pl of ice-cold 
solution III was added and again mixed by invertion before storing on ice for 
5min. This was centrifuged (5min, 4®C), and the supernatant 
phenol/chloroform extracted (section 2.15.5). The aqueous phase was 
transferred to a fresh tube and the DNA precipitated by adding two volumes 
of ethanol and incubating for 5min RT before centrifugation (14000g, 5min). 
The DNA was washed with 70% ethanol, dried under vacuum and 
resuspended in 2 0 pl of water.
(iii) Magic™ miniprep method
This is a quick method based on the alkaline lysis method supplied as a kit 
from Promega.
Reagents:
LB (lOOpg/ml ampicillin)
Cell resuspension solution 
Cell lysis solution 
Neutralisation solution 
Column wash 
DNA purification resin 
Magic columns
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Procedure:
This is carried out according to the manufacturer's instructions. Overnight 
cultures (l-3ml) were grown in LB, centrifuged (14000g, 2min) and the 
pellet resuspended in 0 .2 ml resuspension solution. 0 .2 ml lysis solution was 
added and inverted several times before the addition of 0 .2 ml neutralisation 
solution which was again mixed by inversion. This was centrifuged (14000g, 
5min) and 1ml of resin added to the resulting supernatant. A syringe was 
attached to the column and the DNA slurry pushed through it . The column 
was then washed with 2ml wash solution. The column was centrifuged for 
20sec to remove excess wash solution. The DNA was eluted from the 
column in 50pl of prewarmed water (65-70°C) which was added to the 
column before a 2 0 sec spin.
(iv) Magic™ Maxiprep columns
Reagents:
as for miniprep columns 
Procedure:
The bacterial culture (up to 500ml) was centrifuged (14000g, 15min) and the 
resulting bacterial pellet was resuspended in 15ml resuspension solution. 
15ml lysis solution was added and mixed by inversion. 15ml neutralisation 
solution was added and similarly mixed. The solution was centrifuged 
(14000g, 15min) and the supernatant (45ml) mixed with isopropanol (27ml) 
before being recentrifuged (14000g, 15min). The pellet was resuspended in 
2 ml water. 1 0 ml of resin was added and the suspension poured into the 
Maxiprep column. The suspension was drawn through the column using a 
vacuum line. 13ml of column wash was used to rinse the column before 
being drawn through the column followed by a further 1 2 ml of column wash. 
5ml 80% ethanol was drawn through the column, the residual was removed 
by centrifugation (2000g, 5min). The DNA was eluted from the column by 
the addition of 1.5ml water (65-70®C) and centifugation (2.5rpm 5min). The 
DNA was stored -20®C.
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2.15.2Extraction and purification of phage DNA
(i) Extraction of double stranded M13 DNA (RE)
Reagents:
E.coli JM109 
2xTY 
Procedure:
An overnight culture of JM109 grown in 2xTY was used as an inoculum for a 
fresh 2xTY broth (1:100). This diluted culture was dispensed into aliquots 
(1.5ml) and inoculated with 5pi of phage stock or a plaque from a plate and 
incubated overnight with shaking at 37®C. The RF DNA was extracted using 
the methods described in section 2.15.1(ii,iii).
(ii) Extraction of single stranded M13 DNA
Reagents:
E.coli JM109 
2xTY
PEG 6000 (20%, 2.5M NaCl)
Phenol/chloroform
Ethanol
Proteinase K (5mg/ml)
Sodium acetate (3M pH 5.2)
Procedure:
The M l3 phage was grown as described above but was only incubated for 
5-7hrs. The culture was transferred to a tube, centrifuged (14000g, 5min, 
RT) and the supernatant recentrifuged (14000g,5min, RT). To each 1ml of 
supernatant 250pl of PEG was added and incubated on ice for 15min. The 
PEG precipitate was centrifuged (14000g, lOmin, 4®C) and the supernatant 
removed before recentrifugation (14000g, lOsec, RT). It is very important 
that all the liquid containing PEG is removed from the pellet. The pellet was 
redissolved in lOOpl TE, lOOpl phenol/chloroform was added, vortexed, 
incubated on ice (lOmin), re-vortexed and centrifuged (14000g, 5min, RT). 
The aqueous layer was removed and the DNA precipitated by adding lOpl 
sodium acetate and 250pl ethanol and incubating on ice for 30min The DNA 
was pelleted by centrifugation (14000g, 20min, 4®C), resuspended in lOOpl
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TE and treated with Ipil proteinase K (30min, RT). This was followed by a 
phenol/chloroform extraction (section 2.15.5) and ethanol precipitation 
(section 2.15.6). The DNA was resuspended in 25pl water, 2pl was 
electrophoresed on a 1% agarose gel to check for concentration, and 3 pi 
used for a sequencing reaction (section 2.20.3).
(iii) Extraction of Lambda DNA
Reagents:
PEG 6000 (20%, 2M NaCl in SM buffer)
DE52 in LB
LB plus 5mM CaCl
LB
E.coli NM514 cells 
Proteinase K (O.lmg/ml)
Potassium acetate (3M)
SDS ( 1 0 %)
Isopropanol 
TE pH 8.0
Procedure:
A recombinant/ lambda gtlO plaque was removed from a plate using a sterile 
pasteur pipette and mixed with 0.5ml fresh NM514 plating cells and left for 
15min at RT to allow the phage to adsorb to the cells. (The preparation of 
plating cells is described in section 2.29.5). 5ml of LB (5mMCaCl) was
added to the cells which were incubated with shaking for 4hrs at 37^C . A 
few drops of chloroform was added and the culture shaken for a further 5min 
before being centrifuged (3000rpm, lOmin) in a benchtop centrifuge. The 
supernatant was removed and stored 4°C. To 4ml of supernatant 4ml PEG 
was added, mixed and incubated Ihr on ice. This was centrifuged (3000rpm, 
20min) and the pellet drained to remove all traces of the PEG. The pellet 
was resuspended in 750pl LB and an equal volume of DE52 in LB added. 
This was gently inverted 30 times and then centrifuged (14000g, 5min). To 
750pl of supernatant 13pi of proteinase K was added along with 32pl SDS, 
mixed and left at RT for 5min. 130pl potassium acetate was added and 
incubated 8 8 ®C for 20min followed by lOmin on ice. This was centrifuged
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(14000g, iOmin) and 800pl of supernatant was transferred to a fresh tube and 
an equal volum-e of cold isopropanol added. This was cooled to -70®C for 
lOmin, allowed to warm to RT and centrifuged (14000g, lOmin). The pellet 
was dried under vacuum and resuspended in 20pl TE.
2.15.3 Extraction of genomic DNA from mammalian cells
Reagents:
DNA extraction buffer 
Phenol/chloroform 
Proteinase K (5mg/ml)
Ethanol
Sodium acetate (3M pH 5.2)
PBS
Procedure:
The cell medium was removed and the cell layer washed twice with PBS. 1ml 
of DNA extraction buffer was added to the cells and put on ice for 30min. 
The suspension was centrifuged (14000g, lOmin, 4®C) and the supernatant 
phenol/chloroform extracted (section 2.15.5). Ipl proteinase K was added to 
the aqueous phase and incubated for 30min at RT. This was 
phenol/chloroform extracted (section 2.15.5), the DNA ethanol precipitated 
(section 2.15.6), dried and resuspended in lOpl water.
2.15.4Extraction of DNA from agarose gels
DNA was electrophoresed through agarose gels as described in section
2.17. l(i). Fragments of DNA that were less than 500bp in size were purified 
from agarose gels using NA 45 DEAE paper, whereas fragments of DNA 
larger than this were purified using Geneclean^^.
(i) Geneclean™ method
This method uses a silica matrix to bind the DNA and is based on the method
of Vogelstein and Gillespie (1979).
Reagents:
DNA in agarose gel 
Geneclean™ kit: sodium iodide
"NEW" wash buffer
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Procedure:
The DNA to be purified was electrophoresed through a TAB agarose gel 
(section 2.17.1(i)) and a gel slice containing the required DNA fragment was 
excised from the gel and weighed. Sodium iodide (3x the volume of the 
agarose slice) was added to the agarose and the mixture incubated at 55®C 
until the agarose gel slice had dissolved. "Glassmilk" suspension was added 
to the DNA solution (5pi for up to 5pg DNA), vortexed and incubated on ice 
for 5min to allow the DNA to bind to the silica matrix. The silica matrix was 
pelleted by centrifugation (14000g, 5sec) and the supernatant discarded. The 
pellet was washed by resuspension in 200pl ice cold "NEW" buffer and the 
pellet sedimented by centrifugation (14000g, 5sec). The supernatant was 
removed and this washing procedure was repeated twice more. The DNA 
was recovered from the silica matrix by resuspending the pellet in lOpl water 
and heating at 55®C for 3min followed by centrifugation (14000g, lOsec). 
This recovery procedure was repeated to increase the yield of DNA. The 
DNA was stored -20°C.
(ii) NA 45 DEAE membrane method
Reagents:
NA 45 paper
Arginine/ salt (50mM arginine, IM NaCl)
Water saturated isoamyl alcohol 
Ethanol
Sodium acetate (3M pH 5.2)
Procedure:
The DNA to be purified was electrophoresed through a TAB agarose gel, 
stained with ethidium bromide and visualised under UV light (section
2.17. l(i)) Incisions were made in front and behind the band of interest using 
a clean scalpel blade. Strips of NA 45 paper were inserted into the incisions 
and electrophoresis was continued until the stained DNA band could be seen 
on the paper under UV light. The DNA was eluted from the paper by 
incubating in 0.4ml arginine/salt solution (70°C, 2hrs). The ethidium bromide
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was removed by mixing an equal volume of isoamyl alcohol saturated with 
water and allowing the phases to separate. The upper alcohol phase was 
discarded and the extraction repeated until all traces of the ethidium bromide 
were gone. The DNA was recovered from the lower phase by ethanol 
precipitation (section 2.15.6), dried and resuspended in 20pl water.
2.15.5Extraction of solutions of nucleic acids with phenol/chloroform
Phenol/cloroform extractions were performed by adding an equal volume of 
phenol/chloroform to the aqueous DNA solution and vortexing for lOsec. 
The aqueous and organic phases were separated by centrifugation (14000g, 
2min) and the aqueous phase transferred to a fresh tube. The extraction 
procedure was repeated until the interface between the phases became clear. 
A final extraction using an equal volume of chloroform was performed. The 
nucleic acid was then ethanol precipitated (section 2.15.6).
2.15.6Ethanol precipitation of nucleic acids
DNA was precipitated using one of two methods.
A: Addition of 0.1 volume 3M sodium acetate (pH 5.2) followed by 2.5 
volumes ethanol (3 volumes for oligonucleotides (section 2.15.8)).
B: Addition of 0.5 volume 7.5M ammonium acetate followed by 2.5 volumes 
ethanol (can be used to reduce the coprecipitation of dNTPs but should not 
be used if the precipitated nucleic acid is to be phosphorylated, since T4 
polynucleotide kinase is inhibited by ammonium ions).
After the addition of the ethanol the solutions were vortexed and incubated 
at -20°C for Ihr, -70°c for 30min or in a dry ice/ethanol bath for lOmin. 
Precipitated DNA was collected by centrifugation (14000g, 5-30min). The 
pellet was washed in 70% ethanol, recentrifuged (14000g, 5min) and dried 
under vacuum prior to resuspending in water or TE pH 8.0. The DNA was 
stored at -20°C.
RNA was precipitated by the addition of 0.1 volume 3M sodium acetate
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(pH5.2) followed by 2.5 volume ethanol. The precipitates were cooled to 
-70®C and recovered by centrifugation as described for DNA. The RNA was 
stored at -70®C.
2.15.7 Quantitation of nucleic acid in aqueous solution
The concentration and purity of nucleic acid in aqueous solution was 
estimated by measuring the UV absorbance of the solution over a wavelength 
range of 250-300nm. Pure solutions of DNA and RNA have an absorbance 
peak at 260nm and a 260nm/280nm ratio of 1.8 and 2.0 respectively 
(Sambrook et al., 1989). The concentration of nucleic acid was calculated 
using an OD value of 1.0 at 260nm to be equivalent to 50pg/ml for double 
stranded DNA and 40pg/ml for single stranded nucleic acid. When 
estimating the concentration of oligonucleotides made using an Applied 
Biosystems DNA synthesiser (section 2.15.8), a concentration of 33pg/ml 
was used to calculate the DNA concentration in accordance with 
manufacturer's recommendations.
Alternatively, the concentration of a DNA sample was estimated by 
comparing it to a DNA sample of known concentration. A sample of DNA 
was electrophoresed in the presence of DNA markers of known quantity 
(lambda Hindlll or 0X174 Haelll ). The gel was stained and the DNA 
visualised under UV light. A comparison was made visually between the 
sample and the markers and an estimate made of DNA concentration.
2.15.8 Oligonucleotide synthesis
Reagents:
Synthesised oligonucleotide 
Ammonium hydroxide (18M)
Ethanol (absolute, 70%)
Sodium acetate (3M pH 5.2)
Procedure:
Oligonucleotides were chemically synthesised using an "Applied Biosystems" 
DNA synthesiser, model 318A, according to the manufacturer's instructions.
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The oligonucleotide was cleaved from the support matrix using fresh 
ammonium hydroxide (2 ml) which was pushed in 0.3ml aliquots into the 
column containing the matrix, each aliquot being left in contact with the 
matrix for 20min. The ammonium hydroxide was incubated at 55 for 
15hrs (overnight) to deprotect the oligonucleotide. The oligonucleotide was 
then ethanol precipitated using 3 volumes of ethanol (section 2.15.6) and 
resuspended in 0.5ml water. The concentration of the oligonucleotide was 
measured in a spectrophotometer.
2.16 RNA Extractions
Precautions were taken to prevent ribonulease degradation of RNA by 
soaking all plasticware overnight in 0.1% DEPC and rinsing with sterile 
DEPC treated water. All solutions, except those containing Tris HCl, were 
treated with 0.1% DEPC before autoclaving. The RNAzolB™ reagent 
contains guanidinium thiocyanate which is an inhibitor of RNases 
(Chomczynski and Sacchi, 1987). The vanadyl ribonuclease complex is also a 
potent RNase inhibitor.
2.16.1 Extraction of cytoplasmic RNA from rubella infected Vero cells
Reagents:
PBS
Trypsin/EDTA 
GMEM 
Lysis buffer
Vanadyl ribonucleoside complex (VRC)
TSE
Phenol/chloroform
Ethanol
Sodium acetate (3M pH 5.2)
Procedure:
The medium was poured off of the infected cells. The cell layer was washed 
with PBS, treated with trypsin, the trypsin was neutralised with GMEM and 
then centrifuged (500g, 5 min). Vanadyl (0.5ml) was quickly added to the
84
pellet followed by 4.5 ml ice cold lysis buffer. The suspension was 
centrifuged (lOOOg, 4®C, 3min) and the supernatant transferred to a 50ml 
oakridge tube containing 5ml TSE, 10ml water, 15ml phenol/chloroform and 
mixed rapidly by swirling (lOmin, RT). This was then centrifuged (lOOOg, 
lOmin), the aqueous phase transferred to a fresh tube and 10ml of 
phenol/chloroform added. The sample was mixed and centrifuged as above. 
The aqueous phase was extracted with chloroform (10ml) and centrifuged as 
above. The final aqueous phase was precipitated with 2 volumes of ethanol, 
left to stand at -70®C overnight and then centrifuged (8000g, lOmin) before 
being washed with 70% ethanol and recentrifuged. The RNA pellet was dried 
under vacuum resuspended in lOOpl water and stored at -70°C.
2.16.2 Extraction of RNA from COS-1 cells
Reagents:
RNAzolB™
Chloroform
Isopropanol (absolute, 80%)
Procedure:
Transfected COS-1 cells were lysed directly in the 6 well tissue culture plates 
by the addition of RNAzolB^^ (1ml) onto the PBS washed cell monolayer. 
The cells were solubilised by passing the lysate several times through a 
pasteur pipette before transferring it to an eppendorf tube. Chloroform 
(0.1ml) was added the mixture shaken and incubated on ice for 5min before 
centrifugation (14000g, 15min, 4°C). The aqueous phase was transferred to a 
fresh tube and the RNA precipitated by the addition of an equal volume of 
isopropanol (15min, 4°C) before centrifuging (14000g, 15min 4®C). The 
RNA pellet was washed with 80% isopropanol, dried and resuspended in lOpl 
water.
85
2.17 Electrophoresis
2.17.1 Agarose gel electrophoresis
(i) DNA electrophoresis
Separation of DNA fragments by agarose gel electrophoresis was performed 
at 150V for a time dependent on the gel dimensions and the agarose 
concentration. The concentration of agarose used depended on the size of 
the DNA to be separated, with higher concentrations (2%) being used to 
separate DNA fragments less than 500bp in size. Gels were cast and run in 
IxTAE buffer with 6x loading dye added to the samples. After 
electrophoresis, gels were stained with ethidium bromide (final concentration 
0.5pg/ml) for 20min, destained in water for 5min and the DNA bands 
visualised under UV light.
(ii) RNA electrophoresis
Reagents:
Agarose denaturing gel (1.5%)
Formaldehyde/formamide (89pl/250pl)
RNA running buffer (lOx MOPS)
RNA buffer A 
RNA loading buffer
Procedure:
RNA samples were electrophoresed through a denaturing agarose gel. The 
gel was prepared by dissolving 1.5g of agarose in 72ml of water to which 
10ml of lOx MOPS and 18ml of formaldehyde was added. This was quickly 
cast in a gel tray. The RNA samples (concentrated to 1 pi) in 11.6pl 
formaldehyde/formamide solution and 4.4pl RNA buffer A, were denatured 
by heating for lOmin at 70°C with The samples were cooled on ice for 2min 
before adding 1.5pi RNA loading buffer. The gel was electrophoresed in Ix 
MOPS at 150V, stained with ethidium bromide (5pg/ml, 30min), destained 
4°C overnight and visualised under UV light.
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2.17.2Polyacrylamide gel electrophoresis
(i) DNA sequencing gels
Reagents:
Urea
TBE (lOx)
Acrylamide (40%(w/v) acrylamide [19:1] bisacrylamide)
Ammonium persulphate (10%)
TEMED
Dimethyl dichlorosilane 
Silane 
Ethanol 
Procedure:
31.5g urea was dissolved in a solution of 9.3ml acrylamide and 7.5ml lOx 
TBE in a total volume of 75ml. Ammonium persulphate (420pl) and TEMED 
(75pi) were added and the solution mixed before pouring it between the glass 
plates. The glass plates (31cm x 38.5cm x 0.4mm) had previously been 
cleaned with detergent, MQ and ethanol before being coated. The front plate 
was coated with dimethyl dichlorosilane (repellant) and the back plate with 
methacryloxypropyl-trimethoxy silane (adhesive), both were wiped over with 
ethanol and taped together. When set the gel was pre-run at 75W in Ix TBE 
for 15-30min before the samples were loaded (5pl for a long run and 3pl for 
a short run). Electrophoresis was resumed at 75W constant power for the 
desired length of time depending on the length of sequence required.
(ii) SDS-polyacrylamide-gel-electrophoresis (SDS-PAGE) (Laemmli,
1970)
Reagents:
9% resolving gel
5% stacking gel
water 21.6ml
30% acrylamide mix 14.4ml
4x resolving buffer 12ml
10% ammonium persulphate 0.30ml
TEMED 0.03ml
water 13.9ml
30% acrylamide mix 4.0ml
4x stacking buffer 6.0ml
10% ammonium persulphate 0 .2ml
TEMED 0.02ml
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Butanol saturated with water 
lOx Tank buffer 
Loading dye
Procedure:
A 9% resolving gel was prepared from stock solutions as detailed above, the 
ammonium persulphate and TEMED being added immediately before pouring 
between the cleaned glass plates. The gel was allowed to set for Ihr under 
an overlay of butanol saturated with water. After the gel was set the overlay 
was poured off and the gel surface rinsed with Ix buffer. The stacking gel 
was prepared as detailed above, again the ammonium persulphate and 
TEMED were added immediately before pouring on top of the resolving gel, 
and the comb was inserted at this stage. Once set the comb was removed 
under the tank buffer and the wells washed with tank buffer before loading. 
The samples were boiled in loading dye for 5min before loading on to the gel. 
The gel was electrophoresed in Ix tank buffer at 150V until the dye had 
passed through the stacking gel, and the voltage was then raised to 200V for 
separation of the proteins by the resolving gel. After electrophoresis, the 
proteins were detected either by Coomassie brilliant blue staining, silver 
staining or fluorography (section 2.18.3).
2.18 Detection of Proteins in SDS-Polyacrylamide Gels
2.18.1 Coomassie brilliant bine staining
The protein bands could be visualised by staining the proteins with 
Coomassie brilliant blue stain. The gel was shaken in a box for Ihr 
containing 4x gel volume of stain. The gel was then destained with 
successive changes of destain until the desired reduction in background had 
been achieved.
2.18.2 Silver staining
This staining method is more sensitive than the Coomassie brilliant blue stain,
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being able to detect 1-lOng of protein per band. A silver staining kit 
(Biorad) was used according to the manufacturer's instructions. To reduce 
non-specific background staining it was imperative that all the glassware used 
was cleaned with 50% nitric acid, that gloves were worn and that the gel was
handled with great care.
Reagents:
Fixative enhancer concentrate 
Silver complex solution 
Reduction moderator solution 
Image development reagent 
Development accelerator reagent 
Acetic acid 
methanol
Procedure:
The SDS-PAGE gel was agitated in 200ml fixative enhancing solution (100ml 
methanol, 20ml acetic, 70ml water, 10ml concentrate) for 20-30 minutes and 
then rinsed twice with 200ml water for 10 minutes each. The gel was stained 
in a solution made by adding 5ml silver complex solution, 5ml reduction 
moderator solution, 5ml image development solution and 50ml development 
accelerator solution to 35ml water. The time taken to stain the gel was 
dependant on the intensity of the protein band required. When the intensity 
of the bands allowed visualisation of the protein required the reaction was 
stopped by lOmin agitation in stop solution (5% acetic acid).
2.18.3 Fluorographic detection of radiolabelled proteins
[ ^^S] methionine radiolabelled protein samples were prepared and separated 
by SDS-PAGE as described in section 2.17.2 (ii). After electrophoresis, the 
proteins were precipitated and fixed in the gel by the addition of 4 volumes 
of 30% methanol/10% acetic acid for Ihr ,with gentle agitation. The gel was 
subsequently immersed in EN^HANCE^^ for Ihr. The EN'HANCE™ was 
removed and to precipitate the fluorescent material 4 volumes of water was 
added with shaking for 30min, . The gel was transferred onto 3mm paper and 
dried under vacuum (80°C, 2hrs). After cooling the gel was exposed to X-ray
89
film at -70°C.
2.19 Western Blotting
This method entails the transfer of proteins from a protein gel on to a 
nitrocellulose membrane where the proteins, acting as antigens, can be 
detected by visualising bound antibody.
2.19.1 Preparation of protein gel
SDS-PAGE gels were prepared as described in section 2.17.2 (ii).
2.19.2 Protein transfer
The protein samples were transferred on to the nitrocellulose membrane in 
one of two ways:
(a) using a Trans-blot cell; A sandwich was made consisting of filter pad, 
3MM paper, protein gel, H y b o n d - C ™  super nitrocellulose, 3MM paper and a 
filter pad, all components having been previously soaked in transfer buffer 
for 20min. The sandwich was clamped in a holder and placed into the 
Trans-blot cell which was already full of transfer buffer. This was 
electrophoresed overnight at 25V at 4°C.
(b) using a Semi-dry blotter; A sandwich was made of blotting paper, protein 
gel, Hybond-C™ super nitrocellulose and blotting paper, all components 
having been previously soaked in transfer buffer for 20min. Electrophoresis 
of mini-gels in the semi-dry blotter was at lOV for 15min.
Blots were either processed straight away or stored dry.
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2.19.3 Antigen detection
ECL (Enhanced Chemiluminescence) is a light emitting non-radioactive 
method for detection of specific immobilised antigens using a secondary
antibody conjugated with horseradish peroxidase (Ab-HRP).
Reagents:
Nitrocellulose (western) blot
Blocking solution (5% milk powder in TBST)
TBS
TBST
Primary antibody
Secondary Ab-HRP
ECL detection reagents 1 and 2
Procedure:
Before use both the primary and secondary antibodies were titred using dot 
blots with the antibodies diluted in TBST 3% BSA.
The western blot was slowly shaken in blocking solution for Ihr. After 
removal of the blocking solution the blot was briefly rinsed in TBS before 
being soaked in diluted primary antibody for Ihr. Unbound antibody was 
removed by 4xl0min washes in TBST. The blot was shaken for Ihr in 
diluted secondary Ab-HRP and washed as above. Equal volumes of ECL 
reagents 1 and 2 were mixed together to give 0.125ml/cm^ and poured on top 
of the drained blot. The solution was left in contact with the membrane for 
Imin before being drained, wrapped in Saran-wrap™ and exposed to X-ray 
film. The exposure times varied from 5sec up to Ihr.
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2.20 DNA Sequencing
DNA sequencing reactions were carried out using Sequenase^^2 (USB) 
according to manufacturer's instructions. This kit is based on the dideoxy 
chain termination method of Sanger et a / . ,(1977) and can be applied to single 
stranded or double stranded DNA templates (section 2.19.1,2).
2.20.1 Prepara tion  of single stranded M13 DNA template
Single stranded DNA was extracted and purified as described in section 
2.15.2(ii).
2.20.2 Prepara tion  of double stranded pUC DNA template (Zhang et 
a / . ,1988)
Plasmid DNA was extracted and purified as described in section 2.15.1 (iii).
Reagents:
Sodium hydroxide (2M)
EDTA (2M) pH 8.0 
Ammonium acetate (2M pH 4.6)
Ethanol (absolute, 80%)
Procedure:
3pg of plasmid DNA in 15pl was denatured by the addition of 2pl NaOH and 
2|il EDTA with incubation at RT for 5min. The denatured DNA was 
neutralised by adding 2pi NH^Ac, and after quickly mixing, 60pi of 100% 
ethanol was added to precipitate the plasmid DNA using a dry ice bath for 
lOmin. Following centrifugation (14000g, 20min, 4°C) the DNA pellet was 
washed with 80% ethanol, recentrifuged (14000g, 5min, 4®C), dried under 
vacuum, resuspended in 7pl of water and used immediately in a sequencing 
reaction.
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2.20.3 Sequencing reactions
Reagents:
DNA template 
Primer (5ng/pl)
Sequencing buffer (x5, 200mM Tris.Cl pH 7.5, lOOmM MgCl^,
250mM NaCl)
DTT (O.IM)
Labelling mix, dGTP (x5, 7.5pM dGTP, 7.5pM dCTP, 7.5pM dTTP) 
""S-dATP (lOOOCi/mmol)
Termination mixes -ddA, ddC, ddT, ddG (each consisting of 80pM of 
each dNTP, 50mM NaCl, and 8 pM of the 
respective ddNTP)
Enzyme dilution buffer (lOmM Tris.Cl pH 7.5, 5mM DTT, 0.5mg/ml
BSA)
Sequenase^^2
Stop solution (95% formamide, 20mM EDTA, 0.05% bromophenol 
blue, 0.05% xylene cyanol ff)
Procedure:
DNA sequencing reactions consist of three steps, primer annealing, 
radiolabelling and extension. The primers were annealed to templates by 
mixing 7pl (Ipg) template, 2pl sequenase buffer and Ipl primer and heating 
at 65®C for 2min followed by slow cooling to 30®C. The dGTP labelling mix 
was diluted 5 fold with water and the enzyme was diluted 8  fold with ice cold 
dilution buffer. Labelling reactions contained: lOpl template-primer, 1 pi 
DTT, 2pl dilute labeling mix, Ipl radioactive label, 2pl diluted enzyme. This 
was incubated at RT for 2-5min before being divided into four 3.5pi aliquots. 
Each aliquot was added to one of the four tubes containing a prewarmed 
(37°C) 2.5pl aliquot of one of the four different termination mixes . These 
aliquots were mixed well and incubated at 37°C for 3-5min. Immediately 4pl 
of stop solution was added to each tube. Samples could be loaded onto a gel 
or stored at -20®C. Prior to loading the samples were heated for 2min at 
80°C.
2.20.4 Preparation and electrophoresis of the sequencing gel
Acrylamide gels (5%) were made and electrophoresed as described in section 
2 .17.2(i). After electrophoresis, the DNA was fixed in the gel by immersion
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in 1 0 % methanol/ 1 0 % acetic acid for 2 0 min, then thoroughly rinsed under 
running water to remove all the urea, before drying in a hot air oven at 80°C 
for Ihr. The gel was allowed to cool and was exposed to X-ray film.
2.21 Membrane Immobilisation and Detection of Nucleic Acids
2.21.1 Southern transfer of DNA (Southern, 1975)
Reagents:
Agarose gel 
Denaturing solution 
Neutralising solution 
20xSSC 
2xSSC
Procedure:
DNA was electrophoresed through an agarose gel as described in section 
2.17.1(i). The DNA was denatured by soaking the gel in four volumes of 
denaturing solution for 45min, followed by neutralising solution for 45mins. 
The gel was rinsed in 2xSSC and the blot constructed. The gel was inverted 
onto 3MM paper pre-soaked with 20xSSC, the 3MM being supported above a 
reservoir of 20xSSC, with the 3MM acting as a wick. A piece of 
Hybond-N^^ membrane was placed on top of the gel followed by two pieces 
of 3MM paper pre-soaked in 20xSSC and two pieces of dry 3MM paper. 
Tissues were piled on top of the blot followed by a weight of roughly 500g. 
The blot was left overnight , after which time the membrane was rinsed in 
2xSSC, air-dried and baked (80°C, 2hrs).
2.21.2 Northern transfer of RNA
RNA samples were electrophoresed through a 1.5% denaturing gel as 
described in section 2.17.l(ii). The gel was blotted as described for 
Southern blotting except that 20xSSPE was used instead of SSC. After 
blotting the membrane was not rinsed, as recommended by the membrane 
manufacturer.
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2.21.3 Colony lifts
Reagents:
SDS ( 1 0 %)
Denaturing solution 
Neutralising solution 
2xSSC
LA (lOOxg/ml ampicillin)
Procedure:
Dry Hybond-C^^ nitrocellulose filters were placed on the surface of the agar 
containing the colonies to be lifted. The filters were placed colony side up 
on a fresh LA plate and incubated for 30min at 37°C to give the colonies time 
to adhere to the membrane. A nylon filter disc, prewetted by placing it on 
the surface of a LA plate, was placed on top of the nitrocellulose filter and 
pressed down firmly. This was transferred to the surface of a fresh plate, 
colony side up, and incubated at 37°C for four hrs or until pin-prick colonies 
were visible. More than one set of nylon filters could be taken from the 
nitrocellulose filters. Alignment marks were made with a needle at every 
stage. The nylon filters were removed from the agar surface and treated by 
laying them colony side up onto pre-soaked 3MM paper: 5min in SDS, 15min 
in denaturing solution, 15min in neutralising solution, lOmin in 2xSSC, 
air-dried and baked for 2hrs at 80®C.
2.21.4 Plaque lifts
Replica filters of plaques on a plate were prepared by direct contact of a 
nitrocellulose filter with the plate surface. The nitrocellulose filter was 
treated as described in 2.19.3 but with no SDS treatment and only 5min steps 
for the denaturing and neutralising solutions before being air-dried and baked 
at 80°C for 2hrs.
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2.21.5 DNA hybridisations
Reagents:
Prehybridisation/Hybridisation solution 
Radiolabelled DNA probe 
20xSSC 
SDS ( 1 0 %)
Procedure:
Prehybridisations and hybridisations were carried out in either Hybaid™ 
bottles or in boxes. The membranes from the Southern blots were 
sandwiched between two pieces of nylon bolting mesh which was used to 
separate the rolled up membranes and any additional membranes that were 
processed at the same time. For large numbers of small membranes a box 
was used. Prehybridisation solution was added to the bottle and the bottle 
rotated in a Hybaid^^ Hybridisation oven for 2hrs at 65°C. A box would have 
been incubated in a shaking waterbath. After prehybridisation, a denatured, 
radiolabelled DNA probe (section 2.21.7) was added directly to the solution 
and hybridisation was continued under the same conditions overnight. The 
membranes were washed with SSC in the presence of 0.1% SDS, usually 
6 xSSC, 2xSSC, IxSSC and O.lxSSC, at 65°C, 30min for each wash. A 
decrease in salt concentration increases the stringency and an increase in 
temperature also results in an increase in stringency. The washing conditions 
depended on the specificity of the probe. After washing the membranes were 
placed on a glass plates, wrapped in Saran-wrap^^ and autoradiographed at 
-70®c.
2.21.6RNA hybridisations
RNA hybridisations were performed in RNA hybridisation buffer at 65°C as 
described for DNA hybridisation (section 2.19.5). The membranes were 
subsequently washed in 5xSSPE, 2xSSPE 0.1% SDS and IxSSPE 0.1% SDS, 
each wash was for 30min at 65®C followed by a brief wash in 2xSSPE at RT. 
The membranes were placed on a glass plate , wrapped in Saran-wrap™ and 
autoradiographed at -70°C.
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2.21.7 Preparation of labelled DNA probe using random
hexanucleotide primers
Radiolabelling of DNA probes was carried out using an Amersham 
Multiprime DNA labelling system, based on the method of Feinberg and 
Vogelstein (1983). The DNA used to produce a probe was isolated from 
agarose gels using Geneclean^^ (section 2.15.4(i)). DNA (25ng in lOpl) was 
denatured by heating in a boiling waterbath for 3mins followed by rapid 
cooling on ice. The labelling reaction contained DNA (lOpl), buffer (lOpl), 
primer (5pl), water (18pl), [a-^^P]dCTP (5pl), enzyme (2pl). This was 
incubated for 30min at 37°G before being denatured and added to the 
hybridisation solution.
2.21.8 5’ end labelling of synthetic oligonucleotides
Reagents:
Oligonucleotide
[y-""P]ATP
T4 polynucleotide kinase (PNK) (lOU/pl)
PNK buffer (1 Ox)
Procedure:
The synthetic oligonucleotides were radiolabelled at the 5' end of the 
sequence using the enzyme PNK. The reaction mix of lOpl contained 200ng 
oligonucleotide, 2pl radiolabel and 2pl PNK. The reaction mix was 
incubated at 37°C for 30min followed by heat inactivation of the PNK at 65®C 
for lOmin and cooling on ice.
2.22 Enzymes
2.22.1 Restriction enzyme digests
Restriction digests were carried out according to manufacturer's instructions 
using the buffers provided by the manufacturer unless stated.
DNA was digested in a reaction volume of 20pl, usually at 37*^ 0 for l-2hrs.
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2.22.2 Déphosphorylation of DNA
Déphosphorylation of vector DNA was performed using calf intestinal 
alkaline phosphatase (CIP). Reactions were carried out in CIP buffer 
(section 2.12) for Ihr at 37°C using lU  of enzyme. CIP was inactivated at 
70°C for lOmin, phenol/chloroform extracted (section 2.15.5) and the DNA 
recovered by ethanol precipitation (section 2.15.6).
2.22.3DNA ligations
DNA ligations were performed using T4 DNA ligase according to the 
manufacturer's instructions. Ligations were carried out using lOOng of a 
dephosphorylated vector at an insert:vector molar ratio of 2:1. Cohesive 
end ligations were incubated at 14®C for 16hrs and blunt end ligations at 9°C 
for 16hrs. Ligation products were either diluted or used directly to 
transform competent cells (section 2.23).
2.22.4Filling in of 3* recessed ends
The 3' recessed ends of restriction enzyme digested DNA and purified PCR
products were filled in using the Klenow fragment of DNA polymerase 1.
Reagents:
dNTP's (2mM each)
Klenow ( 6 U/pl)
Nick translation buffer (lOx)
Procedure:
DNA was treated in Ixbuffer containing Ipl of each of the dNTP's and Ipl 
Klenow in a reaction volume of 20pl and incubated for 45min RT. The DNA 
was phenol/chloroform extracted (section 2.15.5) and ethanol precipitated 
(section 2.15.6).
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2.22.5 Phosphorylation of DNA
The enzyme T4 polynucleotide kinase (PNK) catalyzes the transfer of 
phosphate from ATP to a 5'OH DNA terminus.
Reagents:
Dephosphorylated DNA 
PNK buffer (lOx)
ATP (lOOmM)
T4 PNK (lOU/pl)
EDTA (0.5M, pH 8.0)
Procedure:
The reaction mix was set up in a total volume of 50pl using Ipl ATP and 2pl 
PNK and incubated 37®C for Ihr. The reaction was stopped by the addition 
of 4pl EDTA. The reaction mix was then phenol/chloroform extracted 
(section 2.15.5) and ethanol precipitated (section 2.15.6).
2.23 Transformation of Escherichia coli
2.23.1 Preparation of E.coli JM109 competent cells
Reagents:
LB (ampicillin lOOpg/ml)
CaClj (50mM, lOmM Tris HCl pH 8.0)
Procedure:
1ml of an overnight culture was used to inoculate 19ml of fresh broth. This 
was incubated at 37°C with shaking until mid log phase (0.6 at ODggJ. The 
cells were pelleted (4°C, 2000 rpm, 15min) and resuspended in 10ml ice-cold 
CaCl^. The cells were left on ice before being centrifuged as above. The 
pellet was resuspended in 0 .8 ml ice-cold CaCl^, to give a final volume of 1 ml 
of cells. The cells were left for a minimum of Ihr, on ice, before being 
aliquoted into 0 .2 ml for transformations.
2.23.2 Transformation of DH5 cells with plasmid DNA
High efficiency DH5 competent cells were used according to the 
manufacturer's instruction.
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Reagents:
Ligation mix 
SOC
LA (lOOpg/ml ampicillin)
X-gal (20mg/ml)
IPTG (lOOmM)
Procedure:
1-lOng of ligated (Ipl) mix was incubated on ice with 20pl of competent 
cells for 30min before heat shocking at 42®C for 45sec, and returning to ice 
for 2 min. SOC (80pl) was added and the cells were shaken at 37®C for 
60min before plating on LA plates. For plasmids where blue/white selection 
operated, X-gal (40pl) and IPTG (lOpl) were added to the agar in each dish. 
The plates were incubated 37®C overnight.
2.23.3 Transform ation of JM109 with plasmid DNA
The procedure was the same as described in section 2.23.2 except the 
ligation mix was added to 0 .2 ml of cells which were incubated on ice for 
15min followed by 2 min heat shock at 42®C and 15min further incubation on 
ice. 0.8ml of LB was added and the cells were shaken at 37®C for 60min 
before plating on LA.
2.23.4 Transform ation of E.coli with M13 DNA
Reagents:
X-gal (20mg/ml)
IPTG (lOOmM)
H top agar 
2xTY agar
Procedure:
Transformation of DH5 or JM109 were carried out as for plasmids (section
2.20.2). After the second incubation on ice the cells were added to 4ml 
warm H top agar along with 0.2ml exponentially growing JM109, 40pl X-gal 
and lOpl IPTG. This was quickly poured on to the top of a pre-warmed plate 
and incubated overnight 37®C.
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2.24 Polymerase Chain Reaction
2.24.1 PCR based amplification of RNA (RT-PCR)
PCR amplification of RNA has to be carried out in two stages, the first is the 
generation of cDNA using reverse transcriptase eg from Rous associated 
virus 2 (RAV-2), followed by PCR amplification to generate DNA. The RNA 
was from Rubella virus infected Vero cells.
Reagents:
PCR buffer (xlO) with MgCl^ 
dNTP mix (1.25mM each dNTP)
Primer 1 
Primer 2 
RAV-2 (24U/pl)
Taq DNA polymerase (5U/pl)
Procedure:
A 50pl reaction mix was set up comprising Ipg RNA, 5pi buffer, 8 pi dNTP 
mix, 700ng primer 1, and Ipl RAV-2. The reaction mix was incubated at 
42°C for 30min. The RNA-DNA hybrid was denatured by heating in a boiling 
waterbath for 5min and then cooled on ice. 700ng primer 2 was then added 
to the reaction mix along with 2.5U Taq polymerase and a layer of liquid 
paraffin. The reaction mix was then incubated in a Hybaid thermocycler™ 
incorporating 1  cycle of dénaturation (95°C, 5min), 25 cycles of annealing 
(temperature depended on the primer sequences, Imin), and extension (72®C, 
Imin), dénaturation (95°C, Imin) followed by 1 cycle of annealing (X°C, 
Imin) and extension (7min). The PCR product was electrophoresed on an 
agarose gel (section 2.17.1(i)).
2.24.2PCR based amplification of DNA
Reagents:
Primer 1 (IpM)
Primer 2 (IpM)
PCR buffer (xlO)
MgCl^ (25mM)
dNTP mix (1.25mM each dNTP) 
Taq polymerase (5U/pl)
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Procedure:
DNA was amplified in a 50pl reaction mix comprising the reagents listed 
above using 1.5mM MgClj, 8 pl dNTP mix and 2.5U Taq polymerase, under a 
layer of liquid paraffin. The 27 cycles were as described in section 2.24.1.
2.24.3 Cloning of PCR products
PCR products were electrophoresed through agarose gels and extracted from 
the agarose using Geneclean™ (section 2.15.4(i)), 3' recessed ends were 
filled in (section 2.22.4), phosphorylated (section 2.22.5),and the DNA 
ligated into Smal digested pUC13 or 18 (section 2.22.3) followed by 
transformation o î E.coli DH5 cells (section 2.23.2).
2.25 Transfection of COS-1 Cells
2.25.1 DEAE-Dextran mediated transfection of COS-1 cells
Exogenous DNA was introduced into COS-1 cells using a DEAE-dextran
based transfection method (Lopata et al., 1984).
Reagents:
DMEM
DMEM plus 10% DMSG 
DMEM plus 80pM chloroquine 
PBS
Trypsin/EDTA
Procedure:
Semiconfluent monolayers of cells were prepared for transfection by seeding 
35mm diameter wells in a six well plate with 3x10^ cells 18hrs prior to 
transfection. For each transfection the DNA was prepared as individual 
transfection cocktails (section 2.11). At 18hrs post seeding the medium was 
aspirated off and the cells were washed with pre-warmed (37°C) PBS. The 
transfection cocktail was evenly applied over the cell monolayer surface and 
the cells incubated, with occasional gentle shaking, at 37°C for 30min. 2mls 
of DMEM supplemented with chloroquine was added to the cells and 
incubation continued for a further 2.5hrs. The medium was removed by
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aspiration and replaced with 1ml DMEM supplemented with DMSO. After 
2.5min the DMEM/DMSO medium was aspirated off and replaced with 3ml 
of fresh pre-warmed (37°C) DMEM. The cells were incubated at 37°C for 
48-72hrs. After incubation the cells were harvested appropriately.
For analysis of radiolabelled proteins the cells were radiolabelled using [^^S] 
methionine. The DMEM was aspirated off and the cells washed with met' 
MEM. [^^S] methionine (75pCi) was added to 1ml met MEM and this was 
added to the cells prior to incubation 37®C for 3hrs. The cells were 
harvested using RIPA buffer and the proteins electrophoresed by SDS-PAGE 
(section 2.17.2(ii)).
2.26 mRNA In  vitro Translation
In vitro translations were carried out according to the manufacturer's
instructions. The procedure used a coupled transcription/translation reaction
based on the rabbit reticulocyte translation system (Pelham et al., 1976) 
Reagents:
TNT™ SP 6  coupled reticulocyte lysate system (Promega)
[^^S] methionine
RNasin ribonuclease inhibitor
Procedure:
The plasmid DNA was prepared using the Magic™ miniprep method (section
2.15.1 (iii)) and used in the following reaction mix:
TNT rabbit reticulocyte lysate 25pl
TNT reaction buffer 2 pl
SP 6  RNA polymerase Ipl
Amino acid mixture minus methionine Ipl
[^^S] methionine (lOOOCi/mmol) lOmCi/ml 4pl
RNasin ribonuclease inhibitor Ipl
DNA Ipg
water to 50pl
The reaction mix was incubated at 30°C for 2hrs. 5 pi of the reaction mix was 
removed, added to 20pl SDS-PAGE loading dye and the proteins separated 
by SDS-PAGE (section 2 .17.2(ii)). The gel was dried and exposed to X-ray
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film (section 2.18.3).
2.26.1 Co-translational processing of proteins produced in vitro using 
canine pancreatic microsomal membranes
Microsomal membranes were used in conjunction with the TNT^^
reticulocyte lysate system according to the manufacturer's instructions. 
Reagents:
TNT^^ coupled reticulocyte lysate system 
[^^Sjmethionine 
RNasin ribonuclease inhibitor 
Canine pancreatic microsomal membranes 
Procedure:
Reactions were set up as described for the reticulocyte lysate system
(section 2.26) except that the total volume including 2 .5pi of membranes was 
25pl. 5pl of loading dye was added to 15pl of the reaction mix before 
analysis by SDS-PAGE .
2.27 Expression of Recombinant Proteins in Escherichia coli 
The DNA sequences to be expressed were cloned in to the glutathione S- 
transferase (GST) gene fusion vectors using standard molecular biology 
techniques.
2.27.1 Induction of the fusion protein
Reagents:
LB (ampicillin lOOpg/ml)
IPTG (lOOmM)
Procedure:
1ml of an overnight culture of recombinant E.coli grown in LB was added to 
9ml of fresh LB and incubated with shaking at 37°C until an OD^ qq of 0.6-1.0 
(about 2 hrs) was reached. lOOpl IPTG was added to the culture and 
incubation was continued for a further 5hrs. The culture was centrifuged 
(14000g, 2 min) and the pellet from 1ml of culture was resuspended in 50pl 
IxSDS-PAGE loading dye. The lysed cultures were boiled for 3min before
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loading and separating through a SDS- PAGE (section 2.17.2(ii)).
2.27.2 Purification of the fusion protein
Reagents:
PBS
PBS, 1% Triton XlOO
Glutathione (5mM in 50mM Tris HCl pH 8.0)
Glutathione agarose
Procedure:
E.coli containing recombinant or parental pGEX vectors were grown as 
detailed above (section 2.29.1). The pellet from 1ml of culture was 
resuspended in lOOpl PBS-Triton XlOO. This was sonicated in a sonicating 
water bath of ice cold water for 3x20 sec bursts. The lysed cells were 
centrifuged (14000g, 5min, 4®C) and the supernatant removed . Glutathione 
agarose beads were washed with PBS and used as a 50% solution (v/v). 50pl 
of the 50% bead solution was added to the supernatant and mixed gently by 
hand over a 3 minute period. The beads were centrifuged (500g, Imin) and 
the supernatant removed. The beads were washed twice with 1ml PBS before 
the fusion protein was eluted from the beads using 2 x 2  minute washes of 
25 pi (50% bead volume) aliquots of glutathione buffer.
2.27.3 Cleavage of the fusion protein
Reagents:
Purified fusion protein (section 2.23.2)
Human thrombin (170pg/ml)
NaCl
CaCl^
Tris HCl pH 7.5 
Procedure:
The fusion protein was purified as detailed in section (2.27.2). The fusion 
protein (80pl) was incubated at 25°C for Ihr in the presence of 85ng
thrombin in 19.5pi buffer.
Thrombin 0.5pl
CaClg 2.5mM
NaCl 150mM
Tris-HCl 50mM
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The cleaved protein was analysed by electrophoresis (section 2.17.2(ii)) and 
staining (section 2.18.1,2).
2.28 Adsorption of Serum
2.28.1 Adsorption of serum using COS-1 cells
Reagents:
Serum
PBS
Trypsin/EDTA
Procedure:
Confluent monolayers of COS-1 cells from a 175cm^ flasks were trypsinized 
(section 2.10.1) and resuspended in PBS. The cells from each flask were 
washed to remove all traces of medium before being resuspended in 0.5ml 
PBS. 0.5ml serum was added to the cells from one flask and incubated with 
shaking at 37°C for Ihr. The cells were centrifuged (14000g, 5sec) and the 
diluted serum used to resuspend another batch of washed cells. These cells 
were incubated 18hrs at 4°C. The cells were centrifuged again and the serum 
stored at -70®C.
2.28.2 Adsorption of serum using Escherichia coli
0.5ml serum was used to resuspend a pellet of E.coli from  a 10ml overnight 
culture. Adsorption was for Ihr at 37°C with shaking followed by 18hrs at 
4°C. The E.coli cells were precipitated by centrifugation (14000g, 5min), 
and the serum was filter sterilised and stored at -70°C.
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2.29 Construction of a cDNA library
2.29.1 cDNA synthesis
cDNA synthesis was carried using an Amersham cDNA synthesis system 
according to the manufacturer's instructions. Details of the mRNA and 
primers for the three libraries constructed are given in chapter 3.
2.29.2 cDNA cloning
cDNA cloning was carried out using an Amersham cDNA cloning system 
according to the manufacturer's instructions.
2.29.3Ligation of cDNA into cloning vector
Double stranded cDNA was ligated into EcoRl digested and 
dephosphorylated pUC13 (section 2.22.3).
2.29.4 Preparation of plating cells
Reagents:
E. coli NM514 cells 
LB containing 0.4% maltose 
MgSO^ (lOmM)
Procedure:
1ml from an overnight culture of NM514 was used to inoculate 50ml of 
prewarmed LB. The culture was incubated with vigorous shaking at 37®C 
until the ODggg had reached 0.5 (2.5x10^ cells/ml), when it was cooled on ice, 
the cells were precipitated by centrifugation (3000rpm, lOmin, 4®C),and the 
cells resuspended in 15ml ice-cold MgSO^. The cells were stored at 4°C.
107
2.30 Epitope Scanning (PEPSCAN)
The peptide synthesis and analysis were carried out according to the 
manufacturer's instructions and were based on the methods of Geysen et al., 
(1984).
2.30.1Peptide synthesis
The peptides were synthesised on solid polyethylene pins, based on a 
microtitre plate format, using Fmoc amino acids (more details on the 
chemistry involved are discussed in chapter 7). Using the software provided 
a schedule was generated for the synthesis of a set of octameric peptides 
overlapping by 7 amino acids. The schedule details the amount of each 
amino acid that was required each day and to which pin it had to be added.
Reagents:
Fmoc-amino acid active esters 
Hydroxybenzotriazole (HOBt)
Dimethylformamide (DMF)
Methanol 
Piperidine 
Acetic anhydride 
Diisopropylethylene (DIPEA)
Trifluoroacetic acid (TFA)
Dichloromethane 
Ethanedithiol (EDT)
Triethylamine (TEA)
Anisole
HCl
Procedure:
The required amount of HOBt was dissolved in the appropriate volume of 
DMF and used to dissolve the required amount of each amino acid for each 
day's synthesis. The blocks of pins were deprotected with 20% piperidine in 
DMF for 30min followed by a 5min wash in DMF, a 2min wash in methanol, 
and two 5nun washes in methanol before being air dried. 150pl of the 
appropriate amino acid was added to the designated wells. The blocks were 
washed for 5min in DMF and aligned in the tray of amino acids. The blocks 
were stored in a clean airtight container for 18 hours. After the addition of
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the amino acids the blocks were washed in DMF (2min), methanol (3x 2min), 
and air dried. The blocks were then deprotected and washed as above before 
the addition of the next amino acid. This was repeated until all the amino 
acids had been added. After the final deprotection, wash and dry, the blocks 
were acetylated by placing them in 150pl DMF:acetic anhydride: TEA 5:2:1 
(v/v/v) for 90min followed by a wash in DMF (2min), methanol (3x 2min), 
and air drying. The side chains were then deprotected and neutralised in 
150pl TFA:anisole:EDT, 95:2.5:2.5 (v/v/v) for 4hrs. The blocks were 
removed from the solution and air dried. They were then sonicated in 0.1% 
HCl in methanol/water (1:1) for 15min and air dried. The blocks were stored 
at 4°C with dessicant.
2.30.2 ELISA testing procedure
Reagents:
Test reagent (monoclonal/polyclonal serum)
PBS
Pre-coat buffer 
Conjugate buffer 
Substrate buffer 
ABTS
Secondary antibody HRP conjugate 
Procedure:
Before the pins were used each block was disrupted and sonicated (section
2.30.3). The pins were incubated at 25®C, with agitation for Ihr in microtitre 
plates containing 200pl/well of pre-coat buffer. The pins were then 
incubated at 4®C, with agitation, overnight with the antisera, diluted in 
pre-coat buffer. The pins were washed thoroughly (4 x lOmin) in PBS at RT 
with agitation. The pins were incubated for Ihr at the appropriate dilution of 
secondary antibody HRP conjugate in conjugate buffer, (175pl/well). The 
pins were washed again before being incubated in 150pl/well ABTS/substrate 
buffer (2mg/ml), at RT with agitation, in the dark for 45min. The reaction 
was stopped by removing the pins from the solution. The plates were read at 
405nm in a Labsystems Multiscan® Biochromatic spectrophotometer using
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the Labsytems MultiCalc programme. The pins were disrupted and sonicated 
(section 2.30.3) before being used for another sample or stored at 4®C. The 
removal of bound antibody from the pins was checked by performing the 
ELISA procedure using only secondary antibody.
2.30.3 Disruption and sonication
Reagents:
Disruption buffer 
Methanol
Procedure:
The blocks were disrupted and sonicated in disruption buffer (65®C, lOmin), 
followed by washing in MQ water at 60®C (2 x 30sec, 1 x 30min). The block 
was totally immersed in a bath of boiling methanol for 15sec before being air 
dried and used with another serum or stored at 4®C.
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Chapter 3
CLONING AND SEQUENCING OF THE 
RUBELLA STRUCTURAL PROTEINS
CLONING AND SEQUENCING OF THE RUBELLA STRUCTURAL
PROTEINS
3.1 SUMMARY
The nucleotide sequence of the subgenomic RNA of the Thomas strain of RV 
has been determined. Three cDNA libraries were constructed using oligo 
dT-cellulose purified mRNA from rubella virus infected Vero cells. Libraries 
1 and 2 were constructed in lambda gtlO and used oligo dT as a primer to 
initiate first strand synthesis. Library 3 was constructed in pUC13 and used 
three anti-sense primers complementary to regions in the capsid (C), E 2  and 
in the non-structural (NS) protein coding regions. Putative positive clones 
were isolated and probed with the primers and pKTH345 (Vidgren et al., 
1987), (section 2.3). Positive clones were obtained that contained E l,  part 
of the E2 and part of the NS coding sequences.
PGR technology was used to obtain sequences coding for the E2 structural 
protein and part of the C protein, using primer sequences from published data 
(Vidgren a/., 1987; Takkinen a/., 1988).
Sequence comparisons between the coding sequence for the Thomas strain E l 
glycoprotein and the published sequences for the E l glycoprotein of three 
other wild type strains and two vaccine strains showed a total of 17 
differences in the amino acid sequence, but only one difference was unique to 
the Thomas strain. Comparisons between the data on the E2 sequence 
showed a total of 18 amino acid changes with only one being unique to the 
Thomas strain. The sequence data on the C protein was incomplete, but 
covered nucleotides 6429-6726 and nucleotides 6878-7377, with the later 
sequence having nine nucleotide substitutions compared to the Therien 
sequence (Frey et al., 1989).
I l l
3.2 INTRODUCTION
Sequence data for the E l glycoprotein from different strains of RV have 
become available over the years, details can be found in the discussion to this 
chapter (section 3.5) with comparisons to the Thomas rubella strain 
sequence. The entire nucleotide sequence of the genomic RNA of the 
Therien strain was determined by Dominguez et ah, (1990), Appendix 1.
3.3 AIMS
The aim of this part of the study was to clone and sequence the structural 
proteins of the Thomas strain in order to develop recombinant proteins for 
use in antibody screening and diagnosis. The sequence information was also 
required for epitope mapping studies to identify potential antibody binding 
sites (Chapter 7).
NB. Numbering of the nucleotides and amino acids relates to the sequence of 
the complete rubella genome published by Dominguez et al., (1990).
3.4 RESULTS
3.4.1 Cloning of the s tructural glycoproteins
3.4.1.1 cDNA library  in lambda gtlO
Two cDNA libraries were constructed in lambda gtlO using mRNA isolated 
from rubella infected vero cells (A.Knight, PC). The RNA was extracted 
from the cells in lysis buffer using the vanadyl extraction method (section
2.16.1). Oligo dT was used as the primer for the first strand cDNA 
synthesis. The double stranded cDNA was packaged into lambda gtlO using 
an m vitro packaging kit. The library was plated out and the plaques 
replicated onto nitrocellulose filters (section 2.21.4). Library 1 was screened 
with a cDNA probe, pKTH345, which encodes for the E2 and 5' end of the
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E l glycoproteins. Positive recombinants were plaque purified upto three 
times and at each purification round the plaques were lifted onto 
nitrocellulose and hybridised with the pKTH345 probe.
Seventeen plaque purified clones were selected and the DNA extracted 
(section 2.15.2 (iii)). The DNA was digested with EcoRI, end labelled and 
electrophoresed on a 1.5% agarose gel (section 2.17.1 (i)). The gel was 
fixed, dried and autoradiographed. A variety of different sized fragments 
were visualised, the largest being 1.4kb. DNA was prepared from the nine 
clones with the largest fragments, EcoRI digested and electrophoresed 
through an agarose gel. Southern blotted (section 2.21) and hybridised with 
^^ P labelled rubella sequence from pKTH345. The end labelling (fig 3.1a) 
showed that clones 23, 40 and 41 contained an additional EcoRI restriction 
site giving two fragments. However, the Southern blot (fig 3.1b) confirmed 
that only the larger 1.4kb fragment was part of the rubella E1/E2 sequence 
due to the hybridisation with the rubella sequence from pKTH345. The 
rubella sequence was extracted from clone 23 and ligated into pUC13 and 
into M13mpl8 for sequencing (section 2.20). For the remainder of this thesis 
clone 23 in pUC13 has the designation pJNl.
Library 2 was made the same way as library 1 but it was screened with the 
PstI 0.9kb fragment of pKTH345, which encodes for the E2 glycoprotein. 
pKTH345 when digested with PstI gives two fragments of 1.1 kb and 0.9kb, 
the 1.1 kb fragment can be further digested with Xhol allowing the isolation 
of the 0.9kb fragment using Geneclean™ (fig 3.2). Eighteen putative 
positive plaques were selected, the DNA extracted and digested with EcoRI 
and Southern blotted. Restriction digests with five enzymes, Kpnl, PstI, 
Pvul, EcoRI and BamHI, indicated that clone 4 contained all of E l and the 5' 
end of E2 (fig 3.3). Digestion with Kpnl indicated that clone 4 contained an 
extra site from the published sequence of the Therien strain (Frey etal.,\9%9).
113
Clones
kb X 22 23 34 37 40 41 45 47 49 X
0 # . e e
Ê
0 . 5 6 - e
0 .1 2 5 -  #
Fig 3.1a Autoradiograph of end labelled rubella positive cDNA clones 
digested with EcoRI and separated on a 1.5% agarose gel, 
indicates Clones 23, 40 and 41 have two EcoRI fragments.
Clones
kb X 2 2  23 34 37 40 41 45 47 49 X
2.3 -  
2.0  -
0.56 —
Fig 3.1b Autoradiograph of a Southern blot of EcoRI digested putative 
rubella cDNA clones probed with the rubella sequence of 
pKTH345 (Vidgren et al., 1987).
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Fig 3.2 Location of the probe from the rubella sequence of the cDNA
pKTH345 (Vidgren et al., 1987), used to screen the Thomas RV 
cDNA libraries for rubella positive recombinant clones 
containing the E2 coding sequence.
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Fig 3.3 Restriction digests of clone pJN2 electrophoresed through a 1% 
agarose gel. The fragment sizes confirm that pJN 2 contains the 
E l coding sequence. Lane (1) 0X174 Haelll markers;(2) Kpnl; 
(3) PstI; (4) Pvul; (5) EcoRI; ( 6 ) BamHI.
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Clone 4 was ligated into pUC13 and into M13mpl8 for sequencing (section 
2.20). For the remainder of this thesis clone 4 in pUC13 has the designation 
pJN2.
3.4.1.2 cDNA library in pUC13
cDNA library 3 was constructed in pUC13 from poly(A) mRNA (section
3.3.1.1) using three 15mer oligonucleotide primers. The primers were 
synthesised in the 5'-3' direction from the anti-sense strand. The sequences 
for the primers were selected to produce cDNA clones covering E2, C and 
the start of the NS coding sequence. The sequences and location of the 
primers, 871 A, 872A, 873A, are shown in fig 3.4. Half of the double 
stranded cDNA was ligated into EcoRI digested and phosphatased pUC13. 
The resulting transformants were transfered onto fresh LA plates in a grid 
formation. Colony lifts (section 2.21.3) were made of the transformants onto 
nylon filters which were hybridised with the PstI fragment of pKTH345 and 
primers 871A and 872A.
Twenty nine clones were selected which hybridised with the PstI fragment of 
pKTH345, of which 10 contained inserts when digested with EcoRI. On 
sequencing, clone pB88 was found to be 500bp in length and homologous to 
the 3' end of the coding sequence of E2. Clone R87 when digested with 
EcoRI gave two fragments of l.Okb and 0.7kb, neither of which appeared to 
match the rubella sequence in the data base. A more extensive search of the 
data base indicated that the "A" rich sequence of R87 matched a genomic Alu 
sequence. This is a repetitive DNA sequence of 300bp, which could have 
been cloned from Vero cell RNA.
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■AAA
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873A
871A
872A
873A
GGTCGATCCGTTCCC (nt 5279-5265)
GGGGTAGTAGAAGCC (nt 6323-6508)
AGGCGCGGCGGCACA (nt 8181-8167)
Fig 3.4 Sequence and relative location within the rubella genome of the 
three primers, 871 A, 872A, 873A, used for the first strand 
synthesis of cDNA library 3.
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Twenty-seven putative rubella clones were selected after probing with 872A, 
seven clones contained inserts when digested with EcoRI. Clone U 6  was 
1.9kb in length but the remainder were under 0.6kb. The ends of U 6  were 
sequenced but no match could be found in the data base. The sequence was 
very "A,T" rich indicating that it was probably not rubella. This was 
confirmed by an homology search when the complete rubella genome 
sequence was published (Dominguez et al., 1990).
There were many putative positive clones when probed with 871 A, the 
largest, clone N5, being 0.75kb. Subsequent analysis of the sequence data 
confirmed the cDNA fragment to be homologous to the region 4527-5279 in 
the NS coding region (Dominguez et al., 1990).
The remainder of the cDNA was ligated into EcoRI digested and 
dephosphorylated pUC13. The transformants were probed with the 191bp 
Pstl/PvuII fragment from the 5' end of the rubella sequence from pKTH345 
(fig 3.2). This should have hybridised only with the transformants that 
contained the 5' E2 coding sequence but the clone with the largest insert was 
found by restriction digests and finally sequencing to be the E l coding 
sequence (fig 3.5). The clone, designated p28/34, had a 17 nucleotide 
poly(A) tail. This phenomenon also occurred during another attempt at 
obtaining a library containing E2 clones (Al-Mumin, 1991).
3.4.1.3 PCR cloning of E2 and Capsid coding sequences 
Basic strategy
RNA was extracted from Vero cells infected with the Thomas strain of 
rubella. A specific primer to produce cDNA from the RNA was used along 
with RAV2, reverse transcriptase. The single stranded cDNA was amplified 
in a standard PCR reaction using two specific primers and Taq DNA 
polymerase (section 2.24.1). The PCR reaction mix was electrophoresed
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Fig 3.5 Restriction digests of the E l cDNA clone p28/34
electrophoresed through a 1% agarose gel. Lane (l)AccI; 
(2)BalI; (3)EcoRI; (4)KpnI; (5)NaeI; ( 6 )NarI; (7)XhoI; ( 8 ) 
lambda Hindlll markers.
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on a 1.5% agarose gel (section 2.17.1(i)) and the desired PCR product 
isolated from the gel using Geneclean™ (section 2.15.4(i)). The ends of the 
PCR product were filled in using Klenow (section 2.22.4), kinased (section 
2.22.5), ligated into a Smaldigested and phosphatased pUC13 (section 
2.22.3) and transformed into JM109 or DH5 cells. The presence of the PCR 
product in the transformants was checked by DNA small scale plasmid 
preparations and restriction digests. Final confirmation that the correct 
region of cDNA had been amplified and cloned was obtained by sequencing 
(section 2.20). For each of the primer pairs used in the PCR reaction the "R" 
annotation denotes that the primer is being used to synthesise the anti-sense 
strand.
PCR synthesis of the 5’ portion of E2
The 5' end of the E2 structural protein was obtained using the primer pair 
877 and 878R, the 878R primer being utilised in the reverse transcription 
reaction.
877 CCGCTCGGCGCGCCATCCTTGGC (nt 7307-7329)
878R TGGAGTTCGCCGCGGTGGTGAGA (nt 7740-7719)
The 390bp fragment was made up of 100 nucleotides from the carboxyl end 
of the capsid, which includes the putative E2 signal peptide and 290 
nucleotides of the 5' E2 coding sequence. The reverse transcription and PCR 
reactions were carried out as described previously. The PCR product was 
cloned into pUC13, transformed into JM109 and designated pE2/5. An 
agarose gel of the PCR product can be seen in fig 3.6.
PCR synthesis of the complete E 2  coding sequence
The entire E2 coding sequence including the 5' end of the E l  coding 
sequence was obtained using the primer pair 877 and 885R, the latter being
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Fig3.6 1.5% agarose gel of PCR products generated to contain the 3'
capsid and E2 structural coding sequences. Lane (1)3’ capsid; 
(2)5' E2; (3)complete E2 with 5'El; (4)0X174 Haelll markers
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used in the reverse transcription reaction.
877 see above
885R TAGGCGTTGACAGCCCAGAAGGT (nt 8521-8498)
The PCR product was cloned into pUC13 and transformed into DH5 cells 
and designated pE2T3. pE2T3 was 1215bp in length and comprised 100 
nucleotides of the carboxy-terminus of the capsid at its amino-terminus and 
268 nucleotides of the amino-terminus of the E l coding sequence at its 
carboxy-terminus. An agarose gel of the PCR product can be seen in fig 3.6.
Synthesis of the capsid
The 3' end of the capsid, including 40 nucleotides of the E2 putative signal 
peptide, was obtained using the primer pair 882 and 8 8 OR, with an annealing 
temperature of 6 8 °C.
882 ACCGACCAACCCGTTCCAAGCAG (nt 6878-6900)
880R " CGAGCAAGAGCCCGGCAAGGAAG (nt 7377-7355)
The 499bp PCR product was cloned into pUC13 and transformed into DH5 
cells and designated C3/1. An agarose gel of the PCR product can be seen in 
fig 3.6.
The 5' end of the capsid coding sequence including 70 nucleotides prior to 
the mature capsid was obtained by PCR using the primer pair 8 8 6  and 887R 
(G.Scopes, PC). The template for the reaction was an aliquot of cDNA that 
was being used to make a new library. The 298bp PCR product was cloned 
into pUC13, transformed into JM109 and designated C5/1.
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8 8 6  GTCATCACCCACCGTTGTTTCGC (nt 6429-6452)
887R AGTCCCTGCGCTGGCCACGG (nt 6726-6707)
The sequence encoding the middle region of the capsid (nt 6728-6878) 
proved to be elusive. Reverse transcription and PCR reactions were set up 
using different primer pairs that would give a variety of sizes of PCR 
product. Two PCR products were obtained which appeared to be the correct 
size to cover the middle region but on cloning and sequencing were found to 
contain only the primer sequences and no other rubella sequence. Different 
samples of RNA were used including purified mRNA, different conditions for 
the primer pairs ie altering annealing temperatures and magnesium levels, and 
using different reverse transcriptases ie MMLV and Taq DNA polymerase. It 
has been reported that Taq polymerase has reverse transcriptase activity 
(Jones and Foulkes, 1989; Tse and Forget, 1990), therefore the Taq 
polymerase can be used for the reverse transcription and the PCR 
amplification. During this study the 150bp fragment required to join C5/1 
and C3/1 was not obtained.
A diagrammatic representation of the location of the cDNA clones obtained is 
shown in fig 3.7.
3.4.2 Sequence analysis of the structural proteins 
E l sequence
From the cDNA libraries, three clones containing the cDNA encoding for the 
E l structural protein were available for sequencing. However none of the 
clones were full length. The largest clone, pJN2 lacked the carboxy- 
terminus, and pJNl and p28/34 lacked the amino-terminus. The clone pJNl 
was subcloned into M13 m p l 8  and sequenced using the "Sequenase^^ kit" 
which is based on the dideoxy sequencing method of Sanger et ah, 1977. 
When the sequence was difficult to interpret due to compressions of the bases
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C5/1 
C3/1
pE2T3
pE2/5
pB88
pJN2
pJNl
p28/34
0.75kb
0.3kb
0.5kb
1.2kb
0.4kb
0.5kb
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1.4kb
1.4kb
Fig 3.7 Location of cDNA clones containing Thomas rubella sequences, 
obtained from the traditional cDNA libraries and by PCR, 
within the RV genome.
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the templates were made with dITP replacing the dGTP, along side templates 
made using dGTP.
Using the published sequence data for the Therien strain (Vidgren el al., 
1987), smaller subclones were made and cloned into either M13 m p l 8  or 
mpl9 using different restriction sites to give a series of overlapping clones. 
Digestion of pJNl with Smal gave an extra fragment thus indicating that an 
additional Smal site was present in the sequence. This was later confirmed 
by sequencing to start at position 8716. A diagrammatic representation of 
the different fragments that were sequenced, along with the relative location 
and the direction of the sequencing, is shown in fig 3.8.
The consensus sequence from the Thomas strain was compared to the 
published RV sequences for wild type strains, Therien (Vidgren et ah, 1987; 
Dominguez et al., 1990), M33 (Nakhasi et al., 1986; Clarke et al., 1987), 
Judith (Ho-Terry et al., 1988), and the vaccine strains RA27/3 (Nakhasi et 
al., 1989) and HPV77 (Zheng et al., 1989). The sequence of the cDNA 
encoding the Thomas strain E l structural protein along with a "Clustal" 
analysis (performed by P.Sanders) of all the above mentioned strains is shown 
in fig 3.9.
The deduced amino acid sequence for the E l protein from the Thomas strain 
of rubella was also compared to the deduced amino acid sequence of the 
other strains, again using a "Clustal" analysis (P.Sanders, PC). The 74 base 
substitutions led to 17 differences in amino acid sequence with only one 
change being unique to the Thomas strain (fig 3.10).
E2 sequence.
Two methods were used to obtain cDNA clones encoding for the E2 
structural protein, cDNA library in pUC13 and by PCR cloning of infected
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Fig 3.8 Sequencing strategy for the E l cDNA. Each of the fragments 
were cloned into M13 mplB or mpl9 and sequenced using 
"Sequenase™".
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Fig 3.9 Sequence comparison of the RV El structural protein coding
sequence.
Thom => Thomas (this thesis, Newcombe et al., 1994) GenBank L19421 
Ther (V) => Therien (Vidgren et al., 1987)
Ther (D) => Therien (Dominguez et al., 1990)
M33 (N) => M33 (Zheng et a l ,  1989)
M33 (C) => M33 (Clarke et a l ,  1987)
Judith => Judith (Ho-Terry et a l ,  1988)
HPV77 => HPV77 (Zheng et a l ,  1989)
RA27/3 => RA27/3 (Nakhasi et a l ,  1989)
The numbering of the nucleotides relates to Dominguez et a l ,
1990 Appendix 1. The amino acids are numbered from the start 
of the mature protein. The reference to Judith at amino acid 91 
is as a result of the publication of the amino acid sequence 
(Ho-Terry et a l ,  1988). The numbers 1, 2 and 3 under the 
sequences refer to the nucleotide positions of differences 
within the codons of the different strains. Alternative amino 
acids are shown for the different strains, the common amino acid 
is the upper one.
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Fig 3.9 Sequence comparison of the RV El structural protein coding sequence
8 1 9 3  8253
Thomas GGCG033CCX3CCGCCCTCACCXKXKTa:TCXTGC«XXXÎTACAACCCCCœ-<KXTATGGCGAGGAGGCTTrCACCTACCTCTGCACTGCACCGGGGTGCGCCACTCAAACACCTGTCCCC 
Thor V GGCXXX»XIXXGCCCTCACa3CGGTCGTCCTGCAG«Xn'ACAACCCCCCC-<XX:TATCXrayCGAGGCTTTCACCTACCTCTGCACTCX:ACOaX3GTGOGCCACICAAGCACCTGTCCCC 
Thor D OXGCàXXïKXXKXCTCACOGCGGTOTCXntîCAaiCXnrACAACCCCaXr-CXXrTATGGCGAGGAaXTrTa^CCTACCTCTGCACTGCACœGGGTGCGCCACTCAAGCACCTGTCXrC 
M 33: H GGCTa3GC0GC0GCCCTCAC0G0GGT0GTCT:TGCaGG<OTACAA(XXXCXr-<XX:TATGGCGAGGAiCXyrmCACCTACCTCTGCACTGCACCGO3(rrGCGœACTCAAGCACCTGTCCCC 
M 33; C &-OtXXGCOGCaXTXTCAP»aGTCGTCCTGCAKyCTACAACœCXXCCGa:TATGGCGAGGAGGCTTTC:AOTACCTCT(KJkCTGCACXXyXXTOXCCACTCAAACACCTGTCCCC 
Judith
HPV77 GGCtKXTX33KXGCCCTCACaKaUSTCGTCCTGK»GGGGTACAACCaXCC-GCCTATGGCCAGGAGGCTTTOVCCTACrrCTGCACTGCACCGGGGTGOCœACTCAAACACCTGTCCrC 
RA27/3 GG<XCOGCXXXX«XX:TCACaX»;TCCT(XTGCAGGGGTACAACCCCCCC-<KXTATGGCGAGGA[XKTTTCACCTACCTCTGCACTGCACCGGGGTGCGCCACTCAAGCACCTGTCXXX
GlyAlaAlaAlaAlaLouThrAlaValValLouGlnGlyTyrXsnProPro AlaTyrGlyGluGluAlaPhoThrTyrLeuCysThrAlaProGlyCysAlaThrGlnThrProValPro 
S63/-20 +1 Ala
8313 8173
Thomas GTGOGCCTCGCTGGOGTCCGCTTTGAGTCCAAGATTGTGGACGGCGGCIGCTTCGCCCCATGGGACCTCGAGGCCACTGGAGCCTGCATTTGOGAGAICCCCACTGATGTCTOGTGCGAG 
Thor V GTGaX%ICGCICGOGT(%T:TTTTGAGTCCAAGATTGTGGACGGCGGCIGCITTGCCCCATGGGACCTOGAGGCCACTGGAGCCTCCATTTGCGACATCCCCACIGATGTCTCGTGOGAG 
Ther D GTGCGCCTOGCTGGOGTCOGTTTTGAGTCCAAGATTGTGGAOGGCGGCTGCTTTGCCCCATGGGACCTCGAGGCCACTGGAGCCTGCATTTGCGAGATCCCCACTGATGICTCGTGOGAG 
K33: N GTGOGCCTCGCTGGOGTCCGCTTTGAGTCCAAGATTGTGGAOGGCGGCTGCTTTGCXXXATGGGACCTCGAGGCCACIGGAGCCIGCATTTGCGAGATCCCCACTGAIGTCTOGTGOGAG 
K33; C GTGOGCCTCGCOGGCGTCGGCTTOGAGTCTAAGATTGTGGAOGGCGGCTGCTTTGCCCCCTGGGACCTOGAGGCTACTGGAGCCTGCATTTGCGAGATCCCCACTGATGTIIOGIGOGAG 
Judith
HPV77 GTGCGCCTCGCCGGOGTCGGCTTCGAGTCTAAGATTGTGGAOGGCGGCTGCTTTGCœCATGGGACCTOGAGGCTACTGGAGCCTGCATTTGCGAGATCCCCACTGATGTTTCGTGOGAG 
RA27/3 GTGOGCCTCGCÎGGCGTCOGCTTrGAGTœAAGATTGTGGAOGGOGGCTGCTTTGCCCCATGGGACCTCGACGCCACTGGAGCCTGCATTTGCGAGATCCCCACTGATGTCTCSTGCGAG
ValArgLouAlaGlyValArgPhoGluSerLysIloValAspGlyGlyCysPhoAlaProTrpAspLouGluAlaThrGlyAlaCysIloCysGluIloProThrAspValSorCysGlu 
603/21 Gly
8433  8493
Thomas GGCTTAGGGGCCTGGGTACXXACaGCXCCTTGOGCGCGCATCTGGAATGGTACACAGCGCGCGTGCACCTTCIGGGCTGTCAACGCCTACTCCTCTGGOGGGTACGCGCAGCTGGCCTCT 
Ther V  GGCTTGGGGGCCTGGGTACCOGCASCCCCITGCGCGOGCATCTGGAATGGCACACAGCGOGCGTGCACCTTCTGGGCTGTCAACGCCTACTCCTCTGGCGGGTAOGOGCAGCTGGCCTCT 
Thor D GGCIIGGGGGCCTGGGTACCOGqGCCCCTTGCGOGOGCATCTGGAATGGCACACAGCGOGCGIGCACCTTCTGGGCTGTCAAOGCCTACTCCTCTGGOGGGTAOGOGCAGCIGGCCTCT
M 33; C GGCTTGGGGGCCTGGGTACXXACAGCCCCTIGCGCGOGCATCTGGAATGGCACaCAGCGCGCGTGCACCTTCTGGGCTGTCAAOGCCTACTCCTCTGGOGGGTACXXXÎCAGCTGGCCTCT 
Judith
HPV77 GGCTIGGGGGCCTGGGTACCCACAGaXCTTGOGOGCGCATCTGGAATGGCACACAGOGCGCGTGCACCTTCTGGGCTGTCAACGCCTACTCCTCTGGCGGGTACGCGCAGCIGGCCTCT 
RA27/3 GG(TTGGGGGCCTGGGTACCCACAGCCC(:TTGOGCGOGCATCTGGAATGG<a(%C*GOGCGCGTGCACCTTCTGGGCrGTCAAOGCCTACTCCTCTGGCGGGTAOGCGCAGCTGGCCTCT
GlyLeuGlyAlaTrpValProThrAlaProCysAlaArglloTrpAsnGlyThrGlnArgAlaCysThrPhoTrpAlaValAsnAlaTyrSorSorGlyGlyTyrAlaGlnLouAlaSor 
643/61 Ala Ala(J)
8553 8613
Thomas TACTTCAACCCTGGCGGCAGCTACTACAAGCAGTACCACCCTACCGCGTGCGAGGTTGAACCTGCCTTCGGACACAGOGACGCGGCCTGCTGGGGCTTCCCCACCGACACCGTGATGAGC 
Ther V TACTTCaACCCTGGCGGCAGCTACTACAAGCaGTACCACCCTACOGCSTGCGAGGTTGAACCTGCCrTCGGACACAGOGACGCXKSCCTCCTGGGGCTTCCCCACOGACACCGTGATGAGC 
Thor D TACTTCAACCCTGGCGGCAGCTACTACAAGCAGTACCACCCTACOGCCTGCGAGGTTGAACCTGCCTTCGGACACAGCGAOGCGGCCTGCTGGGGCITCCCCACCGACACCGTGATGAGC 
H33; K TACTTCAACCCTGGOGGCAGCrACTACAAGCflGTACCACCCTACClGOGTGCGAGGTTCAACCTGCCTTCGGACACAGCGACGCGGCCTGCIGGGGCTTCCCCACCGACACOGTGATGAGC 
H33; C TACTTCAACCCTGGCGGCAGCTACTACAAGCAGTACCACCCCACXXXCTGOGAGGTTGAACCTGCCTTOGGACACAGCGACGOGGCCIGCTGGGGCTTCCCCACCGACACXtnGATGAGC 
Judith
HPV77 TACTTCAACCCTGGCXKCAGCTACTACAAGCAGTACCACCCCACCGCGTGCGAGGTTGAACCTGCCTTCGGACACAGOGAOGCGGCCTGCTGGGGCTTCCCCACXGACACXGTGATGAGC 
R A 27/3 TACTTCAACCCIGGCGGCAGCTACTACAAGCASTACCACCCTACCGCGTGCGAGGTTCAACCTGCCTTOGGACACAGCGACGCGGCCTGCrGGGGCTICOCCACCGACACCGIGATGAGC
TyrPhoAsnProGlyGlySorTyrTyrLysGlnTyrHisProThrAlaCysGluValGluProAlaPhoGlyHisSorAspAlaAlaCysTrpGlyPhoProThrAspThrValMotSor
683/101
8673 8733
Thomas GTGTTOGCCCTTGCTAGCTACGTCCAGCACCCTCACAAGACCGCCOGGGTCAAGTTCXIATACAGAGACCAGGACOGTCTGGCAACTCTCCGITGCCXSGOGTGICGTGCAACGTCACCACT 
Thor V GTGTTaXXXTTGCTACCTACGTCCAGCACCCTCACAAGACCGTCCGGGTCAAGTTCCATACAGAGACCAGGACCGTCTGGCAACTCICaiTTGCCGGCGTGTCJGTGCAACGTCACCACT 
Ther D CTGTTOGCCCTTGCTAGCTACmCCAGCA(%CTCACAAGACCGTCCGGGICAAGTTCCATACAGAGACCAGGACCGTCTGGCAACTCTCCGTTGCCGGCGTGTOGTGCAAOGTCACCACT 
K33: M GTGTTCGCCCTaX?AGCTAOGTCCAGCACCCTCACAAGACOGTCOGGGTCAAGTTTCATACAGAGACTAGGACTGTCTGGCAACICTCCGTTGCIGGOGTGTOGTCCAACGTCAOCACT 
K33: C GTGTTCGCCCTOGCTASCTACGTCCAGCACXXTCACAAGACarrCOGGGTCAAGTTTCATAOGAGACTAGGACCGTCTGGCAACTCTCCGTAGCOGGCGIGICGTGCAACGTCACCACT 
Judith
RA 27/3 GTGTTCGCCCTCXOTrAGCTAOGTCCAGCACCCTCACAAGACCGTCOGGGTCAAGTTTCATACAGAGACTAGGACTGTCTGGCAACTCTCXCTTGCTGGOGTGTOGTGCAACGTCACCACT
ValPhoAlaLouAlaSorTyrValGlnHisProHisLysThrAlaArgValLysPhoHisThrGluThrArgThrValTrpGlnLouSerValAlaGlyValSorCysAsnValThrThr 
723/141 Val
8793 8853
Thomas GAACACCCGTTCTGCAACACJGCXGCACCGACAACTCGAGGTCCAGGTCCCGCCCGACCCOGGGGACCIGGTTGAGTACATTATGAATTACACCGGCAATCAGCAGTCCOGGTGGGGCCTC
Ther D CAACACCOGTTCTGCAACACGCOGCACGGACAACTCCAGGTCCAGGTCCaXXXCACCCCGGGGACCTGGTTGAGTACATTATGAATTACACOGGCAATCAGCAGTCCCGGTGGGGCCTC 
H33; H GAACACCCGTTCTGCAACACCCCGCACGGACAACTOGAGGTCCAGGTCCTGCCTGACCXTGGGGACCTGGTTGAGTACATTATGAACCACACOGGCAATCACCASTCœGGTGGGGCCTC 
H33: C 
Judith 
HPV77
RA27/3 GAACACCCGTICTGCAACACGCOGCACGGACAACTCGAGGTCCAGGTCCTGCCTGACCCTGGGGACCTGGTTGAGTACATTATGAACCACACCGGCAATCAGCAGTCXCGGTGGGGCCTC 
 ........................ ....... ...2...y.....3...........3..............3x**«<....................3 ..3 .... . . .. . . .. . . .. . .
CluHisProFheCysAsnThrProHisGlyGlnteuGluValGlnValProProAspProGlyAspLouValGluTyrlleKetAsnTyrThrGlyAsnGlnGlnSorArgTrpGlyLou 
763/181 Lou His
8913 8973
Thomas GGGAGCCCGAATTGCCACGGCCCOGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTCGGGGCCACXHrCAGAGCGTœCœGCTGCGCCTGGTCGACGCC 
Ther V GGGAGCCCGAATTGCCAOGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTCGGGGCCACGCCAGAGCCCCCCCCGCTGOGCCTGGTCGAœCC 
Thor D GGGAGCCCGAATTGCCACGGCCCCGATTGGGœTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGCGGGCCACGCCAGAGCGCCCCCCGCTGOGCCTGGTCGACGCC 
M33: M GGGAGCCCJGAATTGCrATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGGGGGTCACCCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC 
M33: C aK3AGCCCGAATTGTCATGGCCCCGATTCGGCCTCCCC3GGTTTGCCAACGCCACTCCCCTGACTGCTCGCCGCTTGTGGGCGCCACGCCAGAGCGTCCCCGGCTGCXXCTGGTCGACGCX: 
Judith
HPV77 GGGAGCaXAATTGTCATGGCCCCGAtTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCTCGCGGCTTGTGGGGGCCACGCCAGAGCGTCCCCGGCTGCGCCTGGTCGACXXrC 
RA27/3 GGGAGCCCGAATTGCCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACCCCATTCCCCTGACTGCTCGCGGCTTGTGGCGGTCACCCCAGAGCGTCCCCGGCTGCGCCTGGTCGACGCC ..............................g..........,.]........................
GlySorProAsnCysHisGlyProAspTrpAlaSerProValCysGlnArgHisSerPrcAspCysSerArgLeuValGlyAlaThrProGIuArgProArgLeuArgLouValAspAla 
803/221 Val
129
9033 9093
Thomas GAaa«XCa:Ta:T«aXaVCTOCCCCTGGG<XaXXGAGCrrGTGCCTCACGCCTGTCATA(XX:TCTCAGGCXXXKAAGTGCXXy«::TCCACATACGCXXnXXyWXX:TACGGCCATGCrACC
Ther V 6ACGACCCO:TGCTGCG<»CTGCCXXrrGGACXXGGOCAGGTGT«XïrCACGCCTGTCATAGGCTCT(»GGCCXXXAAtnGa3GACTCCACATACGCXOTGGACCGTACGGCCATGCTACC 
Ther D GAœACCCCCTGCTGCXXACTGœCCTCXaCCaaXX3ACCTGTGGGTCACtXXTGTCATAGGCTCTC»GGaXXXAAGTG0GGACTCCACATA0[X»:rGGA«CTACaXXATGCTAœ 
M33: H GAa»CCCCCTGCTGCa»CT<XXXXTGaKXOKKX;AGGTGTGGGTCAOCXX:TCTCATA«CTCTCAGGaKXraUÆT«XX»CTCCACATACGCXXrrGGACOT
^ith
HTV77 CACGACX%X%IGCT(X%X%CIGCCCCX3%(XX%%(X%ÜW%TrGT«%TCA0GCCTGTCATAGGCICICAGGaXXX%AGIG0GGACT(%:ACAT 
RA2T/3 ^CGACCCCCTGCTGOGCACTGCCCCTGGGCCOGG^^
AspAspProLeuLeuArgThrAlaProGlyProGlyGluValTrpVelThrProValIleGlySerGlnAlaArgLysCysArgLeuHisIleArgAlaGlyProTyrGlyHisAlaThr843/261 «
9153 9213
Thomas <nOTAAATGCXXX»GTGGATCX:ACCCCCACACCACa«KI»CXXXTGGCACCCACCGGGCCCCTTGGGGCTGAAGTTaU«ÎACAGTTCGCXXXXnGGCCCTGCCACGCGCGTTGGCXKXA 
Ther V CTCGAAATGCCCGAGTGGATCX»0GCXXACAaa«X7«;aykCCXXrrGGCATCXACaKGCCCCrTGGGGCTGAAGTTCAAGACAGTTCGCCXXOTGGCXXTGCCACGCACCTTAGCGCCA 
Ther D GTO»AAIGCCCGAGTGGAT(rACGCCXACACCACX»G<XACCCCTGGCATCCACCGGGCCCCrTGGGGCTGAAGTTCAAGACAGTTCGCCCGGTGGCCCTGœACGCACGTTAGCGCCA 
M33; K CTCGAAATGCCCXU«rrGGAICXaaKXXACTCTACCAGCGACCCXTGGCACCCATO»3CaXTTGCGGTTGAACTTCAAGACAGTTaXXCGGTGGCCCTGa3\CGCGCXOTAGCCCCA 
M33: C CTCGAAAIGCC0GAGTGGAICX»aKXXACACTAaaUX2»CCCX:TGGCACCCACCGGGCCCCTTGGGGCrGAAGTTCAAGACAGTTCGœCGGTGGCCCTGCCACGCGCGTTAGCGCCA 
, COGAGTGGATCXAOGCCCACACCACCAGOGACCCCTGGCACTX:ACCGGGaXCTTGGGGCTGAAGTTCAAGAakGTTOGa»arrrj-.rCCrGCCACGOKCTTAGCGCCA 
HPV77 GTŒAAATGCaxaGTCGATCCAOGCCCACACTACCAGOGACCCCTGGCACCCACCGGGCCCCTTGGGGCTGAAGTTCAAGACAGTTŒCCCGGTGGCCCTGCCACXXJÎCGTTAGCGCCA 
RA27/3 GTCGAAATGCCayCTGGATCX:AOGCCCACTCTACCaGCGACm:TGGCA(XCACCCGGCCCCTTGaXrrTGAAGTTCAAGACAGTTCGCCCGGTGGœCTGCCAœCGCGTTAGCGCCA
ValGluMetProGluTrpIleHisAlaHisThrThrSerAspProTrpHisProProGlyProLeuGlyLeuLysPheLysThrValArgProValAlaleuProArgAlaLouAlaPro
883/301 Ser Arg Thr
9273 9333
Ther V CmaxaATGTG0GTGTGACCGGGTGCTACCAGTG0GGTACCCCXTXTy:TGGTGGAAGGCCTTGCCCC0GGGGGAGGCAATTGCCATCTCACCGTCAATGGCGAGGAa;TC^TCGm7rr
M33: H CXXCG(aATGTGCGTGTGACOOGGTGCTAajyGTGOGGTACCCCaXSCTGGTGGAAGGCCTTGCCCOGGGGGGAGGGAACTGCCATCTTACOGTCAATGGCGAGGATGTCGGCGCCTTC 
M33: C CCTCGCAATGTCCGTGTGACaxanGCTACXaGTGCGGTACCCCXXKTOTGGIGGAAGGCCTIGCCCCAGGGGGAGGGAACTGCCATCTTACOGTCAATGGCGAGGACGTCGGCGCCTTC 
J u d i t h  CCTCCCAATGTGOGTGTGACCGGCTGCTACCAGTGCGGTACCCCCGOGCTGGTGGAAGGCCTTGCCCCAGGGGGAGGGAATTGCCATCTCACCGTCAATGGCGAGGAC33TCGGCGCCGTC 
HPV77 CCTCGCAATGTGOGTGTGAQXGCTGCTAaaGTGCGGTACCXXOGCGCTGGTGGAAGGCCTTGCCCCASGGGGAGGGAACTGCCATCTTACCGTCAATGGCGAGGACGTCSGCGCCTTC 
RA27/3 CCCOGCAATGTGOGTGTGACOGGGTGCTACCAGTGCGGTACCCCOGOGCTGGTGGAAGGCCTTGCCCCGGGGGGAGGGAATTGCCATCTCACXGTCAATGGCGAGGATGTOGGOGCCTTC
ProArgAsnValArgValThrGlyCysTyrGlnCysGlyThrProAlaLeuValGluGlyLeuAlaProGlyGlyGlyAsnCysHisLeuThrValAsnGlyGluAspValGlyAlaPhe
Leu Val
9393____________________________  9453
Thomas CCCCCTGGGAAGI ICüICACCGCCGCCCTCCTCAACACCCCCCCGCCCTACCAAGTCAGCTGCGGGGGCGAGAGCGATCGCGCGAGCGCGCGGGTCATTGATCCCGCCGCGCAATCGTTT 
Ther V œCCCTGGGAAGII<aXCACOGCCGCCCICCI<aACACaXXCaaXCTACCAAGTCAGCTGCGGGGGCGAGAGOGATCXXGOGAGCGCGCCGGTCATCSACCCOGCOGOGCAATOGTTT 
Ther D CCCCCTGGGAAGI r<^ICACCGCCGCCCICCTCAACACCCCCCOGCCCTACCAAGTCAGCTGCGGGGGCGAGAGCGATOGOGCGACOGCGOGGGTCATCGACCCOGGCGCGCAATCGTTT 
h33; K CCCCCIGGGAAGIICGTCACCGCCGCCCICCTCAACACTCCCCCGCCCTACCAASTCAGCTGOGGGGGTGAGAGOGATCGOGOGAGCGCCOGGGTCATTGACCCOGCOGOGCAATOGTTT 
*Ü3: C CCCCCIGGGAAGTTCGTCACOGCOGCCCTCCTCAACACTCCCCCGCCCTACCAAGTCAGCTGOGGGGGTGAGAGCGATCGCGCGAGCgcGCGGGTCATTGAeCCCGCCGCGCAATCGTTT 
Judith CCCCCTGGGAAGI IQ^TCACCGOCGCCCTCCTCAACACCCCCCOGCCCTACCAAGTCAGCTGOGGGGGOGAGAGOGATOGCGCGACOGOGCGGGTCATTGACCCCGCOGCGCAATOGTTT 
HPVn CCCCCTGGGAAGI ILGICACCGCGGCCCTCCICAACACTCCCCOGOCCTACCAACTCAGCTGOGGGGGTGAGAGCGATCGOGCGAGCGCGCGGGTCATTGACCCOGCCGOGCAATOGTTT 
RA27/3 CCXXXrrGGGAAGTTCGTCACXGCCGCCCTCCTCAACACTCCCCOGCCCTACCAAGTCAGCTGOGGGGGCJGAGAGCGATOGCGOGAGCGCGCGGGTCATTGACCCCGCCGCGCAATCGTTT
ProProGlyLysPheValThrAlaAlaLeuLeuAsnThrProProProTyrGlnValSerCysGlyGlyGIuSerAspArgAlaSerAlaArgValIleAspProAlaAlaGlnSerPhe
963/381 Thr
Th 9573
Ther V ACOGGOGTGGIGTATGGCACACACACCACIGCIGIGICGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCCCATIGGTGGCAGCTCACTCTGGGOGCCACTTGOGCCCTCCCACTC 
Ther 0 ACCSGCGTGGTGTATGGCACACACACCACTGCTGIGÎCGGAGACCCGGCAGACCIGGGOGGAGTGGGCTGCTGCCCATTGGTGGCAGCTCACTCIGGGOGCCATTTGOGCCCTCCCACTC 
H33: n ACCGGOGTGGIGIATGGCACACACACCACIGCÏGIGICGGAGACCCGGCAGACCTGGGOGGAGIuGGCTGCTGCTCATTGGIGGCAGCTCACTCTGGGOGCCATTTGCGCCCTCCTACTT 
**33; C ACOGGOGIGGIGIATGGCACACACACCACIGCTGIGÏCüGAGACCOGGCAGACCTGGGOGGAGTGGGCTGCTGCTCATTGGTGGCAGCTCACTCTGGGCGCCATTTGCGCCCTCCCACTC 
Judith ACOGGCXiTGGIGIATGGCACACACACCACIGCIGIGICGGAGACCCGGCAGACCTGGGOGGAGTGGGCTGCTGCCCATTGGTGGCAGCTCACTCTGGGOGCOGTCTGOGCCCTCCTACTC 
HPV77 ACOGGCGTGGIGIATGGCACACACACCACTGCTGTGICGGAGACCCGGCAGACCTGGGCGGAGTGGGCTGCTGCTCATTGGTCGCAGCTCACTCTGGGOGCCATTTGCGCCCTCCTACTC 
8h2T/3 ACCGGCGIGGTGTATGGCACACACACCACIGCTGTGTCGGAGACCOGGCAGACCTGGGCGGAGTGGGCTGCTCCCCATTGGTGGCAGCTCACTCTGGGOGCCATTTGOGCCCTCCTACTT
ThrClyValValTyrGlyThrHisThrThrAlaValSorGIuThrArgGlnThrTrpAlaGluTrpAlaAlaAlaHisTrpTrpGlnLeuThrLeuGlyAlalleCysAlaLeuLeuLeu
Thr Pro
Val
9633 9593
Thomas GCCGGCIIACTCGCIIGCTGTGCCAAATGCIIGTACTACIIGOGCGGOGCTATAGOGCCGCGCTAGTGGGCCCCCGOGCGAAACCCGCACTAGCCCACTASATTCCOGCACCTGTTGCTG 
Ther V GCTGGCIIACTOGCIIGCTGTGCCAAAIGCIIGTACTACTTGCGCXXXajCTATAGCGCCGCGCTAGTGGGCCCCCGOGCGAAACCCGCACTAGGCCACTAGATTCCOGCACCTGTIGCIG 
Ther D GCTGGCTTACTCX^ I'IuCIGIGCCAAATGCIIGIACTACTTGCGOGGOGCTATAGCGCCTOGCTAGTGGGCCCCCGCGCGAAACCCGCACTAGGOCACTAGATCCCOGCACCTGTTGCTG 
**33: ** GCTGGCTTACTCGCTTGCTGTGCCAAATGCTIGTACTACIIüCGCCGCGCTATAGOGCOGOGCTAGCGGGCCCCOGCGOGAAACCCGCACTAGCCCACTAGATTCCCGCACCTGTIGCTG 
**33: C GCTGGCTTACTOGCTTGCTGTGCCAAAIGCIIGIACTACI IGCtoCuGOGCTATAGCACCGOGCTAGOGGGCCCCOGOGCGAAACCOGCACTAGOCCACTAGATTCCCGCACCTGTTGCIG 
^^^^h GCTGGCIIGCTOGCIIGCTGTGCCAAGIGCIIGTACTACTTGOGOGGCGCTATAGOGCOGOGCTAGTGGGCCCCOGOGTGAAACCCGCACTAGCCCACTAGATTCCCGC-CCTGTTGCTG
8^^/^ ^^^^^^^^*^P*^*-TGTGCCAAAIGCIIGTACTACTIGCGCGGCGCTATAGCGC0GCGCTAGTGGGCCCCCG0GCGAAACC0GCACTAGCCCACTAGATTCCCGCACCTGTTGCTG
AlaGlyLeuLeuAlaCysCysAlaLysCysLeuTyrTyrLeuArgGlyAlalleAlaProArg 
1013/461 481
9753 
Thomas CATAGpA 
Ther V TATATpA 
Ther D TATAGpA 
M33: N CATAGpA 
M33: C CATAGpA 
Judith TATAGpA 
HPV77 CATAGpA 
RA27/3 CATAGpA
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T h o m a s  
T h e r  V  
T h e r  D  
M 3 3  N  
M 3 3  C  
J u d i t h  
H P V 7 7  
R A 2 7 3
V EM PEW IH A H TTSD PW H PPG PLG LK FK TV R PV A L PR A L A PPR N V R V T G C Y Q C G T PA SL V E G L A PG G G N C H L T V N G E D V G A FPPG K FV T A A L N T PPP Y Q V S
T h o m a s  
T h e r  V  
T h e r  D  
M 3 3  N  
M 3 3  C  
J u d i t h  
H P V 7 7  
R A 2 7 3
4 5 0  4 8 1
C G G E SD R A SA R V ID PA A Q SFTG W Y G TH TTA V SETR Q TW A EW A A A H W W Q LTLG A IC A LLLA G LLA C C A K C LY Y LR G A IA PR  
S  T  P
I  
I  
I
Fig 3.10 Comparison of the RV El amino acid sequence
Thom => Thomas (this thesis, Newcombe et al, 
Ther (V) => Therien (Vidgen et al, 1987)
Ther (D) => Therien (Dominguez et al, 1990) 
M33 (N) =>M33 (Zheng et al, 1989)
M33 (C) => M33 (Clarke et al,  1987)
Judith => Judith (Ho-Terry et al, 1988)
HPV77 => HPV77 (Zheng et al, 1989)
RA27/3 => RA27/3 (Nakhasi et al,  1989)
1994))
The amino acids are numbered from the start of the mature protein.
* Consitutive substitution *** putative glycosylation site
epsl, eps2 and eps3 (Terry et al, 1989) 
eps 4 (Mitchell et al, 1992)
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Vero cell RNA. cDNA clone pB 8 8  was synthesised using the primer 873A 
for the first strand synthesis. The cDNA was 500bp in length and located at 
the 3' end of the E2 sequence (nt7682-8181). The sequence contained a Kpnl 
site at nucleotide 8015, not found in the Therien sequence (Vidgren et al., 
1987). The new Kpnl site was also found in the other cDNA clones that 
covered this part of the E2 sequence, pJN2 and pE2T3.
Capsid sequence
Two cDNA clones encoding parts of the C structural protein were obtained 
by PCR. The sequence data for clone C5/1 was incomplete but adequate to 
ascertain that it was homologous to the 5' end of the C structural protein in 
the region nucleotides 6429-6726. This clone contained the 5' end of the C 
coding region with an additional 70 nucleotides at the carboxy-terminus.
The sequence data for C3/1 was also incomplete but again adequate to locate 
it at nucleotides 6878-7377, the 3' end of the C coding region. It also 
included 40 nucleotides of the E2 putative signal peptide. Of the 430 
nucleotides sequenced there were nine nucleotide substitutions when 
compared to Therien (Dominquez et al., 1990), which resulted in nine amino 
acids substitutions. The differences may be due to sequencing errors as the 
DNA was only initially sequenced in order to confirm the presence of rubella 
sequence.
Non-structural sequence
cDNA clone N5 was isolated from a cDNA library in pUC13 using the primer 
871 A, which was used to initiate first strand synthesis of the cDNA. The 
subsequent publication of the genome sequence (Dominguez et al., 1990) 
revealed that N5 was located at nucleotides 4527-5279.
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3.5 DISCUSSION 
cDNA cloning
cDNA clones encoding 95% of the structural protein coding sequence of the 
Thomas strain of RV were obtained from cDNA libraries. The RNA was 
isolated from infected Vero cells. The cDNA libraries were generated using 
either oligo dT or specific oligonucleotide primers to initiate first strand 
synthesis. The sequence for the primers for the PCR reactions were taken 
from the published data on the Therien strain (Vidgren et al., 1987; Takkinen 
et al., 1988).
The isolation of the E l clone, p28/34 was unexpected as the cDNA library 
was initiated by the three specific primers, 871 A, 872A and 873A, none of 
which were in the E l coding region. p28/34 contained no sequence 
homology to the primers used, therefore the sequence may have been initiated 
by self-priming. This also happened during the construction of another 
cDNA library (Al-Mumin, 1990). The phenomenon of self-priming has been 
reported in the cloning of pestivirus Bovine Viral Diarrhoea (BVDV). The 
reverse transcription of BVDV to synthesisecDNA was inefficient and low 
molecular weight RNA species <200bp in size were isolated from the viral 
RNA. It was assumed that these low molecular weight cellular RNAs served 
as random primers on the BVDV RNA (Collet et al., 1988). The RNA in this 
study was from RV infected Vero cells and could contain small RNA species 
capable of acting as primers. This could also explain the isolation of cDNA 
clones containing the "Alu" sequences, an "A" rich repetitive sequence of 
about 300bp. Vero cells are Green monkey kidney cells and it is known that 
all higlf^eukaryotes have an abundance of repetitive DNA sequences. Alu 
sequences are especially abundant, varying in number depending on the species 
of eukaryote, recurring about a million times in the human genome. These 
sequences are so named because of the presence of a target site for the 
restriction enzyme Alul.
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The absence of the 150bp region (nt 6727-6877) of the C coding region may 
be due to secondary structure. This region is 76.8% G/C rich, which may 
have caused problems during the PCR reaction. A variety of primer pairs 
were tried in an effort to obtain this region. It would seem that the reaction 
conditions and primer sequences needed to be optimised further to obtain this 
region. RNA isolated from peg precipitated virus may have been better, 
reducing any interference from cellular RNAs.
Sequence analysis 
E l sequence
The nucleotide sequence encoding the structural protein E l of the Thomas 
strain consists of 1443 nucleotides (481aa) as in other strains. There is a 
palindromic region capable of forming a stem loop structure at the 3' end 
which may be involved in initiation of replication of the RV (Nakhasi et al., 
1990)(fig 1.6). The stem loop consists of a four member loop, TATA, and a 
G-C rich stem, 57 nucleotides upstream of the poly(A) tail.
A comparison was made between the Thomas strain and the published 
sequences for the wild type stains Therien, M3 3 and Judith and the vaccine 
strains HPV77 and RA27/3, revealing a 95% homology between strains. 
There were a total of 74 base substitutions of which 12 were at the first 
position, 6  at the second position and 56 at the third position in the codon. 
The substitutions resulted in 17 amino acid changes (one amino acid 
contained two nucleotide substitutions) between the strains but only one 
substitution was unique to Thomas, Ala^^  ^ =>Val (Ala*^  ^ =>Val, numbering 
from the start of the mature El)(fig 3.10). When compared to the Thomas 
strain these changes resulted in 7-8 amino acid changes with the Therien 
strain (Vidgren et al., 1987; Dominguez et ah, 1990), 1-3 amino acid changes 
with the M33 strain (Clarke et al., 1987; Nakhasi et al., 1986), 5 amino acid 
changes with Judith (Ho-Terry a/., 1988), 8  amino acid changes with
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RA27/3 (Nakhasi et al., 1989) and 2 amino acid changes with HPV77 (Zheng 
et al., 1989). This data along with the number of substitutions between each 
of the strains is shown in table 3.1. The data shows that there is a greater 
number of mutations between the vaccine strain RA27/3 and the wild type 
strains ( 8 - 1 2 ) compared to the number of mutations between the vaccine 
strain HPV77 and the wild type strains (1-8). HPV77 was attenuated from 
M33 with a single amino acid change Arg^°  ^=>Gly (Arg Gly numbering 
from the start of the mature E l sequence) (M33 (N) sequence) in E l,  along 
with one in the capsid and three in E2. The similarity in protein sequence 
between HPV77 and M33 could explain the high incidence of side effects 
from the vaccine which resulted in its withdrawal from the market in 1979. 
HPV77.DK12 had a ratio of 49% side effects in vaccinees compared to 14% 
from RA27/3 (Polk et al., 1982).
Table 3.1 The num ber of substitutions observed in the deduced amino 
sequence of the E l  s truc tura l protein between the eight 
strains analysed in this study.
Thomas Therien
(V)
Therien
(D)
M3 3 
(N)
M3 3 
(C)
Judith HPV77 RA27/3
Thomas 7 8 1 3 5 2 8
Therien
(V)
3 6 6 6 7 1 1
Therien
(D)
7 7 8 8 1 2
M3 3 
(N)
2 4 1 8
M3 3 
(C)
6 1 9
Judith 5 1 1
HPV77 8
V Vidgren; D Dominguez; N Nakhasi; C Clarke; references cited on previous 
page.
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The E l sequence of Thomas strain was incorporated into a study by Frey and 
Abernathy, (1993) for "the identification of strain-specific nucleotide 
sequences in the RA27/3 rubella vaccine". The aim of his study was to 
determine if characteristic nucleotide sequences exist in the RA27/3 vaccine 
strain to allow it to be discriminated from other RV strains. From the 
collection of strains made available, including Thomas, the analysis indicated 
that the RA27/3 strain could be identified after PCR of unknown isolates.
E2 sequence
The sequence encoding the E2 structural protein was contained in two cDNA 
clones pE2T3 and pB 8 8 . The nucleotide sequence of pE2T3 was compared 
extensively with the other RV strains, Therien (Vidgren et a l ,  1987; 
Dominguez et a l ,  1990), M33 (Clarke et a l ,  1987), HPV77 (Zheng et a l ,
1989) and RA27/3 (Nakhasi et a l ,  1989), (Al-Mumin, 1991). There was 
over 95% homology between the strains. The M3 3  strain sequenced by 
Clarke et a l ,  (1987), showed a high degree of inconsistency and did not 
agree with the M33 sequence of Zheng et a l ,  (1989). The comparison of 
the deduced amino acid sequence was therefore made using Zheng et a l ,  and
fcXvose o  ■A
not^Clarke et a l ,  and is shown in fig 3.11. Comparisons of the entire 24S 
subgenomic RNA of HPV77 and M33 reveals five amino acid changes, one in 
C, one in E l and three in E2 (Zheng et a l ,  1989). The three changes in E2 
are Ser"^ ^^  =>Tyr, Thr“^^  ^=>Ile and Thr"^ ^^  =>Ala. The change at position Thr"^ '  ^
=>Ile could be significant because it results in the loss of a putative N-linked 
glycosylation site at Asn“^ °^. This could alter the secondary structure of the 
protein and effect the E1:E2 heterodimer configuration which in turn could 
change the viral tropism and infectivity of HPV77 (Zheng et al., 1989).
A comparison was made between the nucleotide and deduced amino acid 
sequence of pE2T3 and pB 8 8  to see if there were any variations due to the 
different methods used to obtain the clones, PCR amplification and cloning
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1 E2->
E2 Thom 268 RSARHPWRIRFGAPQAFLAGLLLAAVAVGTARAGLQPRADMAAPPTLPQPPRAHGQHYGH
E2 TherrV H W T A TL R
E2 TherrD H W T A TL C
E2 M33rNa H W A A MP R
E2 HPV77rZ R W A A MP R
E2 RA27/3rN H S 
*
A
*
V
*
MP R
E2 Thom 308
! ! ! ! ! ! 
HHHQLPFLGHDGHHGGTLRVGQHYRNASDVLPGHWLQGGWGCYNLSDWHQGTHVCHTKHM
E2 TherrV A Y
E2 TherrD R Y
E2 M33rNa R H
E2 HPV77rZ R H
E2 RA27/3rN R H
*
E2 Thom 368
! ! ! ! ! ! 
DFWCVEHDRPPPATPTPLTTAANSTTAATPATAPDPCHAGLNDSCGGFLSGCGPMRLRHG
E2 TherrV A P STT A A
E2 TherrD D P STT A R
E2 M33rNa D S STT P R
E2 HPV77rZ D S YIA P R
E2 RA27/3rN D S STT A R
* * * *
327
3 8 7
4 4 7
E2 Thom 448 ADTRCGRLICGLSTTAQYPPTRFGCAMRWGLPFWELWLTARPEDGWTCRGVPAHPGTRC 
E2 TherrV C A
E2 TherrD C A
E2 M33:Na C T
E2 HPV77:Z C T
E2 RA27/3:N Y T
5 0 7
E 2 Thom 5 0 8  PELVSPMGRATCSPASALWLATANALSLDHALAAFVLLVPWVLIFMVCRRACRRRGAAAA 5 6 7
E 2 T h e r iV  L S
E 2 T h e r r D  L L
E2 M 3 3 :N a F  L
E 2 H P V 77:Z  F  L
E2 R A 2 7 /3 :N  F  L
E2 Thom  5 6 8  LTAWLQGYNPPAYG 5 8 2
E 2 T h e r r V
E2 T h e r r D
E 2 M 33rN a
E2 HPV77 r Z
E 2 R A 2 7 /3 rN
Fig 3.11 Sequence comparison of RV E2 structural protein coding sequence.
Thom=> Thomas (Al-Mumin, PhD thesis, 1991)
Ther(V) => Therien (Vidgren et al, 1987)
Ther(D) => Therien (Dominguez et al, 1990)
M33 => M33 (Zheng et al, 1989)
HPV77 => HPV77 (Zheng et al, 1989)
RA27/3 =>RA27/3 (Nakhasi et al, 1989)
* => conservative amino acid change ! ! ! => glycosylation site
1 => putative E2 signal peptide
2 => E2 trans-membrane anchor
3 => putative El signal peptide
137
and traditional cloning using cDNA . Due to the nature of PCR amplification 
misincorporation by the Taq DNA polymerase may occur and the incidence of 
misincorporation increases as the annealing temperature rises, ie 70°C instead 
of 50®C (Tindall et a l ,  1988), as was the annealing temperature in the PCR 
of pE2T3. Within the region covered by pB 8 8 , there was only one amino 
acid change in the deduced sequence between pE2T3 and pB 8 8  at Ile^ ^^  => 
Arg and this change was unique to pB 8 8  when compared to the other 
sequences. The confirmation of this change would require sequencing of 
more E2 clones to eliminate the possibility of sequencing errors. The change 
at nucleotides 8018-8019 led to an additional Kpnl restriction site in both 
pB 8 8  and pE2T3 and is also found in M33 and HPV77 but not in Therien or 
RA27/3.
Capsid sequence
The two PCR derived sequences encoding the C structural protein showed 
good homology with the C sequence of the Therien strain (Dominguez et ah,
1990). Clone C3/1 differed by nine nucleotides, all of which were at the 
second position in the codon therefore resulting in nine amino acid changes. 
The relatively high incidence may be due to sequencing errors.
Non-structural sequence
The cDNA clone N5 was located at nucleotides 4527-5279 in the NS coding 
region, corresponding to the position of the helicase motif (Dominguez et 
ah, 1990). The sequence showed over 95% homology with the 
corresponding sequence of the Therien strain (Dominguez et al., 1990), the 
only published sequence of the NS coding region of the RV. Clone N5 was 
available to be used as a probe for the isolation of associated regions of the 
NS coding sequence during a project designed to sequence all of the Thomas 
NS proteins, along with the sequences for Cendehill and other wild type 
strains (P.Johnson, PC).
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Sequence data has been obtained by PCR and the construction of cDNA 
libraries encoding the E l,  E2 part of C structural proteins and a region of NS 
proteins of the Thomas strain of the RV. There are differences between the 
sequence of the Thomas strain and the other RV strains to which it was 
compared but few were unique to the Thomas strain. The biological 
significance of any of these changes is unknown.
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Chapter 4
EXPRESSION OF RUBELLA E l PROTEIN
IN E. COLI
EXPRESSION OF RUBELLA E l PROTEIN IN ESCHERICHIA COLI
4.1 SUMMARY
The complete E l coding sequence and various subfragments were expressed 
in E.coli using a series of pGEX expression vectors. All but two of the 
constructs produced visible glutathione S-transferase (GST)-El fusion 
proteins by conventional staining methods. All the visible GST-El fusion 
proteins appeared to be antigenic when reacted with human polyclonal serum.
Two subfragments were designed to contain either three or four of the 
described epitopes located in E l (Terry et al., 1988; Mitchell et al., 1992b). 
Purified fusion protein from the construct containing four epitopes showed 
high specificity (80%) and sensitivity (81%) when used as a recombinant 
antigen in an ELISA system against a panel of human polyclonal sera 
(W.Starkey, PC). Cleavage of the fusion protein using thrombin proved 
unsuccessful.
4.2 INTRODUCTION
There are two ways that foreign DNA can be expressed in E.coli, either by 
producing fusion proteins by cloning the foreign DNA downstream and in 
frame with a bacterial protein coding sequence or as a native protein where 
the initiation site for protein synthesis is contained within the cloned DNA 
sequence. The bacterial coding sequences used for fusion proteins include 
13-galactosidase, (to express for example Hepatitis B core antigen (Stahl et 
al., 1981) and human proinsulin (Wetzel et al., 1981)), glutathione 
S-transferase,( fused with methionine sulphoxide reductase (Rahman et al., 
1992), Taenia avis antigens (Johnson et al., 1989)), and Staphylococcus 
aureus protein A, ( fused with RV El (Terry et al., 1989)).
For this study expression of rubella sequences was achieved using fusions
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with GST in the pGEX series of vectors. There are several pGEX vectors 
available which vary in their MCS, thus allowing cloning of foreign sequences 
in the correct ORE for expression as fusion proteins with GST. The E l 
fragments were fused to the carboxy-terminus of GST from Schistosoma 
japonicum  (Smith et al,. 1986, 1988), expression being controlled by the tac 
promoter. The tac promoter is a hybrid trp-lac promoter that is regulated by 
the lac repressor (Amann et al., 1983) and provides inducible, high level 
expression of adjacent coding sequences. It consists of the -35 region of the 
trp promoter fused to the - 1 0  region of the lac promoter and contains the 
lac operator. This confers lac control (derepression by IPTG) to a trp 
promoter and also results in a promoter with consensus -35 and -10 regions. 
When induced the tac promoter is one of the strongest known E.coli 
promoters (Harris et al., 1986). pGEX vectors contain a lacF gene which 
provides an elevated level of repressor, ensuring that there is sufficient 
repressor even with a high copy number vector.
In addition to the bacterial promoter, the other major consideration is an 
efficient ribosomal binding site. In E.coli this includes an initiation codon 
(ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides 
upstream of the initiation codon (Shine and Dalgarno, 1975). This purine 
rich sequence, which is called the Shine-Dalgarno sequence, is 
complementary to the 3' terminus of E.coli 16S rRNA. Binding of the 
ribosome to mRNA is thought to be promoted by base pairing between the 
Shine-Dalgarno sequence in the mRNA and the sequence at the 3' terminus of 
the 16S rRNA (Steitz et al., 1979).
In the pGEX vectors translation termination occurs due to the presence of 
stop codons in each of the reading frames after the MCS.
One of the problems encountered with expression in E.coli is the inability of
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the organism to accurately mimic certain post-translational modifications 
found in eukaryotic systems, such as glycosylation (Bially et al., 1987). 
Another problem is one of insolubility leading to accumulation of proteins in 
inclusion bodies. Although in the inclusion bodies the protein is protected to 
some extent from protease activity and therefore accumulates more efficiently 
than it would if soluble, there may be difficulty with purification. A 
dénaturation step may be necessary for solubilising the protein, eg sonication 
with 8 M urea, but this may lead to irreversible dénaturation of the protein.
The structural proteins of RV have been produced in a number of expression 
systems, in bacteria, mammalian cells, insect cells and vaccinia virus, 
(Londesborough et a l ,  1992; Al-Mumin et al., 1992; Hobman et al., 1988; 
Oker-blom et al., 1989; Sanchez and Frey, 1991). The potential of 
recombinant proteins for rubella antibody screening has been shown by the 
use of E.coli and baculovirus expressed E l proteins in assays to detect IgG 
and IgM, however the recombinant proteins were not as effective as virally 
defined antigens, (Terry et al., 1989; Londesborough et al., 1992; Seppanen 
et al., 1991).
Terry et al., (1989) expressed the whole of the E l protein and also the 
region between amino acids 207-353 as a fusion protein with the IgG binding 
region of Staphylococcus aureus protein A and used this in an immunoassay 
to detect rubella specific IgM. The results were comparable to those 
obtained using two commercial kits, Rubenz M (Northumbria Biologicals 
Ltd.) and Rubazyme M (Abbott), although the Rubenz M kit appeared to be 
more sensitive when the levels of IgM were low. The major drawback with 
this fusion is the strong affinity protein A has for IgG, necessitating the use 
of IgG to precoat the plates and further blocking of any vacant protein A IgG 
binding sites with IgG.
142
The E.coli expression vector LB03 (Londesborough et ah, 1992) gave RV E l 
fusion proteins which required solubilisation in 8M urea. Size fractionated 
antigen showed that the bulk of the fusion protein produced was either 
homopolymers or heteropolymers resulting in only small amounts of 
monomeric E l being available. The antigen derived from the Judith strain 
had a lower detection efficiency than the whole virus antigen when used with 
naturally infected serum samples. However, the reverse was observed with 
post-vaccination serum (vaccination with RA27/3). It has been suggested 
that the epitopes expressed by RA27/3 are not identical to the epitopes 
expressed by the wild type virus strain Judith. There are sequence 
differences in E l between Judith and RA27/3 (chapter 3). Neither of the 
Judith based antigens used in the Londesborough et al., study gave a true 
indication of the antibody response to RA27/3. This has important 
implications in the use of recombinant antigens in rubella diagnosis and 
assessment of immune status.
4.3 AIMS
The aim of this study was to generate soluble recombinant proteins using a 
bacterial expression system that could act as an efficient antigen for detecting 
human rubella antibodies in an ELISA system. The bacterial system would 
facilitate cheap and reproducible large scale production of the antigens.
4.4 RESULTS
4.4.1 Construction of the GST-El expression vectors 
Specific subfragments of the E l coding region were generated either by PCR 
amplification or restriction enzyme digestion of the E l cDNA clones p37/10 
and p45/l. Clone p37/10 contains the full length E l coding sequence with 
the bovine light chain signal peptide (BSP) from pUS1002 (section 2.3) at
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the amino-terminus. Clone p45/l has the same sequence as p37/10 but with 
the removal of the carboxy-terminal trans-membrane anchor coding region. 
The constructions of p37/10 and p45/l are described in detail in chapter 6. 
The restriction fragments and the PCR products were electrophoresed 
through an agarose gel (section 2.17.1(i)). The correct fragment was 
isolated from the agarose using either Geneclean'^^ (section 2.15.4(i)) or 
NA45 DEAE membrane (section 2.15.4 (ii)). The PCR generated fragments 
were then digested to give cohesive ends suitable for cloning. The fragments 
were ligated into the appropriate pGEX vector and transformed into DH5 
competent cells. The transformants were analysed using small scale plasmid 
extractions (section 2.15.1). The E l sequences were either subcloned into 
pGEX-2T or pGEX-3X as appropriate. A restriction map of pGEX-2T is 
shown in fig 4.1, along with the MCS of pGEX-3X. Fusion proteins 
expressed in pGEX-2T may be cleaved with thrombin and those expressed in 
pGEX-3X cleaved with factor Xa.
The position of the rubella sequences in the various constructs in relation to 
the E l  coding sequence is shown in fig 4.2. Details of the rubella sequences 
used in the formation of the GST-El constructs are shown in table 4.1. The 
sequences for the primers used to PCR amplify the rubella sequences prior to 
cloning are shown in table 4.2. Each of the primers contains a restriction site 
and "R" denotes priming of the anti-sense strand. The PCR products
generated using the different primer pairs are shown in fig 4.3. pUS1507 
and pUS1508 were constructed by P.Sanders (PC).
Two of the constructs pUS1503, pUS1509 were constructed to contain only 
the sequences of previously identified epitopes. Terry et a l ,  (1988), 
described three epitopes (epsl, 2, and 3) between nucleotides 8985 -8910 
and this region is contained in pUS1503 and pUS1509. In addition to the 
three epitope sequences, pUS1509 has a fourth epitope (eps4) described by
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ThrcxnCio
I Leu Pm GV Ser i
CTG GTT CCG CGT GGA TCC CCG GGA ATT CAT 
I (  I H  _  «
( Sma 1 ‘
966921
ATC GAA GGT CGT GGG ATC CCC GGQ AAT TCA TOG TGA CTG ACT GAC
t--------M I I  ^ Slop codon*
_  8amHI Sm al EcoRI .   —
Bal I (463|
Ptac^
p 4 ^  '
Vp
Fig 4.1 Diagram of the pGEX vector with the multiple cloning site for 
pGEX- 2 T and pGEX-3X.
145
p U S lS O O
57K da
E c o R l
p u s  1 5  0 1  PGE^ 
4 6 K d a
P Ü S 1 5 0 2
3 4 .3 K d a
p u s 1 5 0 3  
5 . 8Kda
P U S 1 5 0 4
1 9 .7 K d a
P U S 1 5 0 5
27K da
P U S 1 5 0 6
15K da
* p U S 1 5 0 7
33K da
* p U S 1 5  0 8  
26K da
P U S 1 5 0 9
9 .2 5 K d a
P U S 1 5 1 0  
1 7 . 4Kda
E c o R l
pGEX
Bam H l '
pGEX
Bam Hl
pGEX 97
S m a l
E  1
213 2 85
{ 4 2 3 1 .
Epitopes
481 amino 
acids
4 8 1
E c o R l
376
E c o R l
307
pGEX
BamHl
243___ 286
7  3 1  [- - -...
E c o R l E c o R l
pGEX 307 481
E c o R l Bam Hl
243
E c o R l
pGEX 307 439
BamHl E c o R l
399
S m a l
pGEX 201 363
S m a l S m al
pGEX 213 286
-1..2 3 1
Bam Hl E c o R l
pGEX 155
BamHl
T T r a n s - m e m b r a n e  a n c h o r  
B o v in e  s i g n a l  p e p t i d e
S m a l
Fig 4.2 Information on the relative location of the rubella sequences in 
relation to the El coding^equence in the construction of the 
GST-El fusion proteins! (* constructed by P.G Sanders) |
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Gel 1
Gel 2 0 X Gel 3 0 X
#  e
Fig 4.3 1.5% agarose gels of the PCR amplified DNA fragments used to
clone into the pGEX vectors.
Gel 1 , lane 1 pUS 1503, 134bp
Gel 2, lane 1 pUSlSOS, 726bp
Gel 3, lanes 1 , 2  pUS1506, 404bp
lanes 3, 4 pUS1509, 228bp
0  X174 Haelll marker s
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Mitchell et al., (1992b) located at nucleotides 8889-8969.
Table 4.1 Details of the rubella sequences used in the formation of the 
GST-El fusions
Name Sequence 
position (nt)
Size of 
fragment (bp)
Comments
pUSlSOO 8253-9757 1600 Entire E l,  + BSP
pUSlSOl 8253-9493 1240 Entire E l,  - TMA, + BSP
pUS1502 8253-9168 916 Entire E l,  no signal sequence
pUS1503 8977-9111 134 Epsl, 2  and 3 *, PCR
pUS1504 8169-9757 589 Carboxy-terminus, no eps
pUS1505 8253-8978 726 Amino-terminus, eps 4 * \  PCR
pUS1506 9165-9554 404 Carboxy-terminus region, -TMA,PCR
pUS1507 8543-9451 909 PvuII fragment, Eps 1-4*,**
pUS1508 8851-9341 591 Smal fragment, Epsl-4*,**
pUS1509 8884-9111 228 Epsl-4 *,** PCR
pUSlSlO 8253-8719 467 5' coding region, no signal sequence, 
no eps
Mitchell a/., (1992b)
* Terry et al., (1988)
BSP => bovine signal peptide (Jackson et al., 1992), section 2.3 
TMA => trans-membrane anchor 
PCR => produced by PCR
Table 4.2 Primer pairs used for the PCR of the E l fragments
Name Primer Pair
pUS1503 898 5' CCGGAATTÇGCTCGCGGCTTGTG 3' 
899R 5' GGCCGAATTCACTTGCGCGCCTGA 3'
pUS1505 891 5' GGGGATCCTGGGCCGAGGAGGCTTTCACCT 3'
^ c / u j L v  u  \ ^ K j y j r \  X y j r ï . r \ .±  x  i  j
pUS1506 904 5' GAGTGGATCCACGCCCACACCACC 3' 
905R 5' GCGGAATTCCAGGTCTGCCGGGTC 3'
pUS1509 903 5'GCCGGATCCGGCAATCAGCAGTC 3' 
899R aspUS1503
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During the construction of pUS1503 the sequence of primer 898 was altered 
from the actual sequence (Ç instead of T) resulting in the replacement of 
cysteine with arginine at the 5' end of the fragment, and primer 899R was 
altered with A replacing C, forming a stop codon, thereby eliminating the 
cysteine and preventing the formation of cysteine-cysteine bonds.
4.4.2 Induction of the fusion protein
The E.coli cultures containing the pGEX vector and the pGEX vector plus 
the E l subfragments were induced to produce the fusion proteins by the 
addition of IPTG during log phase, according to the method described in 
section 2.27. The cultures were pelleted 5hrs post induction and the cells 
resuspended in SDS loading dye which also served to lyse the cells. A portion 
of the lysate was electrophoresed through a 9% SDS- PAGE gel (section
2.17.2 (ii)).
4.4.3 Protein gel analysis
The fusion proteins produced were analysed on a 9% SDS PAGE gel as 
described in section 2.17.2 (ii). After electrophoresis the gels were stained 
using Coomassie brilliant blue stain (section 2.18.1), fig 4.4 All the clones 
except pUS1504 and pUS1508 gave clear bands on the gel. The amount of 
visible protein varied between clones, with pUS1505 and pUS1510 producing 
larger amounts of protein compared to pUS1503 and pUS1509.
4.4.4 Western blot analysis
The induced fusion proteins were electrophoresed through a SDS-PAGE gel 
and western blotted onto nitrocellulose as described in section 2.19. The 
proteins were visualised by using the ECL detection method (section 2.19.3). 
The primary antibody was pooled human polyclonal serum from healthy 
individuals (section 2.7). Two batches were routinely used, serum V/B and 
serum B/W, both were from natural infections but gave different responses.
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(kDa) 1 2 3 4 5 6 7 9 10
Fig 4.4 9% SDS-PAGE gel of the bacterial lysates containing the E l
expression vectors. The cultures have been induced with IPTG 
and the gel stained with Coomassie brilliant blue stain.
1) pUS1500
2) pUS1501
3) pUS1502
4) pUS1503
5) pUS1504
6 ) pUS1505
7) pUS1506
8) pUS1509
9) pUS1507
10) pGEX control
indicates  the expressed  fusion protein
150
Both serum samples were preadsorbed with a culture of DH5 cells 
transformed with pGEX-2T as described in section 2.28.2. The primary 
antibody was used at a concentration of 1:1000, diluted in 3% BSA/TBST 
and the secondary antibody, anti-human IgG fab(2) HRP, was used at a 
concentration of 1:5000 again in 3%BSA/TBST.
There was some cross reactivity with E.coli proteins which appeared at low 
levels in all the tracks with both serum samples, also an intense band 
appeared across the blot with serum V/B. No antigen band was visible for 
pUS1504 or pUS1508. The constructs pUS1500, pUS1501, pUS1502 gave 
multiple bands which may have been breakdown products or premature 
termination. Fig 4.5 shows western blots that were detected with V/B. 
There appeared to be no significant cross reaction with the pGEX control.
4.4.5 Purification of the fusion protein
Purification of the fusion proteins produced by pUS1503, pUS1505, 
pUS1507, pUS1509, pUS1510 and the pGEX control was carried out 
according to the method described in section 2.27.2, using glutathione 
agarose beads. At each stage of the process a sample was taken and analysed 
by SDS-PAGE gel and stained with Coomassie brilliant blue. The cultures 
appeared to grow at the same rate but the protein yield varied between the 
different fusions which resulted in a variation in the yield of purifiable 
protein. Not all the fusion proteins produced a product which could be 
purified. The fusion protein of pUS1507 appeared to be insoluble and 
therefore was not purified, (P.Sanders, PC.), however this may relate to it 
being the largest of the constructs subjected to the purification process, 
p u s  1503 gave the highest yield of purified protein after the pGEX control. 
Fig 4.6 shows Coomassie brilliant blue stained SDS-PAGE gels of the 
purified proteins at different stages of the purification process. A gel of the 
purified fusion proteins from pUS1503, pUS1505 and pUS1509 were western
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4 9 .5 -
3 2 .5 -
Fig 4.5 Western blot of the induced fusion proteins detected with
preadsorbed pooled human sera (V/B) using the ECL detection
system.
1 ) pUS1500
2 ) pUS1501
3) pUS1502
4) pUS1503
5) pUS1504
6 ) pUS1505
7) pUS1506
8 ) pUS1509
9) pUS1507
1 0 ) pGEX control
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31
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Fig 4.6 Coomassie brilliant blue stained 9% SDS-PAGE gel of the
fusion proteins at different stages of the purification process
1 ) protein standards
2 ) pGEX control cells
3) pGEX control sonicated cells
4) glutathione agarose beads after washing
5) sonicated cells after binding of protein onto beads
6 ) purified protein, pGEX
V pUS1503 cells
8 ) pUS1503 sonicated cells
9) sonicated cells after binding of protein onto beads
1 0 ) glutathione agarose beads after washing
1 1 ) purified protein, pUS 1503
1 2 ) protein standards
13) pUS1509 cells
14) sonicated cells after binding of protein onto beads
15) glutathione agarose beads after washing
16) purified protein, pUS 1509
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blotted and the protein detected as described in section 4.4.4 using serum 
V/B (fig 4.7).
4.4.6 Cleavage of the fusion protein
Cleavage of the fusion protein to separate the GST from the E l protein was 
attempted using the method described in section 2.24.3, on pUS1503 and 
pUS1509. The cleaved proteins were electrophoresed on a 4-20% prepoured 
gradient gel (Biorad) and silver stained (section 2.18.2). It was possible to 
see a reduction in the size of the fusion protein, corresponding to the GST 
protein, indicating cleavage, but no E l protein was visible. This was repeated 
using bovine thrombin (55U/ml) in place of the human thrombin. The method 
was altered slightly in that the bovine thrombin (lOpl) was mixed directly 
with the protein bound to the beads, and incubated for Ihr at 25°C. The 
reaction was mixed and spun with the supernatant being mixed with loading 
dye. The samples were electrophoresed through a 10-20% prepoured gel and 
silver stained but no cleaved proteins were seen.
4.4.7 ELISA studies
p u s  1503 and pUS1509 gave strong responses on the western blots (fig 4.5), 
and the fusion proteins could be purified using glutathione beads. With this 
in mind the question was posed as to whether either of these fusion proteins 
could be used as a recombinant antigen in an ELISA assay to test for the 
presence of rubella antibodies in human serum. A large panel of sera were 
available which had already been screened for RV antibodies by standard 
tests, LA, SRH and EIA. The assay was carried out by W. Starkey, St 
Thomas' Hospital, London, according to the method described below.
The ELISA assay was set up as follows, 96 well plates were coated for one 
hr at 37®C with 5pl/well affinity purified GST/El fusion protein from either 
p u s  1503 or pUS1509 or GST from pGEX containing cells, using
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-  49.5 -
_  32.5 _
Fig 4.7 Western blot GST/El fusion proteins, purified using glutathione 
agarose beads and detected using preadsorbed pooled human 
polyclonal sera (V/B) using the ECL detection system.
1) purified pUS 1503
2) purified p u s  1509
3) pUS 1505 sonicated cells
4) pUS 1505 sonicated cells after binding of protein onto
the beads
5) p u s  1505 glutathione agarose beads afer washing
6 ) pUS1505 purified protein
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carbonate/bicarbonate coating buffer pH 9.6, followed by three washes with 
PBS containing 0.5% Tween 20 (PBST). Non-specific binding was blocked 
with 1% BSA in coating buffer for one hr at 37®C, followed by three washes 
in PBST. Test sera were added at 1:20 dilution in PBST containing 1% BSA 
for one hr (PBSTB) at 37°C followed by three PBST washes. Biotin labelled 
monoclonal anti-human IgG (Fc specific) was added at 1:1000 in PBSTB for 
one hr at 37°C followed by three washes. Extravidin-peroxidase was added 
at 1:1000 in PBSTB for one hr at 37®C followed by three washes in PBST. 
The peroxidase substrate was added according to the manufacturer's 
instructions and the reaction stopped with 25pl/well 3M sulphuric acid. 
Optical density values were read at 490nm using a Dynatech MR700 
automated plate reader (W.Starkey, PC).
Forty-two sera were used in the study, 32 rubella positive sera and 10 rubella 
negative sera, (status confirmed by LA) . Clone pUS1509, containing the E l 
fragment covering the four epitopes, showed a level of sensitivity of 81% 
(number of positive rubella sera giving a positive result with the recombinant 
antigen) compared to 53% with pUS1503, which contains the E l fragment 
covering three epitopes. Both clones showed the same level of specificity of 
80% (number of negative rubella sera giving a negative result with the 
recombinant antigen). A summary of the results is shown in table 4.3.
The overall summary of all the results for each of the constructs containing 
the E l rubella sequences is shown in table 4.4.
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Table 4.3 ELISA for rubella specific IgG using E l  fusion proteins as 
antigens
dUS1503 as antigen
Positive by 
recombinant 
ELISA
Negative by 
recombinant 
ELISA
Total number 
of sera 
analysed
Rubella positive sera* 17 15 32
Rubella negative sera* 2 8 1 0
Total 42
Sensitivity 53%
Specificity 80%
PUS1509 as antigen
Positive by 
recombinant 
ELISA
Negative by 
recombinant 
ELISA
Total number 
of sera 
analysed
Rubella positive sera * 26 6 32
Rubella negative sera* 2 8 1 0
Total 42
Sensitivity 81%
Specificity 80%
*The sera were designated rubella positive or negative according to the LA 
results.
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Table 4.4 Summary of the results for each of the pGEX expression 
vectors containing the rubella E l sequence
Name Comments Solubility SDS-
PAGE
Western ELISA
pUS1500 E l,  +BSP ND + + ND
pUS1501 E l,  -TMA, +BSP ND + + ND
pUS1502 E l,  no signal sequence ND + + ND
pUS1503 Epsl, 2 and 3 H—h + 4- +
pUS1504 Carboxy-terminus ND - - ND
pUS1505 5' coding region, Eps4 + ++ ++ ND
pUS1506 Carboxy-terminus, -TMA ND + + ND
pUS1507 PvuII fragment, Eps 1-4 poor + + ND
pUS1508 Smal fragment, Eps 1-4 NP - - ND
pUS1509 Epsl-4 4—h + + +
pUS1510 5' coding region, no Eps + ++ + ND
BSP => Bovine signal peptide 
TMA=> trans-membrane anchor 
ND => not determined 
NP => no protein detected
other symbols ( +/++/-) represent varying protein levels
4.5 DISCUSSION
RV E l subfragments have been generated from cDNA clones p37/10 and 
p45/l, and subcloned into the expression vector pGEX. The vector, 
containing the GST protein sequence was transformed into DH5 E.coli and 
on induction with IPTG produced a range of fusion proteins of the expected 
sizes. The fusion proteins were analysed on a SDS-PAGE gel and western 
blotted.
The yield of protein varied between constructs, with an increase in yield on
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removal of the hydrophobic domains, with the most abundant being pUS1505 
and pUSlSlO. pUS1504 and pUS1508 did not appear to produce a protein 
at all, not even the GST portion of the fusion protein was detectable. The 
reason for this has not been ascertained but could be due to a conformation 
which makes it susceptible to proteolysis.
The largest construct, pUSlSOO, containing the whole of the E l protein plus 
the BSP gave several bands on the western blot and not always a protein 
band corresponding to the full size protein. This could be due to premature 
termination of translation or to proteolysis. Studies involving expression of 
foreign proteins in E.coli have shown evidence of codon usage effects with 
high level expression, resulting in effects on the level of product formed 
(Dale, 1990).
The solubility of the fusion protein appeared to increase as the size of the 
fusion protein decreased in size. The smallest fusion produced the highest 
levels when purified using glutathione agarose beads, and on large scale 
production produced 3.5mg/1 protein (W.Starkey, PC), a figure comparable 
to the levels reported for other GST fusions. However, production was still 
lower than for the GST protein alone. Cleavage of the fusion protein showed 
a reduction in size relating the GST part of the fusion protein but no protein 
relating to the rubella part. This may be due to the relative low levels of 
protein used in the cleavage experiment.
The uncleaved fusion proteins of pUS1503 and pUS1509 were used in an 
ELISA assay to detect rubella antibodies and showed a high level of 
sensitivity and specificity. pUS1509 proved to more sensitive reacting with 
81% (26/32) of the rubella positive serum samples compared to 53% with 
pUS1503. This could be due to the presence of the putative neutralisation 
domain, E I 2 1 3 -E I 2 3 9 , not found in pUS1503, (Mitchell et al., 1992b). Chaye
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et al., (1992) also mapped two neutralising monoclonal antibodies and a 
haemagglutination inhibition monoclonal antibody to the region E I 2 1 4 -E I 2 4 0 . 
The epitope described by Mitchell et al., (1992b) when synthesised as a 
peptide, showed good correlation with whole RV antigen when used in an 
ELISA system for evaluating serum antibody levels from vaccinated and 
naturally infected populations but showed little or no reactivity with CRS 
sera or patients who have exhibited repeated failure to respond to 
immunisation. RV persistence in CRS patients may be due to development of 
selective immunological tolerance to neutralisation domains on RV E l 
protein as a result of exposure of the immature fetal immune system to RV 
(Mitchell et al., 1992b).
Niether of the two fusion proteins tested in the ELISA assay with 42 
samples, were 1 0 0 % sensitive or specific when compared to the diagnosis by 
LA. Of the two serum samples which gave false positive results one serwm 
gave a false positive result with both fusion proteins . This serum when 
tested against the fusion proteins in a western blot also gave a positive result 
but was also shown to be weakly positive with the GST protein alone 
(W.Starkey, PC). The false positive results may be due to cross reactivity, 
the rubella sequence in pUS1503 and pUS1509 shows some limited homology 
with several other E.coli proteins and human proteins. This same serum was 
tested using PEP SCAN (chapter 7) and showed very little reactivity with the 
peptides covered by the four epitopes. False negatives may be due to the 
structural conformation of the fusion protein on the ELISA plates masking 
the epitopes or low levels of antibodies to these particular epitopes failing to 
bring the OD reading above the set cut off limit.
This information suggests that it may be necessary to use a larger number of 
epitopes than found in pUS1509 in order to detect rubella antibodies in all 
serum samples. Seppanen et al., (1991) expressed complete E l  and E2
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proteins in Baculovirus and obtained a good correlation with these and whole 
virus antigen using convalescent sera but not with sera from recent RV 
infection. Improved detection of rubella antibodies could be obtained using 
rubella antigen preparations based on the complete E l protein, which would 
posses epitopes not present in the above subfragments or peptides. This was 
also the conclusion from the recombinant antigens tested by Londesborough 
et a l ,  (1992).
GST/El fusions have been shown to react with human anti-RV serum under 
reducing conditions. Initial experiments indicate that the two fusion proteins 
(pus 1503 and pUS1509) containing three and four epitopes appear to have 
insufficient discrimination for routine diagnostic use in an ELISA system for 
the detection of RV antibodies. This may be due to the size of the protein 
and thereby the number of epitopes available to detect sufficient rubella 
antibodies to give a positive signal in the ELISA. It may also be due to 
aberrant folding of proteins expressed in E.coli, altering the conformation of 
the protein on the ELISA plate and thereby masking the epitopes. The 
absence of glycosylation due to the expression in E.coli would effect the 
folding of the fusion protein and therefore the formation of conformational 
epitopes .
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Chapter 5
IN VITRO TRANSLATION OF THE E l  
STRUCTURAL PROTEINS
IN  VITRO  TRANSLATION OF THE E l  STRUCTURAL PROTEINS
5.1 SUMMARY
cDNA sequences coding for the E l and E2 structural proteins were cloned 
into a pGEM-4Z vector which has an SP6  promoter for RNA synthesis. In  
vitro translation of the rubella E l and E2 structural proteins was carried out 
in a one tube transcription/translation system based on the rabbit reticulocyte 
lysate translation system. The E l and E2 sequences differed in their signal 
peptides and consensus AT G start sequences (Kozak, 1987). All the clones 
generated proteins of the correct size but with varying efficiency. In addition 
proteins from those clones which gave the highest levels of translation were 
successfully processed using canine pancreatic microsomal membranes 
indicating that the signal peptide was functioning correctly. These clones 
were; p42/5 E l  + bovine signal peptide (BSP)
p43/6 E l -Trans-membrane anchor (TMA) + BSP 
p 8 8 / 8  E l and E2 + E2 signal peptide 
p89/4 E2 and E l -TMA + E2 signal peptide 
p61/4 E2 - part of TMA + E2 signal sequence.
5.2 INTRODUCTION
Cell-free protein synthesising systems are available for the translation of 
eukaryotic and prokaryotic mRNAs. One such system utilises a rabbit 
reticulocyte lysate which is prepared from chemically induced anaemic 
rabbits. The reticulocytes are harvested by centrifugation, washed and lysed. 
After centrifugation to remove the stroma the lysate is treated with 
micrococcal nuclease to destroy endogenous mRNA (Pelham et al., 1976). 
Removal of the endogenous mRNA reduces the background levels of 
translation. The lysate contains the cellular components necessary for 
protein synthesis; tRNA, rRNA, initiation, elongation and termination
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factors. The lysate can be made in the laboratory (Sambrook et ah, 1989) or 
purchased in kit format. mRNA can be added to the lysate or the DNA can 
be added to a coupled lysate system (TNT™, Promega) which provides a 
one tube reaction for transcription and translation, this is the system used in 
this study. The DNA is cloned into vectors which have a SP6 , T7 or T3 
promoter, to express sequences cloned downstream. Radiolabelled 
methionine is incorporated into the synthesised protein so that protein 
products can be identified by SDS-PAGE.
During protein synthesis it is possible to ascertain the ability for 
co-translational processing and post-translational modifications eg, 
proteolytic signal peptide cleavage and glycosylation, by the addition of 
canine pancreatic microsomal membranes. Microsomes are closed vesicles 
derived from fragmented rough endoplasmic reticulum (RER) and are studded 
with ribosomes. The ribosomes are always found on the outside surface of 
the microsomal vesicles, the interior being chemically equivalent to the 
luminal space of the ER.
The scanning model for initiation of translation in eukaryotes states that the 
40S ribosomal subunit binds initially at the 5' end of mRNA and then 
migrates, stopping at the first AUG codon in a favourable context for 
initiating translation, (Kozak, 1989). The "first-AUG" rule applies to 90-95% 
of the vertebrate sequences analysed (Kozak, 1987). From the same survey 
of 699 5'-noncoding sequences from vertebrate mRNA a consensus sequence 
emerged for the initiation of translation;
(GCC)GCCACCATGG
G
The most highly conserved position in this motif is the purine at position -3, 
with 97% of the vertebrates having a purine (mostly A) at this position. The
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periodical occurrence of G in positions -3, - 6 , and -9 , may help ribosomes 
stay in frame during translation.
Proteins enter the secretory pathway of mammalian cells by translocation 
across the membrane of the RER. A signal peptide, an amino-terminal leader 
sequence, directs the protein to the ER. Typical signal peptides consist of 
approximately 2 0  amino acids with a basic amino-terminus, a central 
hydrophobic core of about 1 0 - 1 2  amino acids and small, neutral amino acids 
(eg Gly or especially Ala) located at position - 1  and -3 relative to the signal 
peptidase cleavage site (Perlman et al., 1983; von Heijne, 1984). The 
signal peptide is guided to the ER by two components, the signal-recognition 
particle (SRP), which cycles between the ER membrane and the cytosol and 
binds to the signal peptide, and a SRP receptor, located in the membrane of 
the ER. The binding between the SRP and the signal peptide occurs as soon 
as the peptide emerges from the ribosome. This SRP-signal peptide-ribosome 
complex then binds to the SRP receptor, the SRP is displaced and translation 
continues with the the ribosome now located on the ER membrane. 
Co-translational passage of the polypeptide chain occurs across the 
membrane of the RER. The signal peptide is cleaved by signal peptidase, 
located in the lumen of the RER, creating a new amino-terminus for the 
mature protein. The hydrophobic core is thought to be responsible for 
initiating export and for binding to the SRP, and the region -5 to -1 for 
conferring processing specificity (von Heijne, 1983). In the case of integral 
membrane proteins, translocation is interrupted by the presence of a 
hydrophobic trans-membrane anchor (TMA) which mediates a stable 
association between the protein and the membrane.
Examination of the sequences upstream from the amino-termini of E2 and E l 
reveals that both are preceded by sequences that have the characteristics 
typical of signal peptides. Both signal peptides have been shown to be
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functional, (Hobman et al., 1988; Oker-Blom et al., 1990) but not completely 
defined.
Previous attempts within the research group to express E l  in animal cells 
resulted in low levels of protein production when using half of the putative 
E l signal peptide (pU SlllO ) (Al-Mumin, 1991). Another construct utilising 
the putative E l signal peptide was also transfected into animal cells with 
poor results (A.Knight PC). In vitro translation can provide information on 
the effectiveness of the AT G start, the signal peptide, and whether the 
correct size of protein is being made.
5.3 AIMS
To produce E l and E2 glycoproteins, either as individual proteins or as a 
polyprotein, from cDNA clones modified for expression by utilising a variety 
of translation initiation sequences and to determine the effectiveness of the 
signal peptide for translocation through the ER. It was hoped that utilisation 
of a signal peptide from a successfully expressed clone producing a bovine 
IgG light chain (Jackson et ah, 1992) might increase protein production. To 
analyse constructs devoid of the E l trans-membrane anchor with the aim of 
utilising the coding sequence to produce a secreted E l protein in mammalian 
cells (chapter 6 ).
5.4 RESULTS
5.4.1 Construction of clones to express E l  and E2 proteins 
The cloning and sequencing of the E l structural proteins used in the 
construction of vectors for the in vitro translation have been discussed in 
chapter 3. All of the sequences contain an ATG for translation initiation and 
were ligated into the pGEM-4Z vector which has SP 6  and T7 promoters (fig
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5.1). The vectors/RV cDNA were transfected into competent DH5 cells 
(section 2.23.2). Unless stated all the clones subsequently used were in the 
orientation to allow transcription from the SP 6  promoter. Table 5.1 gives 
the information of the sequences used in the construction of the expression 
vectors. Table 5.2 shows the sequences of the primer pairs used to PCR 
amplify the cDNA to incorporate the ATG start signal and the restriction 
sites for cloning. A diagram of the constructs is shown in fig 5.2.
Table 5.1 Sequences used in the construction of the expression vectors
Name Comments
p42/5 BSP, entire E l coding sequence, +TMA
p43/6 BSP, E l coding sequence, -TMA
p57/5 EISP, 3' E2 and E l coding sequence, +TMA
p58/3 EISP ( 1 0  amino acids), E l coding sequence, 4 amino acids of TMA
p61/4 E2SP, E2 coding sequence, +TMA
p 8 8 / 8 E l and E2SP, E l and E2 coding sequences, +E1 and E2 TMA
p89/4* E l and E2SP, E l and E2 coding sequences, +E2 TMA, -E l TMA
BSP bovine signal peptide 
EISP putative E l signal peptide 
E2SP putative E2 signal peptide 
TMA trans-membrane anchor 
p57/5 A.Knight (PC) 
p61/4 Al-Mumin, 1991
* p89/6 was constructed in same way as p89/4 but downstream of the T7 
promoter
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Xmn I 1939
SspI
2144 AatW 
2262
Narl
2563,
PGEM-4Z
Vector
(2746bp)
lacZ
S P 6  i
E c o R  I 
S a d  
Kpn\ 
Ava I 
Sma I 
B a m H  I 
Xba I 
Sail 
A ccl 
Hinc II 
Pstl 
Sphi 
Hind III
T T 7
1 Start 
7 
17 
23 
23 
25 
28 
34
40
41
42 
50 
56 
58 
70
SP6 Transcription Start
I---------- ►
5 ' . . .  GGATT TAGGT 6ACAC TATAG AATAC 
SP6 Promoter
GAATT CGAGC TCGGT ACCCG GGGAT CCTCT AGAGT CGACC TGCAG
II— w  I I .......................................................
EcoR I S a d Ava I BamH I Xba I
Xma I
Sm al
S a /1 
Accl 
Hinc II
Pst\
17 Transcription Start 
 1
GCATG CAAGC TTGTC TCCCT ATAGT GAGTC GTATT AGAGC . . .  3'
I 11 I T7 Promoter
Sph I Hind III
Fig 5.1 pGEM-4Z vector promoter and multiple cloning site sequence.
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p 4 2 / 5
p 4 3 / 6
P 5 7 / 5
p 5 8 / 3
p 6 1 / 4
p 8 8 / 8
p 8 9 / 4
<- 1.6 Kb
El
pGEM
E c o R I H i n d i
BamHI 
<-------
E c o R I
1 . 2  Kb
E c o R I
El
H i n d i
-------------- pGEM
A a t l l / E c o R I
BamHI
1 . 7  Kb
I El
H i n d l l l
pGEM
1 . 4  Kb
H i n d u  
—>
f El
E c o R I / P s t I
pGEM
E c o R I
0 . 9  Kb
I E2 pGEM
E c o R I P s t l / E c o R I
2.45 Kb
E2 El
E c o R I P s t l  
2 i l  Kb
pGEM
E c o R I
I E2
E c o R I
El
P s t l  n HEI
------------ pGEM
A a t l l / E c o R I
E 1 /E 2  s i g n a l  p e p t i d e 0  B o v i n e  s i g n a l  p e p t i d e
Fig 5.2 Composition of the rubella sequences used in construction of the 
expression vectors for the in vitro expression of E l and E2 
structural proteins.
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Table 5.2 Sequences of primer pairs used in the construction of the
expression vectors
Name Primer
location*(nt)
Primer sequence
p42/5
p43/6
8268-8283 
8499-8521 R
GGGGATCCTGGGCCGAGGAGGCTTTCACCT
BamHI
TAGGCGTTGACAGCCCAGAAGGT
H ind i
p61/4 7307-7322 
8175-8192 R
AACGAATTCACCATGGGCCGCTCGGCGCGCCAT 
EcoRI Ncol 
AACGAATTCCTAGCGGCGGCGACAGGCGC 
EcoRI
p 8 8 / 8
p89/4
7306-7323 
8234-8212 R
GCGGAATTCACCATGGCCCGCTCGGCGCGCCATC 
EcoRI Ncol 
GTACCCCTGCAGGACGACCGCGG 
Pstl
* location refers to the position within the rubella sequence 
all primers were synthesised in the 5'=>3' direction 
"R" denotes the sequence from the antisense strand
5.4.2 Analysis of expression by in vitro translation
5ml cultures of all the clones described above were grown overnight and the
DNA extracted using "mini-prep" columns (sections 2.15.1 (iii)). Ipg of
DNA was then used in the in vitro translation using the "TNT" reticulocyte 
lysate system (section 2.26). After incubation 5pi of lysate was mixed with 
loading dye and electrophoresed through a 4-15% SDS PAGE gradient gel 
(section 2.17.2 (ii)). The gel was then fixed, treated with a fluorographic 
enhancer (section 2.18.3) dried and autoradiographed over various time 
periods. Different exposure times were necessary due to the variation in 
signals for the different proteins. Fig 5.3 shows a composite photograph of 
the tracks from the gel. Clones p42/5, p43/6, p/61/4, p 8 8 / 8 , p89/4 and p89/6
169
(kDa) 1 2 3 4 5 6 7 8 9
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Fig 5.3 In vitro translation of expression vectors containing RV E l and 
E2 coding sequences, electrophoresed through a 4-15% gradient 
PAGE gel.
1 ) protein markers
2) p42/5 El+TMA
3) p43/6 El-TMA
4) p57/5 3'E2 and El
5) p58/3 El with 4 amino acids of TMA
6)p61/4 E2 +TMA
7) p 8 8 / 8  E2 and El +TMA
8 ) p89/6 E2 and El -TMA (T7 promoter)
9) protein markers
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appeared to produce more protein, indicated by a stronger signals, than the 
other clones. The most abundant protein was from p89/6 which made use of 
the T7 promoter. All the clones gave proteins of the expected size.
5.4.3 In  vitro translation in the presence of microsomal membranes
Clones p42/5, p43/6, p61/4, p 8 8 / 8  and p89/4 were used and the reactions 
were set up to include canine pancreatic microsomal membranes (section
2,26.1). After incubation 15pi of each lysate was mixed with loading dye and 
electrophoresed through a 10% SDS-PAGE gel (section 2.17.2 (ii)). Fig 5.4 
shows the autoradiograph of the proteins translated in the presence and 
absence of the microsomal membranes. The results are summarised in table 
5.3.
Table 5.3 Molecular weights (kDa) of the proteins generated during in 
vitro translation in the presence of microsomal membranes
p42/5
E l
+TMA
p43/6
El
-TMA
p61/4
E2
+TMA
p 8 8 / 8
E2+E1
+TMA
p89/4
E2+E1
-TMA
E l non-translocated 53 (53) 46 (42) 53
El glycosylated 61 (58) 52 (47) 61 52
E2 non-translocated 33 (34)
E2 glycosylated 41.5 44 44
E2 cleaved 30
E1+E2 non-translocated 84 ( 8 8 ) 77 (77)
The expected molecular weights are shown in parentheses.
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1 2 3 4 5 6 7
(kDa)
8 9 10 11 12
9 2 .5 -  
69 -
46 —
s-
30
Fig 5.4 In vitro translation of expression vectors containing RV E l and 
E2 coding sequences in the absence and presence of canine 
pancreatic microsomal membranes.
1 ) C '“ protein markers
2) p42/5 El+TMA
3) p43/6 El-TMA
4) p61/4 E2 +TMA
5) p 8 8 / 8 E2 and El +TM.A
6) p89/4 E2 and El -TMA
7) C " protein markers
8) p42/5 El+TMA
9) p43/6 El-TMA
10) p61/4 E2 +TMA
1 1 ) p 8 8 / 8 E2 and El +TMA
12) p89/4 E2 and El -TMA
canine microsomal membranes
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5.5 DISCUSSION
Clones were constructed containing E l,  E2 or E1+E2 for in vitro translation 
in a reticulocyte lysate system in order to ascertain the potential for the 
proteins to be expressed in animal cells. The sequences of the clones varied 
at both ends depending on the presence of a particular signal peptide and the 
absence or presence of a trans-membrane anchor. The signal peptide is 
necessary for translocation across the ER and the absence of a 
trans-membrane anchor would produce a secreted protein. The signal peptide 
was either the putative E2 signal peptide, the putative E l signal peptide or a 
BSP. Suomalainen et al., (1990) used an artificial signal peptide to 
investigate cleavage between the capsid and E2 stating that the E l and E2 
signal peptides are designed to function from inside a long polyprotein rather 
than at the amino-terminus. Two of the clones, p43/6 and p89/4, containing 
E l were devoid of a trans-membrane anchor. All of the clones produced a 
protein of the expected size in the in vitro translation system, but some 
proteins were produced more efficiently than others.
In order to undergo translation an initiation site is required, namely an 
inframe ATG within the correct consensus sequence (Kozak, 1987). The 
ATG starts for the constructs are listed below:
Kozak GCCACCATGG
G
p42/5 tCCACCATGGtc
p43/6 tCCACCATGGtc
p57/5 ttACCATGGg
p58/3 ttCACCATGGt
p61/4 ttCACCATGGg
p 8 8 / 8 ttCACCATGGc
p89/4 ttCACCATGGc
173
It can be seen that all the sequences have a G at position +4 and an A at -3, 
these are considered the important nucleotide positions. Although some of 
the nucleotides did not conform to the consensus, the sequence still acted as 
a translational start. Analysis of the different nucleotides at each position 
which still allowed translation were studied by Kozak (1987). The "t" at -4 
and -5 positions for p57/5 were found in 7% and 20% respectively of 
sequences in the Kozak (1987) study. The "t" at position -5 in p58/3, p61/4, 
p 8 8 / 8  and p89/4 was found in 20% of sequences studied compared to 39% 
for "C".
Those clones with the most efficient in vitro translation were p42/5, p43/6, 
p61/4, p 8 8 / 8  and p89/4. From the consensus sequences the reason for lower 
efficiency of translation of p58/3 is unknown as the sequence is the same as 
in p61/4, p 8 8 / 8  and p89/4. The rubella sequence in p58/3 has been shown to 
express low levels of protein in COS-1 cells (Al-Mumin, 1991). The 
consensus sequence for p57/5 is shorter than considered optimal but is 
sufficient to allow low levels of translation. Those clones with the least 
efficient translation, p57/5 and p58/3 contained all or part of the natural E l 
signal peptide.
The efficiency of translation in the presence of the microsomal membranes is 
greatly reduced, to as low as 2 0 % of that in the absence of membranes, in the 
"TNT" lysate system. Of the 20% translated only 90% is subsequently 
processed. This led to translocated and untranslocated products being 
present on the autoradiograph. In the presence of the membranes the signal 
peptide should have been cleaved from the protein thus resulting in a 
decrease in size but this would be masked by glycosylation which would 
result in an increase in size. E l and E2 have three and four glycosylation 
sites respectively, this could result in several products of different size if the 
glycosylation at any particular site was incomplete. Other bands on the
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autoradiograph could be due to premature termination, internal initiation or 
proteolytic cleavage as has been found by others (Hobman et al., 1998).
p42/5 (El + TMA) and p43/6 (El - TMA) shows bands corresponding to 
translocated and non translocated protein with the former being the largest 
due to glycosylation. Glycosylation of the proteins could have been proven 
by treatment with endo-13-#- acetylglucosaminidase H (endo H), which 
cleaves the internal N-glucosamine residues of the high mannose 
carbohydrates formed by glycosylation which would result in a reduction in 
size of the protein.
p61/4 (E2) shows three bands that could correspond to cleaved but 
unglycosylated, non-translocated and translocated with glycosylation. The 
E2 signal peptide has the ability to mediate translocation in the absence of E l 
as demonstrated by others, (Oker-Blom et ah, 1990). Cleavage of the signal 
peptide would result in a decrease of approximately 3 kDa, which is the 
observed change. The microsomal membranes are very delicate and could be 
damaged during freezing and thawing. Ruptured membranes could expose 
the newly formed protein to the action of signal peptidase, normally found 
bound to the ER membrane which could cleave the signal peptide from the 
protein. This could be proven by the enzymic action of protease which could 
be added to the reaction mix post translation. The protease would degrade 
any protein not protected by translocation into the membranes.
p 8 8 / 8  (E2 and E l +TMA) and p89/4 (E2 and E l - TMA) display several 
protein bands relating to the presence of untranslocated E1/E2, translocated, 
cleaved and glycosylated E l,  and translocated and glycosylated E2. With 
p 8 8 / 8  there are protein bands in between the bands representing 
non-translocated and glycosylated El which could represent different levels 
of glycosylation. The difference in size between these bands of 2kDa is
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equivalent to the size increase at one glycosylation site (Hobman et al., 
1991). The results indicate that the E2 signal peptide is functional, and that 
E l and E2 are separated at the cleavage site prior to the mature E l sequence 
(Oker-Blom et ah, 1990). The E2 in this construct is slightly larger (l.SkDa) 
than the E2 in clone p61/4 hence the different sizes of the E2 proteins.
In conclusion E l and E2 cDNA sequences containing E2 and bovine signal 
peptides were successfully translated in the reticulocyte lysate system in the 
presence and absence of microsomes which resulted in translocation, 
glycosylation and cleavage of the signal peptide. The clones should therefore 
be capable of expression in vivo in mammalian cells.
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Chapter 6
EXPRESSION OF E l AND E2 STRUCTURAL 
PROTEINS IN MAMMALIAN CELLS
EXPRESSION OF E l AND E2 STRUCTURAL PROTEINS IN
MAMMALIAN CELLS
6.1 SUMMARY
Expression vectors designed to produce RV E l,  secreted E l lacking the 
trans-membrane anchor (TMA), E2, E2 and E l polyprotein and E2 and E l 
polyprotein lacking the E l trans-membrane anchor were transfected into 
COS-1 cells using the DEAE-dextran method. Western blots of the 
transfected cell lysates probed with rubella positive human sera confirmed 
expression of E l,  E l -TMA, and E2 proteins. All five constructs, E l,  
El-TMA, E2, E2+E1, E2+E1-TMA, appeared to express rubella proteins as 
shown by positive immunofluorescence with anti-rubella human sera. 
Insufficient protein was harvested to enable the protein to act as an antigen 
to detect anti-rubella IgM in a M antibody capture radioimmunoassay 
(MAORI A).
6.2 INTRODUCTION
RV structural proteins have been expressed in a number of systems eg E.coli 
(Al-Mumin et ah, 1992; Londesborough et al., 1992), insect cells 
(Oker-Blom et al., 1989), vaccinia (Sanchez and Frey, 1992), mammalian 
cells (Hobman et ah, 1988), with E.coli and baculovirus expressed proteins 
being tested as recombinant antigens, (Terry et ah, 1989; Londesborough et 
ah, 1992; Seppanen et ah, 1991). The recombinant proteins produced in 
E.coli and baculovirus were not however as effective as virally produced 
antigens in ELISA. Mammalian cell expression of RV proteins has been used 
to investigate the processing of the structural proteins but not as yet for 
antigen production (Hobman et ah, 1988, 1989, 1990, 1992, 1993; Baron et 
ah, 1992).
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Mammalian cells have a major advantage over other systems for the 
production of recombinant proteins in that the polypeptide undergoes the 
appropriate post-translational modifications which may not be performed 
accurately, if at all , by non-mammalian cells (Bially, 1987). Glycosylation is 
one of the most common post-translational modifications that viral and 
cellular membrane proteins undergo. This modification takes place before or 
during folding with the addition of large, hydrophilic oligosaccharide core 
units considered to be necessary for the correct folding of the nascent 
polypeptide chain. The function of the units is probably to render folding 
intermediates, which are generally more hydrophobic than fully folded
proteins, more soluble, and less likely to form irreversible aggregates, (Doms 
et al., 1993). RV E l has three glycosylation sites and E2 has three or four 
glycosylation sites depending on the virus strain. Although removal of one 
site may not effect the antigenicity of the protein, removal of two or more 
results in a reduction or loss of antibody binding under non-reducing 
conditions. For the influenza haemagglutinin, elimination of one 
glycosylation site is tolerated but loss of three or more partially or
completely blocks correct folding and transport out of the ER (Gallagher et 
al., 1992). Correct folding of RV proteins is necessary to expose the 
haemagglutination and neutralising epitopes, (Hobman et al., 1991; Qui et 
a l ,  1992).
In order to express cloned sequences in mammalian cells a shuttle vector is 
usually employed. A shuttle vector is one that is capable of replicating in
both prokaryotic and mammalian cells and contains a bacterial origin of
replication and drug resistant marker eg ampicillin resistance, together with 
the sequences for expression and sometimes replication in mammalian cells. 
The eukaryotic sequences include an expression cassette consisting of a 
promoter/enhancer, splice donor and acceptor sites, polyadenylation site, 
termination sites and multiple cloning site for insertion of foreign cDNAs.
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Also included is an expression cassette for the drug resistance marker eg the 
gpt gene. A eukaryotic origin of replication may be included and the SV40 
virus promoter contains the viral origin of replication. This is used to 
replicate the vector in COS-1 cells. The vector used in this study was 
p u s  1000 (section 2.3) fig 6.1. It was derived from the vector pEESgpt and 
contains a HCMV promoter, driving expression of inserted cloned sequences 
and an SV40 origin of replication (Whittle et al., 1987, Jackson et al., 1992).
The SV40 based vectors replicate in COS-1, African Green Monkey kidney 
CV-1 cells (section 2.5), which were chosen for this study and are routinely 
used for analysing expression of cloned genes. These cells are fibroblasts 
that have been transformed with an origin-defective mutant of SV40 which 
codes for the wild-type T-antigen. COS-1 cells contains a single integrated 
copy of the mutant SV40 DNA (Gluzman, 1981). These cells express T 
antigen but are unable to replicate the SV40 DNA due to the deletion. 
However, plasmid DNA which contains the viral origin of replication eg 
p u s  1000, can be replicated to a high copy number (2-4 x 10  ^ copies/cell). 
This system can not be used to generate stable cell lines but is excellent for 
transient expression (Gluzman, 1981). In transient expression systems DNA 
is introduced into cells and, after one to three days, the cells are harvested 
and the products of the expression analysed.
There are many different methods used to transfer the genes into mammalian 
cells, but for transient expression in COS-1 cells the DEAE-dextran 
technique is routinely used. DEAE-dextran, first used to improve the 
efficiency of virus infection (McCutchan and Pagano, 1968), has been used to 
improve the uptake of plasmid DNA for transient expression. The addition of 
a DMSG shock has been shown to increase transfection 50 fold (Lopata et 
al., 1984), and it was a modified version of this that was used in this study 
(section 2.25).
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Calcium phosphate co-precipitation involves incubating the cells with DNA in 
the form of a co-precipitate which sediments onto the cells, becomes 
adsorbed on to the cell membrane and is then taken up into the cytoplasm 
through a calcium requiring process. After a period of incubation the 
precipitate is washed off from the cells (Graham and Van de Eb, 1973). This 
method is often used for stable cell line transfections.
DNA encapsulated in liposome vesicles can be delivered to the cells by 
polyethylene glycol-mediated fusion . The unilamellar liposomes are formed 
from a positively charged lipid eg DOTMA (N-[l-(2,3 dioleoyloxy) 
propyl]-N,N,N-trimethylammonium chloride), (Boehringer), which form 
complexes with the DNA that are then taken up by the cell. Other similar 
products are available.
Other methods for transfection include micro-injection, electroporation and 
protoplast fusion.
6.3 AIMS
The aim of this study was to confirm that the cloned sequences expressed in 
vitro could also be expressed in pUSlOOO in vivo prior to the development of 
continuous cell lines producing E l structural proteins. To determine whether 
proteins lacking trans-membrane anchors could be secreted into the medium 
and evaluate whether secreted and or in vivo cellular RV proteins could be 
used for rubella ELISA and MACRIA.
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6.4 RESULTS
6.4.1 Construction of vectors for in vivo expression of RV structural 
proteins
The cloned rubella E l and E2 structural proteins were initially analysed by in 
vitro expression in a rabbit reticulocyte lysate assay (Chapter 5). Each 
rubella coding sequence was on an EcoRl cassette, therefore the sequences 
were purified and ligated into the EcoRl site of the expression vector 
pUSlOOO (section 2.3), (fig 6.1). The vector alone was used as a control. 
DNA for transfections were extracted from overnight 50ml bacterial cultures 
of each clone using Magic'^^ maxiprep columns (section 2.15.1(vi)). The 
clones were designated as follows;
Name Comments
p37/10 E1+ Bovine signal peptide (BSP), +TMA
p45/l E l +BSP, -TMA
pEES2 E2 + E2 signal peptide, +TMA (Al-Mumin, 1991)
p90/l E2 and E l,  E2 signal peptide, +TMA
p91/17 E2 and E l,  E2 signal peptide, -El TMA
6.4.2 Transfection in to COS-1 cells
COS-1 cells were passaged according to the method described in section
2.13.1 and 500ng of DNA for each vector transfected into the cells as 
described in section 2.25. For each of the expression vectors 3x10^ cells 
were transfected for each of the following, DNA extraction, RNA extraction 
and protein extraction from both the cells and supernatant using both 
standard culture medium (DMEM) and protein free medium. COS-1 cells 
were also grown and transfected on coverslips and subsequently analysed for 
RV protein production by immunofluorescence (section 2.14.3).
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6.4.2.1 Confirmation of transfection using DNA extractions
DNA was extracted from the cells (section 2.15.3) 48-72hrs post 
transfection, digested with EcoRl and fractionated on 1% agarose gels. The 
gels were Southern blotted (section 2.21) and probed with a radiolabelled 
EcoRl fragment of p37/10 containing the RV E l  sequence. The resulting 
autoradiograph of extracted DNA from transfections of p37/10 can be seen in 
fig 6.2 and confirms that the cells have been transfected with the DNA.
6.4.2.2 Confirmation of transcription by RNA extractions
RNA was extracted from the cells transfected with the different expression 
vectors (section 2.13.2) and northern blotted (section 2.21). The ^^ P 
radiolabelled EcoRl fragment of p90/l, containing both E l and E2 coding 
sequences, was used as a probe. RNA fractionated on a 1.5% denaturing 
gel is shown in fig 6.3(a) and an autoradiograph of the same RNA after 
northern hybridisation with the RV E l and E2 probe is shown in fig 6.3(b). 
RNA of the expected size for each of the rubella sequences can be seen. 
There was no vector RNA detected.
6.4.2.3 Detection of intracellular recombinant protein
Cell monolayers were washed with PBS, lysed in RIPA buffer, the protein 
fractionated by electrophoresis through a 9% SDS-PAGE gel (section 2.17.2 
(ii)) and western blotted (section 2.19). The RV proteins were detected 
using the ECL detection system (section 2.19.3) and COS-1 cell adsorbed 
anti-rubella human serum (section 2.28.1). After autoradiography, fig 6.4, 
two proteins were seen for each of the E l constructs and one protein band 
for E2, with the molecular weights of 58kDa and 51.5kDa for E l,  48kDa 
and 43.5kDa for El-TMA, and 38kDa for E2. No proteins were seen with 
the no DNA and vector only controls. Non-specific binding was seen in all 
the tracts due to cross reactivity between the serum and other COS-1 cell 
proteins.
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PA
gpt
hcmvy
Ss
H
Amp
Fig 6 . 1 pUS 1000 vector map
MCS => multiple cloning site 
5'-HindIII-XbaI-ClaI-SmaI-SstI-EcoRI-3'.
E => EcoRI H => Hindlll B => BamHI Ss => SstI 
hcmv => humna cytomegalovirus promotor/enhancer 
=> direction of transcription 
PA => poly(A) addition site 
gpt => gpt expression cassete 
Amp => ampicillin resistence marker 
ori => origin of replication
1 2 3 4  5 6  7 8  kb
- 2.0
è
Fig 6.2 Southern blot of DNA extracted from COS-1 cells transfected 
with expression vectors containing RV El coding sequences 
probed with radiolabelled EcoRl fragment of p37/10 (E l) 
coding sequence.
(1) p37/10 digested with EcoRl
(2) p37/10 uncut
(3) no DNA control digested with EcoRl
(4) no DNA control uncut
(5) pUSlOOO vector control digested with EcoRl
( 6 ) pUSlOOO vector DNA uncut
(7) extracted p37/10 from COS-1 cells digested with EcoRl
( 8 ) extracted p37/10 from COS-1 cells uncut
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Fig 6.3(a) 1.5% formaldehyde denaturing gel of RNA extracted from
COS-1 cells transfected with expression vectors containing RV
coding sequences.
1 ) RNA markers
2 ) p37/10 El
3) p45/l El-TMA
4) pEES2 E2
5) p90/l E2+E1
6 ) p91/17 E2+E1-TMA
7) pUSlOOO Vector
8 ) no DNA
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Fig 6.3(b) Northern blot of 6.3a) RNA extracted from COS-1 cells 
transfected with expression vectors containing RV 
coding sequences probed with radiolabelled EcoRl 
fragment of p90/l (E1+E2).
1 ) p37/10 El
2 ) p45/l El-TMA
3) pEES2 E2
4) p90/l E2+E1
5) p91/17 E2+E1-TMA
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(kDa) 1
58 -
51.5 _  
48 -
4 3 .5 -  W k #
3 8 -
Fig 6.4 Western blot of proteins extracted from COS-1 cells transfected 
with expression vectors containing RV coding sequences 
detected with COS adsorbed human anti-rubella serum and the 
ECL detection system.
1) p37/10 El
2) p45/l El-TMA
3) p45/l El-TMA
4) pEES2 E2
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6.4.2.4 Detection of secreted recombinant protein
The supernatant was harvested and an aliquot concentrated using centricon 
30, which has a molecular weight cut off of 30kDa. The protein samples 
were reduced from 2 ml to 2 0 0 pl, and then treated as for cellular proteins 
( 6 .4.2 .3). The medium used to grow the COS-1 cells contains 10% FCS 
which contains such high levels of BSA that the SDS-PAGE gels do not run 
properly. A very wide band of BSA at 6 6 kDa was produced distorting the 
rest of the samples. The El-TMA protein should run at about 45kDa so the 
distortion made any observation of this protein very difficult. The utilisation 
of protein free media gave far less background but no clear bands relating to 
the E l proteins. No rubella proteins were detected when protein free media 
was used. The cells may require weaning on to the protein free media in 
order for the recombinant protein production to occur at detectable levels.
6.4.2.5 Detection of intracellular recombinant protein by 
immunofluorescence
The coverslips covered with cells were washed with PBS, fixed and 
permealised with methanol for 5min. Treatment then continued as described 
in section 2.14.3. The primary antibody was COS-1 cell adsorbed 
anti-rubella human serum (section 2.28.1) used at 1 : 1 0 0  with the anti-human 
conjugate at 1:80. All the cells transfected with expression vectors 
containing rubella cDNA showed fluorescence with the anti-rubella serum. 
There was no fluorescence with the no DNA or vector only controls or with 
the PBS control (PBS instead of serum). Photographs of cells transfected 
with E l and El-TMA are shown in fig 6.5. A conjugate from a different 
supplier was used for the E2 and E2/E1 constructs and although fluorescence 
could be seen the signal was lower and the subsequent photographs very 
faint. Low power microscopy of the immunofluorescence clearly 
demonstrated that the level of successful transfection was only 5-10%, fig 
6.5(1). The fluorescence appeared to be localised in the ER with a
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concentration of protein in the vicinity of the Golgi.
The results are summarised in table 6.1.
Table 6.1 Summary of the results from the transfection of COS-1 cells 
with the expression vectors containing RV coding sequences.
Name Comment
DNA
detected
RNA
detected
Cellular
protein
detected
Secreted
protein
detected
Immuno­
fluorescence
p37/10 E l + + + nd +
p45/l El-TMA + + + - +
pEES2 E2 nd + + nd +
p90/l E2+E1 nd + - nd +
p91/17 E2+E1-TMA nd + - - +
p37/10 + 
pEES2
E l and E2 nd + - nd +
P45/1 + 
pEES2
El-TMA and 
E2
nd + - - +
pUSlOOO vector _* - - -
nd => not detected for
* => DNA and RNA present but not detectable with the RV probes
6.5 DISCUSSION
cDNA clones coding for the RV E l protein, El-TMA, E2, E2+E1 and 
E2+E1-TMA were ligated into the shuttle vector pUSlOOO and transfected 
into COS-1 cells. Monitoring of the transfections was carried out by
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Fig 6.5
O
Immunofluorescence of COS-1 cells transfected with expression 
vectors containing El and El-TMA coding sequences, using 
pooled human anti-rubella serum (I/lOO dilution) and anti-IgG 
FITC secondary conjugate.
(1) Low power (xlOO) of p37/IO (E l)
(2) p37/10 (E l) (x400)
(3) p45/l (El-TMA) (x400)
(4) pEES2 (E2) (x400)
(5) P37/10 and pEES2 (x400)
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Southern blot analysis, northern blot analysis, western blot analysis and 
immunofluorescence. Vector DNA was successfully transfected into the cells 
and rubella sequences transcribed as shown by northern blots. Protein 
products were not always detected or the levels of proteins that were 
expressed in this system were low when immunoblotted. 
Immunofluorescence of the transfected cells however indicated that 
expression of the RV proteins coded for by all the constructs was occurring 
but that the number of cells expressing the proteins was only about 5%. This 
was reflected in the poor detection of expressed proteins by western blot 
analysis.
Western blot of the expressed proteins from cell lysates produced bands 
corresponding to E l,  El-TMA and E2 but not the clones containing E1+E2. 
The E l proteins appeared as two bands and the E2 as a single band. This 
could be due to inefficient glycosylation of E l with the higher band 
representing complete glycosylation of E l and the lower band the 
unglycosylated form. This conclusion is reflected in the molecular weights of 
the protein bands observed, 58kDa and 51.5kDa for E l,  48kDa and 43.5kDa 
for El-TMA, and 38kDa for E2, which agree with the expected values 
reported by others. The apparent non-glycosylation of a portion of each 
protein could be due to overloading of the ER due to the high level 
expression of the vectors thus disturbing cellular metabolism. The expression 
of the E1+E2 constructs or E l with E2, did not yield sufficient proteins to 
be detected by the immunoblot system used, the reason for this is unclear.
In the absence of E2 protein RV El glycoprotein is unable to be transported 
to the Golgi complex, as has been reported for the E l of SFV (Lobigs et al., 
1990), and accumulates in a pre-Golgi compartment which consists of a 
tubular network of smooth membranes distinct from, but in continuity with, 
the RER, (Hobman et a l ,  1992; Baron et al., 1992). The
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immunofluorescence of the expressing COS-1 cells suggests the presence of 
E l in the ER and also an accumulation of protein in the expected location of 
the Golgi. Due to the close proximity of the pre-Golgi and Golgi 
compartments they can not be differentiated by light microscopy therefore 
immunofluorescence of the cells expressing E l and E2 could not differentiate 
between these regions to give the exact location. Hobman et ah, (1992) 
have shown that the site of E l arrest has distinct properties from the RER, 
intermediate department, or Golgi: (a) membrane proteins that serve as 
markers of RER or Golgi are excluded from this compartment; (b) agents that 
disrupt RER and Golgi integrity did not effect it; (c) its morphological 
organisation is different from that of the RER, Golgi and intermediate 
compartment. However, KDEL-containing luminal ER proteins, BiP (protein 
binding protein) and PDI (protein disulphide isomerase) seem to have access 
to this region. The BiP and PDI proteins are able to bind to the hydrophobic 
regions of aberrant folded proteins thus preventing their exit from the ER 
therefore resulting in the proteins degradation (Pelham, 1989). In the 
pre-Golgi compartment E l has a half life of 6 hrs (Hobman et al., 1992). If  
the same mechanisms are working in our study then the continual degradation 
of the E l protein would restrict the amount available for isolation and 
subsequent detection.
Baron and Forsell, (1991) used cDNA clones of E l and E2 which had an 
artificial optimised signal peptide at the start of the sequence. Our study 
made use of a bovine immunoglobulin signal peptide to increase protein 
expression. A synthetic signal peptide was chosen by Baron and 
Forsell,(1991) in order to eliminate any problems due to the fact that the 
normal E l and E2 signal peptide are designed to function from inside long 
polypeptides rather than the amino-terminus. Using pulse chase and 
sedimentation on sucrose velocity gradients E l was initially found as a 
monomer and was slowly converted into an oligomer with no
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intermediate-sized oligomers. The presence of E2 is presumed to prevent the 
formation of the oligomer resulting in the formation of a heterodimer. In 
addition transport arrested E l may exist as disulphide linked dimers or 
trimers and/or noncovalently associated homo-oligomers consisting of five or 
six molecules (Hobman et al., 1992). The E l protein (p37/10) may have 
been formed in this way, while being retained and subsequently degraded.
The El-TM A protein was designed in the hope that it would be secreted from 
the cells. An expression vector containing the E l coding sequence with only 
four amino acids of the trans-membrane anchor and half the putative E l 
signal peptide had been shown by immunoprécipitation to produce low levels 
of secreted protein in COS-1 cells (Al-Mumin, 1991). Utilisation of the 
bovine immunoglobulin signal peptide to increase the levels of expression and 
removal of all the trans-membrane anchor should have produced higher levels 
of secreted E l.  In normal medium the level of serum proteins is so high that 
they can mask the expressed protein on a SDS-PAGE gel, so the cells were 
grown in protein free media post transfection. No recombinant protein was 
detected by western blotting in the cell lysates or the supernatant when 
protein free media was used, the absence of certain growth factors perhaps 
resulting in lower levels of expression, the COS-1 cells not having been 
weaned in the protein free media prior to transfection. The immunoblot and 
immunofluorescence results show that the El-TM A protein is expressed and 
therefore it might be expected that the protein would be secreted. However 
it may be that the El-TMA protein gets arrested in the pre-Golgi 
compartment thereby restricting the secretion. The results of Al-Mumin
(1991) indicate that El-TMA should be secreted with removal of the 
trans-membrane anchor perhaps making the protein fold in such a way as to 
prevent the binding of the ER retention proteins, BiP and PDI. The inability 
to detect secreted E l in the current study may be because truncated E l is 
infact arrested in .the pre-Golgi compartment and the protein detected by
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Al-Mumin, (1991) was due to release on cell death.
Diagnostic testing of human serum samples in the MACRIA assay, using E l 
and El-TMA as antigens, gave readings the same as the control (W.Starkey, 
PC). This assay was selected as being more sensitive than an ELISA, due to 
the low levels of protein available but because of this the system was not 
optimised for this particular reagent. The antigen preparation would contain 
other cellular components which could interfere with the assay.
Increased expression of the RV proteins could be achieved by a higher level 
of transfection by using different vectors, different methods of transfection 
and different cell lines. DEAE-dextran may not be the best system of 
transfection to use as electron microscopy studies have shown numerous 
autophagic vacuoles and lysosomes in COS cells due to the DEAE-dextran 
(Hobman et ah, 1992). Another method available makes use of liposome 
encapsulation agents eg DOTMA, DOTAP, Lipofectin, all of which have been 
tried during this study. Examination of RNA from transfected cells showed 
that efficient transcription was occurring but translation was apparently poor. 
The system is straight forward to implement but needs to be optimised to 
obtain high levels of expression. Expression could be further enhanced by 
transfecting a stable cell line eg CHO cells as employed by Hobman et al.,
(1992); Dogan and Sanders( unpublished).
In conclusion RV E l and El-TMA cDNA with a BSP, and E2 cDNA, with its 
own signal peptide, have been expressed in COS-1 cells with the recombinant 
protein detected using western blot analysis.
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Chapter 7
EPITOPE MAPPING OF RUBELLA E l  
GLYCOPROTEIN 
USING SYNTHETIC PEPTIDES
EPITOPE MAPPING OF RUBELLA E l GLYCOPROTEIN USING
SYNTHETIC PEPTIDES
7.1 SUMMARY
The antigenicity of the rubella virus E l polypeptide was analysed using 
overlapping octameric synthetic peptides. PEP SCAN was used to define 
antibody-binding domains with human rubella positive sera from healthy 
individuals and from those who were convalescing from a recent infection or 
reinfection and from individuals with congenital rubella syndrome. An initial 
study was carried out on the region E I 2 2 3 -E I 3 Q0 , reported to contain three 
haemagglutinating and neutralising epitopes (epsl, eps2 and eps3) (Terry et 
al., 1988). Recognition of peptides varied between the rubella positive sera 
with analysis of the combined data from all the individuals showing reactivity 
to all the previously identified epitopes at 2SD above the mean, with epsl 
being the predominant epitope. Analysis of octapeptides covering the whole 
of E l showed the afore mentioned epitopes had some reactivity with rubella 
positive sera but the majority of El-specific antibodies were against other 
areas in the polypeptide. Variations between sera with regard to the epitopes 
detected made interpretation of any trends due to immune status very 
difficult. Serum samples taken at different times during convalescence 
showed, with two out of three pairs of samples, a reduction in reactivity to 
peptides within eps2 and eps4 with time. PEP SCAN analysis of a panel of 
monoclonal antibodies to E l failed to identify the binding sites.
7.2 INTRODUCTION
An epitope or antigenic determinant is defined as the region that is 
recognised by the binding site or paratope of an antibody molecule. An 
epitope may be either continuous or discontinuous. Continuous protein 
epitopes are defined as short linear stretches of amino acid residues, whereas
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discontinuous epitopes consist of a group of residues that are not contiguous 
in the sequence but are brought together by the folding of the polypeptide 
chain or by the juxta position of two separate polypeptide chains (Van 
Regenmortal, 1989a). Most B-cell epitopes on native proteins are probably 
discontinuous although portions of these may appear as linear epitopes. 
Epitopes can further be described as antigenic or immunogenic. An antigenic 
epitope is a region on a protein molecule to which an antibody can bind, 
whereas an immunogenic epitope is the part of the protein that elicits an 
antibody response when the protein is used as an immunogen.
Using antibody reactive peptide scanning, PEP SCAN, (Geysen et al., 1984, 
1985a) it is possible to identify linear antigenic epitopes (Geysen et al., 
1987a). The system is available as a commercial kit (Cambridge Research 
Biochemicals) with the synthetic peptides synthesised on solid polyethylene 
pins (fig 7.1). The pins are radiation grafted with acrylic acid to provide a 
reactive polyacrylic acid matrix to which mono-t-butyloxycarbonyl- 1 - 6 - 
diaminohexane is coupled. After removal of the temporary t-butyloxy- 
carbonylamino protecting group, a spacer group, B-alanine is added. All the 
amino acids have the alpha-amino group protected with the 9-fluorenyl- 
methyloxycarbonyl (Fmoc) group and the side chains protected by various 
protecting groups, (fig 7.1). All the amino acids derivatives are used in the 
activated form of pentafluorophenyl esters except for serine and threonine 
which are used as oxo-benzotriazine esters. Synthesis of peptides is 
accomplished by repetitive cycling of Fmoc-deprotection, washing and 
coupling at the rate of one amino acid a day. After removal of the final 
Fmoc-protecting group, the terminal amino group is capped by acétylation 
followed by the removal of the side chain protecting group (section 2.30.1). 
The block of pins can now be used to test its reactivity against a range of 
sera.
196
Peptide-Pin schematic
a)
O O R" O I
O
CH3  -C-NH-CH-C-....-NH-CH-C-NH-(CH2 ) 2  -C-NH-(CH2 ) 6  -NH-C 
Acetyl Peptide B-Ala HMD
b)
Fig 7.1 Diagrammatic representation of the polyethylene pin onto
which the synthetic peptide is synthesised (a)and (b)the 
polyethylene block into which the pins are secured
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PEP s CAN technology has been utilised by workers for the analysis of 
different viral and bacterial proteins using monoclonal and polyclonal sera, 
two examples are identification of a linear epitope of the fusion glycoprotein 
of respiratory syncytial virus (Scopes et a l,.1990) and characterisation of 
human antibody-binding sites on the external envelope of HIV-2 (de Wolf et 
al., 1991). The system has also been used for more detailed studies on 
continuous epitopes (Geysen et ah, 1988) by making use of replacement 
analysis. For this peptides are synthesised with each amino acid residue in 
the parent sequence being substituted one at a time by the other 19 natural 
amino acids, keeping the rest of the sequence the same.
Using monoclonal antibodies the rubella E l glycoprotein has been shown to 
contain at least six independent epitopes. These epitopes include domains 
that are important for viral infectivity and haemagglutination (Green et al., 
1986; Waxham and Wolinsky, 1985). Three epitopes, which react with 
haemagglutinating and neutralising antibodies, have been located between 
amino acids El^^^-El^g^ (Terry et al., 1988), using Staphylococcus aureus V 8  
protease and trypsin to generate overlapping peptides. This region was 
selected for the initial study using PEP SCAN.
7.3 AIM
To determine whether individual rubella positive human sera could be used to 
(a) confirm the presence of epitopes in the region El^^g-El^g^ reported by 
Terry et al., (1988); (b) identify epitopes in other regions of E l.  This would 
also provide information on (a) the reactivity of sera from asymptomatic 
rubella positive individuals, those convalescing from RV infections or 
reinfections and individuals with CRS; (b) help to define any changes in 
response with time from paired sera; (c) detect any differences in responses 
between the amino acid sequences of the vaccine strain RA27/3 and wild type
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infections. In addition the peptides were used to try to identify the epitopes 
bound by five monoclonal antibodies. These had previously been shown to 
map to five distinct epitopes within E l by competitive binding assay (Gerna 
et al., 1987).
7.4 RESULTS
7.4.1 Generation of peptides covering the E l region amino acid 223-300
Seventy-one overlapping octameric peptides were synthesised using the 
method described in section 2.30. for the region between E I 2 2 3 -E I 3 0 0  
corresponding to the Thomas E l amino acid sequence and 8  peptides 
synthesised for the region El^^^-El^^^ of the RA27/3 vaccine strain. This 
sequence differs from the other rubella strains by one amino acid (chapter 3), 
located within eps2 at El^^g, Ala =>Val. Each octamer overlapped by seven 
amino acids with the next peptide (fig 7.2). Positive and negative controls of 
tetra-mers were included on the block of pins. The positive control reacted 
with a monoclonal antibody supplied by the manufacturer.
7.4.2 Analysis of serum sample
Serum samples from a random selection of rubella positive and negative 
healthy individuals were selected for testing. The samples had been analysed 
for rubella antibodies as part of a routine screening programme prior to 
emigration or as part of a ante-natal screen . Each of the serum samples had 
been tested for the presence or absence of rubella antibodies by SRH. The 
negative sera were retested using LA to confirm the absence of rubella 
antibodies. The only other information available was the sex of the donor. 
Male donors could be assumed to have naturally acquired antibodies but the 
females could have naturally or vaccine acquired antibodies. Eleven rubella 
positive and three rubella negative sera were analysed by PEP SC AN using the 
ELISA based method (section 2.30.2), which generated an OD reading based
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PNCHGPDWASPVCQRHSPDSCRLVGATPERPRLRLVDADDPLLRTAPGPGEVW VTPVIGSOARKCGLHIRAGPYCHAT
E P S 2  E P S 3  E P S l
PNCHGPDW 
NCHGPDWA 
CHGPDWAS 
HGPDWASP 
GPDWASPV 
PDWASPVC 
DWASPVCQ 
WASPVCQR 
ASPVCQRH 
SPVCQRHS 
PVCQRHSP 
VCQRHSPD 
CQRHSPDS 
QRHSPDSC 
R HS P DS C R  
H S P DS C R L  
S P D S CR L V  
PDSCRLVG 
DSCRLVGA DSCRLVGV
SCRLVGAT SCRLVGVT
CRLVGATP CRLVGVTP
RLVGATPE RLVGVTPE
LVGATPER LVGVTPER
V G A T P ER P  VG V T PER P
GA T P ER P R  GV T P ER P R
A T P E R P R L  V T P E R P R L
T P E R P R L V  
PER PRLVD 
ERPRLVDA 
RPRLVDAD 
PRLVDADD 
RLVDADDP 
LVDADDPL 
VDADDPLL 
DADDPLLR 
ADDPLLR T 
DDPLLRTA 
D P LL RT AP  
P LL RT AP G 
L LR T AP GP  
LRTA PGP G 
RTAPGPGE 
TAPG PG EV 
APGPGEVW 
PGPGEVWV 
GPGEVWVT 
PGEVWVTP 
GEVWVTPV 
EVWVTPVI  
VWVTPVIG 
WVT PVI GS  
V T P V I G S Q  
T P V I G S Q A  
P V I GS Q AR  
V I G S Q A R K  
I GS QA R K C  
GSQARKCG 
SQARKCGL 
QARKCGLH 
A R K C G L HI  
R K C GL H IR  
K C G L H I R A  
C GL HI RA G  
G L H I R A G P  
L H I R A G P Y  
H I RA G P Y C  
I RA G P YC H 
RAGPYCHA 
AGPYCHAT
Fig 7.2 Octameric peptides covering the region E I 2 2 3 -B I 3 QQ and
E I 2 4 1 -E I 2 5 5 . The small region E I 2 4 J-EI 2 5 5  covers the change 
in amino acid sequence between RA27/3 and Thomas,
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on the reactivity of each peptide against each serum. The positive and 
negative control peptides were tested using a specific monoclonal antibody, 
supplied by the manufacturer, which acted as a control for the system. 
Graphical representation of the OD readings for each of the serum samples 
can be seen in fig 7.3. A detailed graph of serum 25 is shown in fig 7.4. A 
list of the ELISA OD readings for all of the serum samples can be found in 
Appendix 4.
7.4.3 Statistical analysis of the ELISA results for the region El^za-El^gg 
In other studies (Goudsmit et al., 1990; Coursaget et al., 1991; de Wolf et 
al., 1991) authors have chosen a number of different criteria to obtain a 
value for background and significant readings. The data was analysed
according to the method described by Radford et al., (1990). The peptides 
were considered reactive if the OD values were 2 standard deviations (SD) 
above the mean of the lowest 25% of the values. The reactivity was also 
calculated at 3 and 4SD above the mean of the lowest 25% of the values. 
Epitopes were defined as groups of peptides with SD's of 2 or more above 
the overall mean. . . An example of the calculations using one of the serum
samples is shown in table 7.1. The data on the significant peptides identified 
with each positive or negative serum was pooled. The individual serum 
samples identify different reactive peptides but pooling the data tends to link 
the reactive peptides together. The number of rubella positive and negative 
sera showing reactivity with a significant peptide at 4SD, 3SD and 2SD 
above the mean of the lowest 25% of values is shown in fig 7.5. The 
reactivity to each of the peptides at 4SD, 3SD and 2SD above the mean of 
the lowest 25% and the overall mean, defining the epitopes, is shown in fig 
7.6, for the rubella positive and negative sera. There is a high degree of 
overlap between the graphs. The amino acid sequences corresponding to the 
significant peptides calculated at 3 and 4SD are shown in table 7.2, with the 
defined epitope sequences in bold. A peptide was considered to represent an
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Table 7.1 SERUM 25 -calculation to find the reactive peptides and 
define the epitope
a)mean of the lowest 25% of values = 0.462 
SD = 0.148
SD x4 + mean = 1.054
SD x3 + mean = 0.908
SD x2 + mean = 0.759
b)overall mean = 0.545 
SD x4 + mean = 1.137
SD x3 + mean = 0.990
SD x2 + mean = 0.842
Out of the 71 peptides tested only four showed reactivity at 2SD and above 
as defined by both forms of analysis.
peptide OD
56 0.895
58 0.929
27 1.070
57 1.143
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Fig 7.3 ELISA readings obtained for each of the synthetic octameric
peptides spanning the El sequence El^^^-Elg^^ for all the serum 
samples analysed.
Positive sera
Serum 32Serum 25
Peptides
Serum 9
Peptides
Serum 18
Peptides
Serum 31
Peptides
Serum 20
Peptides
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Fig 7.3 continued
Positive sera
1.6 +
Serum  1511
Peptides
S erum  1
P eptides
Serum  4
253 263
P ep tid es
Serum  2
Peptides
Serum 10
P eptides
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Fig 7.3 continued
Negative sera
Serum  22Serum  21
P ep tides P ep tides
Serum  33
Peptides
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Fig 7.4 Detailed PEPSCAN of serum 25 showing the ELISA readings 
for each octameric peptide spanning the E l sequence
^ ^ 2 2 3 " ^   ^300.
Serum 25
1.8 
1.6
1.4
E :
lO 1  f
1 -
°o.«
0.4 
0.2 
0
223 233 243 253 263
Peptides
273 283 293
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Rubella positive sera
233 253 263 273 283223 243 293
Peptides
Rubella negative sera
253 263 273223 233 243 283 293
Peptides
Fig 7.5 Number of positive sera, (from a total of 11), and the number 
of negative sera, (from a total of 3), with significant 
reactivity to each of the synthetic octameric peptides 
spanning the El sequence El-^^-El^QQ The significance was 
calculated at 2, 3 and 4SD above the mean of the lowest 25% of 
values (Radford et al., 1990). Observations of 4SD indicates 
that the peptide would also be significant at 2 and 3SD, but 
have been displayed as significant at 4SD.
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Reactive peptides
Rubella positive sera
223 233 243 253 263
Peptides
273 283 293
± ]
Fig 7.6a) Reactivity for each of the synthetic octameric peptides spanning 
the El sequence E I 2 2 3 -E I 3 QQ, calculated at 2, 3 and 4SD above 
the mean of the lowest 25% of values (Radford et al., 1990). 
Observations of 4SD indicates that the peptide would also be 
significant at 2 and 3SD, but have been displayed as significant 
at 4SI).
Reactive peptides
Rubella positive sera
223 233 243 253 263
Peptides
273 283 293
a
Fig 7.6b) Reactivity for each of the synthetic octameric peptides spanning 
the E l sequence E I 2 2 3 -E I 3 QQ, calculated at 2, 3 and 4SD above 
the overall mean. Groups of peptides are indicative of an 
epitope (Radford et al., 1990). Observations of 4SD indicates 
that the peptide would also be significant at 2 and 3SD, but 
have been displayed as significant at 4SD.
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Reactive peptides
Rubella negative sera
223 233 243 253 263
Peptides
273 283 293
Fig 7.6c) Reactivity for each of the synthetic octameric peptides spanning 
the E l sequence E I 2 2 3 -E I 3 0 0 , calculated at 2, 3 and 4SD above 
the mean of the lowest 25% of values (Radford et al., 1990). 
Observations of 4SD indicates that the peptide would also be 
significant at 2 and 3SD, but have been displayed as significant 
at 4SI).
Reactive peptides
Rubella negative sera
c
I
I
CO■oc
g
223 233 243 253 263
Peptides
273 283 293
3
Fig 7.6d) Reactivity for each of the synthetic octameric peptides spanning 
the El sequence El 2 2 3 -El 3 0 0 , calculated at 2, 3 and 4SD above 
the overall mean (Radford et al., 1990). Observations of 4SD 
indicates that the peptide would also be significant at 2  and 
3SD, but have been displayed as significant at 4SD.
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epitope if it contained the core sequences of the respective epitope as 
designated by Lozzi et al., (1990),
epsl peptides 268-283, eps2 peptides 243-250
eps3 peptides 256-260, eps4 peptides 223-235.
The defined epitope sequences correspond to regions covered by eps2 and 
epsl (Terry et al., 1988) and within the neutralising epitope reported by 
Chaye a/., (1992), El^ig-El^^g, which is designated eps4(2) during this 
thesis. The peptides covering eps3 were only significant at 2SD above the 
overall mean. Analysis at 2SD above the overall mean gave more significant 
peptides adjacent to those obtained at 3SD but also more significant peptides 
with the negative sera. At 3SD above the overall mean there were five 
significant peptides with the negative sera, with one in each of epsl, 2 and 3. 
There were no peptides with significant reactivity at 4SD above the overall 
mean. At 3SD and 4SD above the lowest 25% of values there were nine 
significant peptides with the negative sera, two in epsl and one in each of 
eps2, 3 and 4. A list of the significant peptides for each sera is shown in 
table 7.3.
Table 7.2 Amino acid sequences of the significant peptides and 
defined epitopes
HGPDWASPV 233
eps4(2)
2^3 CRLVGATPERPRL 253
eps2
268 APGPGEVWV 2"
epsl
EVWVTPVIGSOARKCGLHIRA
epsl
AGPYGHAT 300
epsl, 2 and 4(2) are underlined with the defined epitopes in bold
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Table 7. 3 List of the significant peptides for each of the sera analysed 
calculated at 2, 3 and 4SD above the mean of the lowest 25% 
of values.
Serum 25 Serum 32 Serum 9 Serum 31 Serum 20
276 226 228 269 226
278* 278 229 224 254
247# 232 243 229 230
277# 268 293 282 281
229 231 227 231
245* 271 228 278
276# 227 231 293
225 230 256
269 243 244*
226* 293* 279*
244* 226# 243*
268* 280#
Serum 2 Serum 1 Serum 4 Serum 10 Serum 18
244 255 262 232 227
256 229 272 223 270
277 273# 278 228 282*
248# 287 226 247#
285* 225 283#
275* 269*
274* 227#
286#
negative sera
Serum 21 Serum22 Serum33
282* 270, 248 238
255* 293,233 253
283* 232, 249 241
23# 237, 262 257 *=> 3SD
277, 247 254 #=> 4SD
231, 244 240
278,266* 227*,267*
256* 255#
257
278
260
255 
233
256 
269#
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7.4.4 Generation of peptides covering the whole of E l
To cover the 481 amino acids of E l,  474 overlapping octameric peptides
were synthesised using the method described in section 2.30.1. Each peptide 
overlapped the neighbouring peptide by seven amino acids. This number of 
peptides were synthesised on five polyethylene blocks A-E (fig 7.7). Each 
block had a positive (PLAQ) and negative (GLAQ) control of a tetrameric 
sequence reactive to a specific monoclonal antibody. Initially each block 
was tested using the controls to check that the synthesis had been successful.
7.4.5 Analysis of serum samples
A variety of serum samples including CRS and convalescent sera were used 
to analyse the reactivity of the E l peptides. The presence of rubella 
antibodies was determined by several methods, SRH, HAI, ELISA, LA 
(J.Best, PC) (Table 7.4). The cause of the acquisition of the rubella 
antibodies was also known for some of the sera. Twelve rubella positive and 
four rubella negative sera were analysed. Three of the twelve sera were 
in that the serum was taken at different time intervals during 
convalescence.
The sera were analysed using an ELISA based system with the primary 
antibody at 1:200 and the secondary antibody (rabbit anti-human IgG/rabbit 
F(ab) 2 ) at 1:1000 (section 2.30.2). The generated OD readings for the 
reactivity of each peptide for each serum are graphically presented in fig 7.8. 
Detailed graphs of serum 75B and serum 69 (negative) are shown in fig 7.9a 
and b.
The Mabs (Gerna et al., 1987) were assayed at a dilution of 1:500 with the 
secondary antibody (rabbit anti-mouse IgG) at 1:1000. The Mab G7H9 is 
commercially available (Northumbria Biologicals), (Tedder et al., 1982), and 
maps to a discontinuous epitope in E l.
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Fig 7.7 Octameric peptides covering the whole of E l sequence arranged 
in block format, pins 1  and 2  on each block are the control 
peptides.
1 A 1(1)
2 A 2(1)
3 A 3(1)
4 A 4(1)
5 A 5(1)
6 A 6(1)
7 A 7(1)
8 A 8(1)
9 A 9(1)
10 AlO(l)
11 AlKl)
12 A12(l)
13 A 1(2)
14 A 2(2)
15 A 3(2)
16 A 4(2)
17 A 5(2)
18 A 6(2)
19 A 7(2)
20 A 8(2)
21 A 9(2)
22 A10(2)
23 All(2)
24 A12(2)
25 A 1(3)
26 A 2(3)
27 A 3(3)
28 A 4(3)
29 A 5(3)
30 A 6(3)
31 A 7(3)
32 A 8(3)
33 A 9(3)
34 A10(3)
35 All(3)
36 A12(3)
37 A 1(4)
38 A 2(4)
39 A 3(4)
40 A 4(4)
41 A 5(4)
42 A 6(4)
43 A 7(4)
44 A 8(4)
45 A 9(4)
46 A10(4)
47 A1K4)
48 A12(4)
PLAQ <
GLAQ <
EEAFTYLC<
EAFTYLCT<
AFTYLCTA<
FTYLCTAP<
49 A 1(5)
50 A 2(5)
51 A 3(5)
52 A 4(5)
53 A 5(5)
54 A 6(5)
GACICEIP<
ACICEIPK
CICEIPTD<
ICE1PTDV<
CEIPTDVS<
EIPTDVSCC
TYLCTAPG<
YLCTAPGC<
LCTAPBCA<
CTAPGCAK
TAPGCATQ<
APGCAT8T(
PGCATQTP<
GCATQTPV<
CATQTPVP<
ATQTpypy<
TQTPVPVR<
OTpyPVRK
TPVPyRLA(
pypVRLAG<
yPVRLAGV(
pyRLA6VR<
VRLAGVRF<
RLAGyRFEC
LAGVRFES<
AGyRFESK<
GyRFESKK
VRFESKIV<
RFESKIVD<
FESKIVDG<
ESKIVDGG<
SKIVDGGCC
KIVDGGCF<
IVDGGCFA<
VDGGCFAP<
DGGCFAPW<
GGCFAPWD(
GCFAPWDK
CFAPWDLE(
FAPWDLEA<
APWDLEAT<
PWDLEATG<
WDLEATGA(
DLEATGACC
LEATGACK
EATGACIC<
ATGAC!CE<
TGACICEK
55 A 7(5)
56 A 8(5)
57 A 9(5)
58 A10(5)
59 All(5)
60 A12(5)
61 A 1(6)
62 A 2(6)
63 A 3(6)
64 A 4(6)
65 A 5(6)
66 A 6(6)
67 A 7(6)
68 A 8(6)
69 A 9(6)
70 A10(6)
71 All(6)
72 A12(6)
73 A 1(7)
74 A 2(7)
75 A 3(7)
76 A 4(7)
77 A 5(7)
78 A 6(7)
79 A 7(7)
80 A 8(7)
81 A 9(7)
82 A10(7)
83 A1K7)
84 A12(7)
85 A 1(8)
86 A 2(8)
87 A 3(8)
88 A 4(8)
89 A 5(8)
90 A 6(8)
91 A 7(8)
92 A 8(8)
93 A 9(8)
94 A10(8)
95 A1K8)
96 A12(8)
IPTDySCE<
PTDVSCEG<
TDySCEGL<
DVSCEGLB<
VSCEGLGA<
SCEGLGAW<
CEGLGAWV<
EGLGAWyP<
GLGAWVPK
L6AWVPTA(
GAWyPTAP(
AWypTAPC<
WVPTAPCA(
VPTAPCARC
PTAPCARK
TAPCARIW(
APCARIWH<
PCARIWNG<
CARI«NGT<
ARINNGTQ(
RIWNGTQR<
IWNGTQRA(
WNGTQRAC<
NGTQRACK
GTQRACTF<
TQRACTFW(
QRACTFWA(
RACTFWAV(
ACTFWAVN<
CTFWAVNA<
TFWAVNAY<
FWAyNAYS<
WAVNAYSSC
AVNAYSSG<
VNAYSSGG<
NAYSSGGY<
AYSSGGYA(
YSSGGYAQ(
SSGGYAQK
SGGYAQLA<
G6YAQLAS<
GYAQLASY<
97 B 1(1)
98 B 2(1)
99 B 3(1)
00 B 4(1)
01 B 5(1)
02 B 6(1)
03 B 7(1)
04 B 8(1)
05 B 9(1)
06 BlO(l)
07 BlKl)
08 B12(l)
09 B 1(2)
10 B 2(2)
11 B 3(2)
12 B 4(2)
13 B 5(2)
14 B 6(2)
15 B 7(2)
16 B 8(2)
17 B 9(2)
18 B10(2)
19 B1K2)
20 B12(2)
21 B 1(3)
22 B 2(3)
23 B 3(3)
24 B 4(3)
25 B 5(3)
26 B 6(3)
27 B 7(3)
28 B 8(3)
29 B 9(3)
30 BIO(3)
31 B1K3)
32 B12(3)
33 B 1(4)
34 B 2(4)
35 B 3(4)
36 B 4(4)
37 B 5(4)
38 B 6(4)
39 B 7(4)
40 B 8(4)
41 B 9(4)
42 BIO(4)
43 B1K4)
44 B12(4)
PLAQ <
GLAQ <
YAQLASYF< 
AQLASYFN( 
QLASYFNP< 
LASYFNPG<
ASYFNPGG(
SYFNPGGS<
YFNPGGSY<
FNPGGSYY<
NPGGSYYK<
PGGSYYKQ<
GGSYYKQY<
GSYYKQYH<
SYYKQYHP<
YYKQYHPK
YKQYHPTA<
KQYHPTAC<
OYHPTACE<
YHPTACEy<
HPTACEVE<
PTACEyEP<
TACEVEPA<
ACEVEPAF<
CEyEPAFG<
EVEPAFGH<
VEPAFGHS<
EPAFGHSD<
PAFGHSDA<
AFGHSDAA<
FGHSDAAC<
GHSDAACW<
HSDAACWG<
SDAACNGFt
DAACWGFPC
AACWGFPT(
ACWGFPTD<
CWGFPTDK
WGFPTDTV<
GFPTDTVH<
FPTDTVMS<
PTDTyMSV<
TDTVMSVF<
DTVKSyFA<
TVHSyPAK
yMsypALA<
HSyPALAS<
SyPALASY<
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346 010(5)
347 011(5)
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Fig 7 . 8  Graphical representation of the ELISA readings obtained for
each of the synthetic octameric peptides spanning the whole E l 
sequence for all the serum samples analysed.
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Fig 7.8 continued
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Table 7.4 Information regarding the serum samples used in the 
analysis of £1 epitopes
Positive
Serum
Antibody test Status of patient
1511 SRH vaccinee
18 SRH vaccinee
63 SRH, CMI, ELISA, HAI, 
LA
CRS (2yrs old)
64 SRH, CMI, ELISA, HAI, 
LA
CRS (ly r  old)
73A
HAI Natural infection (day 10)
73B HAI Natural infection ( 8  weeks)
74A IgM, HAI Natural infection (day 14)
74B Natural infection ( 8  weeks)
75A HAI, SRH, IgM Natural infection (dayl2)
75B HAI, SRH, IgM Natural infection (5 weeks)
70 SRH Reinfection ( 8  weeks)
77 HAI, IgM Reinfection ( 6  weeks)
Negative
serum
67 ELISA
6 8 ELISA
69 ELISA
71 SRH, LA
7.4.6 Statistical analysis of the ELISA results for the whole of E l
The statistical method of Trifilieff et a /.,(1991) was used for the analysis of 
data generated by the ELISA readings for the reactivity of the serum samples 
against the E l peptides. This considers a peptide to be reactive when the
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absorbance was greater than 3SD above the mean of the background 
non-specific binding. The background binding was calculated by ranking the 
absorbance values and averaging the lowest 50% of values. In addition to 
determining the peptides that were significant at 3 SD's we also determined 
those significant at 2 and 4SD above the mean of the lowest 50% of values. 
An example of the calculations involved for one of the sera is shown in table 
7.5.
On an individual basis each serum gave a different pattern of response. The 
data on the significant peptides from all the rubella positive sera was pooled, 
as was the data from the negative sera. Figures 7.10a and b show the number 
of sera with significant reactivity at 2, 3 and 4SD above the mean of the 
lowest 50% of values, for the pooled positive and pooled negative sera, for 
each of the peptides. Along with the epitopes, epsl, 2, and 3 (Terry et 
a/., 1988) there is also a neutralising/ haemagglutinating epitope reported by 
Mitchell et a/.,(1992b) (El^i^-El^gg), which throughout this thesis will be 
designated eps4. There are many significant peptides outside the region 
covered by the previously identified epitopes, epsl-4. Two sera each showed 
one reactive peptide in epsl above 3SD, the remaining region covering epsl, 
2, and 3 contains peptides that are only significant at 2SD.
None of the negative sera showed any reactive peptides within the region 
covered by epsl, 2 or 3 but there were seven significant peptides in the 
region covered by eps4. No peptide showed significant reactivity with all the 
negative sera tested. A list of the significant peptides for the negative sera is 
shown in table 7.8
Paired sera from convalescent patients
Three paired sera were available (table 7.4) for the epitope analysis. Serum 
pair 73, taken six weeks apart, showed 82% agreement between their reactive
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Table 7.5 SERUM 77 - REINFECTION - calculation to find the reactive
peptides at 2SD, 3SD and 4SD above the mean of the lowest 
50% of values
Mean of the lowest 50% of the values
= 0.166
SD of the complete range 
0.059
SD X 2 0.119 + mean = 0.284
SD X 3 0.178 + mean = 0.343
SD X 4 0.237 + mean = 0.403
peptides OD peptides OD
334 0.285 99 0.302
339 0.286 165 0.304
87 0.286 1 0 2 0.308
194 0.286 4 0.308
390 0.287 1 0 1 0.312
291 0.288 444 0.316
2 2 1 0.288 171 0.317
71 0.288 178 0.319
349 0.288 96 0.319
1 0 0 0.288 345 0.322
74 0.288 447 0.324
423 0.289 373 0.326
386 0.289 142 0.334
442 0.291 98 0.335
132 0.293 432 0.341
445 0.294 448 0.342
456 0.295 418 0.342
336 0.295 420 0.355*
340 0.296 97 0.357*
419 0.296 343 0.358*
163 0.296 342 0.361*
140 0.296 387 0.362*
421 0.297 166 0.369*
378 0.298 348 0.372*
347 0.298 138 0.381*
94 0.298 346 0.391*
473 0.298 341 0.41 #
332 0.299 344 0.454#
95 0.301 135 0.46 #
5|C —=>3SD # = > 4 S D
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Fig 7.10a The four graphs show the number of rubella positive sera, out of 
the 1 2  analysed, displaying significant reactivity against the 
overlapping octameric peptides covering the whole of the 
rubella E l sequence,The reactivity has been calculated at 2, 3 
and 4SD above the mean of the lowest 50% of values. 
Observations of 4SD indicates that the peptide would also be 
significant at 2 and BSD, but have been displayed as significant 
at 4SD. The region covered by epsl-4 spans peptides 213-283.
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Fig 7.10a The four graphs show the number of rubella positive sera, out of 
the 1 2  analysed, displaying significant reactivity against the 
overlapping octameric peptides covering the whole of the 
rubella E l sequence,The reactivity has been calculated at 2, 3 
and 4SD above the mean of the lowest 50% of values. 
Observations of 4SD indicates that the peptide would also be 
significant at 2 and 3SD, but have been displayed as significant 
at 4SD. The region covered by epsl-4 spans peptides 213-28j
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Fig 7.10b The four graphs show the number of rubella negative sera, out 
of the 4 analysed, displaying significant reactivity against the 
overlapping octameric peptides covering the whole of the 
rubella E l sequence,The reactivity has been calculated at 2, 3 
and 4SD above the mean of the lowest 50% of values. 
Observations of 4SD indicates that the peptide would also be 
significant at 2 and BSD, but have been displayed as significant 
at 4SD. The region covered by epsl-4 spans peptides 213-283.
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Fig 7.10b The four graphs show the number of rubella negative sera, out 
of the 4  analysed, displaying significant reactivity against the 
overlapping octameric peptides covering the whole of the 
rubella E l sequence,The reactivity has been calculated at 2, 3 
and 4SD above the mean of the lowest 50% of values. 
Observations of 4SD indicates that the peptide would also be 
significant at 2  and 3SD, but have been displayed as significant 
at 4SD. The region covered by epsl-4 spans peptides 213-283.
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peptides. The peptides that were not in agreement were predominantly 
located adjacent to the other reactive peptides that were in agreement. The 
serum sample taken shortly after infection, (73 A), showed three extra 
reactive peptides in the region of eps4 and eps2. The first serum sample of 
pair 74,(74A), also showed three more peptides associated with eps4 and 
eps2 than the second sample. Serum pair 75 showed a 79% agreement for 
the reactive peptides between the samples with all but two peptides not in 
agreement adjacent to those that were. All three pairs of samples had 
reactive peptides in the regions of epsl, 2 and 4, with none associated with 
eps3. The data is graphically displayed in fig 7.8 with the significant 
peptides listed in table 7.6.
CRS patients
Two serum samples were available (table 7.4). Serum 63 had one reactive 
peptide in eps4 and one in epsl both at 2SD, with none associated with eps2 
and eps3. The remaining peptides were predominantly in two regions, 
peptides 59-101 (23 peptides out of 63) and peptides 418-459 (17 peptides 
out of 63). Serum 64 showed a different pattern of reactive peptides, with 
no clusters as seen with serum 63, there were no more than three peptides 
grouped together. There was one reactive peptide in epsl and one in eps2 
and two with two amino acids associated with the region covered by eps3, 
and none for eps4. The lack of reactivity to eps4 with CRS patients was 
recorded when a synthetic peptide of eps4 was used in an ELISA (Mitchell et 
al., 1992b). The reactivity of the sera to each of the peptides is graphically 
displayed in fig 7.8 with the significant peptides listed in table 7.7.
Reinfection sera
The two sera from individuals reinfected with rubella gave different patterns 
with regard to the location of the reactive peptides. Serum 77 had only one 
peptide in the epsl-4 region, in eps4, compared to serum 70 which had
227
Table 7.6 List of reactive peptides for the paired serum samples
calculated at 2, 3 and 4SD above the mean of the lowest 50% 
of values
peptide 73a peptide 73b peptide 74a peptide 74b peptide 75a peptide 75b
3 0.780 4 0.775 3 0.577 2 0.400 3 0.852 3 0.794
4 0.847 5 0.857 4 0.620 4 0.390 4 0.869 4 0.829
5 0.863 6 0.784 5 0.616 6 0.416 5 0.782 6 0.782
6 0.842 13 0.743 6 0.568 62 0.442 6 0.803 19 0.842
59 0.815 22 0.717 61 0.615 65 0.437 19 0.839 20 0.866
61 0.768 62 0.806 62 0.674 * 71 0.500 ♦ 20 0.929 * 21 0.946 *
62 0.882 65 0.874 63 0.533 73 0.481 * 21 0.974 * 22 0.734
65 0.963 * 68 0.814 64 0.556 75 0.513 * 22 0.754 62 0.774
68 0.852 69 0.800 65 0.733 ♦ 81 0.434 62 0.806 65 0.748
69 0.802 70 0.821 68 0.642 82 0.425 65 0.819 69 0.807
70 0.862 71 0.949 ♦ 69 0.653 83 0.434 68 0.813 70 0.807
71 1.044 * 81 0.806 70 0.711 ♦ 84 0.445 69 0.855 73 0.863
81 0.831 82 0.891 * 71 0.784 * 88 0.423 70 0.895 75 0.718
82 0.904 84 0.834 73 0.544 94 0.417 71 0.760 79 0.701
83 0.840 89 0.764 75 0.676 * 101 0.471 73 0.938 ♦ 80 0.828
84 0.787 94 0.898 • 79 0.525 102 0.414 74 0.726 81 0.878
88 0.782 95 0.774 80 0.574 104 0.391 75 0.815 82 0.832
89 0.825 96 0.806 81 0.620 151 0.451 78 0.763 83 0.977 *
90 0.791 97 0.855 82 0.680 * 152 0.492 * 79 0.767 84 1.017 *
94 1.033 ♦ . 98 0.957 ♦ 83 0.628 153 0.406 80 0.809 89 0.697
95 0.824 99 0.849 84 0.659 162 0.401 81 0.904 90 1.259 !
96 0.887 101 0.851 85 0.558 164 0.396 82 0.803 94 0.884
97 0.933 102 0.749 89 0.547 165 0.398 83 0.919 95 0.749
98 0.984 * 141 0.719 91 0.519 231 0.411 84 0.987 * 97 0.729
99 0.787 142 0.840 94 0.660 * 274 0.423 89 0.784 101 0.978 *
100 0.765 164 0.747 95 0.545 280 0.409 90 1.221 ! 102 0.847
101 0.936 165 0.731 96 0.585 283 0.482 * 94 0.861 140 0.907 *
102 0.887 166 0.817 97 0.656 284 0.462 95 0.793 142 0.959 *
142 0.902 167 0.754 98 0.650 285 0.620 ! 97 0.763 163 1.050 *
164 0.807 206 0.744 99 0.572 286 0.420 98 0.752 164 0.707
167 0.790 221 0.728 101 0.681 * 318 0.499 * 101 1.013 ♦ 165 0.771
205 0.768 274 0.758 102 0.647 319 0.427 102 0.962 ♦ 166 0.741
206 0.878 342 0.756 140 0.527 320 0.645 ! 140 0.852 167 0.769
216 0.826 343 0.947 * 141 0.536 321 0.508 * 142 0.945 * 215 1.156 !
221 0.779 344 0.910 * 142 0.657 322 0.592 ! 164 0.797 250 0.760
230 0.846 345 0.847 164 0.606 323 0.579 ! 215 1.139 ! 251 0.742
245 0.902 346 0.793 165 0.623 324 0.578 ! 250 0.783 274 0.838
265 0.785 347 0.776 166 0.590 325 0.622 ! 251 0.759 275 0.876
274 0.888 348 0.917 * 167 0.608 343 0.513 ♦ 274 0.869 289 0.747
313 0.777 349 0.743 183 0.519 346 0.419 287 0.756 290 0.755
334 0.792 367 0.724 206 0.567 348 0.562 * 289 0.851 338 0.808
342 0.778 377 0.851 230 0.610 378 0.458 290 0.752 339 0.726
343 0.856 390 0.775 250 0.600 380 0.440 336 0.749 340 0.706
344 0.812 394 0.824 251 0.584 381 0.401 338 0.847 342 0.739
345 0.843 395 0.763 274 0.633 418 0.438 339 0.805 343 0.868
346 0.855 405 0.722 275 0.598 419 0.444 340 0.786 344 0.752
347 0.843 413 0.992 * 289 0.534 441 0.404 341 0.767 345 0.803
348 1.016 ♦ •418 0.956 ♦ 334 0.591 442 0.514 * 342 0.762 348 0.705
349 0.825 419 0.818 337 0.540 443 0.440 343 0.810 418 0.993 *
386 0.784 420 0.971 * 339 0.605 444 0.397 344 0.740 419 0.890
390 0.791 440 0.836 340 0.536 445 0.429 345 0.765 420 0.809
394 0.844 442 0.885 • 343 0.538 446 0.422 386 0.723 • 442 0.941 *
395 0.804 443 0.749 345 0.568 447 0.482 * 395 0.727 443 0.796
418 0.986 * 444 0.833 346 0.537 448 0.410 418 1.120 ♦ 444 0.743
419 0.802 445 0.817 348 0.695 * 419 0.920 445 0.967 *
420 0.967 ■» 447 0.939 349 0.543 420 0.907 446 0.865
440 0.787 448 0.950 ♦ 386 0.537 442 1.024 * 447 0.830
442 0.855 450 0.827 390 0.567 443 0.881 448 0.981 *
443 0.764 451 0.763 393 0.573 444 0.896 451 0.718
444 C.o71 453 0.753 394 0.599 445 1.094 * 454 0=729
445 0.866 454 0.731 395 0.639 446 0.969 * 456 0.717
446 0.825 455 0.868 418 0.628 447 0.835 457 0.759
447 1.002 * 456 0.745 419 0.567 448 0.905 474 0.743
448 0.880 459 0.770 420 0.635 455 0.752
450 0.782 461 0.796 442 0.601 456 0.734
455 0.768 472 0.719 443 0.536 457 0.776
456 0.806 473 0.758 444 0.581 458 0.767
459 0.789 445 0.597 470 0.726
473 0.772 446 0.549 471 0.757 *=>3SD
447 0.643 473 0.743
448 0.663 ♦ 474 0.820 != >  4SD
473 0.607
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Table 7.7 List of reactive peptides for the serum samples from healthy 
individuals, CRS and reinfections calculated at 2, 3 and 4SD 
above the mean of the lowest 50% of values
peptide 1511 peptide 18 peptide 63 peptide 64 peptide 70 peptide 77
18 0.473 ! 50 0.692 ! 3 1.754 * 3 0.757 11 0.333 * 4 0.308
52 0.646 ! 63 0.598 ! 4 1.563 5 0.739 17 0.252 71 0.288
62 0.274 65 0.363 5 1.623 * 8 1.024 * 18 0.251 74 0.288
63 0.301 221 0.310 6 1.598 23 0.717 19 0.251 87 0.286
65 0.293 241 0.325 22 1.386 48 1.105 ! 20 0.250 94 0.298
75 0.308 247 0.511 59 1.348 59 0.723 21 0.254 95 0.301
94 0.298 284 0.467 ! 61 1.470 62 0.729 22 0.256 96 0.319
99 0.294 287 0.504 ! 62 1.809 * 84 0.723 23 0.396 ! 97 0.357 *
100 0.274 288 0.355 63 1.545 89 0.760 24 0.270 98 0.335
161 0.279 291 0.306 64 1.330 97 0.768 26 0.261 99 0.302
162 0.280 294 0.395 65 1.662 * 98 0.809 35 0.358 * 100 0.288
183 0.335 * 295 0.320 68 1.394 142 0.811 36 0.360 ! 101 0.312
195 0.465 • 296 0.314 69 1.465 151 1.142 ! 47 0.295 102 0.308
269 0.373 ! 305 0.401 ♦ 70 1.600 202 0.730 48 0.292 132 0.293
295 0.469 ! 306 0.560 ! 75 1.326 206 0.888 * 59 0.370 ! 135 0.469 !
299 0.283 309 0.461 ! 79 1.430 250 0.755 60 0.367 ! 138 0.381 !
300 0.278 310 0.394 80 1.590 253 0.720 62 0.277 140 0.296
325 0.269 321 0.457 ! 81 1.598 254 0.748 65 0.284 142 0.334
327 0.279 322 0.504 ! 82 1.559 279 0.834 66 0.270 163 0.296
330 0.294 327 0.310 83 1.574 313 0.750 67 0.250 165 0.304
336 0.274 328 0.478 ! 84 1.551 320 0.747 68 0.273 166 0.369 *
368 0.281 348 0.339 88 1.488 321 0.728 69 0.277 171 0.317
394 0.275 386 0.309 89 1.368 338 0.725 70 0.257 178 0.319
396 0.361 ♦ 390 0.344 90 1.495 343 0.842 71 0.421 ! 194 0.286
425 0.346 * 394 0.497 ! 93 1.330 344 0.778 72 0.399 ! 221 0.288
473 0.370 * 400 0.312 94 1.513 348 0.726 73 0.282 291 0.288
411 0.334 96 1.421 378 0.728 74 0.278 331 0.301
422 0.337 97 1.583 394 0.881 75 0.261 332 0.299
98 1.534 395 0.769 76 0.248 334 0.285
101 1.335 405 0.739 77 0.257 336 0.295
142 1.426 418 0.868 80 0.266 339 0.286
165 1.333 419 0.759 83 0.388 ! 340 0.296
206 1.444 420 0.824 84 0.430 ! 341 0.41 !
230 1.347 437 0.744 88 0.284 342 0.361 *
• = > 3 S D 274 1.372 445 0.717 89 0.278 343 0.358 *
343 1.403 447 0.725 90 0.287 344 0.454 !
!= > 4 S D 344 1.466 448 0.737 92 0.291 345 0.322
346 1.340 455 0.720 94 0.308 ♦ 346 0.391 *
348 1.375 459 0.862 214 0.270 347 0.298
349 1.314 215 0.253 348 0.372 *
386 1.365 216 0.248 349 0.288
390 1.438 217 0.263 359 0.301
394 1.442 224 0.249 373 0.326
395 1.519 249 0.259 378 0.298
418 1.776 ♦ 253 0.265 386 0.289
419 1.509 254 0.264 387 0.362 *
420 1.764 ♦ 265 0.254 390 0.287
442 1.419 273 0.266 418 0.342
443 1.414 274 0.309 * 419 0.296
444 1.463 348 0.273 420 0.355 *
445 1.623 * 421 0.297
446 1.497 423 0.289
447 1.485 432
448 1.637 * 442 0.291
450 1.331 444 0.316
454 1.356 445 0.294
455 1.406 447 0.324
456 1.446 448 0.342
457 1.364 456 0.295
458 1.464 473 0.298
459 1.346
473 1.375
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Table 7.8 List of reactive peptides for the rubella negative sera
calculated at 2, 3 and 4SD above the mean of the
50% of values
peptide 67 peptide 68 peptide 69 peptide 71
3 1.329 20 0.431 ♦ 14 0.262 15 0.744 !
4 1.421 34 0.313 63 0.263 63 0.501
5 1.286 75 0.600 ! 69 0.257 68 0.569
6 1.456 * 177 0.606 ! 71 0.418 ! 71 0.484
17 1.241 183 0.318 72 0.262 72 0.506
19 1.284 185 0.452 ! 73 0.292 73 0.478
22 1.248 208 0.458 ! 75 0.262 74 0.497
48 1.198 209 1.270 ! 89 0.258 75 0.512
62 1.284 368 0.745 ! 90 0.268 78 0.518
65 1.295 94 0.352 ! 88 0.562
69 1.263 100 0.258 89 0.520
77 1.203 110 0.268 90 0.609 *
80 1.317 132 0.563 ! 96 0.494
81 1.279 212 0.267 97 0.561
84 1.258 221 0.349 98 0.505
97 1.324 224 0.303 * 99 0.579 *
98 1.236 283 0.267 100 0.578 *
101 1.208 284 0.319 * 101 0.582 *
137 1.194 285 0.328 * 102 0.538
138 1.310 286 0.331 * 105 0.521
139 1.310 288 0.259 129 0.515
141 1.224 291 0.264 130 0.566
142 1.365 296 0.328 * 131 0.495
163 1.226 318 0.290 154 0.492
165 1.247 320 0.256 160 0.568
167 1.233 323 0.288 161 0.521
289 1.185 324 0.260 163 0.690 !
331 1.188 325 0.263 178 0.497
343 1.303 327 0.274 206 0.532
344 1.353 331 0.258 210 0.574
346 1.296 340 0.273 211 0.920 !
347 1.226 341 0.274 212 0.693 !
349 1.225 348 0.353 ! 213 0.577
390 1.303 368 0.334 * 214 0.613 *
394 1.275 378 0.264 215 0.581 *
395 1.395 418 0.282 216 0.517
407 1.189 442 0.268 217 0.554
418 1.455 * 447 0.261 311 0.476
419 1.311 312 0.475
420 1.202 313 0.486
442 1.238 347 0.578 *
443 1.223 388 0.657 *
444 1.307 390 0.533
445 1.330 391 0.578 *
446 1.239 393 0.609 *
447 1.243 420 0.485
448 1.315 421 0.587 *
451 1.266 432 0.546
452 1.192 435 0.557
454 1.244 437 0.483
455 1.334 440 0.566
456 1.373 441 0.630 *
457 1.260 442 0.600 *
458 1.294 443 0.495
467 1.270 444 0.478
469 1.190 447 0.472
471 1.333 230
472 1.298
* => 3SD 
! =>4SD
reactive peptides within all the defined epitopes. Serum 77 had four 
locations where the reactive peptides were in clusters of five or more, spread 
over the whole E l sequence. Serum 70 only had peptides spread over the 
first 72% of the sequence, with 37 peptides out of 50 (74%) in the region 
covering peptides 17-94. The reactivity of the sera to each of the peptides 
is graphically displayed in fig 7.8 with the significant peptides listed in table
7.7.
Sera from healthy individuals
The two sera showed different patterns to each other and the other sera 
analysed. These sera had half the number of reactive peptides when 
compared to the other samples, with serum 1511 having only one peptide in 
epsl and serum 18 having one in eps4 and two in eps2. Serum 18 had 89% 
of its reactive peptides in the region covering peptides 221-422. These sera 
showed a greater reactivity in the region covering peptides 291-310 than the 
other serum samples. The reactivity of the sera to each of the peptides is 
graphically displayed in fig 7.8 with the significant peptides listed in table
7.7.
Monoclonal antibodies
Each of the monoclonal antibodies (Mabs) analysed showed reactivity to a 
large number of peptides. Some of the peptides were grouped together and 
some showed high readings (to 4SD) at single locations. Some of the 
reactive peptides displayed reactivity against all the Mabs eg peptides 
100-102, which have the sequence SYFNPGGSYY. Apart from this 
sequence being weakly hydrophobic there is no clear reason for the binding, 
table 7.9 shows the reactive peptides at 3 and 4SD for each of the Mab.
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Table 7.9 Reactive peptides at 3 and 4SD above the lowest 50% of 
values for each of the monoclonal antibodies
Mab#
G7H9
Mab
4A6
Mab
3A2
Mab
4C5
Mab
7A6
Mab
2C3
61 4 90 75 63 6
63 73* 1 0 0 1 0 1 72 90*
71 1 0 1 * 1 0 1 * 1 0 2 75* 1 0 1
72* 1 0 2 * 1 0 2 * 199* 8 8 1 0 2
73 130* 206 2 1 0 90* 290
74 2 1 0 * 2 1 0 213 1 0 1 315
75* 2 1 2 230 224 1 0 2 394
98 290* 259 230 290 436
99* 324 281 239* 291 441
1 0 0 * 335 343 281 432 442*
1 0 1 336* 282 440* 445
181 338* 315 441 446
182* 340 442* 450
183 341 443* 451
2 1 0 373* 444*
460*
463
# G7H9 maps to a discontinuous epitope
* 4SD
7.5 DISCUSSION
Overlapping octameric peptides have been synthesised using pin technology™ 
to cover the complete E l sequence and also the region containing the amino 
acids E I 2 2 3 -E I 3 0 0 . The region El^^g-Elggg contains epitopes designated epsl, 
2 and 3 (Terry et al., 1988) and ens4f2l fChave et al.^ 1992b) and the 
binding site for the monoclonal antibody E l-20 (Wolinsky et al., 1993). 
Rubella positive and rubella negative sera from healthy individuals were 
tested in the epitope region, with a variety of sera including CRS, 
reinfections and convalescent, for the complete E l sequence. The PEP SCAN
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data obtained was the reactivity of each sera to individual peptides 
determined by an ELISA assay to detect bound anti-rubella IgG.
PEPSCAN analysis of E I 2 2 3 -E I 3 0 0
The initial study on the region E I 2 2 3 -E I 3 0 0  sought to establish the reliability of 
the system and confirm the presence of epsl, 2 and 3, three epitopes within 
E I 2 4 5 -E I 2 8 5  which had previously been identified using three non-competing 
monoclonal antibodies with S.aureus V 8  protease and trypsin generated 
overlapping peptides (Terry et al., 1988). The reactivity of a peptide 
encompassing all three epitopes was positive in an indirect ELISA assay for 6  
out of 7 rubella IgM positive human sera. There was no data published on 
reactivity to the individual epitopes. This region was further studied using 
PEPSCAN by Lozzi et al., (1990) using pooled high titre anti-rubella IgG 
from hyperimmunised subjects. The results indicated antibody binding to six 
octapeptides corresponding to eps2, five octapeptides to eps3 and six to epsl 
plus a single peptide. Each group of octapeptides had a core of amino acids, 
2 5 0 PER 2 5 2  for eps2, 2 6 0 ADDP 2 6 3  for eps3 and 2 7 3 EVW 2 7 5  and 2 7 8 PVIGSQAR 2 8 5  
for epsl. These results vary slightly from those of Terry et al., (1988).
Terrv et al.. (19881
2i2SRLVGATPERPRLRLVDADDPLLRTAPGPGEVWVTPVIGSOARK2gg 
Eps2 Eps3 Epsl
Lozzi et al.. 09901
2i3SRLVGATPERPRLRLVDADDPLLRTAPGPGEVWVTPVIGSOARK2og 
Epsl Eps3 Epsl Epsl
These observations reveal that epitopes may appear as a cluster with a 
common core (eps 2 ) or as a single peptide (epsl). A response from only a 
single peptide may indicate that it is part of a discontinuous epitope (Van 
Oosten et al., 1989). When peptides on adjacent pins differ in sequence by
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only one amino acid at the termini, the observation of antibody binding to 
one pin and not the adjacent pin is good evidence of specificity of the test 
(Geysen, 1987).
Studies using a PEPSCAN type of analysis have shown that the average 
number of residues identified as forming an epitope can be 3-8 residues (Van 
Regenmortal 1989b), with as few as three residues being essential for 
antibody binding (Geysen et ah, 1988; Trifilieff et ah, 1991). This confirms 
that the octapeptides used in this study should be of sufficient length to 
detect continuous epitopes.
Analysis of the sera from healthy individuals showed that only 1 out of 11 
individuals displayed a response to all three epitopes at 2SD. The most 
prominent epitope was epsl, which displayed reactivity with all the serum 
samples, and the least reactive was eps3, which displayed reactivity with 
three serum samples. The reactivity of each epitope to all the sera is 
summarised in table 7.10. The data indicates that with the more stringent 
criteria none of the sera picks up all four epitopes. The number of epitopes 
detected by each serum varies, with serum 4 only detecting epsl, but six of 
the serum samples detect three of the four epitopes.
It must be noted that sera may only give a single reactive peptide within each 
epitope. The observations of Lozzi et a / . ,(1990) of core residues within 
each of the epitopes should have been reflected in the PEPSCAN by several 
reactive peptides for each serum for any given epitope but this was not the 
case. It may be therefore that although a core residue may be identified the 
associated amino acids are also necessary for antibody binding.
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Table 7.10 Number of sera showing reactivity within the epitopes
Statistical analysis Epsl Eps2 Eps3 Eps4(2)
2SD above the mean of 
the lowest 25% of values
1 0 3 3 6
3SD above the mean of 
the lowest 25% of values
6 3 0 1
4SD above the mean of 
the lowest 25% of values
6 3 0 2
In each case 11 serum samples were analysed.
The peptides significant at 4SD would also be significant at 2 and 3SD but 
the results have been recorded as significant only at 4SD.
Although variations in levels of immunoglobulins have been observed 
between males and females, possible due to hormonal levels (Mitchell et al., 
1992a), with the sera analysed there appeared to be no difference between 
the response seen with the male and female sera. Individual variations may 
have masked any trends due to sex of the donor. Ideally more sera should be 
analysed.
Similarly, individual variation could have masked any differences in the 
observed responses to the peptides covering the amino acid sequence of 
RA27/3 and that of the Thomas strain. The difference between these strains 
is an amino acid change, Val^^g in RA27/3 to Ala^^g in Thomas, in eps2. One 
female serum showed reactivity against peptides containing Val and not Ala 
and one male serum showed reactivity against peptides containing Ala and 
not Val. Two from eight females gave no significant response in this region. 
There were therefore no real differences observed in the response to this 
change in amino acid.
The significance of the change from Ala =>Val would depend on whether the
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amino acid was a critical amino acid ie essential for antibody binding. 
Replacement net studies which replace each amino acid with the other 19 
amino acids in turn indicate whether a residue is (a) a critical residue which 
can not be replaced without impairing antibody binding, (b) limited 
replaceablity, some can be replaced by a limited number of residues without 
affecting binding, (c) replaceable, can be replaced by any amino acid 
therefore not a contact residue and plays a role only as far as it allows the 
correct positioning of neighbouring residues that contribute to the binding 
energy (Van Regenmortal 1989). Study of a data base of 103 replaceability 
patterns showed that when Ala was the parent amino acid, Val had a 
replaceability of 28% and when Val was the parent amino acid, Ala had a 
replaceability of 24% (Geysen et a/., 1988). Although Ala =>Val is 
considered to be a conservative substitution by the "Clustal" analysis, this 
change could effect antibody binding. The amino acid side chains are as 
important to antibody binding as the main chain atoms (Geysen et al., 1988), 
therefore the change of Ala => Val could effect binding elsewhere on the 
protein due to their effect on the conformation of the protein.
PEPSCAN analysis of the whole of E l
PEPSCAN analysis of the entire E l sequence highlighted the individual 
variability. It was not possible to identify any definite trends due to the small 
sample number. Only one sera showed reactivity to epsl-4 and no one 
epitope was detected by all sera. The number of rubella positive and 
negative sera showing reactivity to each of the epitopes above 2SD is shown 
in table 7.11. The number of rubella positive and negative sera reacting to 
each of the individual peptides is shown in fig 7.10a and b
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Table 7.11 Number of sera showing reactivity within the epitopes
Epsl Eps2 Eps3 Eps4
Number of reactive rubella 
positive sera ( 1 2 )
1 0 7 3* 1 0
Number of reactive rubella 
negative sera (4)
0 0 0 2
* Three sera each recognised only two amino acids within the eps3 region. 
The total number of sera tested are in parentheses.
Apart from the previously mapped epitopes, other regions were seen where 
the majority of the sera showed some reactivity. These regions either 
covered a large number of peptides with a few sera showing reactivity to 
many peptides, or a cluster of a small number of peptides showing reactivity 
with most of the sera. Some of these clusters of reactive peptides showed a 
higher binding capacity than to the epsl, 2 and 3 region except for peptide 
274 in epsl which alone reacted with 8  out of 12 sera (8/12). Some peptides 
stood out as being highly reactive eg 6 (8/12), 62 (10/12), 65 (10/12), 84 
(9/12), 94 (9/12), 101 (8/12), 418 (8/12), 419 (8/12), 420 (7/12), 445 (8/12), 
447 (8/12). The reactive areas include peptides 3-6, 17-24, 59-102, 140-142, 
161-167, 214-217, 273-275, 334-349, 394-396, 418-420, 440-461, 470-474. 
The region with the highest peaks were peptides 320-328, with 7 peptides 
displaying reacivity at 4SD.
PEPSCAN analysis using peptides fourteen amino acids long and overlapping 
by three amino acids (Ilonen et al., 1992), showed that all the seropositive 
individuals had antibodies to the peptides covering the known areas 
responsible for neutralisation and haemagglutination but the majority of the 
responses were to peptides outside this area, as shown in this thesis. The 
peaks of antibody binding were scattered throughout the polypeptide but the 
highest peaks were found by the peptides covering the amino acids
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E I 2 7 3 -E I 2 9 9  E l  3 0 3 -El 3 3 9  . These regions were also highlighted in our study 
but fewer peptides were reactive.
Analysis of paired sera
The similarity between the observed reactive peptides for two paired sera 
indicated the reproducibility of the system, with the differences possibly 
indicating real changes. There was a loss of reactive peptides in the epitope 
region with the two serum samples 73 A and 73B and the two serum samples 
74A and 74B when the second sample was analysed. This has also been 
shown with loss of epitopes to HIV trans-membrane protein when successive 
samples were analysed using PEPSCAN, (Goudsmit et al., 1990). Levels of 
antibody to RA27/3 measured using a synthetic peptide (eps4) ELISA has 
been shown to fall with time to below the 15iu cut off level (Mitchell et al., 
1992b). Antibody levels to particular epitopes may fall below the cut off 
values set by the PEPSCAN statistics. Analysis of sera from healthy 
individuals showed fewer reactive peptides than the other samples analysed, 
serum 1511 was taken 22 years post vaccination and could therefore have 
lost antibodies to some of the epitopes.
Analysis of sera from reinfections, convalescence and CRS
With the sera from subjects with CRS, reinfections and convalescencing 
individuals there seemed to be no clear trends apart from those assigned 
generally ie. low reactivity to the epsl-4 region with very little if any 
reactivity to eps3, reactivity outside the epsl-4 region, variation between 
samples from each group. More samples from each group need to be 
analysed. Serum 77 from a reinfected individual had a very high HAI titre of 
20480 (I.Best, PC) but this was not reflected in the PEPSCAN with very 
little reactivity to the haemagglutinating epitopes epsl and 2  with only one 
reactive peptide to the haemagglutinating/ neutralising epitope eps4. This 
could indicate that the antibodies detected in the HAI assay bind to
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conformational epitopes and are therefore possibly not detected in this study 
or that the reactive peptides observed in other parts of E l  using PEPSCAN, 
form additional haemagglutinating epitopes.
The negative sera showed reactivity with many peptides and some at 4SD. 
This has been shown by others (Leinikki et al., 1993) and can cause problems 
with interpretation of results. It may be due to cross-reactivity or that the 
peptides have a non-specific activity for human antibodies (Radford et al., 
1990).
A polyclonal serum may contain antibodies from more than one clone, each 
individually stimulated by the same epitope. These different clonal antibody 
populations may interact with different residues within the same epitope ie 
have recognition patterns different from one another. This would degrade 
the observable specificity for individual residues within an epitope by 
increasing the number of acceptable replacements (Geysen et al., 1988).
PEPSCAN of the monoclonal antibodies
Mapping of the Mabs provided by Dr. Revello (Gerna et al., 1987) using 
PEPSCAN proved to be difficult to interpret. The observation of a small 
number of reactive peptides standing out clearly above background as 
reported by others (McGuinness et al., 1990; Meloen et al., 1987), was not 
seen. Assignment of a binding site to a Mab may include one peptide or a 
cluster. The Mabs analysed in this study all showed large numbers of 
reactive peptides even at 3 and 4SD. This could indicate that the Mabs map 
to discontinuous epitopes. Some peptides were reactive with all of the Mabs 
eg peptides 100-102, at 3 and 4SD. Analysis of a Mab G7H9 known to map 
to a discontinuous epitope (Northumbria Biologicals) gave three clusters of 
peptides all of which were reactive at 3 and 4SD. One of these clusters 
spanned the peptides 1 0 0 - 1 0 2 . One region, peptides 178-183, was unique to
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this particular Mab G7H9. PEPSCAN analysis of a Mab of known location 
within E l also gave several possible binding sites (J.Wolinsky, PC). Others 
have observed peaks at several regions with Mabs and considered this to be 
to reflective of adhesion of the Mab due to factors other than antibody 
epitope binding (Radford et al., 1990), or due to antigen analogues (Kohl et 
ah, 1993). It is also not uncommon for a paratope to bind more strongly to 
certain other epitopes than to the one against which it was raised and for 
which it is supposed to be specific, a phenomenon known as heterospecificity 
(Trifilieff et al., 1991). In the construct of a mimitope to Mab 15 of Foot 
and mouth virus (FMDV), binding occurred to a dipeptide of which there was 
no homologous sequence in the immunogen (Geysen et al., 1986a). These 
factors could hinder the correct mapping of a Mab.
The complexity of human sera can generate a high signaknoise ratio when 
using PEPSCAN analysis due to the problems of antigenic cross-reacivity 
(Trifilieff et al., 1991). This could be reduced by examining reactivity before 
and after incubation of sera with native antigen (Horsfall et al., 1991; Geysen 
et al., 1984). Serum antibodies that react with native antigen but not with 
denatured antigen may recognise only conformational epitopes. Clearer 
results may also be obtained using affinity purified antibodies. The volume of 
sera available for this study was insufficient to facilitate purification of the 
antibodies. The problem of volume of available sera also restricted the 
duplication of results. PEP SCANS of previously used sera indicated that the 
level of detectable antibody had dropped considerably, possibly due to 
non-specific binding of antibody to the surface of the microtiter plate used 
for the assay.
Overall, studies using these peptides highlighted the variations found between 
individuals in the reactivities of anti-rubella antibodies to the octapeptides, 
no two individuals showed the same trends although there were some
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common reactive peptides. This observation has been made with PEPSCAN 
analysis of other viral infected sera eg HIV (Wolf et al., 1991; Goudsmit et 
al., 1990). Controlled experiments using identical antigen preparations to 
immunise animals have resulted in different responses by individual members 
of the same species, be they cow (Radford et ah, 1990), primates (Cassels et 
al., 1992), or rabbits (Geysen et al,. 1987b). This demonstrates that animal 
models may not elicit the same response as a human at this fine level. 
Although there may be common epitopes between species these may produce 
binding antibodies with different fine specificities (Geysen et al., 1986b). 
Different animals do not necessarily respond to all of the epitopes of a given 
antigen (Geysen et a/., 1984). The immunogenic response of an individual 
animal will be complicated if the antigen is readily broken down eg. FMDV. 
The animal is exposed to intact virus and subunits and possibly to individual 
viral proteins all of which could present different epitopes to the immune 
system (Geysen et a\,. 1984).
Although others have restricted the number of polyclonal sera analysed to as 
little as three (Radford et ah, 1990; Cassels et ah, 1992), the diversity in the 
results shown in this study indicate the necessity to analyse more sera. 
Previously identified epitopes (Terry et ah, 1988; Mitchell et ah, 1992b) bind 
antibody but not as extensively as other regions. To analyse this further it 
would be useful to make small proteins (see Chapter 4), that cover the 
regions highlighted as being reactive in the PEPSCAN analysis, which could 
be tested in western blots. Short peptides do not seem to be the answer for a 
universal detection system for rubella E l antibodies, larger peptides or 
chimeric peptides may be the answer.
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Chapter 8 
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FINAL DISCUSSION
The structural proteins of the RV Thomas strain have been cloned and 
sequenced except for a short region of the C protein. Comparisons were 
made between the nucleotide and predicted amino acid sequence of the E l 
glycoprotein of the Thomas strain and the published data of the other RV 
strains. All the strains vary slightly from one another but there is an overall 
homology of 95%. The antibody responses to E l may therefore be the same 
for each of the strains. Best el al., (1992) found no antigenic differences 
when studying the reaction between nine RV strains with a panel of 28 Mabs, 
24 of which were E l specific, by four different assays. However, 
Londesborough et al (1992) suggested that there was an antigenic difference 
between the Judith strain and RA27/3 following neutralisation studies using 
rabbit antisera raised against a Judith E l fusion protein. RA27/3 has been 
shown to have unique nucleotide substitutions (8768, 8879, 8880, 8996, and 
9380) allowing identification of the vaccine strain in cases of possible 
vaccine induced illness (Frey and Abernathy, 1993). Unfortunately no 
sequence comparisons can be made between RA27/3 and the progenitor strain 
as it is no longer available.
The cDNA from the Thomas strain was used to construct expression vectors 
for the production of a GST fusion protein of the whole E l  and 
subfragments of E l in E.coli. Two subfragments contained only cDNA 
encoding for previously identified epitopes. SDS-PAGE and western blot 
analysis of all the fusion proteins indicated that extended regions and a 
sequence without these epitopes produced more fusion protein with a 
stronger signal than the epitope region alone. Initial investigations into the 
use of the epitope fusion proteins as antigens in an ELISA suggested that the 
larger fusion protein pUS1509 (epsl-4) was more efficient at detecting 
rubella antibodies than the smaller antigen, pUS1503, although the sensitivity
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was below 1 0 0 %, therefore if would appear that a larger protein was 
required. Londesborough et al., (1992) used an E l fusion protein but found 
it not as efficient as the whole virus at detecting rubella antibodies, and the 
protein had to be solubilised in 8 M urea which denatures the protein. 
Insolubility of the GST-El fusion proteins prevented the use of very large 
fragments containing the whole of E l but two proteins pUS1505 and 
pus 1510, both larger than pUS1509, are soluble, but have yet to be tested 
in the ELISA, to see if this results in an increase in sensitivity of the test. 
The GST-El fusion proteins can be cleaved using thrombin to facilitate the 
use of the E l protein alone as an antigen, but this proved difficult with 
insufficient protein being detected. It maybe that the folding of the fusion 
protein, as well as structural alterations during binding to the ELISA plate, 
could mask the epitopes, thus reducing the level of measurable response. 
The folding of the protein is an important consideration when expressing a 
protein in E.coli due to the lack of post-translational modifications ie 
glycosylation. Aberrant folding of the E l protein in glycosylation mutants 
resulted in a failure to bind E l specific Mabs under nonreduced conditions 
(Qui et al., 1992).
It would seem that a more natural approach would be the expression of the 
E l proteins in mammalian cells. Proteins expressed in COS-1 cells are 
glycosylated and do not form insoluble inclusion bodies. E l ,  E l  without the 
trans-membrane anchor and E 2  were expressed intracellularly in COS-1 cells. 
The small scale production of these proteins did not generate sufficient 
protein for testing as an antigen in an ELISA. Eukaryotic expression in the 
COS-1 cells therefore requires further optimisation, with transfection of a 
greater number of cells or the use of a continuous cell line, eg CHO cells, to 
maximise production. E l without the anchor sequence failed to produce 
detectable levels of secreted protein. The E l protein does not transport to 
the Golgi without E2 (Baron et al., 1992, Hobman et al., 1992) but these
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workers have not included the use an E l trans-membrane anchor minus 
variant. Al-Mumin, (1991) successfully expressed, albeit at low levels, a
secreted E l,  devoid of all but four amino acids of the putative 
trans-membrane anchor. The construct used for the work presented in this 
thesis utilised a previously defined bovine IgG signal peptide to increase 
expression. cDNA comprising E2 and the E l minus the trans-membrane 
anchor together failed to produce a detectable protein but again the system 
may require further optimisation to generate sufficient levels of protein for 
assessment in an ELISA or MACRIA.
PEPSCAN analysis was used to investigate the antibody response of a range 
of human rubella positive and negative sera to overlapping octameric 
peptides covering the E l sequence. The results demonstrated that every sera 
showed a unique profile with regard to the level of antibody binding to each 
of the peptides. The previously defined epitopes (epsl-4) constitute only a 
small part of the protein with the majority of antibody binding domains being 
located in other regions of the El protein. Lymphocyte proliferation studies 
using synthetic peptides (Mitchell et al., 1993) has indicated the location of 
five distinct immunoreactive regions in the RV E l. The study used peptides 
which were of varying lengths (16-33 amino acids), therefore the size of the 
domains identified were dependent on the peptide selected. The domains 
identified by Mitchell et al., (1993) span regions outside the region covered 
by epsl-4 as well as spanning the epsl-4 region. This suggests that the 
epitope sequence contains linked or overlapping B- and T-cell antigenic sites 
and also that the other T-cell domains identified outside the region epsl-4 
could overlap the B-cell domains indicated in this thesis. The T-cell study 
may require a reduction in the size of the peptides to ascertain a more precise 
location of the T-cell epitopes. The study in this thesis also requires the 
analysis of more serum samples to obtain a more accurate identification of 
the B-cell epitopes. The results of this thesis as well as those of Mitchell et
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al., (1993) and Lovett et al., (1993) clearly indicate that each subject 
exhibits a different profile of antibody binding and that binding domains span 
the whole of the E l protein.
The region designated eps4 in this thesis has been identified as containing B- 
and T-cell epitopes and has been used to detect rubella antibodies in a 
commercial ELISA assay (Zrein et al., 1993). The peptide responded very 
well when compared to whole virus with recently immunised subjects. When 
the peptide was initially studied by Mitchell et al., (1992b), the peptide was 
unable to detect low levels of antibodies and antibodies in CRS patients, 
suggesting that the peptide did not contain the necessary epitopes for these 
serum types. It may therefore be necessary to use an antigen that covers 
more of the E l sequence.
The E l protein contains many antibody binding domains to which individuals 
exhibit varying degrees of binding efficiency. It would therefore seem 
appropriate that a recombinant antigen should be as large as possible to 
encompass as many binding domains as possible. It may be necessary to 
include the E2 sequence owing to the results of Katow and Suguira,(1988) in 
identifying that CRS patients have higher levels of E2 antibodies than El 
antibodies. Insolubility problems with the expression of large proteins in 
E.coli would suggest that the recombinant protein should be expressed in 
mammalian cells. Therefore it may be that production of an E1+E2 
recombinant protein expressed in mammalian cells may produce a more 
effective antigen for the detection of rubella antibodies in human sera.
245
Chapter 9 
REFERENCES
ABERNATHY, E S., WANG, C-y. and FREY, T.K.: Effect of antiviral 
antibody on maintenance of long-term rubella virus persistent infection on 
Vero cells. J.Virol. 64 (1990) 5183-5187.
ABBOTT, G.G., SAFFORD, J.W., MacDONALD, R.G., CRAINE, M. and 
APPLEGREN, R.R.: Development of automated immunoassays for the 
immune status screening and serodiagnosis of rubella virus infection. 
J.Virol.Meth. 27 (1990) 227-240.
ALBERTS, B., BRAY, D., LEWIS, I., RAFF, M., ROBERTS, K. and 
WATSON, ID .:  Molecular biology of the cell. Garland, New York, 1989.
AL-MUMIN, S.: Production of recombinant rubella virus antigens. PhD 
thesis (1991)
AL-MUMIN, S., NEWCOMBE, I., STARKEY, W., BEST, J.M., SPIER, 
R.E., and SANDERS, P.G.: Production of recombinant rubella antigens. In: 
SPIER, R.E., GRIFFITHS,J.B., MacDONALD,C., (eds). Animal cell 
technology: development, processes and products. Butterworth-Heinemann, 
Oxford, 596-598.
AMANN, E., BROSIUS, J. and PTASHNE, M.: Vectors bearing a hybrid 
trp-lac promotor uesful for regulated expression of cloned genes in E.coli. 
Gene 25 (1983) 167.
ATKINS, G.J., DALY, E.A., SHEAHAN, B.J., HIGGINS, D.G. and SHARP, 
P.M.: Multiple sclerosis and molecular mimicry. Neuropath.App.Neurobiol. 
16 (1990) 179-180.
ATKINS, G.J., MOONEY, D.A., FAHY, D.A., NG, S.H. and SHEAHAN, 
B.J.: Multiplication of rubella and measles viruses in primary rat neural cell 
cultures: revelance to a postulated triggering mechanism for multiple 
sclerosis. Neuropath.App.Neurobiol. 17 (1991) 299-308.
AVILA, L., RAWLS, W.E. and DENT, P.B.: Experimental infection with 
rubella virus. I. Acqiured and congenital infection in rats. I.Infect.Dis. 126 
(1972) 585-592.
BANATVALA, I.E. and BEST, J.M.: Rubella. In BROWN, F. and WILSON, 
SIR, G. (eds.) Topley and Wilson's Principles of Bacteriology, Virology and 
Immunity. Edward Arnold, London, 1984, pp.271-302.
BARDELETTI, G., KESSLER, N. and AYMARD-HENRY,N.: Morphology, 
biochemical analysis and neuraminidase activity of rubella virus. Arch. Virol. 
49 (1975) 175-186.
BARDELETTI, G., TEKTOFF, I. and GAUTHERN, O.: Rubella virus 
maturation and production in two host cell systems. Intervirology 11 (1979) 
97-103.
246
BARON, M.D., EBEL, T. and SUOMALAINEN, M.: Intracellular transport 
of rubella virus structural proteins expressed from cloned cDNA. J.gen. Virol. 
73 (1992) 1073-1086.
BARON, M.D. and FORSELL, K.: Oligomerisation of the structural proteins 
of rubella virus. Virology 185 (1991) 811-819.
BEST, J.M.: Rubella vaccines:past, present and future. Epidem. Inf. 107 
(1991) 17-30.
BEST, J.M. and BANATVALA, I.E.: RUBELLA. In ZUCHERMAN, A.I. 
(ed.) Principles and Practice of Clinical Virology. John Wiley and Sons Ltd. , 
1990, pp.337-374.
BEST, J.M., BANATVALA, I.E. and BOWEN, I.E.: New Japanese Rubella 
vaccine: comparative trials. B.M.J. (1974) 221-224.
BEST, J.M. and O'SHEA, S.: Rubella virus. In Diagnostic procedures for 
viral rickettsial and chlamydial infections. 6 th edn. American Public Health 
Association, 1989, pp.731-795.
BEST, J.M., THOMSON, A., NORES.J.R., O'SHEA, S. and BANATVALA, 
I.E.: Rubella virus strains show no major antigenic differences. Intervirology 
34 (1992) 164-168.
BHASKARAM, P., RAMALAKSHMI, B.A., RAMA RAJU, L A. and 
RAMAN, L.: Need for protection against rubella in India. Indian J.Pediatr. 
58 (1991) 811-814.
BIALLY, H.: Recombinant proteins:virtual authenticity. Bio/Technology 5 
(1987) 883-890.
BIRNBOIM , H.C. and DOLY, J.: A rapid alkaline extraction procedure for 
screening recombinant DNA. Nucleic Acid Res. 7 (1979) 1513.
BOEGE, V., WENGLER, G. and WITTMANN-LIEBOLD, B.: Partial amino 
acid sequences of Sindbis and Semlike forest virus specific core 
proteins.Virology 103 (1980) 178-190.
BOWDEN, D.S. and WE ST AW AY, E.G.: Changes in glycosylation of rubella 
virus envelope proteins during maturation. J.gen.Virol. 6 6  (1985) 201-206.
BRINTON, M.A,: Non-arbo togaviruses. In SCHLESINGER, R.W. (ed.) The 
togaviruses. Academic press. New York, 1980, pp.623-666.
BROWN, E.G., FURESZ, J., DIMOCK, K., YAROSH, W. and 
CONTRERAS, G.: Nucleotide sequence analysis of Urabe mumps vaccine 
strain that caused meningitis in vaccine recipients. Vaccine 9 (1991) 840-842.
247
BUIMOVICI-KLEIN, E., LANG, P B., ZIRING, P R. and COOPER, L.Z.: 
Impaired cell-mediated immunity response in patients with congenital rubella. 
Correlation with gestational age at time of infection. Pediatrics 64 (1979) 
620-626.
BURGESS, M.A.: Rubella reinfection - what risk to the fetus?. Med.J.Aust. 
156 (1992) 824-825.
BURKE, J.P., HINMAN, A.R. and KRUGMAN, S.: International symposium 
on prevention of congenital rubella infection. Rev.Infec.Dis. 7 (1985)
BYTCHENKO, B.: Expanded programme on immunization in the European 
region. World Health Organization, Regional Office for Europe, Copenhagen 
(1990).
CASSEES, F.J., DEAL, C D., REID, R.H., JARBOE, D.L., NAUSS, J.L., 
CARTER, J.M. and BOEDEKER, E C.: Analysis of Escherichia coli 
colonization factor antigen 1 linear B-cell epitope, as determined by primate 
responses, following protein sequence verification. Inf.Immun. 60 (1992) 
2174-2181.
Centers for disease control: Increase in rubella and congenital rubella 
syndrome- United States, 1988-1990. M.M.W.R. 40 (1991) 93-99.
Centers for disease control: Congenital rubella syndrome among the 
Amish-Pennsylvania, 1991-1992. M.M.W.R. 41 (1992) 468-476.
CHAGNON, A. and LAFLAMME, P.: Effect of acidity on rubella virus. 
Can.J.Micro. 10 (1964) 501-503.
CHAN AS, A C ., GOULD, E.A., CLEGG, J.C.S. and VARMA, M.G.R.: 
Monoclonal antibodies to Sindbis virus glycoprotein E l can neutralize, 
enhance infectivity and independently inhibit haemagglutination of 
haemolysis. J.gen.Virol. 58 (1982) 37-56.
CHANTLER, J.K and TINGLE, A.: Replication and expression of rubella 
virus in human lymphocyte populations. J.gen.Virol. 50 (1980) 317-328.
CHANTLER, J.K., FORD, D.K. and TINGLE, A.J.: Rubella associated 
arthritis: rescue of rubella virus from peripheral blood lymphocytes two years 
post vaccination. Infect.Immun. 32 (1981) 1274-1280.
CHANTLER, J.K., FORD, D.K. and TINGLE, A.J.: Persistent rubella 
infection and rubella associated arthritis. Lancet 1 (1982) 1323-1325.
CHANTLER, J.K., TINGLE, A.J. and PETTY, R.E.: Persistent rubella virus 
infection associated with chronic arthritis in children. N.Eng.J.Med. 313 
(1985) 1117-1123.
248
CHAYE, H.H., MAURACHER, C.A., TINGLE, A.J. and GILLAM, S.: 
Cellular and humerol immune responses to rubella virus structural proteins 
E l,  E2, and C. J.Clin.Micro. 30 (1992a) 2323-2329.
CHAYE, H., CHONG, P., TRIPET, B., BRUSH, B. and GILLAM, S.: 
Localization of the virus neutralizing and heamagglutinin epitopes of E l 
glycoprotein of rubella virus. Virology 189 (1992b) 483-492.
CHEW-LIM, M., SCOTT, T. and WEBB, H E .:  An ultrastructure study of 
cerebellar lesions induced in mice by three inoculations of avirulent Semlike 
Forest virus. Acta Neuropathol. 41 (1978) 55-59.
CHOMCZYNSKI, P. and SACCHI, N.: Single-step method of RNA isolation 
by acid guanidinium thiocyanate-phenol-chloroform extraction. 
Anal.Biochem. 162 (1987) 156-159.
CLARKE, D M ., LOO, T.W., HUI, I., CHONG, P. and GILLAM, S.: 
Nucleotide sequence and in vitro expression of Rubella virus 24S subgenomic 
messenger RNA encoding the structural proteins E l,  E2, and C. Nucleic Acid 
Res. 15 (1987) 3041-3057.
CLARKE, D M., LOO, T.W., McDONALD and GILLAM, S.: Expression of 
Rubella virus cDNA coding for the structural proteins. Gene 65 (1988) 
23-30.
COLLETT, M.S., LARSON, R., GOLD, C., STRICK, D., ANDERSON, D. 
and PURCHIO, A.F.: Molecular cloning and nucleotide sequence of the 
pestivirus Bovine Viral Diarrhoea virus.Virology 165 (1988) 191-199.
COOPER, L.Z.: Congenital rubella in the United states. In KRUGMAN, S. 
and GERS HAN, A. (eds.) Progress in clinical and biological research - 
Infections of the fetus and the newborn infant. Liss, New York, 1975, 
pp .1-34.
COOPER, L.Z., ZIRING, P R .,  OCKERSE, A.B., FED AN, B.A., KIELY, B., 
KRUGMAN, S.: Rubella clinical manifestations and management. Am.J.Dis. 
Child. 118 (1969) 18.
COURSAGET, P., LESAGE, G., LE CANN, P., MAYELO, V. and 
BOURDIL, C.: Mapping of linear B-cell epitopes of hepatitis B surface 
antigen. Res.Virol. 142 (1991) 461-467.
CUSI, M.G., METELLI, R. and VALENSIN, P.E.: Immune responses to wild 
and vaccine rubella viruses after rubella vaccination. Arch.Virol. 106 (1989) 
63-72.
249
DALCANTO, M.C. and RABINOWITZ, S.G: Central nervous system 
demyelination in Venezuelan equine encephalomyelitis infection. An 
experimental model of virus-induced myelin injury. J.Neurol.Sci. 149 (1981) 
397-418.
DALE, J.W.: Molecular genetics of bacteria. John Wiley and Sons, 
Chichester, 1989.
DALGARNO, L., RICE, C M. and STRAUSS, J.M.: Ross River virus 26S 
RNA: complete nucleotide sequence and deduced sequence of the encoded 
structural proteins.Virology 129 (1983) 170-187.
DEREYMAKER, A.M., FRYNS, J.P., ARS, B., ANDRESCESCOU, J. and 
Van den BERGHE, H.: On the etiology of hearing loss in a population of 155 
institutionalized children. Acta oto-rhino-laryngologica beig. 45 (1991) 
283-291.
DING.M. and SCHLE SINGER, J.M.: Evidence that Sindbis virus nsP2 is an 
autoprotease which processes the virus nonstructural polyprotein.Virology 
171 (1989) 280-284.
DOMINGUEZ, G., WANG, C-y. and FREY, T.K.: Sequence of the genome 
RNA of rubella virus: Evidence for genetic rearrangement during togavirus 
evolution.Virology 177 (1990) 225-238.
DOMS, R.W., LAMB, R.A., ROSE, J.K. and HELENIUS, A.: Folding and 
assembly of viral membrane proteins. Virology 193 (1993) 545-562.
DORAIS INGHAM, S. and GOH, K.T.: The rubella immunity of women of 
child-bearing age in Singapore. Annals Academy of Medicine 10 (1981) 
238-241.
EDWARDS, J., MANN, E. and BROWN, D.T.: Conformational changes in 
Sindbis virus envelope proteins accompanying exposure to low pH. J.Virol. 
45 (1983) 1090-1097.
ENDERS, G., NICKERL-PACHER, U., MILLER, E. and 
CRADOCK-WATSON, I.E.: Outcome of confirmed periconceptional
maternal rubella. Lancet (1988) 1445-1447.
FEINBERG, A.P. and VO GEL STEIN, B.: A technique for radiolabeling DNA 
restriction endonuclease fragments to high specific activity. Anal.Biochem. 
132 (1983) 6-13.
FENNER, F.: Classification and nomenclature of viruses. Intervirology 7 
(1976) 1-115.
250
FILIPENKO, D., HOBMAN, T.C., MacDONALD, I. and GILLAM, S.: In 
situ detection of rubella RNA and antigens in cultured cells. J.Virol.Meth. 22
(1988) 109-118.
FOGEL, A. and PLOTKIN, S.: Markers of rubella virus strains in RK13 cell 
culture. J.Virol. 3 (1969) 157.
FREY, T.K. and ABERNATHY, E.S.: Identification of strain-specific 
nucleotide sequences in the RA27/3 rubella virus strain. J.Infect.Dis. 168 
(1993) 854-864.
FREY, T.K. and MARR, L.D.: Sequence of the region coding for virion 
proteins C and E2 and the carboxy terminus of the nonstructural proteins of 
Rubella virus:comparison with alphaviruses. Gene 62 (1988) 85-99.
FREY, T.K., MARR, L.D., HEMPHILL, M L . and DOMINGUEZ, G.: 
Molecular cloning and sequencing of the region of the Rubella virus genome 
coding for glycoprotein El.Virology 154 (1986) 228-232.
FREY, T.K., MARR, L.D., SANCHEZ, A. and SIMMONS, R.B.: 
Identification of the 5' end of the Rubella virus subgenomic RNA.Virology 
168 (1989) 191-194.
GALAZKA, A.: Rubella in Europe. Epidemiol. Infect. 107 (1991) 43-54.
GALLAGHER, P.J., HENNEBERRY, J.M., SAMBROOK, J.F. and 
GETHING, M.J.H.: Glycosylation requirements for intracellular transport 
and function of the hemagglutinin of infuenza virus. J.Virol. 66 (1992) 
7136-7145.
GAROFF, H., FRISCHAUF, A.M., SIMONS, K., LEHRACH, H. and 
DELIUS, H.H.: The capsid protein of Semlike forest virus has clusters of 
basic amino acids and prolines in its amino-terminal region. Proc. Natl. Acad. 
Sci. USA 77 (1980) 6376-6380.
GERNA, G., REVELLO, M.G., DOVIS, M., PETRUZZELLI, E., ACHILLI,
G., PERCIVALLE, E. and TORSELLINI, M.: Synergistic neutralization of 
rubella virus by monoclonal antibodies to viral haemagglutinin. J.gen.Virol. 
68 (1987) 2007-2012.
GEYSEN, H.M., MELOEN, R.H. and BARTELING, S.J.: Use of peptide 
synthesis to probe viral antigens for epitopes to a resolution of a single 
amino acid. Proc. Natl. Acad. Sci. USA 81 (1984) 3998-4002.
GEYSEN, H.M., BARTELING, S.J. and MELOEN, R.H.: Small peptides 
induce antibodies with a sequence and structural requirement for binding 
antigen comparable to antibodies raised the native protein. Proc. Natl. Acad. 
Sci. USA 82 (1985) 178-185.
251
GEYSEN, H.M., RODDA, S.J. and MASON, T.J.: A priori delineation of a 
peptide which mimics a discontinuous antigenic domain. Mol.Immun. 23 
(1986) 709-715.
GEYSEN, H.M., RODDA, S.J., MASON, T.J., TRIBBICK, G. and 
SCHOOFS, P.G.: Strategies for epitope analysis using peptide synthesis. 
J.Immun.Meth. 102 (1987a) 259-274.
GEYSEN, H.M., TAINER, J.A., RODDA, S.J., MASON, T.J., 
ALEXANDER, H., GETZOFF, E D. and LERNER, R.A.: Chemistry of 
antibody binding to a protein. Science 235 (1987b) 1184-1190.
GEYSEN, H.M., MASON, T.J. and RODDA, S.J.: Cognitive features of 
continuous antigenic determinants. J.Mol.Rec. 1 (1988) 32-41.
GLUZMAN, Y.: SV40- transformed simian cells support the replication of 
early SV40 mutants. Cell 23 (1981) 175-182.
GOUDSMIT, J., MELOEN, R. and BRASSEUR, R.: Map of sequential B cell 
epitopes of the HIV-1 transmembrane protein using human antibodies as 
probe. Intervirology 31 (1990) 327-338.
GRAHAM, F.L. and VAN DE EB, A.J.: A new technique for the assay of 
infectivity of human adenovirus 5 DNA. Virology 52 (1973) 456-467.
GRAKOUI, A., LEVIS, R., RAJU, R., HUANG, H.V. and RICE, C M.: A 
cis-acting mutation in the Sindbis virus junction region affects subgenomic 
RNA synthesis. J.Virol. 63 (1989) 5216-5227.
GREEN, K.Y. and DORSET, P H.: Rubella virus antigens:localization of 
epitopes involved in hemagglutination and neutralization by using monoclonal 
antibodies. J.Virol. 57 (1986) 893-898.
GREEN, R.H., BALSAMO, M R ., GILES, J.P., KRUGMAN, S. and 
MIRICK, G.S.: Studies of the natural history and prevention of rubella. 
Amer.J.Dis.Child. 110 (1965) 348.
GREGG, N.McA.: Congenital cataract following German measles in the 
mother. Trans. Opthal. Soc. Aust. 3 (1941) 35-46.
GRIGERA, P R .,  MATHIEU, M E . and WAGNER, R.R.: Effect of 
glycosylation on the conformation of epitopes of the glycoprotein of 
Vesicular stomatitis virus (New Jersey serotype).Virology 180 (1991) 1-9.
HAHN, Y.S., STRAUSS, E.G. and STRAUSS, J.H.: Mapping of RNA 
temperature sensitive mutants of Sindbis virus: Assignment of
complementation groups A, B, and G to nonstructural proteins. J.Virol. 63
(1989) 3142-3150.
252
HAIRE, M, and HADDEN, D.S.M.: Rapid diagnosis of rubella by direct 
immunofluorescent staining of desquamated cells in throat swabs. 
J.Med.Micro. 5 (1972) 231-235.
HANCOCK, E.J., POT, K., PUTERMAN, M.L. and TINGLE, A.J.: Lack of 
association between titres of HAI antibody and whole-virus ELISA values for 
patients with congenital rubella syndrome. J.Infect.Dis. 154 (1986) 
1031-1033.
HARRIS, T.J.R.: Expression of heterologous genes in E.coli. Micro.Sci. 3
(1986) 28-31.
HEGGIE, A.D.and ROBBINS, F.C.:Natural rubella acquired after birth: 
clinical features and complications. Am.J.Dis.Child. 118 (1969) 12-17.
HEGGIE, A.D.: Pathogenesis of the rubella exanthem:Distribution of rubella 
virus in the skin during rubella with and without rash. J.Infect.Dis. 137 
(1978) 74-77.
von HEIJNE, G.: Patterns of amino acids near signal-sequence cleavage sites. 
Eur.J.Biochem. 133 (1983) 17-21.
von HEIJNE, G.: How signal sequences maintain cleavage specificity. 
J.Mol.Biol. 173 (1984) 243-251.
HELENIUS, A., KARTENBECK, J., SIMONS, K. and FRIES, E.: On the 
entry of Semliki forest virus into BHK-21 cells. J.Cell.Biol. 84 (1980) 
404-420.
HEMPHILL, M L ., FORNG, R-Y., ABERNATHY, E.S. and FREY, T.K.: 
Time course of virus-specific macromolecular synthesis during rubella virus 
infection in vero cells.Virology 162 (1988) 65-75.
HERRMANN, K.L.: . In Diagnostic procedures for viral, rickettsial and 
chlamydial infections. American Public Health Association, Washington DC, 
1979, pp.725-766.
HERRMANN, K.L.: Rubella in the United States: toward a strategy for 
disease control and elimination. Epidem. Inf. 107 (1991) 55-61.
HILLEMAN, M R., BUYNAK, E.B., WEIBEL, R E. and STOKES, J.: Live, 
attenuated rubella-virus vaccine. N.Eng.J.Med. 279 (1969) 300-303.
HOBMAN, T.C, SHUKIN, R. and GILLAM, S.: Translocation of Rubella 
virus glycoprotein E l into the endoplasmic reticulum. J.Virol. 62 (1988) 
4259-4264.
253
HOBMAN, T.C., LUND STROM, M.L. and GILLAM, S.: Processing and 
intracellulartransport of rubella virus structural proteins in COS 
cells.Virology 178 (1990) 122-133.
HOBMAN, T.C., QUI, Z., CHAYE, H. and GILLAM, S.: Analysis of rubella 
virus E l glycosylation mutants expressed in COS cells.Virology 181 (1991) 
768-772.
HOBMAN, T.C., WOODWARD, L. and FARQUHAR, M.G.: The rubella 
virus E l glycoprotein is arrested in a novel post-ER, pre-golgi compartment. 
J.Cell.Biol. 118 (1992) 795-811.
HOBMAN, T.C.: Targeting of viral glycoproteins to the Golgi complex. 
Trends in Microbiology 1 (1993) 124-130.
HOBMAN, T.C., WOODWARD, L. and FARQUHAR, M.G.: The rubella 
virus E2 and E l spike glycoproteins are targeted to the Golgi complex. 
J.Cell.Biol. 121 (1993) 269-281.
HOLMES, D.S. and QUIGLEY, M.: A rapid boiling method for the 
preparation of bacterial plasmids. Anal.Biochem. 114 (1981) 193-197.
HORSFALL, A.C., HAY, F, C,, SOLTYS, A.J. and JONES, M.G.: Epitope 
mapping./ Trends in Immunology, 12.(1991)211-213.
HORSTMANN, D M.: Discussion paper: the use of primates in experimental 
viral infections - rubella and the rubella syndrome. Ann.NY.Acad.Sci. 162 
(1969) 594-597.
HO-TERRY, L. and COHEN, A.: Degradation of rubella virus envelope 
components. Arch.Virol. 65 (1980) 1-13.
HO-TERRY, L. and COHEN, A.: Rubella virus hemagglutinin: association 
with a single virion glycoprotein. Arch.Virol. 84 (1985) 207-215.
HO-TERRY, L., TERRY, G.M., LONDESBOROUGH, P., REES, K.R., 
WIELAARD, F. and DENIS SEN, A.: Diagnosis of fetal rubella infection by 
nucleic acid hybridization. J.Med.Virol. 24 (1988) 175-182.
HO-TERRY, L., TERRY, G.M. and LONDESBOROUGH, P.: Diagnosis of 
foetal rubella virus infection by polymerase chain reaction. J.gen.Virol. 71
(1990) 1607-1611.
HOVI, T. and VAHERI, A.: Rubella virus-specific ribonucleic acids in 
infected BHK21 cells. J.gen.Virol. 6 (1970) 77-83.
HUYNH, T V., YOUNG,Y.A. and DAVIS, R.W.:In GLOVER, D M. (ed), 
DNA cloning, volumel, IRL press, Oxford, 1985, pp56-l 10
254
ILONEN, J., SEPPANEN, H., NARVANEN, A., KORKOLAINEN, M. and 
SALMI, A.A.: Recognition of synthetic peptides with sequences of rubella 
virus E l polypeptide by antibodies and T lymphocytes. Virol.Immun. 5
(1992) 221-228.
JACKSON, T., MORRIS, B. and SANDERS, P.G.: Nucleotide sequences and 
expression of cDNAs for bovine anti-testosterone monoclonal IgGl antibody. 
Mol.Immun. 29 (1992) 667-676.
JOHANSSON, B., MORAN, T.M. and KILBOURNE, E D .: 
Antigen-presenting B cells and helper T cells cooperatively mediate 
intravirionic antigenic competition between influenza A virus surface 
glycoproteins. Proc. Natl. Acad. Sci. USA 84 (1987) 6869-6873.
JOHNSON, K.S., HARRISON, G.B.L., LIGHTOWLERS, M.W., O'HOY, 
K.L., COUGLE, W.G., DEMPSTER, R.P., LAWRENCE, S B., VINTON, 
J.G., HEATH, D.D. and RICKARD, M.D.: Vaccination against ovine 
cysticerosis using a defined recombinant antigen. Nature 338 (1989) 585-587.
JONES, M.D. and FOULKES, N.S.: Reverse transcription of mRNA by 
Thermus aquaticus DNA polymerase. Nucleic Acid Res. 17 (1989)
8387-8388.
KAARIANEN, L. and SODERLUND, H.: Structure and replication of 
alphaviruses.Curr.Top.Microbiol.Immun. 82 (1978) 15-69.
KALKKINEN, N, OKER-BLOM, C and FETTERS ON, R.F: Three genes 
code for Rubella virus structural proteins E l,  E2a, E2b, and C. J.gen.Virol. 
65 (1984) 1549-1557.
KAROUNOS, D.G. and THOMAS, J.W.: Recognition of common islet 
antigen by autoantibodies from NOD mice and humans with IDDM. Diabetes 
39 (1990) 1085-1090.
KATOW, S. and SUGIURA, A.: Antibody response to individual rubella virus 
proteins in congenital and other rubella virus infections. J.Clin.Micro. 21 
(1985) 449-451.
KATOW, S. and SUGIURA, A.: Low pH-induced conformational change of 
rubella virus envelope proteins. J.gen.Virol. 69 (1988) 2797-2807.
KIELIAN, M.C. and HELENIUS, A.: Role of cholesterol in fusion of Semliki 
Forest virus with membranes. J.Virol. 52 (1984) 281-283.
KIELIAN, M.C. and HELENIUS, A.: pH induced alterations in the fusogenic 
spike proteins of Semliki Forest virus. J.Cell.Biol. 101 (1985) 2284-2291.
KOBAYASHI, N.: Hemolytic activity of rubella virus.Virology 89 (1978) 
610-612.
255
KOBAYASHI, N. and SUZUKI, M.: Characterization of rubella
virus-induced hemolysis. Arch.Virol. 71 (1982) 149-154.
KOHLI, E., BOURGEOIS, M.C., BOUR, IB .  and POTHIER, P.: Epitope 
mapping of the major inner capsid protein of group A rotavirus using peptide 
synthesis.Virology 194 (1993) 110-116.
KONO, R., HAYAKAWA, Y., HIBI, M. and ISHII, K.: Experimental vertical 
transmission of rubella virus in rabbits. Lancet 1 (1969) 343-347.
KOONIN, E.V., GORBALENYA, A.E., PURDY, M.A., ROZANOV, M.N., 
REYES, G.R. and BRADLEY, D.W.: Computer-assisted assignment of 
functional domains in the nonstructural polyprotein of hepatitis E virus: 
delineation of an additional group of positive-strand RNA plant and animal 
viruses.Proc. Natl. Acad. Sci. USA 89 (1992) 8259-8263.
KOZAK, M.: Comparison of initiation of protein synthesis in prokaryotes, 
eukaryotes, and organelles. Microbiol.Rev. 47 (1983) 1-45.
KOZAK, M.: Compilation and analysis of sequences upstream from the 
translational start site in eukaryotic mRNAs. Nucleic Acid Res. 12 (1984) 
857-872.
KOZAK, M.: An analysis of 5' noncoding sequences from 699 vertebrate 
messenger RNAs. Nucleic Acid Res. 15 (1987) 8125-8148.
KOZAK, M.: The scanning model for translation: An update. J.Cell.Biol. 108 
(1989) 229-241.
LAEMMLI, U.K.: Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature 227 (1970) 680-685.
LEINIKKI, P., LEHTINEN, M., HYOTY, H., PARKKONEN, P., 
KANTANEN, M. and HAKULINEN, J.: Synthetic peptides as diagnostic 
tools in virology. Adv.Virus.Res. 42 (1993) 149-186.
LIEBHABER, H., RIORDAN, J.T. and HORSTMANN, D M.: Replication of 
rubella virus in a continuous line of African Green Monkey kidney cells 
(Vero). Proc.Soc.Exp.Biol.Med. 125 (1967) 636-643.
LIEBHABER, H. and GROSS, P.A.: The structural proteins of rubella 
virus.Virology 47 (1972) 684-693.
LINDEGREN, M., FEHRS, L.J., HADLER, S.C. and HINMAN, A.R.: 
Update: Rubella and congenital rubella syndrome, 1980-1990. Epidem. Rev. 
13 (1991) 341-348.
256
LOBIGS, M., ZHAO, H. and GAROFF, H.: Function of Semliki Forest virus 
E3 peptide in virus assembly: replacement of E3 with an artificial signal 
peptide abolishes spike heterodimerization and surface expression of E l. 
J.Virol. 64 (1990) 4346-4355.
LONDESBOROUGH, P., TERRY, G.M. and HO-TERRY, L.: Reactivity of a 
recombinant rubella E l antigen expressed in E.coli. Arch.Virol. 122 (1992) 
391-397.
LOP AT A, M.A., CLEVELAND, D.W. and SOLLNER-WEB, B.: High level 
transient expression of a chloramphenicol acetly transferase gene by 
DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide 
or glycerol shock treatment. Nucleic Acid Res. 12 (1984) 5707-5017.
LOVETT, A.E., McCARTHY, M. and WOLINSKY, J.S.: Mapping
cell-mediated immunodominant domains of the rubella virus structural 
proteins using recombinant proteins and synthetic peptides. J.gen.Virol. 74 
(1993) 445-452.
LOZZI, L., RUSTICI, M., CORTI, M., CUSI, M.G., VALENSIN, P.E., 
BRACCI, L., SANTUCCI, A., SOLDANI, P., SPREAFICO, A. AND NERI, 
P.: Structure of rubella E l glycoprotein epitopes established by multiple 
peptide synthesis. Arch.Virol. 110 (1990) 271-276.
LUND STROM, M L ., MAURACHER, C.A. and TINGLE, A.J.: 
Characterization of carbohydrates linked to rubella virus glycoprotein E2. 
J.gen.Virol. 72 (1991) 843-850.
MASTROMARINO, P., CIOE, L., RIETI, S. and ORSI, N.: Role of 
membrane phospholipids and glycolipids in the Vero cell surface receptor for 
rubella virus. Med.Microbiol.Immunol. 179 (1990) 105-114.
MASTROMARINO, P., RIETI, S., CIOE, L. and ORSI, N.: Binding sites for 
Rubella virus on erythrocyte membrane. Arch.Virol. 107 (1989) 15-26.
MAURACHER, C.A., GILLAM, S., SHUKIN, R. and TINGLE, A.J.: 
pH-dependent solubility shift if rubella virus capsid protein.Virology 181
(1991) 773-777.
M cCa r t h y , m ., l o v e t t , a ., k e r m a n , r .h ., Ov e r s t r e e t , a . and
WOLINSKY, J.: Immunodominant T-cell epitopes of rubella virus structural 
proteins defined by synthetic peptides. J.Virol. 67 (1993) 673-681.
McCUTCHAN, J.H. and PAGANO, J.S.: Enhancement of the infectivity of 
simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran. 
J.Nat.Can.Inst. 41 (1968) 351-356.
257
M c D o n a l d ,  H.L., HOBMAN, T.C. and GILLAM, s.: The influence of 
capsid protein claevage on the processing of E2 and E l glycoproteins of 
rubella virus. Virology 183 (1991) 52-60.
McGUINNESS, B., BARLOW, A.K., CLARKE, I.N., FARLEY, I.E., 
ANILIONIS, A., POOLMAN, J.T. and HECKELS, I.E.: Deduced amino acid 
sequences of class 1 protein (porA) from three strains of Neisseria 
meningitidis. J.Exp.Med. 171 (1990) 1871-1882.
MEL ANC ON, P. and GAROFF, H.: Processing of Semliki forest virus 
structural polyprotein: role of the capsid protease. J.Virol. 61 (1987) 
1301-1309.
MELOEN, R.H., PUYK, W.C., MEIJER, D.J.A., LANKHOF, H., 
POSTHUMUS, W.P.A. and SCHAAPER, W.M.M.: Antigenicity and
immunogenicity of synthetic peptides of Foot and Mouth disease virus. 
J.gen.Virol. 68 (1987) 305-314.
MI, S., DURBIN, R., HUANG, H.V., RICE, C M. and STOLLAR, V.: 
Association of the Sindbis virus RNA methyltransferase activity with the 
nonstructural protein nsPl.Virology 170 (1989) 385-391.
MIKI, N.P.H. and CHANTLER, J.K.: Differential ability of wild-type and 
vaccine strains of rubella virus to replicate and persist in human joint tissue. 
Clin.Exp.Rheum. 10 (1992) 3-12.
MILLER, C.L.: Rubella in the developing world. Epidem. Inf. 107 (1991) 
63-68.
MILLER, E., CRADOCK-WATSON, I.E. and POLLOCK, T.M.: 
Consequences of confirmed maternal rubella at successive stages of 
pregnancy. Lancet (1982) 782-784.
MILLER, E., WAIGHT, P.A., VURDIEN, I.E., JONES, G., TOOKEY, PA. 
and PECKHAM, C.S.: Rubella surveillance to December 1992: second joint 
report from the PHLS and National Congenital Rubella Surveillance 
Programme. Communicable Disease Report 3 (1993)
MINGLE J.A.A,: Frequency of rubella antibodies in the population of some 
tropical african countries. Reviews of Infectious Diseases 7 (1985) 68-71.
MITCHELL, L.A., ZHANG, T. and TINGLE, A.J.: Differential antibody 
responses to rubella virus infection in males and females. J.Infect.Dis. 166 
(1992a) 1258-1265.
MITCHELL, L., ZHANG, T., HO, M., DECARIE, D., TINGLE, A., ZREIN, 
M. and LACROIX, M.: Characterization of rubella virus-specific antibody 
responses by using a new synthetic peptide-based enzyme-linked 
immunosorbent assay. J.Clin.Micro. 30 (1992b) 1841-1847.
258
MITCHELL, L A ., DECARIE, D., TINGLE, A.I., ZREIN, M. and 
LACROIX, M.: Identification of immunoreactive regions of rubella virus E l 
and E2 envelope proteins by using synthetic peptides. Virus Research 29
(1993) 33-57.
MORGAN-CAPNER, P., HODGSON, J., HAMBLING, M.H., DULAKE, C., 
COLEMAN, T.J., BOSWELL, P.A., WATKINS, R.P., BOOTH, I., STERN, 
H., BEST, J.M. and BANATVALA, J.E.: Detectiion of rubella-specific IgM 
in subclinical rubella reinfection in pregnancy. Lancet (1985) 244-246.
MURPHY, F.A., HALONEN, P.E. and HARRISON, A.K.: 
Electronmicroscopy of the development of rubella virus. J.Virol. 2 (1968) 
1223-1227.
MURPHY, F.A.: Togavirus morphology and morphogenesis. In
SCHLESINGER, R.W. (ed.) The togaviruses. Academic press. New York, 
1980, pp.214-316.
NAKHASI, H.L., MEYER, B.C. and LIU, T.: Rubella virus cDNA-sequence 
and expression of E l envelope protein. J.Biol.Chem. 261 (1986)
16616-16621.
NAKHASI, H.L., THOMAS, D., ZHENG, D. and LIU, T.: Nucleotide 
sequence of capsid,E2 and El protein genes of rubella virus vaccine strain 
RA27/3. Nucleic Acid Res. 17 (1989) 4393-4394.
NAKHASI, H.L., ZHENG, D., CALLAHAN, L., DAVE, J R. and LIU, T-Y.; 
Rubella virus: mechanism of attenuation in the vaccine strain (HPV77). Virus 
Research 13 (1989) 231-244.
NAKHASI, H.L., ROUAULT, T.A., HAILE, D.J., LIU, T-Y. and 
KLAUSNER, R.D.: Specific high-affmity binding of host cell proteins to the 
3' region of rubella virus RNA. New Biol 2 (1990) 255-264.
NAKHASI, H.L., COA, X-Q., ROUAULT, T.A. and LIU, T-Y: Specific 
binding of host cell proteins to the 3'-terminal stem loop structure of rubella 
virus negative-strand RNA. J.Virol. 65 (1991) 5961-5967.
NAWA, M.: Focus formation by rubella virus and rabbit kidney (RK-13) cell 
culture and its application to virus titration. Arch.Virol. 60 (1979) 75-78.
NEWCOMBE, J., STARKEY, W., AL-MUMIN, S., KNIGHT, A.I., BEST, 
J.M., and SANDERS ,P.G.: Recombinant rubella E l fusion proteins for 
antibody screening and diagnosis. Clinical and Diagnostic Virology (1994)
OKER-BLOM, C., KAARIANEN, N., KAARIANEN, L. and PETTERSON, 
R.F: Rubella virus contains one capsid protein and three envelope 
glycoproteins E l ,  E2a, and E2b. J.Virol. 46 (1983) 964-973.
259
OKER-BLOM, C., ULMANEN, L, KAARIANEN, L. and PETTERSON, R.F: 
Rubella virus 40s genome RNA specifies a 24s subgenomic mRNA that 
codes for a precursor to structural proteins. J.Virol. 49 (1984a) 403-408.
OKER-BLOM, C: The gene order for Rubella virus structural proteins is 
NH2-C-E2-E1-COOH. J.Virol. 51 (1984b) 354-358.
OKER-BLOM, C., PETTERSON, R.F and SUMMERS, M.D: Baculovirus 
polyhedrin promotor-directed expression of Rubella virus envelope 
glycoproteins, E l and E2, in Spodoptera frugiperda cells.Virology 172
(1989) 82-91.
OKER-BLOM, C., JARVIS, D.L. and SUMMERS, M.D.: Translocation and 
cleavage of rubella virus envelope glycoproteins: identification and role of 
the E2 signal sequence. J.gen.Virol. 71 (1990) 3047-3053.
O'SHEA, S., BEST, J.M., BANATVALA, J.E. and SHEPARD, W.M.: 
Development and persistence of class-specific antibodies in the serum and 
nasopharyngeal washings of rubella vaccinees. J.Infect.Dis. 151 (1985) 89-98
O'SHEA, S., MUTTON, D. and BEST, J.M.: Invivo expression of rubella 
antigens on human leucocytes: detection by flow cytometry. J.Med.Virol. 25 
(1988) 297-307.
O'SHEA, S., WOODWARD, S., BEST, J.M., BANATVALA, I.E., HOLZEL, 
H. and DUDGEON, J.A.: Rubella vaccination: persistence of antibodies for 
10-21 years. Lancet (1988) 909-909.
OU, D., CHONG, P., TRIPET, B. and GILLAM, S.: Analysis of T- and 
B-cell epitopes of capsid protein of rubella virus by using synthetic peptides. 
J.Virol. 66 (1992a) 1674-1681.
OU, D., CHONG, P., McVEISH, P., JEFFERIES, W.A. and GILLAM, S.: 
Characterization of the specificity and genetic restriction of human CD4 
cytotxic T cell clones reactive to capsid antigen of rubella virus. Virology 191 
(1992b) 680-686.
OU, J-H., STRAUSS, E.G. and STRAUSS, J.H.: Comparative studies of the 
3'-terminal sequences of several alphavirus RNAs.Virology 109 (1981) 
281-289.
OU, J-H., RICE, C M., DALGARNO, L., STRAUSS, E.G. and STRAUSS, 
J.H.: Sequence studies of several alphavirus genomic RNAs in the region 
containing the start of the subgenomic RNA. Proc. Natl. Acad. Sci. USA 79 
(1982) 5235-5239.
PARKMAN, P.D., BUESCHER, E L. and ARTENSTEIN, M.S.: Recovery of 
rubella virus from army recruits. Proc.Soc.Exp.Biol.Med. I l l  (1962) 
225-230.
260
PARKMAN, P.D., BUESCHER, E L .,  ARTENSTEIN, M.S., McCOWN, 
J.M., MUNDON, F.K. and DRUZD, A.D.: Studies of rubella. 1. Properties of 
the virus. J.Immun. 93 (1964) 595-607.
PARKMAN, P.D., PHILLIPS, P.E., KIRSCHSTEIN, R.L. and MEYER,
H.M.: Experimental rubella virus infection in the rhesus monkey. J.Immun. 95
(1965) 743-752.
PARKMAN, P.D., MEYER, H.M., KIRSCHSTEIN, R.L. and HOPPS, H E.: 
Attenuated rubella virus. 1. Development and laboratory characteristics. 
N.Eng.J.Med. 275 (1966) 569-574.
PATTERSON, R.L., KOREN, A. and NORTHROP, R.L.: Experimental 
rubella virus infection of marmosets (Saguinus species). Lab.Animal Sci. 23 
(1973) 68-71.
PAYMENT, P.D., AJDUKOVIC, D. and PAVILANIS, V.: Le virus de la 
rubeole.ll. Replication dans les cellules Vero et effets de I'actinomycete D et 
du cyclohexamide. Can.J.Micro. 21 (1975) 710-717.
PELHAM, H.R.B. and JACKSON, R.J.: An efficient mRNA-dependant 
translation system from reticylocyte lysates. Eur.J.Biochem. 67 (1976) 
247-256.
PELHAM, H.R.B.: Control of protein exit from the endoplasmic reticulum. 
Annu.Rev.Cell Biol. 5 (1989) 1-23.
PERLMAN, D. and HALVORSON, H.O.: A putative signal peptidase 
recognition site and sequence in eukaryotic and prokaryotic signal peptides. 
J.Mol.Biol. 167 (1983) 391-409.
PHILLIPS, C.A., MELNICK, J.L., YOW.M.D., BAYATPOUR, M. and 
BURKHARDT, M.: Persistence of virus in infants with congenital rubella and 
in normal infants with a history of maternal rubella. J A M.A. 193 (1965) 
111-113.
PLOTKIN, S.A. and VAHERI, A.: Human fibroblasts infected with Rubella 
virus produce a growth inhibitor. Science. 15 (1967) 659-661.
POLK, F., MODLIN, J.F., WHITE, J.A. and DeGIROLAM, P.C.: A 
controlled comparison of joint reactions among women recieving one of two 
rubella vaccines. Amer.J.Epidem. 115 (1982) 19-25.
QUI, Z , TUFARO, F. and GILLAM, S.: The influence of N-linked 
glycosylation on the antigenicity and immunogenicity of rubella virus E l 
glycoprotein.Virology 190 (1992) 876-881.
261
QUI, Z., HOBMAN, T.C., McDONALD, H.L., SETO, N O. and GILLAM, 
S.: Role of N-linked oligosaccharides in processing and intracellular 
transport of E2 glycoprotein of rubella virus. J.Virol. 66 (1992) 3514-3521.
RADFOFD, A.J., WOOD, P R., BILLMAN-JACOBE, H., GEYSEN, H.M., 
MASON, T.J. and TRIBBICK, G.: Epitope mapping of the Mycobacterium  
bovis secretory protein MPB70 using overlapping peptide analysis. 
J.Gen.Micro. 136 (1990) 265-272.
RAHMAN, M.A., BROT, N. and WEISSBACH, H.: High level expression 
and purification of peptide methionine sulfoxide reductase in E.coli. Cell 
Mol.Bio. 38 (1992) 529-542.
RAWLS, W.E.: WHO collaborative study on the sero-epidemiology of 
Rubella. Bullitin of the World Health Organisation 37 (1967) 79-88.
REGAMEY, R.H., D eB ARB lERI, A., HENNES SEN, W., IKIC, D. and 
PERKINS, F.T.(ed) International symposium on rubella vaccines, London, 
1968. Symposia series in Immunological standardisation. Karger, Basel, New 
York (1969)
RICE, C.M. and STRAUSS, J.M.: Nucleotide sequence of the 26S mRNA of 
Sindbis virus and deduced sequence of the encoded virus structural proteins. 
Proc. Natl. Acad. Sci. USA 78 (1981) 2062-2066.
ROBINSON, W. and MERIGON, T.; Synthesis of viral-specific ribonucleic 
acid in rubella virus infected cells. J.Virol. 4 (1969) 901-903.
RORKE, L.B. and SPIRO, A.J.: Cerebral lesions in congenital rubella 
syndrome. J.Pediatr. 70 (1967) 243-255.
ROTHBARD, J.B. AND TAYLOR, W.R.: A sequence pattern common to T 
cell epitopes. EMBO. J. 7 (1988) 93-100.
ROIZMAN,B.:Multiplication if viruses. In FIELDS, B.N. and KNIPE, D.M. 
(eds.) Virology. Raven Press, New York, 1990, pp.815-840.
ROUSSEAU, S. and HEDMAN, K.: Rubella infection and reinfection 
distinguished by avidity of IgG. Lancet (1988) 1108-1109.
SALONEN, E-M., HOVI, T., MEURMAN, O., VESIKARI, T. and VAHERI, 
A.: Kinetics of specific IgA, IgD, IgE, IgG, and IgM antibody responses in 
rubella. J.Med.Virol. 16 (1985) 1-9.
SAMBROOK, J , FRITSCH, E.F. and MANIATIS, T.; Molecular cloning; a 
laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, New York, 1989.
262
SANCHEZ, A. and FREY, T.K.: Vaccinia- vectored expression of the rubella 
virus structural proteins and characterization of the E l and E2 glycosidic 
linkages.Virology 183 (1991) 636-646.
SANGER, F., NICKLEN, S. and COULSON, A.R.: DNA sequencing with 
chain terminating inhibitors. Proc. Natl. Acad. Sci. USA 74 (1977) 
5463-5467.
SCHATZMAYR, H.G.: Aspects of rubella infection in Brazil. Rev.Infec.Dis. 
7 (1985) 53-55.
SCHLESINGER, S and SCHLESINGER, J.M.: Replication of Togaviridae 
and Flaviviridae. In FIELDS, B.N. and KNIPE, D.M. (eds.) Virology. Raven 
Press, New York, 1990, pp.697-712.
SCHMIDT, N.J., LENNETTE, E.H. and DENNIS, J.: A plaque assay for 
rubella virus based upon hemadsorption. Proc.Soc.Exp.Biol.Med. 132 (1969) 
128-133.
SCHOPFER, K., MATTER, L. and FLUELER, U.W.E.: Diabetes mellitus, 
endocrine autoantibodies and prenatal rubella infection. Lancet 2 (1982) 159.
SCOPES, G.E., WATT, P.J. and LAMBDEN, P R.: Identification of a linear 
epitope on the fusion glycoprotein of respiratory syncytial virus. J.gen.Virol. 
71 (1990) 53-59.
SEAY, A.R. and WOLINSKY, J.S.: Ross River virus-induced demyelination. 
II. Ultrastructural studies. Ann.Neurol. 14 (1983) 559-568.
SEDMAN, S. A., GELEMBIUK, G.W. and MERTZ, I.E.: Translation 
initiation at a downstream AUG occurs with increased efficiency when the 
upstream AUG is located very close to the 5' cap. J.Virol. 64 (1990) 
453-457.
SEDWICK, W.D. and SOKOL, F.: Nucleic acid of rubella virus and its 
replication in hamster kidney cells. J.Virol. 5 (1970) 478-489.
SEPPANEN, H., HUHTALA, M-L., VAHERI, A., SUMMERS, M.D. and 
OKER-BLOM, C.: Diagnostic potential of Baculovirus-expressed rubella 
virus envelope proteins. J.Clin.Micro. 29 (1991) 1877-1882.
SHINE, J. and DALGARNO, L.: Determinant of cistron specificity in 
bacterial ribosomes. Nature 34 (1975) 254.
SHOPE, R.E.: Epidemiology: mechanisms of cause, distribution and
transmission of viral disease. In FIELDS, B.N., KNIPE, D M., MELNICK, 
J.L. and ROIZMAN, B. (eds.) Virology. Raven press. New York, 1985, 
pp .145-152.
263
SMITH, D.B., DAVERN, K M., BOARD, P.O., TIU, W.U., GARCIA, E.G. 
and MITCHELL, G.F.: Mr 26,000 antigen of Schistosoma japonicum 
recognized by resistant WEHI 129/1 mice is a parasite glutathione 
S-transferase. Proc. Natl. Acad. Sci. USA 83 (1986) 8703-8707.
SMITH, D.B. and JOHNSON, K.S.: Single-step purification of polypeptides 
expressed in E.coli as fusions with glutathione S-transferase. Gene (1988) 
31-40.
SMYTH, J.M.B., SHEAHAN, B.J. and ATKINS, G.J.: Multiplication of 
viraient and demyelinating Semliki Forest virus in the mouse central nervous 
system: consequences in BALB/c and SJL mice. J.gen.Virol. 71 (1990) 
2575-2583.
SOUTHERN, E.M.:Detection of specific sequences among DNA fragments 
separated by gel electrophoresis. J.Mol.Biol. 98 (1975) 503-517.
SQUADRINI, F., TAPARELLI, F., DERIENZO, B., GIOVANNINI, G. and 
PAGANI, C.: Rubella virus isolation from cerebrospinal fluid in postnatal 
rubella encephalitis. B.M.J. 2 (1977) 1329-1330.
STAHL, S., MacKAY, P., MAGAZIN, M., BRUCE, S. and MURRAY, K.: 
Hepatitis B virus core antigen: synthesis in E coli and application in 
diagnosis. Proc.Natl.Acad.Sci.USA 79 (1982) 1606-1610.
STEITZ, J.A.: Genetic signals and nucleotide sequences in mRNA. In 
GOLDBERGER, R.F. (ed.) Biological regulation and development. Plenum 
press. New york, 1979, pp.349.
STEWART, G.L., PARKMAN, P.D., HOPPS, H E ., DOUGLAS, R.D., 
HAMILTON, J.P. and MEYER, H.M.Jr.: Rubella-virus hemagglutination- 
inhibition test. N.Eng.J.Med. 276 (1967) 554-557.
STRAUSS, E.G., LEVINSON, R., RICE, C.M., DALRYMPLE, J. and 
STRAUSS, J.H.: Nonstructural proteins nsP3 and nsP4 of Ross River and 
O'Nyong-nyong viruses: Sequence and comparison with those of other 
alphaviruses.Virology 164 (1988) 265-274.
STRAUSS, E.G., RICE, C.M. and STRAUSS, J.H.: Sequence coding for the 
alphavirus nonstructural proteins is interrupted by an opal termination codon. 
Proc. Natl. Acad. Sci. USA 80 (1983) 5271-5275.
STRAUSS, E.G. and STRAUSS, J.M.: Structure and replication of the 
alphavirus genome. In SCHLESINGER, S. and SCHLESINGER, M.J. (eds.) 
The togaviridae and flaviviridae. Plenum press. New York, 1986, pp.35-90.
SUOMALAINEN, M., GAROFF, H. and BARON, M.D.: The E2 signal 
sequence of rubella virus remains part of the capsid protein and confers 
membrane association i?i vitro. J.Virol. 64 (1990) 5500-5509.
264
SWAN, C.; Rubella in pregnancy as an aetiological factor in stillbirth. Lancet 
(1948) 744-746.
TAKKINEN, K., VIDGREN, G., EKSTRAND, J., HELLMAN, U., 
KALKKINEN, N, WERNSTEDT, C. and PETTERSON, R.F: Nucleotide 
sequence of the rubella virus capsid protein gene reveals an unusually high 
G/C content. J.gen.Virol. 69 (1988) 603-612.
TEDDER, R.S. and YOA, J.L: The production of monoclonal antibodies to 
rubella haemagglutinin and their use in antibody-capture assays for 
rubella-specific IgM. J.Hyg. 88 (1982) 335-350.
TERRY, G.M., HO-TERRY, L., LONDESBOROUGH, P. and REES, K.R.: 
Localization of the rubella E l epitopes. Arch. Virol. 98 (1988) 189-197.
TERRY, G.M., HO-TERRY, L., LONDESBOROUGH, P. and REES, K.R.: A 
bio-engineered Rubella E l antigen. Arch.Virol. 104 (1989) 63-75.
THOMAS, H.I.J. and MORGAN-CAPNER, P.: Rubella-specific IgG subclass 
avidity ELISA and its role in the differentiation between primary rubella and 
rubella reinfection. Epidem. Inf. 101 (1988) 591-598.
THOMAS, H.I.J. and MORGAN-CAPNER, P.: The use of antibody avidity 
measurements for the diagnosis of rubella. Reviews Med.Virol. 1 (1991) 
41-50.
THOMSON, A., DAVIS, G., BEST, J.M. and WHITESIDE, J.P.: Growth of 
rubella virus in a glass bead propagator. J.Virol.Meth. 25 (1989) 119-122.
TINDALL, K.R. and KUNKEL, T.A.: Fidelity of DNA synthesis by the 
Thermus aquaticus DNA polymerase. Biochem. 27 (1988) 6008-6013.
TINGLE, A.J., CHANTLER, J.K., POT, K.H., PATY, D.W. and FORD, 
D.K.: Postpartum rubella immunisation: association with development of 
prolonged arthritis, neurological sequelae, and chronic rubella viremia. 
J.Infect.Dis. 152 (1985) 606-612.
TOMS, G.L. and MOSTRATOS, A.: Haemadsorption-negative assay of 
rubella virus in baby hamster kidney cells. Arch.Ges.Virusforsch 41 (1973) 
199-202.
TONDURY, G. and SMITH, D.W.: Fetal rubella pathology. J.Pediat. 68
(1966) 867-879.
TRIFILIEFF, E., DUBS, M.C. and VAN REGENMORTEL, M.H.V.: 
Antigenic cross-reactivity potential of synthetic peptides immobilized on 
polyethylene rods. Mol.Immun. 28 (1991) 889-896.
265
TRUDEL, M., NADON, F., COMTOIS, R., PAYMENT, P., BONNE AU, A. 
and LECOMTE, J.: Identification of rubella virus structural proteins by 
immunoprécipitation. J.Virol.Meth. 5 (1982) 191-197.
TSE, W.T. and FORGET, B.G.: Reverse transcription and direct
amplification of cellular RNA transcripts by Taq polymerase. Gene. 88
(1990) 293-296.
UMINO, Y., SATO, S., FUKUDA, A., HISHIYAMA, M. and SUGIURA, A.: 
Improvement in potency assay of measles-mumps-rubella trivalent vaccine: 
interference between components and measures for its elimination. 
J.Virol.Meth. 27 (1990) 159-168.
UMINO, Y., SATO, S., KATOW, S., MATSUNO, T. and SUGIURA, A. : 
Monoclonal antibodies directed to E l glycoprotein of rubella virus. 
Arch.Virol. 83 (1985) 33-42.
VAANANEN, P., MAKELA, P. and VAHERI, A.: Effect of low level 
immunity on response to live rubella virus vaccine. Vaccine 4 (1986) 5-8.
VAHERI, A. and HOVI, T.: Structural proteins and subunits of rubella virus. 
J.Virol. 9 (1972) 10-16.
VALENSIN, P.E., ROSSOLINI, G.M., CUSI, M.G., ZANCHI, A., CELLESI,
C. and ROSSOLINI, A.: Specific antibody patterns over a two-year period 
after rubella immunization with RA27\3 live attenuated vaccine. Vaccine 5
(1987) 289-294.
VAN ALSTYNE, D.V., KRYSTAL, G., KETTYLES, G.D. and BOHN, E.M.: 
The purification of rubella virus(RV) and determination of its polypeptide 
composition.Virology 108 (1981) 491-498.
VAN OOSTEN, J.V., LANGEVELD, S., VOORMA, H.O., WEISBECK, P., 
de VRIES, P., OSTERHAUS, A., UYTDEHAAG, F. and MELOEN, R.: 
Epitope mapping of the fusion protein of measles virus. In Cold Spring 
Harbor Laboratory, Vaccines 89. , 1989, pp.521-527.
VAN REGENMORTEL, M.H.V.: The concept and operational definition of 
protein epitopes. Phil.Trans.R.Soc.Lond. 323 (1989a) 451-466.
VAN REGENMORTEL, M.H.V.: Structural and functional approaches to the 
study of protein antigenicity. Immunology Today 10 (1989b) 266-272.
VIDGREN, G., TAKKINEN, K., KALKKINEN, N., KAARIAINEN, L. and 
PETTERSON, R.F.: Nucleotide sequence of the genes coding for the 
membrane glycoproteins E l and E2 of rubella virus. J.gen.Virol. 68 (1987) 
2347-2357.
266
WAKESMAN, B.H. and REINGOLD, S.C.: Viral etiology of multiple 
sclerosis: where does the truth lie?. Trends in Neuroscience 9 (1986) 
388-391.
WANNIAN, S.: Rubella in the Peoples Republic of China. Rev.Infec.Dis. 7 
(1985) 72.
WAXHAM, M.N. and WOLINSKY, I.S.: Immunochemical identification of 
rubella virus hemagglutinin.Virology 126 (1983) 194-203.
WAXHAM, M.N. and WOLINSKY, J.S.: Rubella virus and its effect on the 
central nervous system. Neurol.Clin 2 (1984) 367-385.
WAXHAM, M.N. and WOLINSKY, I S.: A model of the structural 
organisation of Rubella virus. Rev.Infec.Dis. 7 (1985) 133-139.
WELLER, T.H. and NEVA, F.A.: Propagation in tissue culture of cytopathic 
agents from patients with rubella-like illness. Proc.Soc.Exp.Biol.Med. I l l
(1962) 215-225.
WESTAWAY, E.G., BRINTON, M.A., GAIDAMOUICH, S.Y. and et al.,: 
Flaviviridae. Intervirology 24 (1985) 183-192.
WETZEL, R., KLEID, D.G., CREA, R., HEYNEKER, H.L., YANSURA,
D.G., HIROSE, T., KRASZEWSKI, A., RIGGS, A.D., ITAKURA, K. and 
GOEDDEL, D.V.: Expression in E.coli of a chemically synthesized gene for a 
mini-C analog of human proinsulin. Gene 16 (1981) 63-71.
WHITTLE, N., ADAIR, J., LLOYD, C., JENKINS, L., DEVINE, J., 
SCHLOM, J., RAUBITSCHEK, A., COLCHER, D. and BODMER, M.: 
Expression in COS cells of a mouse-human chimaeric B72.3 antibody. Protein 
Engineering 1 (1987) 499-505.
WILSON, G., MILES,A. and PARKER, M.T. (ed) In: Topley and Wilson's 
principles of bacteriology, virology and immunology, 7th edn. Edward 
Arnold, London, 1984.
WOLF, F., MELOEN, R.H., BARKER, M., BARIN, F. and GOUDSMIT, J.: 
Characterization of human antibody-binding sites on the external envelope of 
human immunodeficiency virus type 2. J.gen.Virol. 72 (1991) 1261-1267.
WOLINSKY, J.: Rubella. In FIELDS, B.N. and KNIPE, D.M. (eds.) 
Virology. Raven Press, New York, 1990, pp.815-840.
WOLINSKY, J.S.: Subacute scerosing panencephalitis, progressive rubella 
panencephalitis, and multifocal leukoencephalopathy. In WAKSMAN, B.H. 
(ed.) Immunologic mechanisms in neurologicic and psychiatric disease. Raven 
press. New York, 1990, pp.259-268.
267
WOLINSKY, J.S., McCARTHY, M., ALLEN-CANNADY, O., MOORE, 
W.T., JIN, R., CAO, S-N., LOVETT, A. and SIMMONS, D.: Monoclonal 
antibody-defined epitope map of expressed rubella virus protein domains. 
J.Virol. 65 (1991) 3986-3994.
WOLINSKY, J.S., SUKHOLUTSKY, E., MOORE, W.T., LOVETT, A., 
M cCa r t h y , M. and ADAME, B.: An antibody- and synthetic 
peptide-defined rubella virus E l glycoprotein neutralization domain. J.Virol. 
67 (1993) 961-968.
ZHANG, T., MAURACHER, C.A., MITCHELL, L A. and TINGLE, A.J.: 
Detection of rubella virus specific immunoglobulin G (IgG), IgM, IgA 
antibodies by immunoblot assays. J.Clin.Micro. 30 (1992) 824-830.
YANISH-PERRON, C., VIEIRA, J. and MESSING, J.: Improved M13 phage 
cloning vectors and host strains, nucleotide sequence of M l3 ,mpl8 and 
pUC19 vectors. Gene 33 (1985) 103-119.
YOUNG, S.E.J. and RAMSEY, A.M.; The diagnosis of rubella. B.M.J. 2
(1963)1295-1296.
ZHANG, H R., SCHOLL, J., BROWSE, J. SOMERVILLE, C : Double 
stranded DNA sequencing as a choice for DNA sequencing. Nucleic Acid 
Res. 16 (1988) 1220.
ZHENG, D., DICKENS, L., LIU, T. and NAKHASI, H.L.: Nucleotide 
sequence of the 24s subgenomic messenger-RNA of a vaccine strain (HPV77) 
of rubella virus:comparison with a wild-type strain (M33). Gene 82 (1989) 
343-349.
ZREIN, M., JONCAS, J.H., PEDNEAULT, L., ROBILLARD, L., DWYER, 
R.J. and LACROIX, M.: Comparison of a whole-virus enzyme immunoassay 
(EIA) with a peptide-based EIA for detecting rubella virus immunoglobulin G 
antibodies following rubella vaccination. J.Clin.Micro. 11 (1993) 1521-1524.
268
APPENDIX
Appendix 1 Nucleotide sequence of the Therien strain of RV (Dominguez et aL, 1990)
10 20  30 40 50 60 70 80 90
CAATGGAAGC TATCGGACCT CGCTTAGGAC TCCCATTCCC ATGGAGAAAC TCCTAGATGA GGTTCTTGCC CCCGGTGGGC CTTATAACTT
100 110 120 130 140 150 160 170 180
AACCGTCGGC AGTTGGGTAA GAGACCACGT CCGATCAATT GTCGAGGGCG CGTGGGAAGT GCGCGATGTT GTTACCGCTG CCCAAAAGCG
190 2 00  210 2 20  230 2 40  2 50  2 60  270
GGCCATCGTA GCCGTGATAC CCAGACCTGT GTTCACGCAG ATGCAGGTCA GTGATCACCC AGCACTCCAC GCAATTTCGC GGTATACCCG
28 0  290 300 3 10  320 330 ■ 3 40  3 50  360
CCGCCATTGG ATCGAGTGGG GCCCTAAAGA AGCCCTACAC GTCCTCATCG ACCCAAGCCC GGGCCTGCTC CGCGAGGTCG CTCGCGTTGA
370 3 80  3 90  400 410 4 20  430 440 450
GCGCCGCTGG GTCGCACTGT GCCTCCACAG GACGGCACGC AAACTCGCCA CCGCCCTGGC CGAGACGGCC AGCGAGGCGT GGCACGCTGA
460 470 4 80  490 5 00  5 10  520 530 540
CTACGTGTGC GCGCTGCGTG GCGCACCGAG CGGCCCCTTC TACGTCCACC CTGAGGACGT CCCGCACGGC GGTCGCGCCG TGGCGGACAG
550 560 5 70  580 5 90  600 610 620 630
ATGCTTGCTC TACTACACAC CCATGCAGAT GTGCGAGCTG ATGCGTACCA TTGACGCCAC CCTGCTCGTG GCGGTTGACT TGTGGCCGGT
640 650 660 670 680 690 700 7 10  720
CGCCCTTGCG GCCCACGTCG GCGACGACTG GGACGACCTG GGCATTGCCT GGCATCTCGA CCATGACGGC GGTTGCCCCG CCGATTGCCG
7 30  740 7 50  7 60  770 7 80  790 800 810
CGGAGCCGGC GCTGGGCCCA CGCCCGGCTA CACCCGCCCC TGCACCACAC GCATCTACCA AGTCCTGCCG GACACCGCCC ACCCCGGGCG
820 830 840 850 860 870 880 890 900
CCTCTACCGG TGCGGGCCCC GCCTGTGGAC GCGCGATTGC GCCGTGGCCG AACTCTCATG GGAGGTTGCC CAACACTGCG GGCACCAGGC
910 920 930 940 950 960 970 980 990
GCGCGTGCGC GCCGTGCGAT GCACCCTCCC TATCCGCCAC GTGCGCAGCC TCCAACCCAG CGCGCGGGTC CGACTCCCGG ACCTCGTCCA
100 0  1010  1020  1030  1040  1 050  1060  1 070  1080
TCTCGCCGAG GTGGGCCGGT GGCGGTGGTT CAGCCTCCCC CGCCCCGTGT TCCAGCGCAT GCTGTCCTAC TGCAAGACCC TGAGCCCCGA
1090  1 100  1110  112 0  1130  1140  1150  1 160  1170
CGCGTACTAC AGCGAGCGCG TGTTCAAGTT CAAGAACGCC CTGTGCCACA GCATCACGCT CGCGGGCAAT GTGCTGCAAG AGGGGTGGAA
1180  119 0  120 0  1210  1220  1230  1 240  1250  1260
GGGCACGTGC GCCGAGGAAG ACGCGCTGTG CGCATACGTA GCCTTCCGCG CGTGGCAGTC TAACGCCAGG TTGGCGGGGA TTATGAAAGG
1270  128 0  129 0  1300  1310  132 0  1330  134 0  135 0
CGCGAAGTGC GCCGCCGACT CTTTGAGCGT GGCCGGCTGG CTGGACACCA TTTGGGACGC CATTAAGCGG TTCCTCGGTA GCGTGCCCCT
136 0  137 0  138 0  1390  1400  1410  1420  1430  1440
CGCCGAGCGC ATGGAGGAGT GGGAACAGGA CGCCGCGGTC GCCGCCTTCG ACCGCGGCCC CCTCGAGGAC GGCGGGCGCC ACTTGGACAC
145 0  146 0  1470  148 0  149 0  1500  1510  1520  1530
CGTGCAACCC CCAAAATCGC CGCCCCGCCC TGAGATCGCC GCGACCTGGA TCGTCCACGC AGCCAGCGAA GACCGCCATT GCGCGTGCGC
1540  155 0  156 0  157 0  1580  1590  1600  161 0  162 0
TCCCCGCTGC GACGTCCCGC GCGAACGTCC TTCCGCGCCC GCCGGCCAGC CGGATGACGA GGCGCTCATC CCGCCGTGGC TGTTCGCCGA
1630  164 0  165 0  166 0  1670  1680  169 0  170 0  1710
GCGCCGTGCC CTCCGCTGCC GCGAGTGGGA TTTCGAGGCT CTCCGCGCGC GCGCCGATAC GGCGGCCGCG CCCGCCCCGC CGGCTCCACG
172 0  1730  1740  175 0  1760  1770  178 0  179 0  1800
CCCCGCGCGG TACCCCACCG TGCTCTACCG CCACCCCGCC CACCACGGCC CGTGGCTCAC CCTTGACGAG CCGGGCGAGG CTGACGCGGC
181 0  1820  1830  1840  1850  1860  1870  188 0  1890
CCTGGTCTTA TGCGACCCAC TTGGCCAGCC GCTCCGGGGC CCTGAACGCC ACTTCGCCGC CGGCGCGCAT ATGTGCGCGC AGGCGCGGGG
1900  1 910  1920 1930  1940  195 0  196 0  197 0  1980
GCTCCAGGCT TTTGTCCGTG TCGTGCCTCC ACCCGAGCGC CCCTGGGCCG ACGGGGGCGC CAGAGCGTGG GCGAAGTTCT TCCGCGGCTG
1 990  2 000  2 010  .2 0 2 0  2 030  2 0 4 0  205 0  2 0 6 0  2 070
CGCCTGGGCG CAGCGCTTGC TCGGCGAGCC AGCAGTTATG CACCTCCCAT ACACCGATGG CGACGTGCCA CAGCTGATCG CACTGGCTTT
2 0 8 0  2 090  2 100  2 1 1 0  2 120  2 1 3 0  214 0  215 0  2 160
GCGCACGCTG GCCCAACAGG GGGCCGCCTT GGCACTCTCG GTGCGTGACC TGCCCGGGGG TGCAGCGTTC GACGCAAACG CGGTCACCGC
2 1 7 0  2 180  2 190  2 200  2 210  222 0  2 2 3 0  2 2 4 0  2 250
CGCCGTGCGC GCTGGCCCCC GCCAGTCCGC GGCCGCGTCA CCGCCACCCG GCGACCCCCC GCCGCCGCGC CGCGCACGGC GATCGCAACG
226 0  2 270  2 280  2 290  2 300  231 0  232 0  2 3 3 0  2 340
GCACTCGGAC GCTCGCGGCA CTCCGCCCCC CGCGCCTGCG CGCGACCCGC CGCCGCCCGC CCCCAGCCCG CCCGCGCCAC CCCGCGCTGG
2 3 5 0  2 360  2 370  2 380  2 390  240 0  2 4 1 0  2 4 2 0  2 430
TGACCCGGTC CCTCCCATTC CCGCGGGGCC GGCGGATCGC GCGCGTGACG CCGAGCTGGA GGTCGCCTGC GAGCCGAGCG GCCCCCCCAC
2 4 4 0  2 4 5 0  2 460  2 470  2 480  249 0  250 0  2 5 1 0  2520
GTCAACCAGG GCAGACCCAG ACAGCGACAT CGTTGAAAGT TACGCCCGCG CCGCCGGACC CGTGCACCTC CGAGTCCGCG ACATCATGGA
2 5 3 0  2 5 4 0  2 5 5 0  2 560  2 570  258 0  2 5 9 0  2 600  2610
CCCACCGCCC GGCTGCAAGG TCGTGGTCAA CGCCGCCAAC GAGGGGCTAC TGGCCGGCTC TGGCGTGTGC GGTGCCATCT TTGCCAACGC
2 6 2 0  2 6 3 0  2 640  2 6 5 0  2 660  2 6 7 0  2 6 8 0  2 6 9 0  270 0
CACGGCGGCC CTCGCTGCAA ACTGCCGGCG CCTCGCCCCA TGCCCCACCG GCGAGGCAGT GGCGACACCC GGCCACGGCT GCGGGTACAC
2 7 1 0  272 0  2 730  2 7 4 0  2 7 5 0  2 7 6 0  277 0  2 7 8 0  279 0
CCACATCATC CACGCCGTCG CGCCGCGGCG TCCTCGGGAC CCCGCCGCCC TCGAGGAGGG CGAAGCGCTG CTCGAGCGCG CCTACCGCAG
269
2 800 2 810 2820 2830 284 0 285 0 2860 287 0 288 0
CATCGTCGCG CTAGCCGCCG CGCGTCGGTG GGCGTGTGTC GCGTGCCCCC TCCTCGGCGC TGGCGTCTAC GGCTGGTCTG CTGCGGAGTC
289 0 2900 2910 2920 2930 2940 2950 296 0 297 0
CCTCCGAGCC GCGCTCGCGG CTACGCGCAC CGAGCCCGTC GAGCGCGTGA GCCTGCACAT CTGCCACCCC GACCGCGCCA CGCTGACGCA
298 0 299 0 3 000 3010 3020 303 0 3040 305 0 3060
CGCCTCCGTG CTCGTCGGCG CGGGGCTCGC TGCCAGGCGC GTCAGTCCTC CTCCGACCGA GCCCCTCGCA TCTTGCCCCG CCGGTGACCC
307 0 308 0 3090 3100 3110 3120 3130 314 0 3150
GGGCCGACCG GCTCAGCGCA GCGCGTCGCC CCCAGCGACC CCCCTTGGGG ATGCCACCGC GCCCGAGCCC CGCGGATGCC AGGGGTGCGA
316 0 3170 3180 3190 3200 3210 3220 3230 3 240
ACTCTGCCGG TACACGCGCG TCACCAATGA CCGCGCCTAT GTCAACCTGT GGCTCGAGCG CGACCGCGGC GCCACCAGCT GGGCCATGCG
325 0 3 260 3270 3280 3 290 3300 331 0 3320 3 330
CATTCCCGAG GTGGTTGTCT ACGGGCCGGA GCACCTCGCC ACGCATTTTC CATTAAACCA CTACAGTGTG CTCAAGCCCG CGGAGGTCAG
3340 3 350 3360 3370 3 380 3390 3400 3 410 3 420
GCCCCCGCGA GGCATGTGCG GGAGTGACAT GTGGCGCTGC CGCGGCTGGC ATGGCATGCC GCAGGTGCGG TGCACCCCCT CCAACGCTCA
3 430 3 440 3450 346 0 3 470 3480 3490 3 500 3 510
CGCCGCCCTG TGCCGCACAG GCGTGCCCCC TCGGGCGAGC ACGCGAGGCG GCGAGCTAGA CCCAAACACC TGCTGGCTCC GCGCCGCCGC
3 520 3 530 354 0 355 0 3560 3570 3580 3 590 3600
CAACGTTGCG CAGGCTGCGC GCGCCTGCGG CGCCTACACG AGTGCCGGGT GCCCCAAGTG CGCCTACGGC CGCGCCCTGA GCGAAGCCCG
3 610 3620 363 0 3640 3650 3660 3670 3 680 3690
CACTCATGAG GACTTCGCCG CGCTGAGCCA GCGGTGGAGC GCGAGCCACG CCGATGCCTC CCCTGACGGC ACCGGAGATC CCCTCGACCC
3 700 371 0 372 0 3730 374 0 3750 3 760 3770 378 0
CCTGATGGAG ACCGTGGGAT GCGCCTGTTC GCGCGTGTGG GTCGGCTCCG AGCATGAGGC CCCGCCCGAC CACCTCCTGG TGTCCCTTCA
379 0 380 0 3 810 3820 3830 3840 3850 3860 387 0
CCGTGCCCCA AATGGTCCGT GGGGCGTAGT GCTCGAGGTG CGTGCGCGCC CCGAGGGGGG CAACCCCACC GGCCACTTCG TCTGCGCGGT
388 0 389 0 3900 3 910 3920 3930 3940 395 0 396 0
CGGCGGCGGC CCACGCCGCG TCTCGGACCG CCCCCACCTC TGGCTTGCGG TCCCCCTGTC TCGGGGCGGT GGCACCTGTG CCGCGACCGA
3 9 7 0 . 3980 3 990 4000 4010 4020 4030 4040 4050
CGAGGGGCTG GCCCAGGCGT ACTACGACGA GCTCGAGGTG CGCCGCCTCG GGGATGACGC CATGGCCCGG GCGGCCCTCG CATCAGTCCA
4 060 4 070 4080 4090 4100 4110 412 0 4130 4140
ACGCCCTCGC AAAGGCCCTT ACAATATCAG GGTATGGAAC ATGGCCGCAG GCGCTGGCAA GACTACCCGC ATCCTCGCTG CCTTCACGCG
4150 4160 4170 4180 4190 4200 4210 4220 4230
CGAAGACCTT TACGTCTGCC CCACCAATGC GCTCCTGCAC GAGATCCAGG CCAAACTCCG CGCGCGCGAT ATCGACATCA AGAACGCCGC
4240 4250 426 0 4270 4280 4290 4300 4 310 4 320
CACCTACGAG CGCCGGCTGA CGAAACCGCT CGCCGCCTAC CGCCGCATCT ACATCGATGA GGCGTTCACT CTCGGCGGCG AGTACTGCGC
4330 4340 4350 4360 4370 4380 4390 4400 4410
GTTCGTTGCC AGCCAAACCA CCGCGGAGGT GATCTGCGTC GGTGATCGGG ACCAGTGCGG CCCACACTAC GCCAATAACT GCCGCACCCC
4420 4430 4440 4450 4460 4470 4480 4490 450 0
CGTCCCTGAC CGCTGGCCTA CCGAGCGCTC GCGCCACACT TGGCGCTTCC CCGACTGCTG GGCGGCCCGC CTGCGCGCGG GGCTCGATTA
4510 4520 4530 4540 4550 4560 4570 4580 4590
TGACATCGAG GGCGAGCGCA CCGGCACCTT CGCCTGCAAC CTTTGGGACG GCCGCCAGGT CGACCTTCAC CTCGCCTTCT CGCGCGAAAC
460 0 461 0 462 0 4630 4640 4650 4660 4670 4680
CGTGCGCCGC CTTCACGAGG CTGGCATACG CGCATACACC GTGCGCGAGG CCCAGGGTAT GAGCGTCGGC ACCGCCTGCA TCCATGTAGG
4690 470 0 4710 4720 4730 4740 4750 4760 4770
CAGAGACGGC ACGGACGTTG CCCTGGCGCT GACACGCGAC CTCGCCATCG TCAGCCTGAC CCGGGCCTCC GACGCACTCT ACCTCCACGA
478 0 4790 480 0 4810 4820 4830 4840 4850 4860
GCTCGAGGAC GGCTCACTGC GCGCTGCGGG GCTCAGCGCG TTCCTCGACG CCGGGGCACT GGCGGAGCTC AAGGAGGTTC CCGCTGGCAT
4870 4880 4890 4900 4910 4920 4930 4940 495 0
TGACCGCGTT GTCGCCGTCG AGCAGGCACC ACCACCGTTG CCGCCCGCCG ACGGCATCCC CGAGGCCCAA GACGTGCCGC CCTTCTGCCC
4 960 4 970 4980 4990 5000 5010 502 0 5030 504 0
CCGCACTCTG GAGGAGCTCG TCTTCGGCCG TGCCGGCCAC CCCCATTACG CGGACCTCAA CCGCGTGACT GAGGGCGAAC GAGAAGTGCG
5050 5 060 5070 5080 5090 5100 511 0 512 0 513 0
GTACATGCGC ATCTCGCGTC ACCTGCTCAA CAAGAATCAC ACCGAGATGC CCGGAACGGA ACGCGTTCTC AGTGCCGTTT GCGCCGTGCG
514 0 5150 5160 5170 5180 5190 520 0 521 0 5220
GCGCTACCGC GCGGGCGAGG ATGGGTCGAC CCTCCGCACT GCTGTGGCCC GCCAGCACCC GCGCCCTTTT CGCCAGATCC CACCCCCGCG
5230 5 240 5250 5260 5270 5280 5290 530 0 5310
CGTCACTGCT GGGGTCGCCC AGGAGTGGCG CATGACGTAC TTGCGGGAAC GGATCGACCT CACTGATGTC TACACGCAGA TGGGCGTGGC
532 0 5330 5340 5350 5360 5370 5380 539 0 5400
CGCGCGGGAG CTCACCGACC GCTACGCGCG CCGCTATCCT GAGATCTTCG CCGGCATGTG TACCGCCCAG AGCCTGAGCG TCCCCGCCTT
5 410 5 420 5430 5440 5450 5460 5470 5480 5 490
CCTCAAAGCC ACCTTGAAGT GCGTAGACGC CGCCCTCGGC CCCAGGGACA CCGAGGACTG CCACGCCGCT CAGGGGAAAG CCGGCCTTGA
5 500 5 510 5 520 5530 5540 555 0 5560 5570 5 580
GATCCGGGCG TGGGCCAAGG AGTGGGTTCA GGTTATGTCC CCGCATTTCC GCGCGATCCA GAAGATCATC ATGCGCGCCT TGCGCCCGCA
5 59 0 5600 5610 5620 5630 5640 5650 5660 5670
ATTCCTTGTG GCCGCTGGCC ATACGGAGCC CGAGGTCGAT GCGTGGTGGC AGGCCCATTA CACCACCAAC GCCATCGAGG TCGACTTCAC
5 68 0 5690 5700 5710 5720 573 0 5740 5750 5760
TGAGTTCGAC ATGAACCAGA CCCTCGCTAC TCGGGACGTC GAGCTCGAGA TTAGCGCCGC TCTCTTGGGC CTCCCTTGCG CCGAAGACTA
270
5770 5 780 5790 5800 5810 5 820 5830 5 840 5 85 0
CCGCGCGCTC CGCGCCGGCA GCTACTGCAC CCTGCGCGAA CTGGGCTCCA CTGAGACCGG CTGCGAGCGC ACAAGCGGCG AGCCCGCCAC
586 0 5870 5880 5890 5900 5910 5920 5 930 5940
GCTGCTGCAC AACACCACCG TGGCCATGTG CATGGCCATG CGCATGGTCC CCAAAGGCGT GCGCTGGGCC GGGATTTTCC AGGGTGACGA
5950 596 0 5970 5980 5990 6000 6010 6020 6030
TATGGTCATC TTCCTCCCCG AGGGCGCGCG CAGCGCGGCA CTCAAGTGGA CCCCCGCCGA GGTGGGCTT GTTTGGCTTC CACATCCCGG
6040 6050 6060 6070 6080 6090 6100 6110 6120
TGAAGCACGT GAGCACCCCT ACCCCCAGCT TCTGCGGGCA CGTCGGCACC GCGGCCGGCC TCTTCCATGA TGTCATGCAC CAGGCGATCA
6130 6140 6150 6160 6170 6180 6190 6200 6210
AGGTGCTTTG CCGCCGTTTC GACCCAGACG TGCTTGAAGA ACAGCAGGTG GCCCTCCTCG ACCGCCTCCG GGGGGTCTAC GCGGCTCTGC
6220 6230 6240 6250 6260 6270 6280 6290 6300
CTGACACCGT TGCCGCCAAT GCTGCGTACT ACGACTACAG CGCGGAGCGC GTCCTCGCTA TCGTGCGCGA ACTTACCGCG TACGCGGGGG
6310 6320 6330 6340 6350 6360 6370 6380 6390
CGCGGCCTCG ACCACCCGGC CACCATCGGC GCGCTCGAGG AGATTCAGAC CCCCTACGCG CGCGCCAATC TCCACGACGC CGACTAACGC
6400 6410 6420 6430 6440 6450 6460 6470 6480
CCCTGTACGT GGGGCCTTTA ATCTTACCTA CTCTAACCAG GTGATCACCC ACCGTTGTTT CGCCGCATCT GGTGGGTACC CAACTTTTGC
6490 6500 6510 6520 6530 6540 6550 6560 6570
CATTCGGGAG AGCCCCAGGG TGCCCGAATG GCTTCTACTA CCCCCATCAC CATGGAGGAC CTCCAGAAGG CCCTCGAGGC ACAATCCCGC
6580 6590 6600 6610 6620 6630 6640 6650 6660
GCCCTGCGCG CGGAACTCGC CGGCGGCGGC TCGCAGTCGC GGCGGCCGCG GCCGCCGCGA CAGCGCGACT CCAGCACCTC CGGAGATGAC
6670 6680 6690 6700 6710 6720 6730 6740 6750
TCCGGCCGTG ACTCCGGAGG GCGCCGCCGC CGCCGCGGCA ACCGGGGCCG TGGCCAGCGC AGGGACTGGT CCAGGGCCCC GCCCCCCCCG
6760 6770 6780 6790 6800 6810 6820 6830 6840
GAGGAGCGGC AAGAAACTCG CTCCCAGACT CCGGCCCCGA AGCCATCGCG GGCGCCGCCA CAACAGCCTC AACCCCCGCG CATGCAAACC
6850 6860 6870 6880 6890 6900 6910 6920 6930
GGGCGTGGGG GCTCTGCCCC GCGCCCCGAG CTGGGGCCAC CGACCAACCC GTTCCAAGCA GCCGTGGCGC GTGGCCTGCG CCCGCCTCTC
6940 6950 6960 6970 6980 6990 7 000 7010 702 0
CACGACCCTG ACACCGAGGC ACCCACCGAG GCCTGCGTGA CCTCGTGGCT TTGGAGCGAG GGCGAAGGCG CGGTCTTTTA CCGCGTCGAC
7 0 3 0 704 0 7 050 7060 7070 7 080 7090 7 100 7 11 0
CTGCATTTCA CCAACCTGGG CACCCCCCCA CTCGACGAGG ACGGCCGCTG GGACCCTGCG CTCATGTACA ACCCTTGCGG GCCCGAGCCG
7 12 0 7 1 3 0 7 140 7 150 7160 7 170 7180 7190 720 0
CCCGCTCACG TCGTCCGCGC GTACAATCAA CCTGCCGGCG ACGTCAGGGG CGTTTGGGGT AAAGGCGAGC GCACCTACGC CGAGCAGGAC
7 21 0 722 0 7 230 7 240 7250 7 260 7 270 7280 7 29 0
TTCCGCGTCG GCGGCACGCG CTGGCACCGA CTGCTGCGCA TGCCAGTGCG CGGCCTCGAC GGCGACAGCG CCCCGCTTCC CCCCCACACC
7 3 0 0 7 310 7320 7330 7340 7350 7360 7370 7 380
ACCGAGCGCA TTGAGACCCG CTCGGCGCGC CATCCTTGGC GCATCCGCTT CGGTGCCCCC CAGGCCTTCC TTGCCGGGCT CTTGCTCGCC
7 39 0 7 400 7410 7 420 7430 7 440 7 450 7460 747 0
ACGGTCGCCG TTGGCACCGC GCGCGCCGGG CTCCAGCCCC GCGCTGATAT GGCGGCACCT CCTACGCTGC CGCAGCCCCC CTGTGCGCAC
7 48 0 7 490 7 500 7510 7520 7 530 7 540 7 550 7 56 0
GGGCAGCATT ACGGCCACCA CCACCATCAG CTGCCGTTCC TCGGGCACGA CGGCCATCAT GGCGGCACCT TGCGCGTCGG CCAGCATTAC
7 5 7 0 7 580 7 590 7 600 7610 7 620 7 630 7 640 765 0
CGAAACGCCA GCGACGTGCT GCCCGGCCAC TGGCTCCAAG GCGGCTGGGG TTGCTACAAC CTGAGCGACT GGCACCAGGG CACTGATGTC
7 6 6 0 7 670 7 680 7 690 7700 7 710 7720 7 730 774 0
TGTCATACCA AGCACATGGA CTTCTGGTGT GTGGAGCACG ACCGACCGCC GCCCGCGACC CCGACGCCTC TCACCACCGC GGCGAACTCC
7 750 7 760 7 770 7 780 7790 7 800 7 810 7 820 783 0
ACGACCGCCG CCACCCCCGC CACTGCGCCG GCGCCGTGCC ACGCCGGCCT CAATGACAGC TGCGGCGGCT TCTTGTCTGG GTGCGGGCCG
7840 7 850 7860 7 870 7880 7 890 7 900 7 910 792 0
ATGCGCCTGC GCCACGGCGC TGACACCCGG TGCGGTCGGT TGATCTGCGG GCTGTCCACC ACCGCCCAGT ACCCGCCTAC CCGGTTTGGC
7930 7 940 7 950 7 960 7970 7 980 7 990 8000 8010
TGCGCTATGC GGTGGGGCCT TCCCCCCTGG GAACTGGTCG TCCTTACCGC CCGCCCCGAA GACGGCTGGA CTTGCCGCGG CGTGCGCGCC
8020 8030 8040 8050 8060 8070 8080 8090 8100
CATCCAGGCG CCCGCTGCCC CGAACTGGTG AGCCCCATGG GACGCGCGAC TTGCTCCCCA GCCTCGGCCC TCTGGCTCGC CACAGCGAAC
8110 8120 8130 8140 8150 8160 8170 8180 8190
GCGCTGTCTC TTGATCACGC CCTCGCGGCC TTCGTCCTGC TGGTCCCGTG GGTCCTGATA TTTATGGTGT GCCGCCGCGC CTGTCGCCGC
8200 8210 8220 8230 8240 8250 8260 8270 8280
CGCGGCGCCG CCGCCGCCCT CACCGCGGTC GTCCTGCAGG GGTACAACCC CCGCGCCTAT GGCGAGGAGG CTTTCACCTA CCTCTGCACT
8290 8300 8310 8320 8330 8340 8350 8360 8370
GCACCGGGGT GCGCCACTCA AGCACCTGTC CCCGTGCGCC TCGCTGGCGT CCGTTTTGAG TCCAAGATTG TGGACGGCGG CTGCTTTGCC
8380 8390 8400 8410 8420 8430 8440 8450 8460
CCATGGGACC TCGAGGCCAC TGGAGCCTGC ATTTGCGAGA TCCCCACTGA TGTCTCGTGC GAGGGCTTGG GGGCCTGGGT ACCCGCAGCC
8470 8480 8490 8500 8510 8520 8530 8540 8550
CCTTGCGCGC GCATCTGGAA TGGCACACAG CGCGCGTGCA CCTTCTGGGC TGTCAACGCC TACTCCTCTG GCGGGTACGC GCAGCTGGCC
8560 8570 8580 8590 8600 8610 8620 8630 8640
TCTTACTTCA ACCCTGGCGG CAGCTACTAC AAGCAGTACC ACCCTACCGC GTGCGAGGTT GAACCTGCCT TCGGACACAG CGACGCGGCC
8650 8660 8670 8680 8690 8700 8710 8720 8730
TGCTGGGGCT TCCCCACCGA CACCGTGATG AGCGTGTTCG CCCTTGCTAG CTACGTCCAG CACCCTCACA AGACCGTCCG GGTCAAGTTC
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8740  875p  8760  8770  8780  8790 8800  8810  8820
CATACAGAGA CCAGGACCGT CTGGCAACTC TCCGTTGCCG GCGTGTCGTG CAACGTCACC ACTGAACACC CGTTCTGCAA CACGCCGCAC
8830  8 840  8850  8860  8870  8880  889 0  8900  8910
GGACAACTCG AGGTCCAGGT CCCGCCCGAC CCCGGGGACC TGGTTGAGTA CATTATGAAT TACACCGGCA ATCAGCAGTC CCGGTGGGGC
8920  8930  8940  8950 8960  8970 8980  8 990  9000
CTCGGGAGCC CGAATTGCCA CGGCCCCGAT TGGGCCTCCC CGGTTTGCCA ACGCCATTCC CCTGACTGCT CGCGGCTTGT GGGGGCCACG
9010  902 0  9030  9040  9050  9060  9070  9080  9090
CCAGAGCGCC CCCGGCTGCG CCTGGTCGAC GCCGACGACC CCCTGCTGCG CACTGCCCCT GGACCCGGCG AGGTGTGGGT CACGCCTGTC
9100  9110  9120  9130  9140  9150  9160  917 0  9180
ATAGGCTCTC AGGCGCGCAA GTGCGGACTC CACATACGCG CTGGACCGTA CGGCCATGCT ACCGTCGAAA TGCCCGAGTG GATCCACGCC
9190  9200  9210  9220  9230  9240 9250  926 0  9270
CACACCACCA GCGACCCCTG GCATCCACCG GGCCCCTTGG GGCTGAAGTT CAAGACAGTT CGCCCGGTGG CCCTGCCACG CACGTTAGCG
9280  9290  9300  9310  9320  9330  9340  9350  9360
CCACCCCGCA ATGTGCGTGT GACCGGGTGC TACCAGTGCG GTACCCCCGC GCTGGTGGAA GGCCTTGCCC CCGGGCGAGG CAATTGCCAT
9370  938 0  9390  9400  9410  9420  9430  9440  9450
CTCACCGTCA ATGGCGAGGA CCTCGGCGCC GTCCCCCCTG GGAAGTTCGT CACCGCCGCC CTCCTCAACA CCCCCCCGCC CTACCAAGTC
9460  9470  9480  9490  9500  9510  9520  9530  9540
AGCTGCGGGG GCGAGAGCGA TCGCGCGACC GCGCGGGTCA TCGACCCCGC CGCGCAATCG TTTACCGGCG TGGTGTATGG CACACACACC
9550  9560 9570  9580  9590 9600  961 0  9620  9630
ACTGCTGTGT CGGAGACCCG GCAGACCTGG GCGGAGTGGG CTGCTGCGCA TTGGTGGCAG CTCACTCTGG GCGCCATTTG CGCCCTCCCA
9640  9650  9660  9670  9680  9690  9700  9710  9720
CTCGCTGGCT TACTCGCTTG CTGTGCCAAA TGCTTGTACT ACTTGCGCGG CGCTATAGCG CCTCGCTAGT GGGCCCCCGC GCGAAACCCG
9730  9740  9750
CACTAGGCCA CTAGATCCCC GCACCTGTTG CTGTATAG
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Appendix 2 One and three letter codes used as abbreviations for the 
amino acids.
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glutamic acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I lie Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
W Trp Tryptophane
Y Tyr Tyrosine
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Appendix 3 Sizes of the different markers used throughout this thesis.
Lambda H indlll  markers (bp)
23,130
9,416
6,557
4,361
2,322
2,027
564
125
0X174 H aelll  markers (bp)
1,353
1,078
872
603
310
271
281
234
194
118
72
Biorad SDS-PAGE 
protein markers (Da)
200,000
116.500
97.400 
66,200
45.000
31.000
21.500
14.400
6.500
Biorad SDS-PAGE prestained 
protein markers (Da)
205.000
116.500
80.000
49.500
32.500
27.500
18.500
6.500
methylated protein markers (Da)
200,000
92,500
69.000
46.000
30.000 
14,300
RNA markers (Kb)
9.49
7.46
4.4
2.37
1.35
0.24
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Appendix 4 OD readings for all the serum samples for the peptides 
covering
peptide 25 32 18 31 20 1511 2 1 4 10 9 21 22 33
1 0.422 0.746 0.436 0.613 0.549 0.433 0.429 0.375 0.592 0.651 0.446 0.598 0.621 0.385
2 0.447 0.675 0.477 0.668 0.602 0.429 0.395 0.356 0.658 0.490 0.357 0.550 0.689 0.352
3 0.442 0.629 0.429 0.537 0.419 0.466 0.327 0.334 0.619 0.706 0.568 0.496 0.643 0.504
■4 0.708 0.977 0.695 0.937 0.713 0.645 0.604 0.493 0.775 0.664 0.627 0.769 0.961 0.694
5 0.650 0.741 0.823 0.701 0.573 0.619 0.582 0.593 0.821 0.926 0.562 0.688 0.945 1.422
6 0.591 0.739 0.640 0.702 0.601 0.510 0.528 0.530 0.665 0.659 0.496 0.618 0.665 0.953
7 0.689 1.053 0.617 0.680 0.671 0.592 0.512 0.633 0.818 0.498 0.498 0.844 0.736 0.778
8 0.660 0.956 0.704 0.753 0.772 0.464 0.540 0.540 0.788 0.499 0.459 0.673 0.996 0.690
9 0.675 0.906 0.598 0.732 0.788 0.414 0.583 0.392 0.675 0.591 0.556 0.903 1.264 0.453
10 0.572 0.995 0.578 0.653 0.694 0.493 0.591 0.392 0.828 0.610 0.485 0.829 1.150 0.394
11 0.477 0.779 0.492 0.628 0.625 0.788 0.398 0.486 0.742 0.492 0.400 0.667 1.148 0.677
12 0.525 0.558 0.414 0.546 0.452 0.387 0.319 0.351 0.558 0.548 0.421 0.595 1.012 0.360
13 0.458 0.698 0.498 0.545 0.526 0.403 0.331 0.370 0.606 0.425 0.367 0.570 1.035 0.325
14 0.415 0.576 0.433 0.575 0.518 0.472 0.333 0.309 0.630 0.396 0.355 0.564 1.027 0.394
15 0.461 0.587 0.407 0.572 0.555 0.398 0.262 0.310 0.599 0.356 0.318 0.582 1.176 0.413
16 0.483 0.610 0.444 0.559 0.494 0.469 0.338 0.323 0.829 0.359 0.279 0.725 0.921 1.074
17 0.575 0.854 0.512 0.517 0.490 0.475 0.456 0373 0.792 0.381 0.380 0.925 0.949 0.757
18 0.571 0.630 0.440 0.555 0.465 0.521 0.439 0.433 0.785 0.401 0.378 0.800 0.905 1.236
19 0.596 0.785 0.543 0.573 0.565 0.503 0.490 0.409 0.769 0.400 0.417 0.733 0.986 1.150
20 0.490 0.766 0.544 0.492 0.632 0.435 0.568 0.366 0.916 0.382 0.353 0.581 0.898 1.039
21 0.605 0.836 0.708 0.777 0.922 0.658 0.579 0.518 0.791 0.508 0.500 1.432 1.071 0.890
22 0.388 0.838 0.436 0.474 0.874 0.638 0.678 0.348 0.607 0.517 0.630 0.740 1.293 0.812
23 0.414 1.244 0.348 0.409 0.664 0.657 0.330 0.335 0.465 0.380 0.387 0.584 1.011 0.615
24 0.351 0.601 0.368 0.425 0.393 0.315 0.321 0.243 0.539 0.301 0.342 0.546 0.877 0.314
25 1.070 0.801 1.237 0.644 0.566 0.447 0.446 0.401 0.914 0.444 0.477 0.814 1.262 0.435
26 0.623 0.769 0.525 0.529 0.584 0.579 1.219 0.402 0.949 0.424 0.394 0.784 1.119 0.440
27 0.541 0.706 0.565 0.516 0.567 0.472 0.406 0.339 0.731 0.358 0.339 0.660 1.153 0.584
28 0.451 0.574 0.409 0.456 0.478 0.457 0.544 0.288 0.810 0.348 0.228 0.655 0.876 0.554
29 0.418 0.513 0.407 0.392 0.438 0.378 0.390 0.260 0.836 0.293 0.225 0.599 0.727 0.665
30 0.491 0.728 0.521 0.524 0.615 0.515 0.517 0.364 0.824 0.314 0.286 0.627 0.883 0.604
31 0.634 0.941 0.569 0.558 0.683 0.492 0.620 0.403 0.925 0.335 0.328 0.694 0.891 1.150
32 0.543 0.771 0.513 0.460 0.759 0.462 0.476 0.346 0.733 0.429 0.337 0.509 0.823 1.200
33 0.684 0.920 0.630 0.659 0.683 0.759 0.390 0.631 1.088 0.461 0.382 1.304 0.699 1.842
34 0.482 0.879 0.515 0.539 0.835 0.801 0.685 0.430 0.808 0.557 0.483 0.739 ' 1.441 0.719
35 0.481 0.965 0.359 0.578 0.425 0.704 0.540 0.421 0.734 0.544 0.479 0.790 0.656 1.154
36 0.536 0.508 0.341 0.455 0.417 0.383 0.309 0.281 0.492 0.378 0.323 0.604 0.542 0.525
37 0.377 0.492 0.358 0.394 0.437 0.382 0.281 0.301 0.558 0.335 0.305 0.735 0.834 0.459
38 0.485 0.493 0.288 0.328 0.320 0.746 0.232 0.451 0.910 0.308 0.267 0.551 0.944 0.544
39 0.395 0.523 0.323 0.374 0.326 0.602 0.339 0.269 0.804 0.322 0.281 0.956 1.026 0.434
40 0.594 0.496 0.309 0.336 0.291 0.431 0.301 0.266 1.162 0.255 0.276 0.783 1.190 0.310
41 0.478 0.520 0.386 0.423 0.429 0.676 0.283 0.279 1.012 0.317 0.270 0.719 0.848 0.320
42 0.384 0.520 0.374 0.371 0.538 0.416 0.240 0.269 0.934 0.248 0.205 0.557 0.655 0.354
43 0.473 0.642 0.448 0.465 0.579 0.423 0.365 0.316 0.878 0.395 0.286 0.644 1.056 0.394
44 0.469 0.910 0.609 0.592 0.696 0.551 0.589 0.070 0.666 0.481 0.483 0.890 1.400 0.452
45 0.428 0.959 0.423 0.441 0.475 0.373 0.331 0.316 0.664 0.318 0.386 0.562 0.566 1.441
46 0.683 1.043 0.567 0.562 0.678 0.500 0.587 0.540 0.896 0.559 0.670 0.949 0.928 0.616
47 0.526 0.777 0.581 0.666 0.683 1.011 0.654 0.500 0.838 0.816 0.590 0.788 0.890 0.560
48 0.527 0.687 0.826 0.564 0.628 0.499 0.524 0.393 0.984 0.562 0.488 0.728 1.119 0.550
49 0.541 0.701 0.592 0.514 0.603 0.445 0.484 0.551 0.766 0.585 0.558 0.750 0.602 0.426
50 0.448 0.552 0.651 0.424 0.577 0.398 0.336 0.367 1.180 0.522 0.324 0.715 0.696 0.414
51 0.548 0.668 0.543 0.479 0.604 0.605 0.505 1.304 1.125 0.417 0.313 0.611 0.636 0.395
52 0.723 0.632 0.511 0.448 0.480 0.573 0.455 0.350 1.524 0.375 0.279 0.776 0.713 0.343
53 0.590 0.665 0.701 0.468 0.453 0.606 0.577 0.398 1.502 0.493 0.359 0.826 0.942 0.529
54 0.895 1.425 0.458 0.357 0.506 0.376 0.473 0.277 0.816 0.231 0.269 0.492 0.643 0.352
55 1.143 0.942 0.516 0.389 0.596 0.590 0.786 0.369 0.934 0.332 0.345 0.655 1.246 0.450
56 0.929 0.983 0.685 0.561 0.789 0.723 0.478 0.411 1.189 0.396 0.407 0.797 1.331 0.587
57 0.727 0.895 0.753 0.570 0.920 0.348 0.384 0.349 1.021 0.390 0.363 0.733 0.569 0.391
58 0.570 0.958 0.790 0.586 1.010 0.350 0.520 0.425 0.948 0.415 0.410 0.813 0.729 0.405
59 0.477 0.731 0.552 0.644 0.775 0.400 0.441 0.309 0.664 0.440 0.430 0.678 0.788 0.446
60 0.528 0.663 1.175 0.683 0.678 0.401 0.371 0.278 0.756 0.518 0.344 1.284 0.810 0.411
61 0.402 0.595 1.323 0.461 0.587 0.320 0.339 0.273 0.669 0.384 0.311 1.360 0.572 0.338
62 0.433 0.704 0.560 0.534 0.623 0.364 0.389 0.297 0.820 0.470 0.364 0.654 0.673 0.368
63 0.484 0.573 0.558 0.653 0.665 0.346 0.362 0.276 1.416 0.354 0.320 0.722 0.644 0.366
64 0.423 0.610 0.444 0.406 0.476 0.351 0.427 0.258 1.765 0.307 0.264 0.677 0.630 0.318
65 0.456 0.477 0.437 0.417 0.494 0.355 0.290 0.294 1.295 0.367 0.231 0.627 0.742 0.254
66 0.442 0.505 0.468 0.414 0.504 0.358 0.344 0.318 1.045 0.305 0.245 0.611 0.721 0.303
67 0.413 0.550 0.410 0.412 0.429 0.353 0.511 0.261 0.912 0.304 0.273 0.598 0.786 0.274
68 0.410 0.558 0.413 0.425 0.537 0.357 0.477 0.242 0.927 0.353 0.302 0.614 0.711 0.293
69 0.480 0.713 0.525 0.436 0.423 0.339 0.460 0.341 0.918 0.417 0.319 0.634 0.740 0.311
70 0.527 0.664 0.556 0.616 0.607 0.415 0.378 0.380 0.797 0.422 0.409 0.762 1.036 0.402
71 0.652 0.741 ,0 .553 0.796 0.821 0.456 0.570 0.447 0.842 0.586 0.538 0.937 1.146 0.505
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